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A B S T R A C T
Background
Concerns regarding the safety of transfused blood have led to the development of a range of interventions to minimise blood loss
during major surgery. Anti-fibrinolytic drugs are widely used, particularly in cardiac surgery, and previous reviews have found them to
be effective in reducing blood loss, the need for transfusion, and the need for re-operation due to continued or recurrent bleeding. In
the last few years questions have been raised regarding the comparative performance of the drugs. The safety of the most popular agent,
aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk
of cardiovascular complications and death.
Objectives
To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA)
on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal
dysfunction, and death.
Search methods
We searched: the Cochrane Injuries Group’s Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The
Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010. References in
identified trials and review articles were checked and trial authors were contacted to identify any additional studies. The searches were
last updated in July 2010.
Selection criteria
Randomised controlled trials (RCTs) of anti-fibrinolytic drugs in adults scheduled for non-urgent surgery. Eligible trials compared anti-
fibrinolytic drugs with placebo (or no treatment), or with each other.
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Data collection and analysis
Two authors independently assessed trial quality and extracted data. This version of the review includes a sensitivity analysis excluding
trials authored by Prof. Joachim Boldt.
Main results
This review summarises data from 252 RCTs that recruited over 25,000 participants. Data from the head-to-head trials suggest an
advantage of aprotinin over the lysine analogues TXA and EACA in terms of reducing perioperative blood loss, but the differences
were small. Compared to control, aprotinin reduced the probability of requiring RBC transfusion by a relative 34% (relative risk [RR]
0.66, 95% confidence interval [CI] 0.60 to 0.72). The RR for RBC transfusion with TXA was 0.61 (95% CI 0.53 to 0.70) and was
0.81 (95% CI 0.67 to 0.99) with EACA. When the pooled estimates from the head-to-head trials of the two lysine analogues were
combined and compared to aprotinin alone, aprotinin appeared more effective in reducing the need for RBC transfusion (RR 0.90;
95% CI 0.81 to 0.99).
Aprotinin reduced the need for re-operation due to bleeding by a relative 54% (RR 0.46, 95% CI 0.34 to 0.62). This translates into an
absolute risk reduction of 2% and a number needed-to-treat (NNT) of 50 (95% CI 33 to 100). A similar trend was seen with EACA
(RR 0.32, 95% CI 0.11 to 0.99) but not TXA (RR 0.80, 95% CI 0.55 to 1.17). The blood transfusion data were heterogeneous and
funnel plots indicate that trials of aprotinin and the lysine analogues may be subject to publication bias.
When compared with no treatment aprotinin did not increase the risk of myocardial infarction (RR 0.87, 95% CI 0.69 to 1.11),
stroke (RR 0.82, 95% CI 0.44 to 1.52), renal dysfunction (RR 1.10, 95% CI 0.79 to 1.54) or overall mortality (RR 0.81, 95% CI
0.63 to 1.06). Similar trends were seen with the lysine analogues, but data were sparse. These data conflict with the results of recently
published non-randomised studies, which found increased risk of cardiovascular complications and death with aprotinin. There are
concerns about the adequacy of reporting of uncommon events in the small clinical trials included in this review.
When aprotinin was compared directly with either, or both, of the two lysine analogues it resulted in a significant increase in the risk
of death (RR 1.39, 95% CI 1.02, 1.89), and a non-significant increase in the risk of myocardial infarction (RR 1.11 95% CI 0.82,
1.50). Most of the data contributing to this added risk came from a single study - the BART trial (2008).
Authors’ conclusions
Anti-fibrinolytic drugs provide worthwhile reductions in blood loss and the receipt of allogeneic red cell transfusion. Aprotinin appears
to be slightly more effective than the lysine analogues in reducing blood loss and the receipt of blood transfusion. However, head to
head comparisons show a lower risk of death with lysine analogues when compared with aprotinin. The lysine analogues are effective
in reducing blood loss during and after surgery, and appear to be free of serious adverse effects.
P L A I N L A N G U A G E S U M M A R Y
Anti-fibrinolytic drugs for reducing blood loss and the need for red blood cell transfusions during and after surgery.
Aprotinin, although effective in reducing bleeding, had a higher rate of death than tranexamic acid and aminocaproic acid, which
appeared free of serious side-effects. Aprotinin has been withdrawn from world markets because of safety concerns. This review of over
250 clinical trials found that anti-fibrinolytic drugs used at the time of major surgery reduce bleeding, the need for transfusions of red
blood cells and the need for repeat surgery because of bleeding. With the exception of aprotinin the drugs appear safe.
B A C K G R O U N D
Public concern regarding the safety of transfused blood has
prompted a reconsideration of the role of allogeneic blood trans-
fusion (whole blood or packed red cells from an unrelated donor).
The risks associated with receiving transfusion of allogeneic blood
that has been screened by a competent blood transfusion program
are consideredminimal, with very low risks of transmissionofHIV,
and hepatitis C (Whyte 1997). However, this only applies where
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there is a safe, plentiful, well-regulated supply. The majority of the
world’s population does not have access to such a system, and the
risks of transfusion in developing countries may be much higher
(McFarland 1997). Concerns of patients and clinicians regarding
blood safety have generated enthusiasm for the use of technolo-
gies intended to reduce the use of allogeneic blood (Bryson 1998;
Forgie 1998; Huet 1999; Laupacis 1997). Although allogeneic
blood transfusion has had a unique place in medical practice, we
are obliged to examine the evidence on the benefits, harms and
costs of a range of techniques designed to minimise the use of this
resource. Some of the alternatives to allogeneic blood have their
own risks, and are expensive (Coyle 1999; Fergusson 1999).
Perioperative bleeding is one of the major indications for allo-
geneic blood transfusions worldwide (Levy 2006). However, mas-
sive surgical blood loss is a serious problem that affects many
cardiac surgery patients in particular and has been shown to
have a strong, independent association with in-hospital mortality
(Karkouti 2004). There is also considerable evidence that blood
loss that leads to the transfusion of blood products is harmful, and
that the degree of harm is directly related to the amount of blood
loss (Karkouti 2006). To reduce perioperative blood loss a number
of pharmacological agents have been used, these include the anti-
fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon
aminocaproic acid (EACA).
Aprotinin is a non-specific, serine protease inhibitor, derived from
bovine lung,with anti-fibrinolytic properties. It acts as an inhibitor
of several serine proteases, including trypsin, plasmin, plasma-
kallikrein and tissue kallikrein. Aprotinin also inhibits the con-
tact phase activation of coagulation that both initiates coagula-
tion and promotes fibrinolysis (Fritz 1983; Royston 1998). Dur-
ing cardiopulmonary bypass (CPB) the negatively charged surface
of the CPB circuit activates factor XII, converting prekallikrein to
kallikreinwhich further activates factor XII. This positive feedback
loop acts to intensify the intrinsic coagulation cascade. By inhibit-
ing plasma kallikrein, aprotinin minimises derangements in coag-
ulation and fibrinolysis (Smith 1998). There is also evidence that
aprotinin exerts an indirect preservative effect on platelet function
during extracorporeal circulation (ECC) (Mohr 1992). In many
countries aprotinin is specifically indicated for the reduction of
blood loss during cardiopulmonary bypass.
TXA and EACA are synthetic lysine analogues (synthetic deriva-
tives of the amino acid lysine) that act as effective inhibitors of
fibrinolysis. TXA and EACA act principally by blocking the lysine
binding sites on plasminogen molecules, inhibiting the formation
of plasmin and therefore inhibiting fibrinolysis (Faught 1998).
Tranexamic acid is about ten timesmore potent than aminocaproic
acid and binds much more strongly to both the strong and weak
sites of the plasminogen molecule than EACA (Faught 1998;
Mannucci 1998).
Why it is important to do this review
The efficacy of these three anti-fibrinolytic drugs to reduce periop-
erative blood loss and allogeneic blood transfusion has been stud-
ied extensively. Systematic reviews of these drugs (Henry 1999;
Laupacis 1997; Levi 1999; Munoz 1999; Sedrakyan 2004) have
shown that the use of aprotinin is associated with statistically sig-
nificant reductions in allogeneic blood transfusion requirements
and re-operation due to bleeding. Systematic reviews have also
shown TXA to be effective in reducing exposure to allogeneic
blood transfusion without significant increases in adverse effects
(Henry 1999; Laupacis 1997). In the case of EACA, the evidence
of effect is equivocal with most systematic reviews severely ham-
pered by the small number of trials of this agent.
Based on the evidence of efficacy anti-fibrinolytic drugs have be-
come widely used, particularly in cardiac surgery. Because of their
mode of actions there have been longstanding concerns about the
possibility of adverse effects, with most attention directed at the
risk of thrombosis and renal failure. However meta-analyses of
randomised trials, including previous versions of this Cochrane
review (Henry 1999;Henry 2007), have been reassuring in pro-
viding no convincing evidence of an increased risk of these events
in treated subjects. However, in the case of aprotinin, this view
of an attractive benefit to harm ratio was thrown into doubt by
the publication of several large non-randomised studies (Mangano
2006; Mangano 2007;Schneeweiss 2008). The serious safety con-
cerns raised by these and other studies prompted the United States
Food and Drug Administration (FDA) to re-evaluate its position
regarding the use of aprotinin in cardiac surgery, some thirteen
years after it was initially approved for prophylactic treatment to
reduce perioperative blood loss and blood transfusion (Ferguson
2007). Aprotinin was finally removed from world markets in May
2008. The other drugs reviewed here are still in use.
In the light of these developments and in order to inform decisions
about the use of the two lysine analogues as an alternative to apro-
tinin in cardiac surgery we have updated the Cochrane systematic
review of the three anti-fibrinolytic drugs used as blood-sparing
agents in surgery. This review updates previous estimates of the
efficacy of aprotinin, tranexamic acid, and epsilon aminocaproic
acid in reducing perioperative allogeneic blood transfusion in elec-
tive surgery. In light of the adverse findings from pharmaco-epi-
demiological studies we also provide updated estimates of the ef-
fects of these drugs on clinical outcomes such as all-cause mortal-
ity, thrombosis and renal failure.
O B J E C T I V E S
To examine the evidence for the efficacy of aprotinin, tranexamic
acid, and epsilon aminocaproic acid in reducing allogeneic blood
transfusion, and the evidence for any effect on clinical outcomes
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such as mortality and re-operation rates and complications such
as thrombosis and renal failure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) with a concurrent control
group, or randomised head-to-head comparative trials.
Types of participants
The study participants were adults (over 18 years). Trials were in-
cluded if participants aged less than 18 years were enrolled, but
the type of surgery was predominantly carried out in adult pa-
tients. The surgery performedwas primarily elective but trials were
included if urgent cases were proportionately similar across trial
arms.
Types of interventions
The interventions considered are the anti-fibrinolytic agents: apro-
tinin, tranexamic acid (TXA), and epsilon-aminocaproic acid
(EACA).
Types of outcome measures
Primary outcomes
• the proportion of patients who were transfused with
allogeneic blood, autologous blood, or with both;
• the amounts of allogeneic and autologous blood transfused.
Secondary outcomes
• perioperative blood loss,
• re-operation due to bleeding,
• mortality,
• post-operative complications (myocardial infarction, stroke,
deep vein thrombosis, pulmonary embolism, any thrombosis,
renal failure),
• length of hospital stay.
Search methods for identification of studies
We did not limit the searches by date language or publication
status
Electronic searches
The original review drew on the literature search that was con-
structed as part of the International Study on Perioperative Trans-
fusion (ISPOT) (Laupacis 1997). The original search is listed in
full in Appendix 1.
July 2006 update
To maximise the sensitivity for the retrieval of all potentially rel-
evant studies, the electronic searches of MEDLINE were initially
unrestricted and updated to July 2006. In MEDLINE, two search
filters were then used to restrict the electronic searches and improve
the specificity of the updated searches. Firstly, the ISPOT filter,
which identifies blood transfusion trials, and secondly, a modified
versionof theCochraneCollaborationfilter, which primarily iden-
tifies randomised controlled trials. These search filters were cou-
pled with the specifiedMeSH headings and the relevant text-word
terms. These restricted searches were updated in MEDLINE to
July 2006. Electronic database searches of Excerpta Medica (EM-
BASE) were updated to July 2006 using similar search strategies
to those used in MEDLINE.
July 2010 update
Searches were carried out in July 2010 as part of a larger project
to identify trials in the use of antifibrinolytics.
We searched the following databases;
• the Cochrane Injuries Group’s Specialised Register
(searched July 2010),
• Cochrane Central Register of Controlled Trials (The
Cochrane Library 2010, Issue 3),
• MEDLINE (Ovid SP) 1950 to July 2010,
• EMBASE (Ovid SP) 1980 to July 2010.
Full details of the search strategies are presented in Appendix 2.
Searching other resources
The web sites of International Health Technology Assessment
Agencies were also searched through the International Network of
Agencies of Health Technology Assessment (INAHTA), and the
International Society of Technology Assessment in Health Care
(ISTAHC). The Internet waswidely searched usingGoogle™and
Google™ Scholar. Contact was also made with experts in the field
to identify reports or projects in progress relevant to the review.
The reference lists of related reviews and identified articles were
checked for relevant trials. In addition references in the identi-
fied trials were checked and authors contacted, where possible, to
identify any additional published or unpublished data.
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Data collection and analysis
Electronic database searches were carried out by the Cochrane
Injuries Group Trials Search Co-ordinator, who then collated the
results and passed them on to the author (KK).
Selection of studies
The titles and abstracts identified in the electronic searches were
independently screened by two authors to identify trials in which
adult patients, scheduled for elective or urgent surgery, were ran-
domised to either/or aprotinin, TXA, EACAor to a control group,
who did not receive the intervention. From the results of the
screened electronic searches, bibliographic searches, and contacts
with experts, two of the authors independently selected trials that
met previously defined inclusion criteria.
Data extraction and management
At least two authors independently extracted study characteristics
and outcomes using an article extraction form. The extraction
form was used to record information regarding randomisation
criteria, methodology descriptions, the presence of a transfusion
protocol, the type of surgery involved, treatment outcomes, and
general comments.
Data on the following outcomes were recorded on the data extrac-
tion form: the number of patients exposed to allogeneic blood,
the amount of allogeneic blood transfused, the number of patients
receiving any transfusion (allogeneic blood, autologous blood, or
both), the number of patients experiencing post-operative com-
plications (thrombosis, myocardial infarction, renal failure), and
mortality. Data were also recorded on blood loss, and the pro-
portion of patients requiring re-operation for bleeding. Informa-
tion regarding demographics (age, sex), type of surgery, and the
presence or absence of a transfusion protocol was also recorded.
Data were extracted for allogeneic blood transfusion if they were
expressed as whole blood or packed red cells. Data were extracted
regarding dose size for each drug regimen.
Assessment of risk of bias in included studies
Articles that met the inclusion criteria were independently as-
sessed for methodological quality by two authors using criteria
proposed by Schulz 1995. Disagreements were resolved by con-
sensus. Methodological quality scores obtained for each trial us-
ing the criteria proposed by Schulz 1995 were then entered into
Review Manager using the Cochrane Collaboration’s tool for as-
sessing risk of bias presented in Higgins 2009.
The following domains were assessed for each study:
• sequence generation,
• allocation concealment,
• blinding.
We completed a risk of bias table for each study, incorporating a
description of the study’s performance against each of the above
domains andour overall judgement of the risk of bias for each entry
is as follows; ’Yes’ indicates low risk of bias, ’Unclear’ indicates
unknown risk of bias (not enough information was reported to
assess methodological quality); and ’No’ indicates a high risk of
bias.
Assessment of reporting biases
Funnel plots were inspected for evidence of publication bias.
Data synthesis
Extraction of trial data was performed by one author and checked
by the review team’s statistician if necessary. Data were checked
and entered into Review Manager by one author. Articles iden-
tified as duplicate publications were combined to obtain one set
of data. The study report with the greatest number of patients
was then represented in the analysis. Studies that did not report
data for the number or proportion of patients transfused with
allogeneic blood, or the amounts of allogeneic blood transfused,
were not included for review. However, trials not reporting blood
transfusion data that could be used in the meta-analysis were still
included if they reported adverse event data. For dichotomous
outcome data to be included in the analysis, trial reports had to
provide either numeric data, that is the numbers of events that
occurred in the treatment and control groups, or where there were
no events recorded numerically, the trial report had to provide a
clear statement qualifying and/or quantifying specific events had
or had not occurred.
All analyses were performed using ReviewManager software. Data
on the numbers of patients exposed to allogeneic blood, and the
numbers of patients in each treatment arm, were entered into
Review Manager. The relative risks (RR) for allogeneic blood
transfusion in the intervention group as compared with the con-
trol group, and the corresponding 95% confidence intervals (CI),
were calculated for each trial using the random effects model. The
presence of heterogeneity of treatment effect was assessed using
the Q statistic, which has an approximate chi-square distribution
with degrees of freedom equal to the number of studies minus one
(Der Simonian 1986). A P-value less than or equal to 0.1 was used
to define statistically significant heterogeneity. Statistical hetero-
geneity was also assessed using the I² test. The I² test describes the
percentage of total variation across studies due to heterogeneity
rather than chance. A value of 0% indicates no observed hetero-
geneity and larger values show increasing heterogeneity. Substan-
tial heterogeneity is considered to exist when I² > 50% (Higgins
2002).
The mean number of units of allogeneic blood transfused to each
group, and the corresponding standard deviations, were also en-
tered. As the majority of trials reported the means and standard
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deviations for the amount of blood transfused in all patients in
each comparison group, the data included a number of zero values
for those patients not receiving transfusion. The data are there-
fore likely to be highly skewed. Wherever possible, the mean and
standard deviation for the numbers of units of blood transfused
in those receiving transfusion were recalculated. The new mean
was calculated by dividing the total number of units transfused
in the group by the number of patients transfused. The reported
standard deviation and mean were used to calculate the sum of
squares of the numbers of units transfused for the group. As this is
equal to the sum of squares of the numbers of units transfused in
those receiving transfusion, the new standard deviation was calcu-
lated using this, the new mean and the number of patients trans-
fused. Thus the new values estimate the average amount of blood
received by those transfused in each group. The new values were
then entered into Review Manager to obtain the mean difference
(MD) and 95% CIs to express the average reduction in the num-
ber of units of allogeneic blood given to those patients transfused.
Data in millilitres (mls) were converted to units by dividing by
300.
Subgroup analysis and investigation of heterogeneity
Analysis of a-priori subgroups was performed to determine
whether effect sizes varied according to factors such as;
• the type of surgery,
• the use of transfusion protocols,
• dose regimen, and
• trial methodological quality.
The editorial group is aware that a clinical trial by Prof. Joachim
Boldt has been found to have been fabricated (Boldt 2009). As the
editors who revealed this fabrication point out (Reinhart 2011;
Shafer 2011), this casts some doubt on the veracity of other studies
by the same author. All Cochrane Injuries Group reviews which
include studies by this author have therefore been edited to show
the results with this author’s trials included and excluded. Readers
can now judge the potential impact of trials by this author on the
conclusions of the review.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Two hundred and fifty-two trials met the inclusion criteria. Four
trials were excluded (refer to ’Characteristics of excluded studies’
section of this review). Of the 252 included trials, 131 evaluated
aprotinin, 60 evaluated tranexamic acid (TXA), and 12 evaluated
epsilon aminocaproic acid (EACA) versus control. Forty-nine trials
studied head-to-head comparisons of aprotinin, TXA, and EACA
with or without an untreated control. Of these 49 trials, 25 com-
pared aprotinin with TXA, 12 compared aprotinin with EACA,
seven compared TXA with EACA, and five compared aprotinin
with TXA and EACA. Trials were conducted in many countries
including:
United States (n = 45), Germany (n = 24), UK (n = 17), Canada
(n = 17), Italy (n = 16), Spain (n = 14), Belgium (n = 12), France
(n = 10), Turkey (n = 9), Australia (n = 8), Sweden (n = 8),The
Netherlands (n = 8), Japan (n = 7), China (n = 6), Austria (n =
5), Israel (n = 5), Switzerland (n = 5), Finland (n = 5), Czech
Republic (n = 3), Denmark (n = 3), Taiwan (n = 2), Ireland (n
= 2), Greece (n = 2), Poland (n = 2), Brazil (n = 1), Chile (n
= 1), Dubai (n=1), Egypt (n = 1), India (n = 1), Norway (n =
1), Oman (n=1), Saudi Arabia (n=1) and South Africa (n = 1).
Three studies were multicentre trials, one conducted across sites
in the UK and the United States, one in sites in Australia, New
Zealand, Asia and Europe and one in sites in the United States and
Canada. Themajority of included trials were published in English.
Thirteen trials required translation (Carrera 1994; Corbeau 1995;
Cvachovec 2001; Deleuze 1991; Gherli 1992; Hei 2005; Kahveci
1996; Katzel 1998; Kratzer 1997; Locatelli 1990; Maccario 1994;
Trinh-Duc 1992; Utada 1997). The data from these trials were
included in the analysis.
Of the 252 included trials, 173 were conducted in cardiac surgery,
53 trials were in orthopaedic surgery, 14 involved liver surgery, five
were conducted in vascular surgery, four involved thoracic surgery,
one involved gynaecological surgery, one involved neurosurgery,
and one trial was in orthognathic surgery.
The trial conducted by Lemmer 1994 stratified patients according
to the type of procedure being performed, that is, either primary
CABG or redo CABG surgery. Patients from each group were
then randomised to either aprotinin or placebo. The data obtained
from each of these two groups (primary CABG and redo CABG)
have been analysed separately by the authors. Therefore from this
single trial (Lemmer 1994), two comparisons of aprotinin versus
control have been obtained. This review presents the data from
this trial as follows:
(1) Lemmer_1 1994: represents those patients who underwent pri-
mary CABG and were randomised to either aprotinin or placebo.
(2) Lemmer_2 1994: represents those patients who underwent
redo CABG and were randomised to either aprotinin or placebo.
Description of Dose Regimens
Aprotinin dose range
Three dose stratifications were used: (1) high-dose aprotinin, (2)
low-dose aprotinin, and, (3) cardiopulmonary bypass (CPB) pump
prime aprotinin. For the purposes of this review, any aprotinin
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regimen that did not follow the ’full Hammersmith’ regimen, in-
cluding those studies that described their regimens as ’half Ham-
mersmith’, were classified as low-dose aprotinin. For those trials
that did not involve cardiac surgery, classification of the dose-reg-
imen was based on the total quantity of aprotinin administered.
Trials were classified as ’high-dose’ where participants received a
total dose equal to or exceeding five million kallikrein inactivator
units (KIU) or 700mg of aprotinin.
High-dose aprotinin, described as the ’full Hammersmith’ regi-
men, entails an initial loading dose of two million kallikrein inac-
tivator units (KIU) of aprotinin given intravenously (IV) (280mg)
over a 20 to 30 minute period commencing at the induction of
anaesthesia, followed by a continuous infusion of 500,000 KIU
per hour (70mg/hr) until the end of the operation. In addition,
two million KIU of aprotinin (280mg) is added to the oxygenator
prime or pump prime of the CPB. A ’half Hammersmith’ regimen
is described as follows: a loading dose of one million KIU (140mg)
of aprotinin infused over a 20 to 30 minute period followed by
a continuous IV infusion of 250,000 KIU of aprotinin per hour,
until the end of the operation. An additional dose of one million
KIU is added to the pump prime.
’Prime’ dose aprotinin, for the purposes of this review, included
those regimens that added aprotinin to the pump prime solution
of the CPB exclusively. The dose of aprotinin used in the ’prime’
regimen varied between trials. Sixteen trials studied the efficacy
of ’prime’ dose aprotinin and reported data on the proportion of
participants exposed to allogeneic blood transfusion.Of these trials
12 studied a ’prime’ dose of two million KIU of aprotinin, two
studied a ’prime’ dose of onemillionKIUof aprotinin, one studied
a ’prime’ dose of 500,000 KIU of aprotinin, and one trial studied
a ’prime’ dose of 25,000 KIU/kg (range 1.375 to 2.3 million KIU
in total) of aprotinin.
Tranexamic acid (TXA) dose range
Of the 65 trials that studied the efficacy of TXA versus placebo or
control (current standard practice) and were included in the meta-
analysis of allogeneic blood transfusion exposure; 34 involved car-
diac surgery, 27 involved orthopaedic surgery, two involved liver
surgery, one trial involved gynaecological surgery and one trial
involved vascular surgery. Dose regimens for TXA varied signif-
icantly between trials with varying dose sizes and time frames
for drug delivery. Of the 34 trials involving cardiac surgery, the
TXA loading or bolus dose ranged from 2.5mg/kg to 100mg/kg.
The maintenance dose of TXA for the cardiac trials, ranged from
0.25mg/kg/hr to 4.0mg/kg/hr delivered over 1 to 12 hours. Sim-
ilar variation was observed in trials not involving cardiac surgery.
More detailed information regarding dose regimens is provided in
the ’Characteristics of included studies’ section of this review.
Epsilon aminocaproic acid (EACA) dose range
Of the 16 trials that studied the efficacy of EACA versus placebo or
control (current standard practice) and were included in the meta-
analysis of allogeneic blood transfusion exposure; 11 involved car-
diac surgery, four involved orthopaedic surgery, and one involved
liver surgery. Dose regimens for EACA also varied significantly
between trials. Generally trials used different dose sizes and time
frames for drug delivery. The EACA loading or bolus dose ranged
from 80mg to 15g or 75 to 150mg/kg. The maintenance dose of
EACA ranged from 1g/hr to 2g/hr or 12.5mg/kg/hr to 30mg/kg/
hr infused over varying time periods. More detailed information
regarding dose regimens is provided in the ’Characteristics of in-
cluded studies’ section of this review.
Transfusion ’triggers’ / thresholds
Of the 189 trials of aprotinin, TXA, and EACA versus control
included in the analysis of allogeneic blood transfusion exposure,
158 trials (84%) reported the use of a transfusion protocol, the re-
mainder did not report the use of a transfusion protocol. Of those
trials that reported the use of a transfusion protocol, all included a
transfusion “trigger” value, that being the haemoglobin or haema-
tocrit value, at which point a transfusion of allogeneic and/or au-
tologous blood, was considered necessary. There was significant
variation between trials in the type and value of transfusion thresh-
old used. The lowest transfusion threshold level for haemoglobin
was 5.0g/dL with blood being transfused if the haemoglobin level
during CPB fell below 5.0g/dL (Green 1995). The transfusion
protocol used by Brown 1997 advocated a haemoglobin threshold
level of 6.0g/dL during CPB, whereas other trials involving CPB
advocated a haemoglobin threshold level of 7.0g/dL, or haemat-
ocrit levels (Hct) between 18% to 20% during CPB. In general,
post-operative transfusion threshold levels ranged from Hb 7.0g/
dL to 10.0g/dL, or Hct 20% to 30%.
Risk of bias in included studies
For further details regarding the performance of the studies against
each domain, please see the ’Risk of bias’ tables (Figure 1; Figure
2). A summary of the information in the tables is given below.
Additionally, a visual summary of judgements about eachmethod-
ological quality item for each included trial is shown in Figure 1.
7Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Generation of allocation sequences
The method used to generate allocation sequences was judged to
be adequate in only 78 trials. For all but two of the remaining trials
the method used to generate allocation sequences was judged to
be unclear. For two trials the method of randomisation that was
judged to be inadequate. Refer to results presented in the ’Risk of
bias’ tables.
Allocation concealment
Only 79 trials were judged to have adequately concealed treatment
allocation. For 31 trials the method used to conceal treatment
allocation was judged to be inadequate. For the remaining trials
allocation concealment was judged to be unclear. Refer to results
presented in the ’Risk of bias’ tables.
Blinding
For 170 trials blindingwas judged to be adequate (double blinded),
and unclear for 61 trials. Refer to results presented in the ’Risk of
bias’ tables.
Inclusion of all randomised participants
Of those trials able to be assessed for methodological quality, 124
trials either reported there were no exclusions, or used intention-
to-treat analysis. In 80 trials, where exclusions were reported, these
exclusions were judged unlikely to cause bias. For 37 trials exclu-
sions were either judged to be excessive and likely to cause bias, or
were not reported.
Effects of interventions
Aprotinin
There were 108 trials of aprotinin versus control that reported data
on the proportion of patients exposed to allogeneic blood trans-
fusion. These trials included a total of 11,172 patients, of whom
6259were randomised to receive aprotinin and 4913 patients were
randomised to a control group who did not receive aprotinin. The
apparent imbalance between the aprotinin and control groups re-
sulted from pooling data across different aprotinin dose groups
within trials. Overall, the use of aprotinin significantly reduced
the rate of allogeneic blood transfusion by a relative 34% (RR
0.66, 95% CI 0.60 to 0.72) compared to control. Heterogeneity
between these trials was statistically significant (Chi² = 961.52, df
= 107, P <0.00001; I² = 89%). The absolute risk reduction (ARR)
was 20% (RD -0.20, 95% CI -0.24 to -0.17).
Type of surgery
There were 84 trials of aprotinin versus control that involved car-
diac surgery and provided data on the number of patients exposed
to allogeneic blood transfusion. These trials included a total of
9497 patients, of whom 5329 were randomised to receive apro-
tinin and 4168 patients were randomised to a control group who
did not receive aprotinin. Overall, the use of aprotinin in cardiac
surgery significantly reduced the need for allogeneic blood trans-
fusion by a relative 32% (RR 0.68, 95% CI 0.63 to 0.73) com-
pared to control. (The effect with the Boldt 1991 trial excluded
was unchanged (RR 0.68 (95% CI 0.63 to 0.73).) Heterogeneity
between these trials was statistically significant (Chi² = 329.48, df
= 83, P <0.00001; I² = 75%). The ARR was 21% (RD -0.21, 95%
CI -0.24 to -0.18).
There were 15 trials of aprotinin versus control that involved or-
thopaedic surgery and provided data on the number of patients
exposed to allogeneic blood transfusion. These trials included a
total of 1146 patients, of whom 655 were randomised to receive
aprotinin and 491 patients were randomised to a control group
who did not receive aprotinin. Overall, the use of aprotinin in
orthopaedic surgery significantly reduced the need for allogeneic
blood transfusion by a relative 32% (RR 0.68, 95% CI 0.52 to
0.89) compared to control. Heterogeneity between these trials was
statistically significant (Chi² = 45.47, df = 14, P <0.0001; I² =
69%). The ARR was 13% (RD -0.13, 95% CI -0.20 to -0.05).
There were three trials of aprotinin versus control that involved
thoracic surgery and provided data on the number of patients ex-
posed to allogeneic blood transfusion. These trials included a to-
tal of 78 patients, of whom 38 were randomised to receive apro-
tinin and 40 patients were randomised to a control group who
did not receive aprotinin. The use of aprotinin in thoracic surgery
significantly reduced the need for allogeneic blood transfusion by
a relative 71% (RR 0.29, 95% CI 0.14 to 0.59). Heterogeneity
between these trials was not statistically significant (Chi² = 0.37,
df = 2, P = 0.83; I² = 0%).
There were two trials of aprotinin versus control that involved
vascular surgery and provided data on the number of patients
exposed to allogeneic blood transfusion. These trials included a
total of 188 patients, of whom 105 were randomised to aprotinin
and 83 patients were randomised to a control group who did not
receive aprotinin. The use of aprotinin in vascular surgery had
no effect on the need for allogeneic blood transfusion (RR 1.00,
95% CI 0.97 to 1.03). Heterogeneity between these trials was not
statistically significant (Chi² = 0.01, df = 1, P = 0.84; I² = 0%).
There were two trials of aprotinin versus control that involved
liver surgery and provided data on the number of patients exposed
to allogeneic blood transfusion. These trials included a total of
177 patients, of whom 87 were randomised to aprotinin and 90
patients were randomised to a control group who did not receive
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aprotinin. The use of aprotinin in liver surgery reduced the need
for allogeneic blood transfusion by a relative 42% (RR 0.58, 95%
CI 0.37 to 0.90). Heterogeneity between these trials was not sta-
tistically significant (Chi² = 1.03, df = 1, P = 0.31; I² = 3%).
Data from the trials involving neurosurgery, and orthognathic
surgery could not be analysed due to the small number of trials in
each of these surgical subgroups.
Effect of transfusion protocols
There were 87 trials that compared aprotinin with control and
reported the use of transfusion protocols. These trials included a
total of 9974 patients, of whom 5599 were randomised to apro-
tinin and 4375 were randomised to a control group who did not
receive aprotinin. In those trials where a transfusion protocol was
used, aprotinin significantly reduced the need for allogeneic blood
transfusion by a relative 35% (RR 0.65, 95% CI 0.59 to 0.71).
Heterogeneity between these trials was statistical significant (Chi²
= 924.12, df = 86, P < 0.00001; I² = 91%). (The effect was un-
changed with the Boldt 1991 trial excluded (RR 0.65 (95% CI
0.59 to 0.71).)
There were 21 trials of aprotinin versus control that reported data
on the number of patients exposed to allogeneic blood transfusion
but did not report the use of a transfusion protocol. These trials
included a total of 1198 patients, of whom 660 were randomised
to aprotinin and 538 were randomised to a control group who
did not receive aprotinin. The use of aprotinin statistically sig-
nificantly reduced the need for allogeneic blood transfusion by a
relative 29% (RR 0.71, 95% CI 0.61 to 0.84) compared to con-
trol. Heterogeneity between these trials was statistically significant
(Chi² = 49.74, df = 20, P = 0.0002; I² = 60%).
Effect of dose
In those trials that used a low-dose aprotinin regimen the RR of re-
quiring an allogeneic blood transfusion was 0.65 (95% CI 0.55 to
0.77) compared to control.Whereas in those trials that used a high-
dose aprotinin regimen the RR of receiving an allogeneic blood
transfusion was 0.66 (95% CI 0.61 to 0.71) compared to control.
Therefore there was little difference in effect between high-dose
and low-dose aprotinin. In cardiac surgery when aprotinin was
given as a prime-dose only, the RR of requiring allogeneic blood
transfusion was 0.83 (95% CI 0.71 to 0.96). There was statis-
tically significant heterogeneity present in all three subgroups (P
>0.0001; I² >74%).
The study conducted by Green 1995 was not included in this
analysis as it only provided aggregate data for the number of pa-
tients exposed to allogeneic blood transfusion, without stratifying
allogeneic blood transfusion exposure by dose.
When the high-dose analysis excludes the Boldt 1991 trial, the
effect remains 0.66 (95% CI 0.61 to 0.71).
Volume of blood transfused
Seventy-four trials of aprotinin versus control provided data on the
volume of allogeneic blood transfused in all patients. These trials
included a total of 7820 patients, of whom 4198 were randomised
to aprotinin and 3622were randomised to a control groupwho did
not receive aprotinin. The use of aprotinin resulted in a significant
saving of 1.02 units of allogeneic blood (MD -1.02 units, 95%
CI -1.26 to -0.79 units). Heterogeneity between these trials was
statistically significant (Chi² = 1627.35, df = 69, P <0.00001; I²
= 96%).
Forty trials of aprotinin versus control provideddata on the volume
of allogeneic blood transfused in those patients transfused. These
trials provided data for a total of 3563 patients, of whom 1680
were treated with aprotinin and 1883 did not receive aprotinin
treatment. In those patients transfused the use of aprotinin resulted
in a significant saving of 0.98 units of allogeneic blood per patient
(MD -0.98 units, 95% CI -1.29 to -0.66 units). Heterogeneity
between these trials was statistically significant (Chi² = 197.82, df
= 36, P < 0.00001; I² = 82%).
Blood loss - all surgery combined
A total of 16 trials of aprotinin versus control reported intra-oper-
ative blood loss data. These trials included a total of 883 patients,
of whom 449 were randomised to aprotinin and 434 were ran-
domised to a control group. These trials involved cardiac surgery
(n = 7), orthopaedic surgery (n = 5), thoracic surgery (n = 2), liver
surgery (n = 2) and vascular surgery (n = 1). In aggregate, apro-
tinin treatment reduced intra-operative blood loss on average by
around 192 mls per patient (MD -191.87 mls, 95%CI -280.45 to
-103.28 mls). Heterogeneity between these trials was statistically
significant (Chi² = 40.04, df = 16, P = 0.0008; I² = 60%).
A total of 87 trials of aprotinin versus control reported post-opera-
tive blood loss data. These trials included a total of 7896 patients,
of whom 4394 were randomised to aprotinin and 3502 were ran-
domised to a control group. These trials involved cardiac surgery
(n = 75), orthopaedic surgery (n = 7), thoracic surgery (n = 2),
orthognathic surgery (n = 1), liver surgery (n = 1), and vascular
surgery (n = 1). In aggregate, aprotinin treatment significantly re-
duced post-operative blood loss on average by around 346 mls per
patient (MD -345.88 mls, 95% CI -383.47 to -308.29 mls). Het-
erogeneity between these trials was statistically significant (Chi² =
620.49, df = 86, P <0.00001; I² = 86%).
A total of 17 trials of aprotinin versus control reported total blood
loss data (intra-operative and post-operative blood loss combined).
These trials included a total of 1789 patients, of whom 932 pa-
tients were randomised to aprotinin and 857 were randomised to
a control group. These trials involved cardiac surgery (n = 7) and
orthopaedic surgery (n = 10). In aggregate, the use of aprotinin sig-
nificantly reduced perioperative blood loss by around 416 mls per
patient (MD -415.95 mls, 95% CI -520.38 to -311.51 mls). Het-
11Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
erogeneity between these trials was statistically significant (Chi² =
66.96, df = 16, P <0.0001; I² = 76%).
Blood loss - cardiac surgery
Seven trials of aprotinin versus control involving cardiac surgery
reported intra-operative blood loss data. These trials included a
total of 470 patients, of whom 242 were randomised to aprotinin
and 228 were randomised to a control group. Aprotinin treatment
in cardiac surgery appeared to be only marginally effective in re-
ducing intra-operative blood loss (MD -148.18 mls, 95% CI -
240.21 to -56.14 mls). Heterogeneity between these trials was sta-
tistically significant (Chi² = 13.63, df = 6, P = 0.03; I² = 56%).
Seventy-five trials of aprotinin versus control involving cardiac
surgery reported post-operative blood loss data. These trials in-
cluded a total of 7371 patients, of whom 4132 were randomised
to aprotinin and 3239 were randomised to a control group. The
use aprotinin in cardiac surgery reduced post-operative blood loss
on average by 370 mls per patient (MD -369.62 mls, 95% CI -
408.95 to -330.29 mls). Heterogeneity between these trials was
statistically significant (Chi² = 513.91, df = 74, P <0.00001; I² =
86%). The effect excluding the trials Boldt 1991 and Boldt 1994
is MD -378.45 (95% CI -417.99 to -338.92).
Seven trials of aprotinin versus control involving cardiac surgery
reported total blood loss data (intra-operative and post-operative
blood loss combined). These trials included a total of 1359 pa-
tients, of whom 716 were randomised to aprotinin and 643 were
randomised to a control group. The use of aprotinin in cardiac
surgery significantly reduced the total volume of blood lost during
the perioperative period (MD -448.86 mls, 95% CI -612.82 to
-284.91 mls). Heterogeneity between these trials was statistically
significant (Chi² = 42.60, df = 6, P<0.00001; I² = 86%).
Blood loss - orthopaedic surgery
Five trials of aprotinin versus control involving orthopaedic
surgery reported intra-operative blood loss data. These trials in-
cluded a total of 201 patients, of whom 103 were randomised to
aprotinin and 98 were randomised to a control group. The use
of aprotinin in orthopaedic surgery did not reduce the volume of
blood lost during the intra-operative period (MD -151.05 mls,
95%CI -317.63 to 15.52 mls). Heterogeneity between these trials
was not statistically significant (Chi² = 6.62, df = 4, P = 0.16; I² =
40%).
Seven trials of aprotinin versus control involving orthopaedic
surgery reported post-operative blood loss data. These trials in-
cluded a total of 318 patients, of whom 160 were randomised to
aprotinin and 158 were randomised to a control group. The use
of aprotinin in orthopaedic surgery was only marginally effective
in reducing post-operative blood loss (MD -113.58 mls, 95% CI
-223.69 to -3.46 mls). Heterogeneity between these trials was sta-
tistically significant (Chi² = 18.56, df = 6, P = 0.005; I² = 68%).
Ten trials of aprotinin versus control involving orthopaedic surgery
reported total blood loss data (intra-operative and post-operative
blood loss combined). These trials included a total of 430 pa-
tients, of whom 216 were randomised to aprotinin and 214 were
randomised to a control group. Aprotinin reduced the total vol-
ume of blood lost during the perioperative period on average by
around 399 mls per patient (MD -399.09 mls, 95%CI -562.81 to
-235.37 mls). Heterogeneity between these trials was statistically
significant (Chi² = 22.67, df = 9, P = 0.007; I² = 60%).
Re-operation for bleeding
Sixty-one trials of aprotinin versus control reported data on re-op-
eration for bleeding. These trials included a total of 6117 patients,
of whom 3392 were randomised to aprotinin and 2725 were ran-
domised to a control group who did not receive aprotinin. The
use of aprotinin significantly reduced the need for re-operation for
bleeding by a relative 54% (RR 0.46, 95% CI 0.34 to 0.62). Het-
erogeneity between these trials was not significant (Chi² = 35.44,
df = 42, P = 0.75; I² = 0%). The Boldt 1994 trial had no events,
and therefore provided no data to this analysis. When aprotinin
was used in cardiac surgery, the RR of requiring re-operation due
to bleeding was 0.46 (95% CI 0.34 to 0.63). Again heterogeneity
between these trials was not significant (Chi² = 34.56, df = 39, P
= 0.67; I² = 0%).
Mortality
Sixty-three trials of aprotinin versus control reported data on mor-
tality. These trials included a total of 8876 patients, of whom 4889
were randomised to aprotinin and 3987 were randomised to a
control group who did not receive aprotinin. The use of aprotinin
was not associated with an increased risk of death (RR 0.81, 95%
CI 0.63 to 1.06). Heterogeneity between these trials was not sig-
nificant (Chi² = 29.54, df = 43, P = 0.94; I² = 0%). In the case
of cardiac surgery, the use of aprotinin was not associated with an
increased risk of death (RR 0.84, 95% CI 0.64 to 1.10).
Myocardial infarction
Forty-nine trials of aprotinin versus control reported data for my-
ocardial infarction. These trials included a total of 7137 patients,
of whom 4032 were randomised to aprotinin and 3105 were ran-
domised to a control group who did not receive aprotinin. The use
aprotinin did not increase the risk of myocardial infarction (RR
0.87, 95% CI 0.69 to 1.11). Heterogeneity between these trials
was not statistically significant (Chi² = 27.71, df = 38, P = 0.89;
I² = 0%). When aprotinin was used in cardiac surgery, the relative
risk of myocardial infarction was not statistically significant (RR
0.90, 95% CI 0.71 to 1.14).
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Stroke
Twenty-three trials of aprotinin versus control reported data for
stroke. These trials included a total of 3122 patients, of whom
1862 were randomised to aprotinin and 1260 were randomised to
a control group who did not receive aprotinin. The use aprotinin
did not increase the risk of stroke (RR 0.82, 95%CI 0.44 to 1.52).
Heterogeneity between these trials was not statistically significant
(Chi² = 11.97, df = 19, P = 0.89; I² = 0%). The use of aprotinin in
cardiac surgery was not associated with an increased risk of stroke
(RR 0.81, 95% CI 0.40 to 1.67).
Deep vein thrombosis
Sixteen trials of aprotinin versus control reported data for deep
vein thrombosis (DVT). These trials included a total of 1456
patients, of whom854were randomised to aprotinin and 602were
randomised to a control group who did not receive aprotinin. The
use aprotinin did not increase the risk of deep vein thrombosis
(RR 0.78, 95% CI 0.47 to 1.29). Heterogeneity between these
trials was not statistically significant (Chi² = 6.22, df = 11, P =
0.86; I² = 0%). Three cardiac trials reported data for DVT. The
use of aprotinin was not associated with a statistically significant
increased risk of DVT (RR 1.29, 95% CI 0.36 to 4.58).
Pulmonary embolus
Four trials of aprotinin versus control reported data for pulmonary
embolus (PE). These trials included a total of 585 patients, of
whom 304 were randomised to aprotinin and 281 were ran-
domised to a control group who did not receive aprotinin. The
use of aprotinin did not statistically significantly increase the risk
of PE (RR 1.49, 95% CI 0.42 to 5.29).
Renal failure / dysfunction
Twenty-seven trials of aprotinin versus control reported data for
renal failure / dysfunction. These trials included a total of 5185
patients, of whom 2904 were randomised to aprotinin and 2281
were randomised to a control group who did not receive aprotinin.
The use aprotinin did not statistically significantly increase the
risk of renal failure / dysfunction (RR 1.10, 95%CI 0.79 to 1.54).
Heterogeneity between these trials was not statistically significant
(Chi² = 7.64, df = 16, P = 0.96; I² = 0%). Although there appeared
to be a trend toward an increased risk of renal failure/dysfunction
when aprotinin was used in cardiac surgery, the result was not
statistically significant (RR 1.07, 95% CI 0.76 to 1.51).
Length of hospital stay
Twenty-three trials of aprotinin versus control reported data for
hospital length of stay. These trials included a total of 2017 pa-
tients, of whom 1011 were randomised to aprotinin and 1006
were randomised to a control group who did not receive apro-
tinin. Aprotinin treatment did not reduce the length of hospital
stay (MD -0.25 days, 95% CI -0.71 to 0.20 days). Heterogeneity
between these trials was statistically significant (Chi² = 50.13, df
= 22, P = 0.0006; I² = 56%).
Tranexamic acid
Sixty-five trials compared TXA with control, and reported data on
the number of patients exposed to allogeneic blood transfusion.
These trials included a total of 4842 patients, of whom 2528 were
randomised to TXA and 2314 were randomised to a control group
who did not receive TXA. The use of TXA significantly reduced
the need for allogeneic blood transfusion by a relative 39% (RR
0.61, 95% CI 0.53 to 0.70). Heterogeneity between these trials
was statistically significant (Chi² = 249.33, df = 63, P <0.0001; I²
= 75%). This represents an absolute risk reduction of 18% (RD -
0.18, 95% CI -0.22 to -0.14).
Type of surgery
Thirty-four trials of TXA versus control involved cardiac surgery.
These trials included a total of 3006 patients, of whom 1578 were
randomised toTXA, and1428were randomised to a control group
who did not receive TXA. There was a significant 32% relative
reduction in the rate of exposure to allogeneic blood transfusion
in those patients treated with TXA (RR 0.68, 95% CI 0.57 to
0.81). Heterogeneity between these trials was statistically signifi-
cant (Chi² = 137.35, df = 33, P <0.00001; I² = 76%).
Twenty-seven trials of TXA versus control involved orthopaedic
surgery. These trials included a total of 1381 patients of whom of
whom 722 were randomised to TXA and 659 were randomised
to a control group who did not receive TXA. Again there was a
significant RR reduction of 51% in those participants treated with
TXA (RR 0.49, 95% CI 0.39 to 0.62). Heterogeneity between
these trials was statistically significant (Chi² = 53.86, df = 25, P =
0.0007; I² = 54%).
Two trials of TXA versus control involved liver surgery. These trials
included a total of 296 patients of whom 148 were randomised
to TXA and 148 were randomised to a control group who did
not receive TXA. In liver surgery treatment with TXA did not
reduce the risk of receiving an allogeneic blood transfusion (RR
0.16, 95% CI 0.00 to 32.47). Heterogeneity between these trials
was statistically significant (Chi² = 14.23, df = 1, P = 0.0002; I² =
93%).
One trial of TXA versus control involved vascular surgery. This
trial included 59 patients of whom 30 were randomised to TXA
and 29 were randomised to a control group who did not receive
TXA. In vascular surgery treatment with TXA reduced the risk of
receiving an allogeneic blood transfusion (RR 0.56, 95% CI 0.33
to 0.96).
One trial of TXA versus control involved gynaecological surgery.
This trial included 100 patients of whom 50 were randomised to
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TXA and 50 were randomised to a control group who did not
receive TXA. In gynaecological surgery treatment with TXA did
not reduce the risk of receiving an allogeneic blood transfusion
(RR 1.50, 95% CI 0.75 to 3.01).
Effect of transfusion protocols
Fifty-six trials ofTXAversus control reported the use of transfusion
protocols and provided data on the number of patients exposed to
allogeneic blood transfusion. These trials included a total of 4125
patients, of whom 2156 were randomised to TXA and 1969 were
randomised to a control group who did not receive TXA. The
use of TXA reduced the need for allogeneic blood transfusion by
a relative 43% (RR 0.57, 95% CI 0.48 to 0.67). Heterogeneity
between these trials was statistically significant (Chi² = 248.97,
df = 55, P <0.00001; I² = 78%). There were nine trials that did
not report the use of transfusion protocols. These trials included a
total of 717 patients of whom 372 were randomised to TXA and
345 were randomised to a control group. The use of TXA reduced
the need for allogeneic blood transfusion compared to control (RR
0.76, 95% CI 0.61 to 0.96). Heterogeneity between these trials
was statistically significant (Chi² = 15.48, df = 7, P = 0.03; I² =
55%).
Although the baseline rate of transfusion remained relatively con-
stant across both subgroups (transfusion protocol 44% versus no
transfusion protocol 45%) transfusion rates in the intervention
arms was collectively greater in those trials that did not report the
use of a transfusion protocol compared to those trials that did use
a transfusion protocol to guide transfusion practice (37% versus
26%, respectively).
Volume of blood transfused
Twenty-three trials of TXA versus control reported data on the
volume of blood transfused in all patients. These trials included
a total of 1814 patients, of whom 943 were randomised to TXA
and 871 were randomised to a control group. The use of TXA
resulted in a saving of 0.87 units of allogeneic blood per patient
(MD -0.87 units, 95% CI -1.20 to -0.53 units). Heterogeneity
between these trials was statistically significant (Chi² = 154.24, df
= 20, P <0.00001; I² = 87%).
Thirteen trials of TXA versus control provided data on the volume
of blood transfused in those patients transfused. All 481 patients
received allogeneic blood transfusion. The use of TXA did not
statistically significantly reduce the volume of blood transfused
compared to control (MD -0.34 units, 95% CI -0.80 to 0.11
units). Heterogeneity between these trials was statistically signifi-
cant (Chi² = 45.89, df = 12, P < 0.0001; I² = 74%).
Blood loss - all surgery combined
A total of 17 trials of TXA versus control reported intra-operative
blood loss data. These trials included a total of 1173 patients, of
whom 599 were randomised to TXA and 574 were randomised
to a control group. These trials involved cardiac surgery (n = 4),
orthopaedic surgery (n = 12) and gynaecological surgery (n = 1).
In aggregate, TXA treatment reduced intra-operative blood loss
(MD -121.41 mls, 95%CI -180.19 to -62.63 mls). Heterogeneity
between these trials was statistically significant (Chi² = 49.05, df
= 16, P <0.0001; I² = 67%).
A total of 35 trials of TXA versus control reported post-operative
blood loss data. These trials included a total of 2501 patients, of
whom 1285 were randomised to TXA and 1216 were randomised
to a control group. These trials involved cardiac surgery (n = 22)
orthopaedic surgery (n = 12) and gynaecological surgery (n = 1).
In aggregate, TXA treatment significantly reduced post-operative
blood loss on average by around 247 mls per patient (MD -247.17
mls, 95% CI -294.76 to -199.58 mls). Heterogeneity between
these trials was statistically significant (Chi² = 248.36, df = 34, P
<0.00001; I² = 86%).
A total of 28 trials of TXA versus control reported total blood
loss data (intra-operative and post-operative blood loss combined).
These trials included a total of 1712 patients, of whom 875 pa-
tients were randomised to TXA and 837 were randomised to a
control group. These trials involved cardiac surgery (n = 6), or-
thopaedic surgery (n = 20), gynaecological surgery (n = 1) and
liver surgery (n = 1). In aggregate, the use of TXA significantly
reduced perioperative blood loss by around 414 mls per patient
(MD -414.06 mls, 95% CI -525.19 to -302.92 mls). Heterogene-
ity between these trials was statistically significant (Chi² = 249.58,
df = 27, P <0.00001; I² = 89%).
Blood loss - cardiac surgery
Four trials of TXA versus control involving cardiac surgery re-
ported intra-operative blood loss data. These trials included a to-
tal of 244 patients, of whom 138 were randomised to TXA and
106 randomised to a control group. The use of TXA in cardiac
surgery reduced intra-operative blood loss on average by around
167 mls per patient (MD -166.76 mls, 95% CI -331.24 to -2.27
mls). There is some evidence of statistical heterogeneity between
these trials (Chi² = 5.36, df = 3, P = 0.15; I² = 44%).
Twenty-two trials of TXA versus control involving cardiac surgery
reported post-operative blood loss data. These trials included a
total of 1597 patients, of whom 827 were randomised to TXA
and 770 were randomised to a control group. On average, TXA
treatment reduced post-operative blood loss by around 273 mls
per patient compared to control (MD -272.87 mls, 95% CI -
328.85 to -216.89 mls). Heterogeneity between these trials was
statistically significant (Chi² = 83.41, df = 21, P <0.00001; I² =
75%).
Six trials of TXA versus control involving cardiac surgery reported
total blood loss data (intra-operative and post-operative blood loss
combined). These trials included a total of 391 patients, of whom
210 were randomised to TXA and 181 were randomised to a con-
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trol group. TXA treatment reduced the total amount of blood lost
during the perioperative period by around 300 mls per patient
(MD -300.47 mls, 95% CI -470.74 to -130.21 mls). Heterogene-
ity between these trials was statistically significant (Chi² = 12.19,
df = 5, P = 0.03; I² = 59%).
Blood loss - orthopaedic surgery
Twelve trials of TXA versus control involving orthopaedic surgery
reported intra-operative blood loss data. These trials included a
total of 829 patients, of whom 411 were randomised to TXA
and 418 were randomised to a control group. The use of TXA in
orthopaedic surgery reduced intra-operative blood loss by around
116 mls per patient (MD -115.52 mls, 95% CI -187.88 to -43.16
mls).Heterogeneity between these trialswas statistically significant
(Chi² = 42.52, df = 11, P <0.0001; I² = 74%).
Twelve trials of TXA versus control involving orthopaedic surgery
reported post-operative blood loss data. These trials included a
total of 804 patients, of whom 408 were randomised to TXA
and 396 were randomised to a control group. On average, TXA
treatment in orthopaedic surgery reduced post-operative blood
loss by around 229 mls per patient (MD -228.52 mls, 95% CI
-321.76 to -135.27 mls). Heterogeneity between these trials was
statistically significant (Chi² = 125.01, df = 11, P <0.00001; I² =
91%).
Twenty trials of TXA versus control involving orthopaedic surgery
reported total blood loss data (intra-operative and post-operative
blood loss combined). These trials included a total of 1201 pa-
tients, of whom 605 were randomised to TXA and 596 were
randomised to a control group. The use of TXA in orthopaedic
surgery significantly reduced the total amount of blood lost during
the perioperative period (MD -446.19 mls, 95% CI -554.61 to
-337.78 mls). Heterogeneity between these trials was statistically
significant (Chi² = 85.30, df = 19, P <0.00001; I² = 78%).
Re-operation for bleeding
Twenty-seven trials of TXA versus control reported data on re-
operation for bleeding. These trials included a total of 2386 pa-
tients, of whom 1224 were randomised to TXA and 1162 were
randomised to a control group. The use of TXA did not statis-
tically significantly decrease the risk of re-operation for bleeding
(RR 0.80, 95% CI 0.55 to 1.17). Heterogeneity between these
trials was not statistically significant (Chi² = 12.66, df = 23, P =
0.96; I² = 0%). Of the 27 trials of TXA that reported data for this
outcome 26 involved cardiac surgery. Therefore in the context of
cardiac surgery the use of TXA did not statistically significantly
reduce the risk of re-operation for bleeding (RR 0.79, 95% CI
0.54 to 1.17).
Mortality
Thirty trials of TXA versus control reported mortality data. These
trials included a total of 2917 patients, of whom 1478 were ran-
domised to TXA and 1439 were randomised to a control group.
The use of TXA was not associated with an increased risk of death
(RR 0.60, 95% CI 0.33 to 1.10). Heterogeneity between these
trials was not statistically significant (Chi² = 10.00, df = 17, P =
0.90; I² = 0%). Of the 30 trials of TXA that reported data for
mortality 23 involved cardiac surgery. The use of TXA in cardiac
surgery was not associated with an increased risk of death (RR
0.58, 95% CI 0.26 to 1.28).
Myocardial infarction
Twenty-one trials of TXA versus control reported data for myocar-
dial infarction. These trials included a total of 2186 patients, of
whom 1117 were randomised to TXA and 1069 were randomised
to a control group who did not receive TXA. The use of TXA was
not associated with an increased risk of myocardial infarction (RR
0.79, 95% CI 0.41 to 1.52). Heterogeneity between these trials
was not statistically significant (Chi² = 7.84, df = 12, P = 0.80; I²
= 0%). Of the 21 trials of TXA that reported data for myocardial
infarction 19 involved cardiac surgery. The use of TXA in car-
diac surgery did not increase the risk of myocardial infarction (RR
0.74, 95% CI 0.37 to 1.47).
Stroke
Eighteen trials of TXA versus control reported data for stroke.
These trials included a total of 2027 patients, of whom 1050 were
randomised to TXA and 977 were randomised to a control group.
The use of TXA was not associated with a statistically significant
increase in the risk of stroke (RR 1.23, 95% CI 0.49 to 3.07).
Heterogeneity between these trials was not statistically significant
(Chi² =3.18, df = 7, P =0.87; I² = 0%).Of the 18 trials ofTXA that
reported data for this outcome 17 involved cardiac surgery. In this
surgical setting the risk of stroke was not statistically significantly
increased with the use of TXA (RR 1.44, 95% CI 0.53 to 3.91).
Deep vein thrombosis
Twenty-three trials of TXA versus control reported data for deep
vein thrombosis. These trials included a total of 1472, of whom
746 were randomised to TXA and 726 were randomised to a
control group. TXA treatment did not appear to be associated with
an increase in the risk of developing aDVT(RR0.71, 95%CI 0.35
to 1.43). Heterogeneity between these trials was not statistically
significant (Chi² = 5.71, df = 11, P = 0.89; I² = 0%).Of the 23 trials
of TXA that reported data for DVT four involved cardiac surgery.
Of the 422 patients that underwent cardiac surgical procedures
two patients developed a DVT. These were single events occurring
in the control arms of two separate trials.
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Pulmonary embolism
Fourteen trials of TXA versus control reported data for pulmonary
embolism. These trials included a total of 1006 patients, of whom
527 were randomised to TXA and 479 were randomised to a con-
trol group who did not receive TXA. The use of TXA did not
increase the risk of developing a pulmonary embolus (RR 0.67,
95% CI 0.23 to 1.99). Heterogeneity between these trials was not
statistically significant (Chi² = 2.81, df = 7, P = 0.90; I² = 0%).
Of the 16 trials that reported data for pulmonary embolism six
involved cardiac surgery. Of the 569 patients that underwent car-
diac surgical procedures only two patients developed a pulmonary
embolus. As was the case with deep vein thrombosis these were
single events occurring in the control arms of two separate trials.
Renal failure / dysfunction
Nine trials of TXA versus control provided data for renal failure
/ dysfunction. These nine cardiac surgery trials included a total
of 912 patients, of whom 454 were randomised to TXA and 458
were randomised to a control group. Treatment with TXA did not
appear to increase the risk of developing renal failure or renal dys-
function (RR 0.89, 95% CI 0.33 to 2.37). Heterogeneity between
these trials was not statistically significant (Chi² = 2.52, df = 6, P
= 0.87; I² = 0%).
Hospital length of stay
Ten trials of TXA versus control provided data for hospital length
of stay. These trials included a total of 772 patients, of whom 379
were randomised to TXA and 393 were randomised to a control
group. The use of TXA did not significantly impact on the length
of hospital stay (MD -0.34 days, 95%CI -0.82 to 0.13 days). Het-
erogeneity between these trials was statistically significant (Chi² =
18.42, df = 9, P = 0.03; I² = 51%). For the five trials that involved
cardiac surgery the use of TXA did not significantly reduce the
length of hospital stay (MD -0.08 days, 95% CI -0.34 to 0.18
days).
Epsilon aminocaproic acid
Sixteen trials of EACA versus control provided data on the number
of patients exposed to allogeneic blood transfusion. These trials
included a total of 1035 patients, of whom 530 were randomised
to EACA and 505 were randomised to a control who did not
receive EACA.The use of EACA significantly reduced the need for
allogeneic blood transfusion by a relative 19% (RR 0.81, 95% CI
0.67 to 0.99). Heterogeneity between these trials was statistically
significant (Chi² = 41.12, df = 15, P = 0.0003; I² = 64%). This
represents an absolute risk reduction of 10% (RD -0.10, 95% CI
-0.18 to -0.03).
Type of surgery
Eleven trials of EACA versus control involved cardiac surgery.
These trials included a total of 649 patients, of whom 338 were
randomised toEACAand311were randomised to a control group.
When used in cardiac surgery EACA reduced the need for allo-
geneic blood transfusion by a relative 30% (RR 0.70, 95% CI
0.52 to 0.93). There is some evidence of statistical heterogene-
ity between these trials (Chi² = 16.38, df = 10, P = 0.09; I² =
39%). Four trials of EACA versus control involved orthopaedic
surgery. These trials included a total of 304 patients, of whom
150 were randomised to EACA and 154 patients were randomised
to a control group. The use of EACA in orthopaedic surgery did
not reduce the need for allogeneic blood transfusion compared to
control (RR 1.00, 95% CI 0.93 to 1.08). Heterogeneity between
these trials was not statistically significant (Chi² = 1.01, df = 3, P
= 0.80; I² = 0%). One trial of EACA involved liver surgery. For
this single trial the relative risk of requiring an allogeneic blood
transfusion was 0.93 (95% CI 0.80 to 1.08).
Effect of transfusion protocols
Of the 16 trials of EACA versus control that provided data for
the number of patients exposed to allogeneic blood transfusion,
15 reported the use of a transfusion protocol to guide transfusion
practice. Therefore stratification of the data by the presence or
absence of a transfusion protocol was uninformative.
Volume of blood transfused
Six trials of EACA versus control provided data for the volume
of blood transfused in all patients. These trials included a total of
432 patients, of whom 215 were randomised to EACA and 217
were randomised to a control group who did not receive EACA.
On average, the use of EACA reduced the volume of allogeneic
blood transfused by 1.3 units per patient (MD -1.30 units, 95%
CI -2.14 to -0.45 units). Heterogeneity between these trials was
statistically significant (Chi² = 23.45, df = 5, P = 0.0003; I² =
79%). Three trials of EACA versus control provided data for the
volume of blood transfused in those patients transfused. When the
volume of allogeneic blood transfused was assessed in only those
patients that actually received a blood transfusion the use of EACA
did not reduce the amount of blood transfused (MD 0.22 units,
95% CI -0.34 to 0.79 units). Heterogeneity between these trials
was not statistically significant (Chi² = 0.56, df = 2, P = 0.76; I² =
0%).
Blood loss - all surgery combined
Five trials of EACA versus control reported intra-operative blood
loss data. These trials included a total of 353 patients, of whom
175 were randomised to EACA and 178 were randomised to a
control group. These trials involved cardiac surgery (n = 2) and
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orthopaedic surgery (n = 3). In aggregate, EACA treatment re-
duced the amount of blood lost during the intra-operative period
by around 157mls per patient (MD -156.63 mls, 95%CI -276.92
to -36.33 mls). Heterogeneity between these trials was not statis-
tically significant (Chi² = 5.01, df = 4, P = 0.29; I² = 20%).
Fourteen trials of EACA versus control reported post-operative
blood loss data. These trials included a total of 1174 patients, of
whom 580 were randomised to EACA and 594 were randomised
to a control group. These trials involved cardiac surgery (n = 12)
and orthopaedic surgery (n = 2). In aggregate, EACA treatment
reduced post-operative blood loss on average by 207 mls per pa-
tient (MD -207.49 mls, 95% CI -276.43 to -138.54 mls). Het-
erogeneity between these trials was statistically significant (Chi² =
97.46, df = 13, P < 0.00001; I² = 87%).
Two trials of EACA versus control reported total blood loss data
(intra-operative and post-operative blood loss combined). These
orthopaedic trials included a total of 92 patients, of whom 44 were
randomised to EACA and 48 were randomised to a control group.
The use of EACA in orthopaedic surgery was only marginally
effective in reducing blood loss during the perioperative period
(MD -299.69 mls, 95%CI -522.54 to -76.84 mls). Heterogeneity
between these trials was not statistically significant (Chi² = 0.73,
df = 1, P = 0.39; I² = 0%).
Blood loss - cardiac surgery
Two trials of EACA versus control involving cardiac surgery re-
ported intra-operative blood loss data. These trials included a total
of 79 patients, of whom 40 patients were randomised to EACA
and 39 were randomised to a control group. On average, the use of
EACA in cardiac surgery reduced the amount of blood lost during
the intra-operative period by around 214 mls per patient (MD -
213.58, 95% CI -310.03 to -117.13 mls). Heterogeneity between
these trials was not statistically significant (Chi² = 0.12, df = 1, P
= 0.73; I² = 0%).
Twelve trials of EACA versus control involving cardiac surgery
reported post-operative blood loss data. These trials included a
total of 946 patients, of whom 467 were randomised to EACA
and 479 were randomised to control group who did not receive
EACA treatment. The use of EACA in cardiac surgery reduced
the amount of blood lost during the post-operative period on
average by around 200 mls per patient (MD -200.27 mls, 95%CI
-273.44 to -127.09 mls). Heterogeneity between these trials was
statistically significant (Chi² = 97.18, df = 11, P <0.00001, I² =
89%).
Blood loss - orthopaedic surgery
Three trials of EACA versus control involving orthopaedic surgery
provided intra-operative blood loss data. These trials included a
total of 274 patients, of whom 135 were randomised to EACA
and 139 were randomised to a control group. EACA treatment
in orthopaedic surgery did not reduce the amount of blood lost
during the intra-operative period (MD -40.66 mls, 95% CI -
236.71 to 155.38 mls). Heterogeneity between these trials was not
statistically significant (Chi² = 2.10, df = 2, P = 0.35; I² = 5%).
Two trials of EACA versus control involving orthopaedic surgery
reported post-operative blood loss. These trials included a total
of 228 patients, of whom 113 were randomised to EACA and
115 were randomised to a control group. The use of EACA in
orthopaedic surgery reduced blood loss during the post-operative
period by around 285 mls per patient (MD -285.06 mls, 95% CI
-452.73 to -117.39 mls). Heterogeneity between these trials was
not statistically significant (Chi² = 0.18, df = 1, P = 0.67; I² = 0%).
Two trials of EACA versus control involving orthopaedic surgery
reported total blood loss data (intra-operative and post-operative
blood loss combined). These trials included a total of 92 patients,
ofwhom44were randomised toEACAand48were randomised to
a control group. The use of EACA in orthopaedic surgery reduced
blood loss during the perioperative period by around 300 mls
per patient (MD -299.69 mls, 95% CI -522.54 to -76.84 mls).
Heterogeneity between these trials was not statistically significant
(Chi² = 0.73, df = 1, P = 0.39; I² = 0%).
Re-operation for bleeding
Eight trials of EACA versus control reported data on the number of
patients requiring re-operation for bleeding. These trials included
a total of 922 patients, of whom 470 were randomised to EACA
and452were randomised to a control group.The use of EACAwas
not associated with an increased risk of re-operation compared to
control (RR 0.32, 95% CI 0.11 to 0.99). Heterogeneity between
these trials was not statistically significant (Chi² = 1.84, df = 5, P
= 0.87, I² = 0%). Of the eight trials of EACA that reported data
on re-operations, seven involved cardiac surgery. In this surgical
setting the use of EACA did not increase the risk of re-operation
(RR 0.35, 95% CI 0.11 to 1.17).
Mortality
Eight trials of EACA versus control reported data on mortality.
These trials included a total of 988 patients, of whom 504 were
randomised toEACAand484were randomised to a control group.
The use of EACA was not associated with a statistically significant
increased risk of death compared to control (RR1.07, 95%CI0.44
to 2.57). Heterogeneity between these trials was not statistically
significant (Chi² = 2.30, df = 5, P = 0.81; I² = 0%). Of the eight
trials of EACA that reported data on mortality six involved cardiac
surgery. In this surgical setting the use of EACAdid not statistically
significantly increase the risk of death (RR 1.65, 95% CI 0.50 to
5.43).
Myocardial infarction
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Seven trials of EACA versus control reported data for myocar-
dial infarction. These trials included a total of 896 patients, of
whom 456 were randomised to EACA and 440 were randomised
to a control group. The use of EACA was not associated with an
increased risk of myocardial infarction compared to control (RR
0.88, 95% CI 0.48 to 1.63). Heterogeneity between these trials
was not statistically significant (Chi² = 3.44, df = 4, P = 0.49; I² =
0%). Of the seven trials of EACA that reported data on myocar-
dial infarction six involved cardiac surgery. In this surgical setting
the use of EACA did not increase the risk of myocardial infarction
(RR 0.88, 95% CI 0.48 to 1.63).
Stroke
Eight trials of EACA versus control reported data for stroke. These
trials included a total of 936 patients, of whom 477 were ran-
domised to EACA and 459 were randomised to a control group.
The use of EACAwas not associatedwith an increased risk of stroke
compared to control (RR 0.62 95% CI 0.16 to 2.36). Hetero-
geneity between these trials was not statistically significant (Chi²
= 1.84, df = 4, P = 0.77; I² = 0%). Of the eight trials of EACA
that reported data on stroke, seven involved cardiac surgery. In
this surgical setting the use of EACA did not increase the risk of
stroke (RR 0.70, 95% CI 0.16 to 3.10).
Deep vein thrombosis
Four trials of EACA versus control reported data for DVT. These
trials included a total of 304 patients, of whom 150 were ran-
domised to EACA and 154 were randomised to a control group.
The use of EACAwas not associatedwith an increased risk ofDVT
compared to control (RR 0.78, 95% CI 0.20 to 3.03). Hetero-
geneity between these trials was not statistically significant (Chi²
= 1.02, df = 1, P = 0.31; I² = 2%).
Pulmonary embolism
Three trials of EACA versus control provided data for pulmonary
embolism. These trials included a total of 274 patients, of whom
135 were randomised to EACA and 139 were randomised to a
control group. The use of EACA was not associated with an in-
creased risk of pulmonary embolism compared to control (RR
0.34, 95% CI 0.06 to 2.13). Heterogeneity between these trials
was not statistically significant (Chi² = 0.00, df = 1, P = 0.97; I² =
0%).
Renal failure / dysfunction
Two trials of EACA versus control reported data for renal failure
/ dysfunction. These trials included a total of 235 patients, of
whom 117 were randomised to EACA and 118 were randomised
to a control group. The use of EACA was not associated with an
increased risk of renal failure / dysfunction (RR 0.41, 95%CI 0.14
to 1.22). Heterogeneity between these trials was not statistically
significant (Chi² = 0.48, df = 1, P = 0.49; I² = 0%).
Hospital length of stay
Two trials of EACA versus control reported data for hospital length
of stay. These trial included a total of 228 patients, of whom 113
were randomised to EACA and 115 were randomised to a control
group. The use of EACA did not impact of the length of hospital
stay (MD 0.58 days, 95% CI -3.17 to 4.33 days). Heterogeneity
between these trials was statistically significant (Chi² = 3.13, df =
1, P = 0.08; I² = 68%).
Aprotinin versus tranexamic acid
Twenty-one trials of aprotinin versus TXA reported data on the
number of patients exposed to allogeneic blood transfusion. These
trials included a total of 4185 patients, of whom 2124 were ran-
domised to aprotinin and 2061 were randomised to TXA. There
was no statistically significant difference in the rates of allogeneic
blood transfusion between those patients treated with aprotinin
compared to those treated with TXA (RR 0.90, 95% CI 0.81 to
1.01). Heterogeneity between these trials was statistically signifi-
cant (Chi² = 60.78, df = 20, P <0.0001; I² = 67%). The effect with
Mengistu 2008 excluded was RR 0.92 (95% CI 0.82 to 1.02).
Type of surgery
Eighteen of the 21 trials of aprotinin versus TXA that reported
data on the number patients exposed to allogeneic blood transfu-
sion involved cardiac surgery. These trials included a total of 3983
patients, of whom 2025 were randomised to aprotinin and 1958
were randomised to TXA. Compared to TXA, aprotinin reduced
the rate of allogeneic blood transfusion (RR 0.87, 95% CI 0.76 to
0.99). Heterogeneity between these trials was statistically signifi-
cant (Chi² = 45.01, df = 17, P = 0.0002; I² = 62%). When data
from Mengistu 2008 were excluded, RR was 0.88 (95% CI 0.78
to 1.01).
Effect of transfusion protocols
Of the 21 trials of aprotinin versus TXA that reported data on the
number patients exposed to allogeneic blood transfusion, all but
one reported the use of a transfusion protocol to guide transfusion
practice. Therefore stratification of the data by the presence or
absence of a transfusion protocol proved uninformative.
Volume of blood transfused
Ten trials of aprotinin versus TXA provided data on the volume of
allogeneic blood transfused in all patients. These trials included a
total of 992 patients, of whom 496 were randomised to aprotinin
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and 496 were randomised to TXA. There was a small but statis-
tically significant difference between aprotinin and TXA in the
volume of allogeneic blood transfused (MD -0.24 units, 95% CI
-0.45 to -0.04 units). Heterogeneity between these trials was not
statistically significant (Chi² = 10.87, df = 9; P = 0.28; I² = 17%).
(When data from Mengistu 2008 were removed, MD was -0.21
units, 95% CI -0.39 to -0.02 units). Six trials of aprotinin versus
TXA provided data on the volume of allogeneic blood transfused
in those patients transfused. These trials provided data for 207
transfused patients, of whom 97 were treated with aprotinin and
110 were treated with TXA. There was no statistically significant
difference between aprotinin and TXA in the volume of allogeneic
blood transfused in those patients transfused (MD -0.07 units,
95% CI -0.44 to 0.30 units). Heterogeneity between these trials
was not statistically significant (Chi² = 0.97, df = 5, P = 0.97; I² =
0%).
Blood loss
Thirteen trials of aprotinin versus TXA involving cardiac surgery
provided data for post-operative blood loss. These trials included a
total of 831 patients, of whom 412 were randomised to aprotinin
and419were randomised toTXA.Onaverage, aprotinin appeared
to be more effective in reducing post-operative blood loss than
TXA (MD -145.81 mls, 95% CI -209.99 to -81.62 mls). Het-
erogeneity between these trials was statistically significant (Chi² =
33.86, df = 12, P = 0.0007; I² = 65%). (When data fromMengistu
2008 were removed, MD was -131.54 mls, 95% CI -192.15 to -
70.94 mls.)
Re-operation for bleeding
Seventeen trials of aprotinin versus TXA provided data on the
number of patients requiring re-operation for bleeding. These tri-
als included a total of 4010 patients, of whom 2005 were ran-
domised to aprotinin and 2005 were randomised to TXA. Apro-
tinin appeared to reduce the need for re-operation compared to
TXA (RR 0.69, 95% CI 0.51 to 0.93). Heterogeneity between
these trials was not statistically significant (Chi² = 8.90, df = 13,
P = 0.78; I² = 0%). The BART study (Fergusson 2008) provided
61.4% (weight) of the information for this outcome.
Mortality
Seventeen trials of aprotinin versus TXA reported mortality data.
These trials included a total of 4130 patients, of whom 2060
were randomised to aprotinin and 2070 were randomised to TXA.
There was no statistically significant difference between aprotinin
andTXA (RR1.35, 95%CI 0.94 to 1.93).Heterogeneity between
these trials was not statistically significant (Chi² = 6.78, df = 9, P
= 0.66, I² = 0%). BART study data (Fergusson 2008) dominated
the analysis of this outcome (65.5% weight).
Myocardial infarction
Thirteen trials of aprotinin versus TXA reported data for my-
ocardial infarction. These trials included a total of 3574 patients,
of whom 1778 were randomised to aprotinin and 1796 were
randomised to TXA. There was statistically significant difference
between aprotinin and TXA (RR 1.00, 95% CI 0.71 to 1.42).
Heterogeneity between these trials was not statistically significant
(Chi² = 6.18, df = 10, P = 0.80; I² = 0%). The BART study
(Fergusson 2008) provided 49.6% (weight) of the information for
this outcome.
Stroke
Six trials of aprotinin versus TXA reported data for stroke. These
trials include a total of 2030 patients of whom 1017 were ran-
domised to aprotinin and 1013 were randomised to TXA. There
was no statistically significant difference between aprotinin and
TXA (RR 0.88, 95% CI 0.52 to 1.47). Heterogeneity between
these trials was not statistically significant (Chi² = 1.91, df = 4, P
= 0.75; I² = 0%). BART study data (Fergusson 2008) dominated
the analysis of this outcome (88.5% weight).
Renal failure / dysfunction
Six trials of aprotinin versus TXA reported data for renal failure
/ dysfunction. These trials included a total of 2238 patients, of
whom 1119 were randomised to aprotinin and 1119 were ran-
domised to TXA. There was no statistically significant difference
between aprotinin and TXA (RR 1.02, 95% CI 0.79 to 1.31).
Heterogeneity between these trials was not statistically significant
(Chi² = 1.20, df = 3, P = 0.75; I² = 0%). BART study data
(Fergusson 2008) dominated the analysis of this outcome (94.5%
weight).
Hospital length of stay
Six trials of aprotinin versus TXA reported data for hospital length
of stay. These trials include a total of 2174 patients, of whom 1090
were randomised to aprotinin and 1084 were randomised to TXA.
There was no statistically significant difference between aprotinin
andTXA (MD-0.05, 95%CI -0.92 to 0.83 days). There was some
evidence of statistical heterogeneity between these trials (Chi² =
9.14, df = 5, P = 0.10; I² = 45%).
Aprotinin versus epsilon aminocaproic acid
Twelve trials of aprotinin versus EACA reported data on the num-
ber of patients exposed to allogeneic blood transfusion. These tri-
als included a total of 2200 patients, of whom 1102 were ran-
domised to aprotinin and 1098 were randomised to EACA. The
use of aprotinin significantly reduced the rate of allogeneic blood
transfusion compared to EACA (RR 0.82, 95% CI 0.76 to 0.89).
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Heterogeneity between these trials was not statistically significant
(Chi² = 9.33, df = 11, P = 0.59; I² = 0%).
Type of surgery
Of the 12 trials of aprotinin versus EACA that reported data on
the number of patients exposed to allogeneic blood transfusion,
10 involved cardiac surgery and two involved orthopaedic surgery.
Compared to EACA, aprotinin reduced the rate of allogenic blood
transfusion in cardiac surgery (RR 0.82, 95% CI 0.76 to 0.89)
but not in orthopaedic surgery (RR 0.82, 95% CI 0.48 to 1.40).
Effect of transfusion protocols
Of the 12 trials of aprotinin versus EACA that reported data on
the number of patients exposed to allogeneic blood transfusion,
nine reported the use of a transfusion protocol to guide transfusion
practice and three did not. For the nine trials that reported the use
of a transfusion protocol, aprotinin reduced the rate of allogeneic
blood transfusions compared toEACAby a relative 18% (RR0.82,
95% CI 0.76 to 0.89). Heterogeneity between these trials was not
statistically significant (Chi² = 6.45, df = 8, P = 0.60; I² = 0%). For
those trials that did not report the use of a transfusion protocol
therewas no statistically significant difference aprotinin andEACA
(RR 0.78, 95% CI 0.47 to 1.31). Heterogeneity between these
trials was not statistically significant (Chi² = 2.86, df = 2, P = 0.24;
I² = 30%).
Volume of blood transfused
Five trials of aprotinin versus EACA reported data for the volume
of allogeneic blood transfused in all patients. These trials included
a total of 329 patients, of whom 166 were randomised to aprotinin
and 163 were randomised to EACA. There was no statistically
significant difference between aprotinin and EACA (MD -0.21
units, 95% CI -0.55 to 0.14 units). Heterogeneity between these
trials was not statistically significant (Chi² = 5.14, df = 4, P = 0.27;
I² = 22%). Two trials of aprotinin versus EACA provided data
for the volume of allogeneic blood transfused in those patients
transfused. These trials included a total of 63 transfused patients,
of whom 28 were treated with aprotinin and 35 were treated with
EACA. There was no statistically significant difference between
aprotinin and EACA treatment (MD -0.18 units, 95%CI -0.63 to
0.28 units). Heterogeneity between these trials was not statistically
significant (Chi² = 0.66, df = 1, P = 0.41; I² = 0%).
Blood loss
There were seven trials of aprotinin versus EACA involving cardiac
surgery that reported post-operative blood loss data. These trials
included a total of 454 patients, of whom 230 were randomised to
aprotinin and 224 were randomised to EACA. Aprotinin appeared
to be marginally more effective in reducing post-operative blood
loss than EACA (MD -111.43 mls, 95% CI -220.64 to -2.21
mls).Heterogeneity between these trialswas statistically significant
(Chi² = 25.74, df = 6, P = 0.0002; I² = 77%).
Re-operation for bleeding
Six trials of aprotinin versus EACA reported data on the number of
patients requiring re-operation for bleeding. These trials included
a total of 2075 patients, of whom 1034 were randomised to apro-
tinin and 1041 were randomised to EACA. Although aprotinin
appeared to be more effective than EACA in reducing the number
patients requiring re-operation due to bleeding the difference did
not reach statistical significance (RR 0.70, 95% CI 0.49 to 1.00).
Heterogeneity between these trials was not statistically significant
(Chi² = 0.93, df = 2, P = 0.63; I² = 0%). However, the data from
the BART study (Fergusson 2008) provided 90.1% of the infor-
mation (weight) for this outcome. The results of this one trial
showed that aprotinin was statistically significantly more effective
than EACA in reducing the risk of re-operation for bleeding (RR
0.67, 95% CI 0.46 to 0.98).
Mortality
There were five trials of aprotinin versus EACA that reported mor-
tality data. These trials included a total of 1891 patients, of whom
949 were randomised to aprotinin and 942 were randomised to
EACA. Although the result failed to reach statistical significance,
there appeared to be a trend toward an increased risk of death
in the aprotinin group compared to EACA (RR 1.51, 95% CI
0.99 to 2.30). Again, the results of the BART study (Fergusson
2008) provided most of the information for this outcome (89.9%
weight). Heterogeneity between these trials was not statistically
significant (Chi² = 0.26, df = 3, P = 0.97; I² = 0%).
Myocardial infarction
Four trials of aprotinin versus EACA reported data for myocardial
infarction. These trials included a total of 1676 patients, of whom
830 were randomised to aprotinin and 846 were randomised to
EACA. There was no statistically significant difference in the risk
of myocardial infarction between aprotinin and EACA (RR 1.42,
95% CI 0.90 to 2.22). Heterogeneity between these trials was
not statistically significant (Chi² = 1.27, df = 3, P = 0.74; I² =
0%). Data from the BART study (Fergusson 2008) dominated
this outcome (68.2% weight).
Stroke
Two trials of aprotinin versus EACA reported data for stroke (cere-
brovascular accident). These trials included a total of 1578 pa-
tients, of whom 785 were randomised to aprotinin and 793 were
randomised to EACA.There was no difference in the risk of stroke
between aprotinin and EACA (RR 1.05, 95% CI 0.60 to 1.85).
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Heterogeneity between these trials was not statistically significant
(Chi² = 0.27, df = 1, P = 0.60; I² = 0%). The BART study
(Fergusson 2008) results provided 94.2% of the information for
this outcome.
Deep vein thrombosis
Four trials of aprotinin versus EACA reported data for deep vein
thrombosis. These trials included a total of 300 patients, of whom
153 were randomised to aprotinin and 147 were randomised to
EACA.One trial reported three cases ofDVTall ofwhich occurred
in EACA treated patients (RR 0.14, 95% CI 0.01 to 2.51). There
were no reported cases of DVT in the three remaining trials.
Pulmonary embolism
Three trials of aprotinin versus EACA reported data for pulmonary
embolism. These trials included a total of 270 patients, of whom
138 were randomised to aprotinin and 132 were randomised to
EACA. Three events of pulmonary embolism were reported; two
in aprotinin treated patients and one in EACA treated patients.
There was no statistically significant difference between aprotinin
and EACA treatment (RR 1.33, 95% CI 0.10 to 18.42). Hetero-
geneity between these trials was not statistically significant (Chi²
= 1.45, df = 1, P = 0.23; I² = 31%).
Renal failure / dysfunction
Two trials of aprotinin versus EACA reported data for renal failure
/ dysfunction. These trials included a total of 1595 patients, of
whom796were randomised to aprotinin and799were randomised
to EACA. Although the analysis was dominated by the data from
the BART study (71.6% weight) there was no statistically signif-
icant difference between aprotinin and EACA in the number pa-
tients experiencing renal failure / dysfunction (RR 1.33, 95% CI
0.59 to 2.99). Heterogeneity between these trials was moderate
(Chi² = 2.12, df = 1, P = 0.15; I² = 53%).
Hospital length of stay
Two trials of aprotinin versus EACA reported data for hospital
length of stay. These trials included a total of 1605 patients, of
whom 803 were randomised to aprotinin and 802 patients were
randomised to EACA. There was no statistically significant dif-
ference between aprotinin and EACA (MD -0.49 days, 95% CI -
1.74 to 0.77 days).
Tranexamic acid versus epsilon aminocaproic acid
Eight trials provided direct ’head-to-head’ comparisons of TXA
and EACA and reported data on the number of patients exposed
to allogeneic blood transfusion. These trials included a total of
2003 patients, of whom 1000 were randomised to TXA and 1003
were randomised to EACA. There was no statistically significant
difference betweenTXA andEACA in the rates of allogeneic blood
transfusion (RR 0.97, 95% CI 0.77 to 1.21). Heterogeneity be-
tween these trials was statistically significant (Chi² = 14.01, df =
7, P = 0.05; I² = 50%). All eight trials included in this analysis
reported the use of a transfusion protocol to guide transfusion
practice. Six of the eight trials included in this analysis involved
cardiac surgery. A subgroup analysis of the data from these cardiac
trials showed that the relative risk of receiving an allogeneic blood
transfusion in patients treated with TXA compared to patients
treated with EACA was 1.07 (95% CI 0.79 to 1.46).
Volume of blood transfused
Three trials of TXA versus EACA provided data for the volume of
allogeneic blood transfused in all patients. These trials included
a total of 268 patients, of whom 136 were randomised to TXA
and 132 were randomised to EACA. There was no statistically
significant difference between TXA and EACA (MD -0.28 units,
95% CI -0.59 to 0.03 units). Heterogeneity between these trials
was not statistically significant (Chi² = 0.96, df = 2, P = 0.62; I²
= 0%). Four trials of TXA versus EACA provided data for the
volume of allogeneic blood transfused to those patients transfused.
These trials included a total of 133 patients, of whom 59 were
randomised to TXA and 74 were randomised to EACA. Again
there was no statistically significant difference between TXA and
EACA treatment (MD -0.34 units, 95% CI -0.74 to 0.07 units).
Heterogeneity between these trials was not statistically significant
(Chi² = 0.12, df = 2, P = 0.94; I² = 0%).
Blood loss
Six trials of TXA versus EACA involving cardiac surgery reported
post-operative blood loss data. These trials included a total of 402
patients, of whom 209 were randomised to TXA and 193 were
randomised to EACA. There was no difference between TXA and
EACA in the volume of blood lost during the post-operative period
(MD -4.36 mls, 95% CI -163.35 to 154.63 mls). Heterogeneity
between these trials was statistically significant (Chi² = 33.81, df
= 5, P <0.00001; I² = 85%).
Re-operation for bleeding
Five trials of TXA versus EACA provided data on re-operation for
bleeding. These trials included a total of 1853 patients, of whom
922 were randomised to TXA and 931 were randomised to EACA.
There was no statistically significant difference between TXA and
EACA (RR 1.00, 95% CI 0.73 to 1.39). Heterogeneity between
these trials was not statistically significant (Chi² = 1.81, df = 3, P
= 0.61; I² = 0%). The data of the BART study (Fergusson 2008)
dominated the results of this analysis (93.4% weight).
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Mortality
Five trials of TXA versus EACA provided mortality data. These
trials included a total of 1958 patients, of whom 980 were ran-
domised to TXA and 978 were randomised to EACA. There was
no statistically significant difference betweenTXA and EACA (RR
0.93, 95% CI 0.59 to 1.47). Heterogeneity between these trials
was not statistically significant (Chi² = 1.43, df = 3, P = 0.70; I²
= 0%).The data of the BART study (Fergusson 2008) dominated
the results of this analysis (86.8% weight).
Myocardial infarction
Three trials of TXA versus EACA reported data for myocardial
infarction. These trials included a total of 1687 patients, of whom
840 were randomised to TXA and 847 were randomised to EACA.
There was no statistically significant difference between TXA and
EACA (RR 1.33, 95% CI 0.80 to 2.23). Heterogeneity between
these trials was not statistically significant (Chi² = 0.62, df = 2, P
= 0.73; I² = 0%). The data of the BART study (Fergusson 2008)
dominated the results of this analysis (82.9% weight).
Stroke
Three trials of TXA versus EACA reported data for stroke (cere-
brovascular accident). These trials included a total of 1658 pa-
tients, of whom 820 were randomised to TXA and 838 were ran-
domised to EACA. There was no statistically significant differ-
ence between TXA and EACA (RR 1.33, 95% CI 0.78 to 2.29).
Heterogeneity between these trials was not statistically significant
(Chi² = 0.30, df = 1, P = 0.58; I² = 0%). The data of the BART
study (Fergusson 2008) provided 97.1% (weight) of the informa-
tion for this analysis.
Pulmonary embolism
Three trials of TXA versus EACA reported data for pulmonary
embolism. These trials included a total of 284 patients, of whom
150 were randomised to TXA and 134 were randomised to EACA.
There was only one reported case of pulmonary embolism, this
occurred in EACA treated patients.
Renal failure / dysfunction
Only the BART study (Fergusson 2008) provided data on renal
failure / dysfunction in patients treated with either TXA or EACA.
The results of the BART study showed that there was no statisti-
cally significant difference between TXA and EACA in the rates of
patients experiencing renal failure / dysfunction (RR 0.98, 95%
CI 0.76 to 1.27).
Hospital length of stay
Only the BART study (Fergusson 2008) hospital length of stay
data in patients treated with either TXA or EACA. The results of
the BART study showed that there was no statistically significant
difference between TXA and EACA in the length of hospital stay
(MD -0.64 days, 95% CI -1.82 to 0.54 days).
Aprotinin versus either lysine analogue
Thirty trials of aprotinin versus either TXA or EACA provided
data on the number of patients exposed to allogeneic blood trans-
fusion. These trials included a total of 5566 patients, of whom
2407 were randomised to aprotinin and 3159 were randomised
to a lysine analogue. The use of aprotinin reduced the need for
allogeneic blood transfusion by a relative 10% (RR 0.90, 95% CI
0.81 to 0.99). Heterogeneity between these trials was statistically
significant (Chi² = 70.06, df = 29 (P < 0.0001; I² = 59%). (When
data from Mengistu 2008 were removed, RR was 0.91 (95% CI
0.82 to 1.00).)
In view of the importance of the data on death and myocardial
infarction we compared aprotinin with either tranexamic acid or
aminocaproic acid. There were nineteen trials that reported on
mortality. Of 2115 subjects randomised to aprotinin 71 died,
compared with 85 of 3012 randomised to either lysine analogue.
The increase in mortality with aprotinin was statistically signif-
icant (RR 1.39, 95% CI 1.02 to 1.89). Seventy percent of the
statistical weight came from the Bart trial (Fergusson 2008). In
contrast, there was no significant increase in the risk of myocardial
infarction with aprotinin compared with either lysine analogue
(RR 1.11, 95% CI 0.82 to 1.50).
Impact of trial quality
Aprotinin
Of the 108 trials of aprotinin that provided data on the number
of patients exposed to allogeneic blood transfusion, 33 trials were
assessed as having adequate allocation concealment of treatment
schedule. For these 33 trials the use of aprotinin reduced the rate
of allogeneic blood transfusion by a relative 36% (RR 0.64, 95%
CI 0.53 to 0.79). Heterogeneity between these trials was statisti-
cally significant (Chi² = 665.70, df = 32, P <0.00001; I² = 95%).
In the 63 trials where there was uncertainty regarding the method
of allocation concealment (Unclear), the use of aprotinin reduced
the rate of allogeneic blood transfusion by a relative 31% (RR
0.69, 95% CI 0.64 to 0.75). Heterogeneity between these trials
was statistically significant (Chi² = 179.31, df = 62, P <0.00001;
I² = 65%). In the remaining 12 trials where the method of alloca-
tion concealment was assessed as being inadequate (No), the use
of aprotinin reduced the rate of allogeneic blood transfusion by a
relative 37% (RR 0.63, 95% CI 0.54 to 0.75). Heterogeneity be-
tween these trials was not statistically significant (Chi² = 15.50, df
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= 11, P = 0.16; I² = 29%). These data indicate the effects of apro-
tinin were not significantly greater in those studies that reported
inferior techniques for concealing the randomisation sequence.
Tranexamic acid
Of the 65 trials of TXA that provided data on the number of
patients exposed to allogeneic blood transfusion, 28 were assessed
as having adequate allocation concealment of treatment schedule.
For these 28 trials the use of TXA reduced the rate of allogeneic
blood transfusion by a relative 41% (RR 0.59, 95% CI 0.51 to
0.69). Heterogeneity between these trials was statistically signifi-
cant (Chi² = 41.35, df = 27, P = 0.04; I² = 35%). In the 24 trials
where there was uncertainty regarding the method of allocation
concealment (Unclear), the use of TXA reduced the rate of al-
logeneic blood transfusion by a relative 47% (RR 0.53, 95% CI
0.37 to 0.76). Heterogeneity between these trials was statistically
significant (Chi² = 209.62, df = 23, P <0.00001; I² = 89%). In the
remaining 13 trials where the method of allocation concealment
was assessed as being inadequate (No), the use of TXA reduced
the rate of allogeneic blood transfusion by a relative 27% (RR
0.73, 95% CI 0.62 to 0.86). Heterogeneity between these trials
was not statistically significant (Chi² = 16.38, df = 11 (P = 0.13),
I² = 33%).
Epsilon aminocaproic acid
Of the 16 trials that provided data on the number of patients ex-
posed to allogeneic blood transfusion, five were assessed as having
adequate allocation concealment of treatment schedule. For these
trials the use of EACA did not statistically significantly reduce
the rate of allogeneic blood transfusion (RR 0.82, 95% CI 0.58
to 1.16). Heterogeneity between trials was statistically significant
(Chi² = 14.35, df = 4, P = 0.006; I² = 72%). In the nine trials where
there was uncertainty regarding the method of allocation conceal-
ment (Unclear), the use of EACA did not statistically significantly
reduce the rate of allogeneic blood transfusion (RR 0.68, 95% CI
0.46 to 1.03). Heterogeneity between trials was not statistically
significant (Chi² = 12.54, df = 8, P = 0.13; I² = 36%). In the
remaining two trials where the method of allocation concealment
was assessed as being inadequate (No), the use of EACA did not
statistically significantly reduce the rate of allogeneic blood trans-
fusion (RR 0.93, 95% CI 0.81 to 1.08). Heterogeneity between
these trials was not statistically significant (Chi² = 0.13, df = 1, P
= 0.72; I² = 0%).
Aprotinin versus tranexamic acid
Of the 21 trials that compared aprotinin to TXA, four were as-
sessed as having adequate allocation concealment of treatment
schedule. For these trials the RR of receiving an allogeneic blood
transfusion in those patients treated with aprotinin compared to
those patients treated with TXA was 0.80 (95% CI 0.69 to 0.92).
Heterogeneity between these trials was not statistically significant
(Chi² = 3.60, df = 3, P = 0.31; I² = 17%). In the 13 trials where
there was uncertainty regarding the method of allocation conceal-
ment (Unclear), the RR of receiving an allogeneic blood transfu-
sion was statistically significantly different between aprotinin and
TXA (RR 0.97, 95% CI 0.88 to 1.07). Heterogeneity between
these trials was not statistically significant (Chi² = 19.25, df = 12,
P = 0.08; I² = 38%). (When Mengistu 2008 was removed from
the analysis RR was 0.99 (95% CI 0.91 to 1.08). In the remain-
ing four trials where the method of allocation concealment was
assessed as being inadequate (No), the RR of receiving an allo-
geneic blood transfusion was not statistically significantly different
between aprotinin treated patients and TXA treated patients (RR
0.93, 95% CI 0.62 to 1.39). Heterogeneity between these trials
was statistically significant (Chi² = 10.29, df = 3, P = 0.02; I² =
71%).
Aprotinin versus epsilon aminocaproic acid
Of the 12 trials of aprotinin versus EACA that were assessed for
methodological quality, three were assessed as having adequate al-
location concealment. For these trials the RR of receiving an allo-
geneic blood transfusion in those patients treated with aprotinin
compared to those patients treated with EACA was 0.86 (95%CI
0.71 to 1.05). Heterogeneity between these trials was not statis-
tically significant (Chi² = 2.75, df = 2, P = 0.25; I² = 27%). For
eight trials there was uncertainty regarding the method of allo-
cation concealment (Unclear), the RR of receiving an allogeneic
blood transfusion was not statistically significantly different be-
tween aprotinin and EACA (RR 0.76, 95% CI 0.58 to 0.99).
Heterogeneity between these trials was not statistically significant
(Chi² = 6.19, df = 7, P = 0.52; I² = 0%). For one trial the method
of allocation concealment was assessed as being inadequate (No).
Tranexamic acid versus epsilon aminocaproic acid
Of the eight trials of TXA versus EACA that were assessed for
methodological quality, one trial was assessed as having adequate
allocation concealment (Yes). For five trials there was uncertainty
regarding the method of allocation concealment (Unclear), and
for two trials the method of allocation concealment was assessed
as being inadequate (No). There were too few trials to formally
assess the impact that methodological quality had on treatment
effect.
Aprotinin versus lysine analogues (TXA and EACA
combined)
Of the 29 trials that compared aprotinin to the lysine analogues,
six were assessed as having adequate allocation concealment of
treatment schedule. For these trials the RR of receiving an allo-
geneic blood transfusion in those patients treated with aprotinin
compared to those patients treated with a lysine analogue was 0.82
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(95% CI 0.71 to 0.95). Heterogeneity between these trials was
not statistically significant (Chi² = 6.44, df = 3, P = 0.27; I² =
22%). In the 18 trials where there was uncertainty regarding the
method of allocation concealment (Unclear), the RR of receiving
an allogeneic blood transfusion was not statistically significantly
different between aprotinin and the lysine analogues (RR 0.95,
95% CI 0.86 to 1.04). Heterogeneity between these trials was
not statistically significant (Chi² = 26.77, df = 18, P = 0.08; I² =
33%). (When data from Mengistu 2008 were removed, RR was
0.97 (95% CI 0.89 to 1.06).) In the remaining five trials where
the method of allocation concealment was assessed as being in-
adequate (No), the RR of receiving an allogeneic blood transfu-
sion was not statistically significantly different between aprotinin
treated patients and lysine analogue treated patients (RR 0.92,
95% CI 0.67 to 1.28). Heterogeneity between these trials was sta-
tistically significant (Chi² = 10.34, df = 4, P = 0.04; I² = 61%).
D I S C U S S I O N
This systematic review of the three anti-fibrinolytic drugs, apro-
tinin, tranexamic acid (TXA), and epsilon aminocaproic acid
(EACA), includes a total of 252 randomised controlled trials
(RCTs), which recruited over 25,000 participants. The previous
versions of this Cochrane review (Henry 1999; Henry 2007), in-
cluded a total of 89 trials with 9876 participants and 211 trials
with 20,781 participants, respectively. Although the three drugs
differ somewhat in their modes of action, the results of this review
confirm and strengthen previous findings that they reduce surgi-
cal blood loss and exposure to allogeneic red blood cell transfu-
sion to a degree that is both statistically and clinically significant.
Importantly, the risk of re-operation necessitated by recurrent or
continued bleeding after cardiac surgery was lowered by treatment
with aprotinin and a clear trend was also seen with TXA for that
outcome. These findings are not new, but this updated review pro-
vides additional information regarding two significant questions:
how do the drugs compare with each other and to what extent
are the clinical benefits offset by adverse effects, in particular vas-
cular occlusion? In addressing these questions the updated review
includes data from 49 active comparisons between aprotinin and
the lysine analogues, compared with 29 in the previous review
(Henry 2007). This updated review also adds to the information
about vascular events - capturing 54 more episodes of myocardial
infarction than the earlier version.
The analyses of active comparator trials (direct head-to-head com-
parisons) indicate that aprotinin was slightly more effective than
TXA in reducing the need for red cell transfusion in patients un-
dergoing cardiac surgery (RR 0.87, 95% CI 0.76 to 0.99). How-
ever, the results of the head-to-head comparison showed that apro-
tinin was marginally more effective than TXA in reducing post-
operative blood loss. In the context of cardiac surgery, aprotinin
appeared to be more effective than EACA in reducing the need
for red cell transfusion and post-operative blood loss. Our confi-
dence in ascribing an advantage to aprotinin needs to be moder-
ated by evidence of possible publication bias and uncertainty over
the comparative dose response relationships.
Mortality appeared to be unaffected by treatment with any of
the drugs and there was no evidence that aprotinin, or the lysine
analogues, increased the risks of myocardial infarction or other
serious thrombosis. These latter results conflict with the findings
of recently published observational studies by Mangano et al (
Mangano 2006; Mangano 2007) and Karkouti et al (Karkouti
2006), which showed that the use of aprotinin in cardiac surgery
was associated with an increase in the incidence of renal failure,
myocardial infarction, and all-cause mortality (over five years).
Measures of efficacy: blood loss and need for
transfusion
Aprotinin appeared to be themost efficacious of the three drugs in
reducing perioperative blood loss, the confidence interval (CI) for
the average reduction in blood loss with aprotinin seen in placebo/
inactive controlled trials does not overlap with those of either TXA
or EACA. This conclusion was supported by the sparser literature
from active comparator trials, which found that aprotinin reduced
post-operative blood loss to a greater extent than TXA; a similar
result was seen in the comparison of aprotinin and EACA. It was
notable that the apparent differences between the drugs were only
seen in the context of cardiac surgery. There was no advantage of
aprotinin over TXA when the drugs were used as an adjunct to
orthopaedic procedures.
The three drugs were effective in reducing the proportions of pa-
tients who required transfusion with red blood cells. The pooled
relative risk (RR) values from placebo/inactive controlled trials
were similar. When considering these results it may be relevant
that the baseline rates of transfusion differed considerably between
the trials of aprotinin and the trials of TXA and EACA. The con-
trol-arms of the aprotinin trials had an average transfusion rate of
62%, compared with 44% for the control-arm of the TXA trials
and 54% for the control-arms of the EACA trials. A possible expla-
nation for this difference is that aprotinin has been studied more
extensively and for a longer period of time than TXA and EACA.
It is generally accepted that improvements in surgical technique,
advancements in cardiopulmonary bypass technology, the intro-
duction of auto-transfusion procedures and acceptance of lower
transfusion thresholds have been responsible for a reduction in
the rates of perioperative blood transfusion over time. This time
dependant trend was observed in the trials of aprotinin in cardiac
surgery. It is also possible that trials of aprotinin included more
high-risk patients than trials of the lysine analogues. Such high-
risk patients tend to have a greater propensity for blood loss and
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hence transfusion. Thus, comparisons between drugs based on the
placebo/inactive controlled trials of anti-fibrinolytic drugs may be
confounded at trial level by differences in patient populations.
Publication bias is a further consideration when considering the
placebo/inactive controlled studies of these drugs. As in the previ-
ous versions of this review, an examination of the generated fun-
nel plots suggested a degree of publication bias (favouring active
treatment) in the aprotinin trials (Figure 3), and a similar pattern
was also seen with the trials of TXA (Figure 4) and EACA (Figure
5).
Figure 3. Funnel plot of comparison: 1 Aprotinin versus Control (Blood Transfusion & Blood Loss),
outcome: 1.1 No. Exposed to Allogeneic Blood.
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Figure 4. Funnel plot of comparison: 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss),
outcome: 2.1 No. Exposed to Allogeneic Blood.
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Figure 5. Funnel plot of comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion &
Blood Loss), outcome: 3.1 No. Exposed to Allogeneic Blood.
In the case of cardiac surgery, when aprotinin was included in pair-
wise comparisons of blood transfusion requirements with TXA
and EACA a small trend in favour of aprotinin was seen in each
comparison. When we pooled data on blood transfusions for
head-to-head comparisons of aprotinin with either of the lysine
analogues the advantage of aprotinin was borderline significant
- pooled RR 0.90 (95% CI 0.81 to 0.99). We have previously
published a meta-analysis of the comparative trials of aprotinin
and lysine analogues in cardiac surgery (Carless 2005). In that
study we used a Bayesian meta-analytic approach to determine if
TXA and EACA could be considered equivalent (non-inferior) to
aprotinin in reducing the rate of allogeneic blood transfusion. Al-
though hampered by the small number and size of the trials, our
results showed that for blood transfusion, using a non-inferiority
boundary of 20%, the posterior probability that TXA is equiva-
lent to aprotinin was 0.82.
In other words, the updated analyses make us less sure about the
equivalence of the lysine analogues and aprotinin when used to re-
duce the need for red cell transfusion in cardiac surgery. But these
conclusions do not take account of two additional factors, dose
effects and the possibility of publication bias. As the funnel plots
generated from the head-to-head trials of aprotinin and the lysine
analogues show there appears to be a gap that should be occupied
by small trials favouring the latter drugs (Figure 6; Figure 7; Figure
8; Figure 9). The data are sparse but if this represents non-publica-
tion of such trials it could explain some of the apparent advantages
of aprotinin seen in the overall analyses. This suggestion was made
originally by Beattie 2006 and our updated analysis supports their
conclusions. To find evidence of publication bias in the placebo-
controlled trials of these drugs is perhaps not surprising, but we
thought it less likely to affect the active comparison studies. The
commercial interests in the role of aprotinin (an expensive and
popular drug) as an adjunct to cardiac surgery may lie behind this.
However, it should be noted that none of the reports of the com-
parative trials mentions commercial sponsorship.
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Figure 6. Funnel plot of comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss),
outcome: 4.1 No. Exposed to Allogeneic Blood.
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Figure 7. Funnel plot of comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion &
Blood Loss), outcome: 5.1 No. Exposed to Allogeneic Blood.
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Figure 8. Funnel plot of comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood
Transfusion & Blood Loss), outcome: 6.1 No. Exposed to Allogeneic Blood.
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Figure 9. Funnel plot of comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion), outcome:
7.1 No. Exposed to Allogeneic Blood.
In making comparisons between the average efficacy of the drugs
it is important to consider the possible role of dose as a treatment
effect modifier. When the pooled RR values for aprotinin were
stratified, both low and high doses reduced the incidence of allo-
geneic red cell transfusion by around 35%. This was greater than
the effect of aprotinin when given only as a priming dose - a RR
reduction of 17%. So extending duration of treatment beyond the
priming dose may be important. TXA in doses of 2 to 10g and
in doses below 2g had a similar effect, reducing allogeneic red cell
transfusion by around 30%. There were insufficient data to ex-
plore dose effects in the head-to-head trials of aprotinin and TXA.
Analyses of the comparative trials of aprotinin and the lysine
analogues in orthopaedic surgery were hampered by sparse data.
When the results of placebo/inactive controlled trials were com-
bined TXA appeared to be as effective as aprotinin in reducing
the number of patients exposed to allogeneic blood transfusion.
Conclusions about the relative efficacy of EACA and aprotinin in
orthopaedic surgery were hampered by the small number of trials.
Of the fourteen trials of aprotinin eight (57.1%) were published
between 2000 and 2006. In comparison, of the 21 trials that com-
pared TXA to placebo-control 16 (76.2%) were published in this
time period. As with cardiac surgery, conclusions about the relative
efficacy of the drugs may be confounded by changes in surgical
technique and transfusion practices that have occurred over time.
However, as with the data on blood loss, the apparent advantage
of aprotinin over the lysine analogues on the need for blood trans-
fusion observed in cardiac surgery was not seen in orthopaedic
surgery.
The analyses of the volumes of red cells transfused were difficult to
interpret because of incomplete data in many trials. When all ran-
domised subjects were included in the analyses (which included
some who did not receive a transfusion) the average volumes of
blood transfused were reduced modestly by all three drugs. When
the analysis was confined to individuals who received red cell trans-
fusions the reductions in volume were less marked and a statisti-
cally significant treatment effect was observed only for aprotinin.
There were insufficient data from head-to-head trials to assess the
comparative effectiveness of the three drugs in reducing the vol-
umes of blood transfused.
Clinical significance of avoiding red cell
transfusion
The true value of avoiding allogeneic red cell transfusion remains
unclear (Vamvakas 2001). Patients who are concerned about the
risks of contracting illness as a result of blood transfusion (or ob-
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ject to transfusion on religious grounds) will be more interested
in avoiding it completely, rather than just reducing the volume
of transfused blood. The importance of avoiding the need for
transfusion depends on the probability of avoiding disease trans-
mission or other adverse effects, in particular immunomodulation
thought to be due to transfused white blood cells (Blumberg 1997;
Vamvakas 2001). The significance of the latter remains although a
number of countries now perform leukocyte depletion, either se-
lectively, or universally, before administering red cell transfusions,
despite a lack of convincing evidence that this provides clinical
benefits (Vamvakas 2004). The rate of transmission of HIV or vi-
ral hepatitis in most developed countries is very low, because of the
quality of screening of donated blood (Coyle 1999; Whyte 1997).
These broad assumptions donot apply equally in developing coun-
tries. Allogeneic red cell transfusion is administered frequently and
blood products may be inadequately screened; the prevalence of
viral pathogens amongst donors is high (Kimball 1995;McFarland
1997). In these settings there may be much greater clinical value
in a range of interventions that diminish or avoid the need for
allogeneic blood. However, the costs of the drugs reviewed here
are likely to be prohibitive in developing countries.
Most of the red cell transfusion data reviewed here have been col-
lected in the context of major cardiac surgery, where blood loss
may be substantial. The applicability of the efficacy data to clini-
cal settings where blood loss is minor is questionable. Anti-fibri-
nolytic drugs may be used alongside other interventions designed
to minimise the need for allogeneic red cell transfusion. A variety
of techniques have been employed; most involve the re-infusion
of autologous blood either from pre-operative deposit, acute nor-
movolemic haemodilution, or cell salvage. The latter, in most in-
stances involves the re-infusion of red blood cells that have been
shed into the operative field. The evidence on the efficacy and
safety of these techniques was reviewed extensively by the Interna-
tional Study on Perioperative Transfusion (ISPOT) (Bryson 1998;
Forgie 1998; Huet 1999). The literature on re-infusion techniques
is generally viewed as being of indifferent quality, because of in-
adequate randomisation and lack of blinding of outcomes assess-
ment. However, these techniques probably have a modest blood
sparing effect. Significantly, the efficacy of autologous re-infusion
techniques appears lower when they are used in the context of a
rigorous transfusion protocol. This and the growing evidence on
the efficacy of transfusion triggers indicates that a more conserva-
tive approach to blood transfusion decisions is desirable (Carson
1998; Hebert 1999). This conservative approach, combined with
the selective use of anti-fibrinolytic drugs, may offer the best ap-
proach for managing the transfusion requirements of participants
in high-risk settings such as cardiac surgery.
Other measures of efficacy: need for re-
operation due to bleeding
If the significance of avoiding red cell transfusion is unclear the im-
portance of avoiding re-operation is not. Going back to theatre be-
cause of continued or recurrent bleeding is a serious development
after cardiac surgery and any reduction in the incidence of this
event is clinically significant (O’Brien 2002). The updated meta-
analysis confirmed that aprotinin reduces the rate of re-operation
due to bleeding by about half. This translates into an absolute risk
reduction of 2% and a number needed-to-treat of 50 (95% CI
33 to 100). Similar trends were seen with TXA and EACA, but
the data were sparse and the differences failed to reach statistical
significance. We did not see evidence of publication bias in the
data relating to re-operation rates (Figure 10). When aprotinin
was compared directly with TXA in head-to-head comparative tri-
als the analysis suggested that aprotinin reduced re-operations by
31%.
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Figure 10. Funnel plot of comparison: 7 Adverse Events and Other Outcomes (Active versus Control),
outcome: 7.1 Re-operation for bleeding.
Effects of treatment on all cause mortality
Regardless of the type of surgery, when aprotinin was compared
with no treatment there was no apparent effect on all-cause mor-
tality (RR 0.81, 95% CI 0.63 to 1.06). In the subset of cardiac
surgery trials the result was similar: RR 0.84 (95% CI 0.64 to
1.10). Likewise, when TXA was compared to no treatment the ef-
fect on mortality rate in cardiac surgery was not statistically signif-
icant and the CI was fairly wide (RR 0.60, 95% CI 0.33 to 1.10).
In head to head comparisons there was a trend to higher mortality
with aprotinin than either tranexamic acid or aminocaproic acid
but the analyses were constrained by the relatively small num-
bers of outcomes. As there were no qualitative differences between
tranexamic acid and aminocaproic acid, and any quantitative dif-
ferences between these drugs were small, we compared aprotinin
with either lysine analogue for the outcomes of mortality and my-
ocardial infarction. The risk of death was higher with aprotinin
than with either lysine analogue, although this result was very de-
pendent on the results of the BART trial (Fergusson 2008). There
was no significant increase in the risk of myocardial infarction that
could explain the higher mortality and indeed there were no other
outcome analyses from the head to head trials that could provide
an explanation. It is also possible that the difference was due to
a benefit of the lysine analogues rather than an adverse effect of
aprotinin. In any event this distinction is academic as aprotinin
has been withdrawn from world markets and the lysine analogues
appear almost equally effective in reducing the need for transfu-
sion with allogeneic blood.
Adverse events and other outcomes
Neither aprotinin nor the lysine analogues appeared to increase
the risk of myocardial infarction. In each case the pooled relative
risk was close to one. Most data have been collected for apro-
tinin, which is more often used in cardiac surgery that the lysine
analogues. This probably explains the higher rates of myocardial
infarction in the placebo-treated subjects in the aprotinin trials
(4.5%) than the TXA trials (2.3%). Similarly, the risk of stroke
was not increased by any of these drugs; nor was there any apparent
increase in the risk of developing other thrombotic events (deep
vein thrombosis, pulmonary embolism, ’other thrombosis’).
Data aggregated from 28 randomised trials of aprotinin and nine
trials of TXA showed that neither drug increased the risk of re-
nal dysfunction compared to control. Although the event rate was
slightly higher in aprotinin-treated patients compared to the con-
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trol group (2.4% versus 1.5%) the difference was not statistically
significant.
Potential sources of bias in this review
In our review we found a large number of small trials. These
continue to be published in the literature, even though individually
they contribute very little additional information. In the case of
aprotinin, redundancy in terms of new information has long since
been reached and there is no justification for continuing toperform
placebo-controlled trials. Future investigation should involve large
trials of the relative efficacy and safety of the different drugs (
Hebert 2005). The small size of most of the existing trials raises
concerns about the effects of publication bias. The funnel plot of
the aprotinin trials reveals possible evidence of this - in the form
of a ’missing’ population of small negative trials (Figure 3).
The main study outcome used in these trials was a practice vari-
able - the decision to transfuse a patient with allogeneic red cells.
Although this requires a degree of subjectivity on the part of clini-
cians it is probably not a major source of bias in this meta-analysis
as around 70% of the trials were assessed as being double-blind,
involving the use of an identical placebo.
Sources of heterogeneity
Substantial heterogeneity in trial outcomes was seen. This was
seen in the case of aprotinin for blood loss and blood transfusion
outcomes. However, it was not apparent in the analyses of more
significant clinical outcomes, such as re-operation, myocardial in-
farction and death. It is therefore possible that the subjective na-
ture of the intermediate outcomes, which require judgement about
the degree of blood loss, and the need for transfusion, contributed
to the between study heterogeneity. Despite this heterogeneity we
have little doubt about the existence of a treatment benefit with
these drugs. The variation for blood transfusion variables was in
terms of the size, not the direction, of effect.
We considered a number of other factors that might explain vari-
ation in the size of the treatment effect for blood loss and rates
of transfusion. In the case of transfusion, we stratified the data by
the clinical setting, operation type, the concomitant use of clini-
cal transfusion thresholds (transfusion triggers), and trial method-
ological quality. In the case of blood loss, we stratified the data by
the type surgery performed and the period in which blood loss was
assessed (that is, intra-operative and/or post-operative blood loss).
Basically, none of these provided an adequate explanation for the
degree of heterogeneity seen in these studies. Although effect size
varied somewhat with dose, considerable heterogeneity was seen
within dose strata. Likewise, there was substantial heterogeneity
within the trials of aprotinin in cardiac surgery (that is, for intra-
and-post-operative blood loss, and the rates of transfusion). For
the rates of exposure to allogeneic blood transfusion the adequacy
of concealment of treatment allocation was associated with a small
variation in treatment effect size, but once again there was hetero-
geneity within the different strata of methodological quality.
How do the results compare with the
observational studies?
The most controversial aspect of this review is the lack of evidence
of an increase in the risks of myocardial infarction, stroke, renal
dysfunction and death with aprotinin when compared with no
treatment. This is in keeping with previous published meta-anal-
yses of the randomised controlled trials of anti-fibrinolytic drugs.
In the case of aprotinin this review includes 77% more myocar-
dial infarctions, but only 7% more deaths, than the previous ver-
sion of this review. The updated data-sets comparing aprotinin
with no treatment conflict with those from four recent observa-
tional studies (Karkouti 2006; Mangano 2006; Mangano 2007;
Schneeweiss 2008). Mangano and colleagues (2007) showed that
during five years of follow-up aprotinin-treated patients had a
death rate around 1.6 times higher than that of the untreated con-
trol group. The adjusted hazard ratio (HR) for all-cause mortality
was 1.48 (95% confidence interval 1.19 to 1.85). This study gen-
erated considerable scientific debate with calls for the use of apro-
tinin in cardiac surgery to be abandoned. In 2008 a large phar-
maco-epidemiological study by Schneeweiss 2008 confirmed the
increased risk of death with aprotinin. These investigators stud-
ied the use of aprotinin (33,517 patients) or aminocaproic acid
(44,682 patients) on the day coronary bypass surgery was per-
formed. In this non-randomised study they found that 1512 of
the 33,517 aprotinin recipients (4.5%) and 1101 of the 44,682
aminocaproic acid recipients (2.5%) died. After adjustment, the
estimated risk of death was 64% higher in the aprotinin group
than in the aminocaproic acid group (relative risk, 1.64; 95% con-
fidence interval [CI], 1.50 to 1.78). This difference remained sta-
tistically significant after a range of analytical procedures including
a propensity score matched analysis and an instrumental variable
analysis.
The first large observational study to find and adverse effect of
aprotinin (Mangano 2006, Mangano 2007) was criticized on sev-
eral grounds, including the fact that it was based on a multi-cen-
tre patient registry, not a true population based cohort, that there
were important differences between centres and that a range of
selection biases may have influenced the between-drug compar-
isons. These arguments will not be repeated here as full details are
available in the relevant publications (Bidstrup 2006; Body 2006;
Ferguson 2007; Levy 2006). Our view is not that the studies of
Karkouti 2006; Mangano 2006 and Mangano 2007 were badly
done, but that they have inherent limitations, mainly due to their
observational nature and selection biases that probably cannot be
completely overcome through statistical adjustments by propen-
sity scores and co-variates. These weaknesses were addressed in the
larger study performed by Schneeweiss and colleagues (2008), de-
scribed above. The agreement between these studies adds weight
to the claim that aprotinin does indeed increase the chances of
34Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
death.
In considering the apparently conflicting results of the different
study types it is also important to acknowledge weaknesses in the
database of randomised trials, in particular under-recording of
infrequent events that were not the primary outcomes of the trials.
It is important to note that for dichotomous data to be included
in our analyses, trial reports had to provide either numeric data,
that is the numbers of events that occurred in the treatment and
control groups, or where there were no events recorded, the trial
report had to clearly state this. So, we have some confidence in the
data included in themeta-analyses.However, we acknowledge that
under-reporting of uncommon events that were not the primary
outcomes of these generally small trials is a potential problem with
this literature. In the case of aprotinin our analyses of myocardial
infarction were based on data from 37 (49%) out of a total of 76
trials included in the analyses of blood transfusions. These trials
were larger than average and included 64% of all participants.
Nevertheless, the incomplete data are a potential source of bias
in this and the analyses of other vascular outcomes. We are more
confident of our analyses of mortality in cardiac surgery where, in
the case of aprotinin, data were reported for 60% of all trials and
80% of participants. The most likely effect of under-reporting is
to make estimates imprecise, meaning that fairly small changes
in mortality or occurrence of thrombotic events might have been
missed.
There was a disappointing lack of information in the randomised
trials regarding this putative adverse effect of the drug. Only 18
out of 76 trials of aprotinin documented this outcome, so there is a
potential for bias due to under-reporting. Based on analysis of 107
events in 4174 individuals the point estimate of the pooled RR
with aprotinin (compared with placebo or no treatment) was 1.16
(95% CI 0.79 to 1.70), so we are not confident that we have ruled
out a modest increase in risk. On the other hand the suggestion
of an increase in risk fromMangano 2006 was based on a total of
only 18 events, of which eight occurred in patients treated with
aprotinin. Karkouti 2006 carried out a closely matched analysis
of 898 individuals who received either aprotinin or TXA. Using a
very sensitive measure of renal dysfunction they documented 182
instances, with a higher incidence in aprotinin treated subjects
(RR 1.43, 95% CI 1.10 to 1.86).
There was greater agreement when we consider the results of the
summary analyses of the head to head trials of aprotinin and ly-
sine analogues and the observational studies described above. The
comparison of aprotinin with the combined results of the lysine
analogues found a significantly increased risk of death; similar in
magnitude to what was found in the observational studies, but no
apparent increase in the risk of major thrombotic events. The ab-
sence of a no treatment control group from these analyses means
that we are unable to say whether the differences in mortality
were due to an adverse effect of aprotinin or a protective effect
of the lysine analogues. In addition, the meta-analyses for death
and myocardial infarction were heavily weighted by the results of
the BART trial (Fergusson 2008). These factors limit our ability
to draw firm conclusions about the true effects of the drugs. But
the summary data now available, and the regulatory action taken
against aprotinin, enable us to make some pragmatic recommen-
dations. Despite the possibility that they are inferior to aprotinin
in minimising perioperative blood loss and the need for allogeneic
red cell transfusion both tranexamic acid and aminocaproic acid
appear effective and safe. The experience is greatest with tranex-
amic acid and confidence in the use of this drug has been strength-
ened by the recent publication of the CRASH-2 trial (CRASH-2
2010), which found that two doses of tranexamic acid reduced
overall mortality when administered soon after major trauma.
Conclusions
Antifibrinolytic drugs are effective in reducing blood loss, the need
for allogeneic red cell transfusion, and the need for re-operation
due to continued post-operative bleeding (in cardiac surgery).
Aprotinin appears more effective than the lysine analogues in min-
imising peri and post operative blood loss when used as adjunctive
therapy in cardiac surgery. Strictly speaking, based on their average
effects on the need for red cell transfusion, the lysine analogues do
not meet the criteria for being considered equivalent to aprotinin.
However, comparisons between the drugs need to take account of
the clinical significance of any small advantage of aprotinin, the
dose response relationships for each of the drugs, and the possi-
ble effects of publication bias, which appears to favour aprotinin.
Taking these factors into consideration it may reasonably be con-
cluded that tranexamic acid is as effective as aprotinin, particularly
when it is used as an adjunct to non-cardiac surgical procedures.
The data for epsilon aminocaproic acid are sparser and as a con-
sequence not so convincing.
The updated meta-analyses of the randomised trials comparing
aprotinin with no treatment do not confirm the evidence from
observational studies that aprotinin increases the risks of vascular
occlusive events and mortality. However, there has been a degree
of under-reporting of these adverse events in trials of anti-fibri-
nolytic drugs. The head to head comparisons of aprotinin and the
lysine analogues have yielded results that are closer to those seen
in the observational studies and indicate that aprotinin carries an
increased risk of death. Consequently, the balance of benefit and
harm favours the use of the lysine analogues over aprotinin, and
justifies the regulatory action that resulted in the withdrawal of
aprotinin from international markets in 2008.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Tranexamic acid and epsilon aminocaproic acid provide worth-
while reductions in blood loss and the need for allogeneic red cell
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transfusion. Based on the results of randomised trials their efficacy
does not appear to be offset by serious adverse effects. The evidence
is stronger for tranexamic acid than for epsilon aminocaproic acid.
Implications for research
There is no need for further placebo-controlled trials of anti-fib-
rinolytic drugs in cardiac surgery. The principal need is for large
comparative trials to assess the relative efficacy, safety and cost-ef-
fectiveness of the lysine analogues in different surgical procedures.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alajmo 1989
Methods Patients were randomly divided into two groups according to birth date until an appropriate number
of treated patients was reached. Method of blinding and generation of allocation sequences were
not described
Participants 34 consecutive patients undergoing cardiac operations were randomly divided into two groups:
• Aprotinin group: n = 22, M/F = 12/8, mean (sd) age = 62 (6.6) years
• Control group: n = 12, M/F = 7/5, mean (sd) age = 57.8 (16.3) years
NB: Possible error in the gender data provided for the aprotinin group
Interventions • Aprotinin group received 2 million kallikrein inactivation units (KIU) of aprotinin (280 mg)
at the start of anaesthesia (Trasylol, Bayer Leverkusen, FRG; 10,000 KIU/ml pure aprotinin with
no additives) infused over 20 to 30 minutes. Subsequently, 500,000 KIU/hr (70 mg/hr) of
aprotinin was given until the end of the operation. Additionally, 1 million KIU of aprotinin (140
mg) was given via the priming solution of the extracorporeal circuit.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, haemoglobin
levels, platelet counts
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Patients were randomly allocated into two
groups according to birth date until an appro-
priate number of treated patients was reached
Allocation concealment? No Inadequate
Blinding?
All outcomes
No
Alderman 1998
Methods Patients were randomly divided into two groups by random code, generated in blocks with clinical
center and stratum. Allocation concealment was not described
Participants 870 patients were randomised into two groups:
• Aprotonin group n = 436, M = 87.4%, mean (sd) age = 61.8 (9.1) years
• Control group (Placebo) n = 434, M = 86.9%, mean (sd) age = 62.3 (9.1) years
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Alderman 1998 (Continued)
Interventions • Aprotonin group received a loading dose of 2 million KIU (280 mg), a maintenance dose of
500,000 KIU and a prime dose of 2 million KIU.
• No details were described on the placebo used.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, blood loss, deaths,myocardial
infarction, CABG thrombosis, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random code generated in blocks
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Alvarez 1995
Methods The hospital pharmacy made up identical infusions of the study drugs identifiable only by random
number. Patients were prospectively randomised into two groups by sealed envelopes. The method
used to generate allocation sequences was not described
Participants 100 patients undergoing primary elective cardiac surgery were randomised into one of two groups:
• Aprotinin group: n = 49, M/F = 38/11, mean (sd) age = 63.3 (11.0) years
• Control group (Placebo): n = 51, M/F = 34/17, mean (sd) age = 62.7 (8.2) years
Interventions • Aprotinin group received 250,000 kallikrein inactivation units (KIU) of aprotinin added to
the prime solution of the cardiopulmonary bypass (CPB) system. Before the start of CPB a
further 250,000 KIU of aprotinin, made up to 100 ml with 0.9% saline, was infused
intravenously over 30 minutes.
• Control group received a placebo of equal volumes of 0.9% saline administered at identical
times.
NB: Both the intervention and control group were combined with cell salvage
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, patients receiving autotrans-
fusion, blood loss, mortality, myocardial infarctions, re-operation, patients receiving cell salvage
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
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Alvarez 1995 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes were used to con-
ceal treatment allocation
Blinding?
All outcomes
Yes Double blind
Alvarez 2001
Methods Patients were randomised by a computer-generated random number sequence into either treatment
group. All clinical participants were double blinded until the completion of the trial. Placebo and
treatment solutions were identical in their appearance and packaging
Participants 55 patients undergoing either elective or urgent cardiac surgery were randomised into one of two
groups:
• Aprotonin group: n = 26, M/F = 23/3, mean (sd) age = 63 (8) years
• Control group (Placebo): n = 29, M/F = 22/7, mean (sd) age = 64 (8) years
Interventions • Aprotinin group received 250,000 kallikrein inactivation units (KIU) of aprotinin 280mg
IV at the time of sternal skin closure.
• Control group received a placebo of an equal volume of normal saline solution infused over
20 mins.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, patients receiving autotrans-
fusion, blood loss, mortality, myocardial infarctions, re-operation
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random number sequence
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Alvarez 2008
Methods Patients were allocated according to a computer-generated randomisation sequence. Allocation was
concealed using sealed, numbered envelopes
Participants 95 patients undergoing orthopaedic (knee arthroplasty) surgery. Patients were randomly allocated
to one of two groups:
• Tranexamic acid group: n = 46, M/F = 7/39, mean (sd) age = 71 (9) years
• Control group (Placebo): n = 49, M/F = 10/39, mean (sd) age = 72 (7) years
Interventions • Tranexamic acid group received bolus of 10mg/kg before deflation of tourniquet then
infusion of 1mg/kg/hr starting at the end of operation for six hours post-operation.
• Control group received saline.
Outcomes Outcomes reported: Number of patients requiring blood transfusion, blood loss, volume of blood
transfused, thrombosis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random number sequence
Allocation concealment? No Inadequate - randomised assignment was sealed
in a numbered envelope
Blinding?
All outcomes
Yes Double blind
Amar 2003
Methods Randomisation of patients in blocks of 20 were done by the Biostatistics Department and the
hospital pharmacy using sealed, opaque treatment code envelopes
Participants 69 patients undergoing elective orthopaedic surgery were randomised into one of three groups:
• Epsilon aminocaproic acid group: n = 22, M/F = 11/11, mean (sd) age = 53 (18) years
• Aprotinin group: n = 23, M/F = 13/10, mean (sd) age = 48 (17) years
• Control group (Placebo): n = 24, M/F = 13/11, mean (sd) age = 55 (16) years
Interventions • Epsilon aminocaproic acid (EACA) group received 150 mg/kg EACA bolus in an equal
volume given over 30 minutes followed by an infusion of 15 mg/kg/hr until the end of surgery.
• Aprotinin group received a bolus of 2 million KIU (280mg) given over 30 minutes followed
by an infusion of 500,000 KIU/hour (70mg/hr) until the end of surgery.
• Control group received a placebo of an equal volume of normal saline bolus and infusion.
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Amar 2003 (Continued)
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood units - total
includes intra-operative & 48 hours post-operative, blood loss - total blood loss = intra-operative
& 48 hours post-operative, deep venous thrombosis, pulmonary embolus, hospital length of stay
(days), wound infection, thrombocytopenia, Haemoglobin levels (pre-operative & post-operative)
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random numbers
Allocation concealment? No Inadequate - sealed opaque treatment coded en-
velopes were used to conceal treatment alloca-
tion
Blinding?
All outcomes
Yes Double blind
Andreasen 2004
Methods Patients were randomised by a randomnumber sequence. The randomisation schedule was provided
in sealed envelopes and preparation of the drug or placebo was carried out just prior to anaesthesia
by a staff member not involved in the treatment of the patient
Participants 46 patients undergoing elective coronary surgery. Patients were randomly allocated to one of two
groups:
• Tranexamic acid group (n = 21), M/F = 18/3, mean age (+/-SD) = 62.3 (9.5) years
• Control group (Placebo) (n = 23), M/F = 19/4, mean age (+/-SD) = 63.8 (7.6) years
Interventions • Tranexamic acid group (TXA) group (Cyklokapron, Phizer Consumer Healthcare) received
1.5g TXA as an IV bolus beginning at the induction of anesthesia, followed by a constant
infusion of 200mg/hr until additional 1.5g was given.
• Control group received a placebo of 0.9% normal saline solution.
NB: Cell salvage - postoperatively shed mediastinal blood was returned in all patients using a closed
autotransfusion system
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, deaths, myocar-
dial Infarctions, CABG thrombosis, renal insufficiency, re-operation for bleeding, cell salvage -
autotransfusion 6 hrs, transient ischemic attack (30 day), stroke 30 day
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
56Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Andreasen 2004 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number sequence
Allocation concealment? No Inadequate - used sealed envelopes to conceal
treatment allocation
Blinding?
All outcomes
Yes Double blind
Apostolakis 2008
Methods A randomisation table was used to generate the allocation sequence. No information was provided
regarding allocation concealment
Participants 59 patients undergoing elective thoracic surgery. Patients were randomly allocated to one of two
groups:
• Aprotinin group: n = 29, M/F = 26/3, mean (sd) age = 57.5 (16.3) years
• Control group (Placebo): n = 30, M/F = 27/3, mean (sd) age = 58.5 (9.8) years
Interventions • Aprotinin group, administered immediately after intubation, received a test dose of 1ml then
500,000 KIU intravenously in 50ml of solution over 15 minutes, received the same dose again
after thoracotomy closure.
• Control group received a placebo of an equal volume of normal saline.
Outcomes Outcomes reported: Blood loss, volume of transfused blood (units), mortality, re-operation for
bleeding, length of hospital stay (days)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Armellin 2001
Methods Method of randomisation and allocation concealment were not described
Participants 300 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 150, M/F = 71/72, mean (sd) age = 65.7(11.7) years
• Control group (Placebo): n = 150, M/F = 90/50, mean (sd) age = 65.9 (12.8) years
Interventions • Tranexamic acid group (TXA) received 2.5g of TXA before the skin incision with a further
2.5g of TXA added to the CPB prime solution.
• Control group received a placebo of an equal dose of saline at the same times as TXA.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, mortality, myocardial infarction, re-operation for bleeding, hospital length of stay
(days), fresh frozen plasma (FFP), platelets (units)
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Arom 1994
Methods Method of randomisation and allocation concealment were not described
Participants 200 patients undergoing cardiac surgery were randomised to one of two groups:
• Epsilon aminocaproic acid group: n = 100, M/F = 70/30, mean age = 60 years
• Control group: n = 100, M/F = 71/29, mean age = 55 years
Interventions • Epsilon aminocaproic acid group received 5g of intravenous EACA just before going on
CPB.
• Control group did not receive EACA treatment.
NB: Both groups received 0.03ug/kg of intravenous desmopressin (DDAVP) after CPB
Outcomes Outcomes reported:Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage
(units), cryoprecipitate (units), blood loss (ml)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
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Arom 1994 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Ashraf 1997
Methods Method of randomisation and allocation concealment were not described
Participants 38 patients undergoing coronary artery bypass graft surgery were randomised to one of two groups:
• Aprotinin group: n = 19, M/F = 16/3, median (range) age = 61 (49-72) years
• Control group: n = 19, M/F = 15/4, median (range) age = 65 (50-79) years
Interventions • Aprotinin group received 2 million KIU (280mg) of aprotinin added to the pump prime
solution of the extracorporeal circuit.
• Control group did not receive aprotinin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss 24hrs, mortality, re-exploration for bleeding, pro-inflammatory cytokine levels
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Asimakopoulos 2000
Methods Method of randomisation and allocation concealment not specified
Participants 18 adults undergoing elective coronary artery bypass grafting were randomly allocated to one of
two groups:
• Aprotinin group: n = 8, M/F = 7/1, mean (sd) age = 59 (3.9) years
• Control group: n=10, M/F = 10/0, mean (sd) age = 65 (1.9) years
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Asimakopoulos 2000 (Continued)
Interventions • Aprotinin group received full-dose aprotinin.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood (units), blood loss, myocardial infarction, renal failure, re-
operation for bleeding, cerebrovascular accident (stroke), hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 4/7
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Baele 1992
Methods Method of randomisation was not described. Allocation concealment was inadequately concealed
(sealed envelopes)
Participants 115 consecutive adults undergoing cardiac surgery were randomly allocated to one of two groups:
• Aprotinin group: n = 58, M/F = 45/13, mean (sd) age = 61.6 (9.6) years
• Control group: n=57, M/F = 41/16, mean (sd) age = 62.9 (10.5) years
Interventions • Aprotinin group received 2 million kallikrein inactivator units (KIU) before incision, 2
million (KIU) prior to bypass and a continuous infusion of 500,000 KIU/hr for 5 hours.
• Control group did not receive aprotinin.
NB: Both the intervention and control groups were exposed to pre-operative autologous donation
(7 control and 4 intervention patients), acute normovolemic haemodilution (13 patients in each
group), and/or cell salvage (data not presented)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood (units) blood
loss, mortality,myocardial infarction, myocardial ischemia, pericarditis, cardiac failure, pneumonia,
renal insufficiency, hemiplegia, re-operation, allogeneic + autologous blood usage (units), intensive
care unit (ICU) length of stay (hrs), hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Baele 1992 (Continued)
Adequate sequence generation? Unclear Not reported
Allocation concealment? No Inadequate - sealed envelopes were used to con-
ceal treatment allocation
Blinding?
All outcomes
Unclear Unclear
Bailey 1994
Methods Generation of allocation sequences was by a computer generated random number table. One
investigator made up all the test solutions; a known volume of sterile 0.9% saline was discarded from
500ml bags and replaced with the same volume of test solution so that all bags contained the same
equal volume (500ml). Each set of bags was given a consecutive number. A separate investigator
performed all the patient measurements
Participants 100 patients scheduled to undergo primary elective cardiac surgery employing cardiopulmonary
bypass were consecutively allocated to one of four groups
• Control group (Placebo): n = 25, M/F = 17/8, mean (sd) age = 63 (10) years
• Aprotinin group (High dose): n = 25, M/F = 18/7, mean (sd) age = 64 (13) years
• Aprotinin group (Prime dose): n = 24, M/F = 17/7, mean (sd) age = 59 (11) years
• Aprotinin group (Low dose): n = 26, M/F = 20/6, mean (sd) age = 63 (10) years
Interventions • Control group received a placebo of an intravenous bolus of 500ml of 0.9% saline at
induction of anaesthesia, followed by 500ml of 0.9% saline every hour; a further 500ml of 0.9%
saline was added to the pump prime.
• Aprotinin (High dose) group received an intravenous bolus of 300ml of 0.9% saline with
200ml of aprotinin (2 million kallikrein inactivator units) at induction of anaesthesia, followed by
450ml of 0.9% saline with 50ml aprotinin (500,000KIU) every hour; a further 300ml of 0.9%
saline with 200ml aprotinin (2 million KIU) was added to the pump prime.
• Aprotinin (Prime dose) group received an intravenous bolus of 500ml of 0.9% saline at
induction of anaesthesia, followed by 500ml of 0.9% saline every hour; a further 300ml of 0.9%
saline with 200ml of aprotinin (2 million KIU) was added to the prime pump.
• Aprotinin (Low dose) group received an intravenous bolus of 400ml of 0.9% saline with
100ml of aprotinin (1 million KIU) at induction of anaesthesia, followed by 500ml of 0.9%
saline every hour; a further 400ml of 0.9% saline with 100ml of aprotinin 1 million KIU) was
added to the pump prime.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood (units),
fresh frozen plasma usage (units), blood loss
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Bailey 1994 (Continued)
Adequate sequence generation? Yes Generation of allocation sequences was by a
computer generated random number table
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Basora 1999
Methods Method of randomisation and allocation concealment were not described
Participants 59 patients undergoing elective cardiac surgery were randomised to one of three groups:
• Control group: n = 21, M/F = 16/5, mean (sd) age = 59.8 (10.3) years
• Aprotinin group (Low dose - A2): n = 17, M/F = 12/5, mean (sd) age = 61.2 (13.1) years
• Aprotinin group (Low dose - A4): n = 19, M/F = 14/5, mean (sd) age = 60.9 (7.6) years
Interventions • Control group did not receive aprotinin.
• Aprotinin group (Low dose - A2) received 14,286 KIU/kg (2mg/kg) 15 mins before surgery,
then a continuous dose of 7,143 KIU/kg/hr (1mg/kg/hr) until the end of surgery.
• Aprotinin group (Low dose - A4) received 28,572 KIU/kg (4mg/kg) 15 mins before surgery,
then a continuous dose of 7,143 KIU/kg/hr (1mg/kg/hr) until the end of surgery.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, platelet function
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Bennett-Guerrero 1997
Methods Patients were randomised by means of a computer-generated schedule. Study drug was prepared
according to a protocol by hospital pharmacies
Participants 204 patients undergoing repeat cardiac surgery were randomised to one of two groups:
• Aprotinin group (High dose): n = 99, M/F = 66/33, mean (sd) age = 62 (14) years
• Epsilon aminocaproic acid group: n = 105, M/F = 68/37, mean (sd) age = 63 (12) years
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Bennett-Guerrero 1997 (Continued)
Interventions • Aprotinin group (High dose) received 2 million KIU (280mg) of aprotinin on skin incision,
500,000 KIU/hr as a continuous infusion for 4 hours on initiation of CPB. An additional 2
million KIU (280mg) was added to the CPB prime solution. Patients received 1ml of the study
drug in a blinded manner before the loading dose to test for possible allergy.
• Epsilon aminocaproic acid group received 150mg/kg on skin incision, 30mg/kg over 4 hours
as a continuous infusion on initiation of CPB. In addition, normal saline solution was added to
the CPB prime solution. Patients received 1ml of the study drug in a blinded manner before the
loading dose to test for possible allergy.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), fresh frozen plasma usage (units), platelet usage (units), blood loss, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised by means of a com-
puter-generated schedule
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Benoni 1996
Methods Randomisation into blocks of 12 was done by an independent pharmacologist who was not other-
wise engaged in the study. Pairs of ampoules, each containing 10ml of either the active substance
or the placebo were numbered and packed into envelopes which were opened by the anaesthetist
before administration. These ampoules could be identified only by their numbers, and the ran-
domisation code was known only to the independent pharmacologist. The code was not broken
until the end of the study and until all data had been corrected and included in the database. Ten
patients were excluded from the study after randomisation
Participants 96 patients undergoing total knee arthroplasty were randomly allocated to one of two groups:
• Tranexamic acid group: n = 43, M/F = 13/30, mean (sd) age = 76 (7) years
• Control group (placebo): n = 43, M/F = 10/33, mean (sd) age = 74 (7) years
Interventions • TXA group received 10mg/kg of TXA as a slow intravenous injection towards the end of the
operation (median time 12 minutes - range 1-40 minutes) before deflation of the limb tourniquet.
This dose was repeated after 3 hours from the other ampoule of the pair provided in the envelope.
• Control group received a placebo of equal volumes of normal saline solution (0.9%).
NB: 15 patients from the placebo group received an extra dose of TXA for severe post-operative
63Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Benoni 1996 (Continued)
bleeding, these patients represented the ’placebo-extra’ group
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), blood loss, deep venous thrombosis, pulmonary embolus, wound haematomas, chest pain,
haemoglobin concentrations
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Adequate
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Benoni 2000
Methods Medication was administered using numbered ampoules and the randomisation was performed by
a pharmacist not otherwise engaged in the study
Participants 40 patients undergoing total hip arthroplasty were randomly assigned to one of two groups:
• Tranexamic acid group: n = 20, M/F = 6/14, mean (sd) age = 69.5 (10) years
• Control group (Placebo): n=20, M/F = 11/8, mean (sd) age = 68 (10) years
Interventions • Tranexamic acid group received 10mg/kg IV of TXA (Cyklokapron) at the end of the
operation and received another 10mg/kg IV 3 hours later.
• Control group received corresponding volumes of normal saline (placebo).
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), blood loss, amount of pre-operative autologous donated blood (2 units), infection
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
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Benoni 2000 (Continued)
Blinding?
All outcomes
Yes Double blind
Benoni 2001
Methods Method of randomisation was not described. Medication was concealed by a code only known by
the hospitals chief pharmacist who was not involved in the study
Participants 40 patients undergoing total hip arthroplasty were randomly assigned to one of two treatments
groups:
• Tranexamic acid group: n = 20, M/F = 9/9, mean (sd) age = 66 (9.5) years
• Control group (Placebo): n = 20, M/F = 10/10, mean (sd) age = 68 (9.4) years
Interventions • Tranexamic acid group received 100mg/ml of TXA (Cyklokapron), 10mg/kg (maximum 1g)
in a slow (5-10 minutes) IV injection immediately before the operation.
• Control group received a similar volume of saline as the same times as TXA.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), pulmonary embolus
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate - medication was concealed by a code
only known by the hospitals chief pharmacist
who was not involved in the study
Blinding?
All outcomes
Yes Double blind
Berenholtz 2009
Methods Patients were randomised according to a computer-generated randomisation schedule. Allocation
was concealed through central (pharmacy) allocation
Participants 182 patients undergoing orthopaedic surgery were randomly allocated to one of two groups:
• EACA group: n = 91, M/F = 26/65, mean (sd) age = 55.5 (14.0) years
• Control group: n=91, M/F = 29/62, mean (sd) age = 55.4 (15.5) years
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Berenholtz 2009 (Continued)
Interventions • EACA group, received 100mg/kg administered immediately after anaesthesia followed by
infusion of 10mg/kg/hr continued for 8 hours after surgery.
• Control group received saline.
Outcomes Outcomes reported: Number of patients receiving blood transfusion, volume of blood transfused
(units), blood loss, mortality, pulmonary embolism, myocardial infarction, renal failure, stroke,
thrombosis, deep vein thrombosis, length of hospital stay (days)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were randomised according to a com-
puter-generated randomisation schedule
Allocation concealment? Yes Adequate - allocation was concealed through
central (pharmacy) allocation
Blinding?
All outcomes
Yes Double blind
Bernet 1999
Methods Random code used for randomisation. Drug solutions were prepared by the hospital pharmacy
Participants 70 patients were randomised to one of two groups:
• Tranexamic acid group: n = 28, M/F = 25/3, mean (sd) age = 61.3 (2.86) years
• Aprotinin group: n = 28, M/F = 24/4, mean (sd) age = 58.4 (3.76) years
Interventions • Tranexamic group received 200mL (10g) of TXA administered 20 minutes before
sternotomy. Normal saline placebo was given at the same time as aprotinin doses for the purpose
of blinding.
• Aprotinin group received 200ml (2 million KIU=280mg) of aprotinin administered 20
minutes before sternotomy and 200mL (2 million KIU = 280mg) administered as a continuous
infusion of 50ml/hr (500,000 KIU) until closure of the chest.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma (units), platelets (units), blood loss, mortality, myocardial Infarctions, haema-
tocrit levels, stroke, thrombotic complications, re-exploration for bleeding
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used. All patients received ASA until the day of the operation (100mg/day).
All patients received cell salvage (Imed 960) - 8 hours post-operatively
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Bernet 1999 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random code used for randomisation
Allocation concealment? Unclear Adequate - drug solutions were prepared by the
hospital pharmacy
Blinding?
All outcomes
Yes Double blind
Bert 2008
Methods A computer-generated randomisation list was used to generate the allocation sequence. No infor-
mation was provided regarding allocation concealment
Participants 50 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Aprotinin group: n = 25, M/F = 20/5, mean (sd) age = 65.7 (10.2) years
• Control group: n = 25, M/F = 20/5, mean (sd) age = 67.8 (8.3) years
Interventions • Aprotinin group received loading dose of 2,000,000 KIU before sternotomy, then
continuous infusion of 500,000 KIU until wound closure.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Blood loss, volume of blood transfused (units), re-operation for bleeding,
inflammatory cytokines
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol was not reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A computer-generated randomisation list was
used to generate the allocation sequence
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
67Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bidstrup 1989
Methods The trial drug was provided by the manufacturer (Bayer AG, Leverkusen) in identical case packs,
each of 12 bottles identifiable only by the random number. Method of generating allocation se-
quences was not described
Participants 80 patients undergoing primary aorto-coronary bypass grafting were randomised to either one of
two groups:
• Aprotinin group: n = 40, M/F = 37/3, mean (sd) age = 58.1 (8.6) years
• Control group (Placebo): n = 37, M/F = 32/5; mean (sd) age = 57.7 (8.3) years
Interventions • Aprotinin group received after induction of anaesthesia, a loading dose of 280mg of
aprotinin given intravenously through a central venous cannula over 20 mins, then a continuous
infusion of 70mg/hr was begun and maintained until the patient left the operating theatre. In
addition to the intravenous infusion, another 280mg of aprotinin was added to the priming
volume of the heart lung machine by replacement of an aliquot of the priming volume.
• Control group received an equal volume of saline.
NB: Both intervention and control received preoperative autologous donation (PAD)
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), blood loss (18 -24hrs), mortality
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Bidstrup 1990
Methods Method of randomisation and allocation concealment were not described
Participants 44 patients undergoing aortocoronary artery bypass graft surgery were randomly allocated to one
of two groups:
• Aprotinin group: n = 26, M/F = 21/5, mean (sd) age = 59 (8) years
• Control group: n = 18, M/F = 15/3, mean (sd) age = 58 (8) years
Interventions • Aprotinin group received a loading dose of 280mg (2 million KIU) of aprotinin after
induction of anaesthesia and a constant infusion of 70mg/hr during the operation. A further
280mg was added to the pump prime.
• Control group did not receive aprotinin.
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Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), fresh frozen plasma usage (units), platelets (units), blood loss (18-24hrs), re-operation for
bleeding
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Bidstrup 1993
Methods Patients received aprotinin or placebo (normal saline) from identical bottles supplied by the man-
ufacturer, identifiable only by their random number. Method of randomisation was not described
Participants 96 adult male patients undergoing first-time isolated coronary bypass grafting were randomised to
either one of two groups:
• Aprotinin group: n = 47, mean (sd) age = 59.1 (7.4) years
• Control group (Placebo): n = 49, mean (sd) age = 58.8 (8.5) years
NB: Six patients withdrew from the study, four in the aprotinin group and two in the placebo
group
Interventions • Aprotinin group received 280mg of aprotinin (contained in 200ml) as a loading dose before
the commencement of bypass. An additional 280mg of aprotinin was added to the prime of the
heart-lung machine. A constant infusion of 70mg/hr was maintained during the procedure until
skin closure.
• Control group (placebo) received identical volumes of normal saline.
Outcomes Outcomes reported:Allogeneic blood usage (units), blood loss, haemoglobin levels, platelet counts,
haemoglobin loss, activated clotting times, adverse events, graft patency, re-operation for bleeding,
wound infection
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Bidstrup 1993 (Continued)
Adequate sequence generation? Unclear Not reported
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Bidstrup 2000
Methods Patients were allocated to receive either placebo or active treatment in accordance with a previously
determined randomization schedule in a double blind fashion. Allocation concealment was ade-
quate, active drug and placebo were contained in identical bottles, identifiable only by a random
number
Participants 60 patients undergoing aortocoronary bypass were randomised to one of two groups:
• Aprotinin group (High dose): n = 30, M/F = 24/6, mean (sd) age = 63.0 (7.8) years
• Control group (Placebo): n = 30, M/F = 27/3, mean (sd) age = 61.7 (6.8) years
Interventions • Aprotinin group (High dose) received a loading dose 280mg (2 million KIU) of aprotinin
over 20 minutes after anaesthesia, 280mg of aprotinin added to the pump prime and a
continuous infusion of 70mg/hr until the end of the procedure.
• Control group received a placebo of 0.9% normal saline.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, mortality, myocardial
infarction, re-operation for bleeding, wound infection, neurologic disturbance,
atrial fibrillation/flutter.
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Blauhut 1994
Methods Method of randomisation and allocation concealment were not described. No exclusions or loss to
follow-up reported
Participants 45 patients undergoing cardiopulmonary bypass for coronary surgery were allocated at random to
one of three groups:
• Aprotinin group: n = 15, M/F = 13/2, mean (sd) age = 64.1 (2.2) years
• Tranexamic group: n = 16, M/F = 13/3, mean (sd) age = 62.5 (2.2) years
• Control group: n = 14, M/F = 11/3, mean (sd) age = 62.7 (2.6) years
Interventions • Aprotinin group received a loading dose of 2 million kallikrein inactivator units (KIU) plus a
maintenance dose of 500,000 KIU/hr until the patient was transferred to the recovery area of the
intensive care unit. In addition, 1 million KIU was added to the oxygenator priming fluid, giving
an average total dose of 4.2 million KIU of aprotinin.
• Tranexamic (TXA) group received 10mg/kg of TXA beginning 30 minutes before incision
of the skin and followed by 1mg/kg/hr for 10 hours after the beginning of the surgical procedures.
• Control group did not receive aprotinin or TXA treatment.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), blood loss (24 hrs), mortality, platelet function, coagulation, haematocrit levels
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Boldt 1991
Methods Method of randomisation and allocation concealment were not described. No exclusions or loss to
follow-up reported
Participants 30 male patients undergoing elective aortocoronary bypass grafting were randomised to one of
three groups:
• Cell Salvage group: n = 10, mean (sd) age = 60.4 (7.1) years
• Hemofiltration group: n = 10, mean (sd) age = 62.4 (8.6) years
• Aprotinin group: n = 10, mean (sd) age = 62.7 (7.8) years
• Control group: n = 10, mean (sd) age = 46.6 (16.2) years
NB: Control group did not appear to be part of the randomised schedule. Possibly a non-concurrent
or historical control group
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Boldt 1991 (Continued)
Interventions • Cell Salvage group - a cell separator (Cell Saver IV, Hemonetics) was used during and after
CPB.
• Haemofiltration group had blood concentrated during and after CPB by means of a
hemofiltration device (HF-80, Fresenius, Bad Homburg, FRG).
• Aprotinin group received an infusion of 2 million kallikrein inactivator units (KIU) before
the operation (loading dose) and then as a continuous infusion of 500,000 units/hr until the end
of the operation. In addition, 2 million KIU of aprotinin was added to the priming of the heart-
lung machine. In addition blood concentration during and after CPB was performed with a
hemofiltration device (HF-80, Fresenius, Bad Homburg, FRG) the same as for Group 2.
• Control group underwent neurosurgery operations.
NB: Only Group 2 and Group 3 were compared.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), blood loss (24hrs)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used. Study used neurosurgical patients as a control group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Boldt 1994
Methods Method of randomisation and allocation concealment were not described
Participants 40 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group (High dose): n = 20, mean (sd) age = 64 (4) years
• Control group: n = 20, mean (sd) age = 63 (5) years
NB: Gender data were not reported
Interventions • Aprotinin group (High dose) received 2 million KIU of aprotinin after the induction of
anaesthesia, 500,000 KIU/hr of aprotinin as a continuous infusion until the end of the operation,
and 2 million KIU was added to the CPB pump prime.
• Control group received the same amount of saline solution as aprotinin was administered.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss
(24hrs), re-operation for bleeding, haemoglobin levels
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Boylan 1996
Methods Study agents were prepared by the hospital pharmacy using a randomisation schedule provided in
sealed envelopes. The method used to generate allocation sequences was not described
Participants 45 patients undergoing primary, isolated orthotopic liver transplantation were randomised to one
of two groups:
• Tranexamic acid group: n = 25, mean (sd) age = 49.5 (9.1) years
• Control group (Placebo): n = 20, mean (sd) age = 48.8 (9.6) years
Interventions • Tranexamic acid (TXA) group received a continuous infusion of TXA in normal saline
(40mg/kg/hr to a maximum dose of 20g).
• Control group (placebo) received an equivalent volume of 0.9% normal saline alone.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage
(units), blood loss, mortality, portal vein thrombosis, hepatic thrombosis, hospital length of stay,
intensive care unit (ICU) length of stay, overall donor exposure
Notes Quality assessment score (Schulz criteria):5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - randomisation schedule was pro-
vided in sealed envelopes
Blinding?
All outcomes
Yes Double blind
73Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Brown 1997
Methods Method of allocation concealment was not described. Patients were randomised using a computer-
generated random number sequence
Participants 91 patients scheduled for elective coronary revascularisation were randomly allocated to one of
three groups:
• Control group (Placebo): n = 30, M/F = 24/6, mean (sd) age = 59 (7) years
• Tranexamic acid group (TXA before CPB): n = 30, M/F = 25/5, mean (sd) age = 61 (9) years
• Tranexamic acid group (TXA after CPB): n = 30, M/F = 24/6, mean (sd) age = 62 (10) years
Interventions • Control group received equivalent volumes of normal saline solution.
• Tranexamic acid group received 15mg/kg of TXA before CPB, followed by a TXA infusion
of 1mg/kg/hr for 5hrs.
• Tranexamic acid group received 15mg/kg of TXA after CPB, followed by a TXA infusion of
1mg/kg/hr for 5hrs.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, haematologic/throm-
boelastographic/coagulation characteristics, mortality, myocardial infarction, stroke, re-exploration
for bleeding, infection
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Adequate - computer-generated random num-
ber sequence
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Caglar 2008
Methods A computer-generated randomisation list was used to generate the allocation sequence. No infor-
mation was provided regarding allocation concealment
Participants 100 female patients undergoing myomectomy were randomised to one of two groups:
• Tranexamic acid group: n = 50, mean (sd) age = 34.2 (5.5) years
• Control group: n = 50, mean (sd) age = 36.5 (4.5) years
Interventions • Tranexamic acid group received bolus of 10mg/kg over 10 minutes 15 minutes before
incision, then continuous infusion of 1mg/kg/hr for 10 hours.
• Control group received saline.
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Outcomes Outcomes reported: number of patients exposed to allogeneic blood, blood loss, volume of blood
transfused
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Camarasa 2006
Methods Randomisation was achieved by computer-generated random numbers. The randomised assign-
ment was sealed in an opaque, numbered envelope which was opened only by the nurse who pre-
pared the solutions. This nurse was the only person who knew the patients study groups and did
not participate in any other phase of the trial
Participants 68 patients undergoing total knee replacement were randomised to one of two groups:
• Tranexamic acid group: n = 35, M/F = 9/26, mean (range) age = 73 (61-84) years
• Epsilon aminocaproic acid group: n = 32, M/F = 4/28, mean (range) age = 73 (59-80) years
NB: One patient was excluded from the final analysis
Interventions • Tranexamic acid group received 10mg/kg of TXA administered over 30 minutes
immediately before releasing the tourniquet followed by a continuous intravenous infusion of
10mg/kg for 3 hours.
• Epsilon aminocaproic acid group received 100mg/kg of EACA administered over 30
minutes immediately before releasing the tourniquet followed by a continuous intravenous
infusion of 1g/hr for 3 hours.
NB: Both groups were exposed to cell salvage and pre-operative autologous blood donation (PAD)
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage
(units), blood loss, deep vein thrombosis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes Computer-generated random numbers
Allocation concealment? No Inadequate - randomised assignment was sealed
in an opaque, numbered envelope
Blinding?
All outcomes
Yes Double blind
Capdevila 1998
Methods Randomisation was performed using a random number list generated by computer programme.
Allocation was adequately concealed (administered fluids were prepared by the hospitals central
pharmacy in identical 100-ml bottles)
Participants 23 patients scheduled for orthopaedic surgery of the hip, femur or pelvis for sepsis or malignant
tumours were randomly allocated to one of two groups:
• Aprotinin group: n = 12, M/F = 7/5, mean (sd) age = 48.6 (17.3) years
• Control group (Placebo): n = 11, M/F = 6/5, mean (sd) age = 48.5 (16.3) years
Interventions • Aprotinin group was administered a bolus of 1 million kallikrein inactivation units (KIU)
during a 30 minute injection period, followed by a continuous infusion of 500,000 KIU/hr
throughout the duration of surgery.
• Control group received identical volumes of saline over the same time periods.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss, haemoglobin and haematocrit
levels, coagulation and fibrinolytic pathway explorations, allergic reactions
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was performed using a random
number list generated by computer programme
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Carrera 1994
Methods Randomisation and allocation concealment not specified. No exclusions or loss to follow-up re-
ported. [Spanish language]
Participants 102 patients undergoing cardiac surgery were randomly assigned to one of two groups:
• Aprotinin group: n = 51, M/F = 20/31, mean (sd) age = 54 (13.1) years
• Control group: n = 51, M/F = 21/30, mean (sd) age = 55 (13.0) years
Interventions • Aprotinin group received 2 million kallikrein inhibiting units (KIU) of aprotinin upon
anaesthesia induction, a similar dose in the extracorporeal circulation priming pump, and a
maintenance dose of 500,000 KIU/hr until the removal from the operating theatre.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Number of participants exposed to allogeneic blood, allogeneic blood usage,
fresh frozen plasma usage, platelet usage, blood loss, myocardial infarction
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Casas 1995
Methods Generation of allocation sequences was not specified. Allocation concealment was by sealed en-
velopes. The pharmacy prepared the encoded infusions
Participants 149 patients scheduled to undergo either coronary artery bypass grafting (CABG), heart valve
replacement or annuloplasty, combined valve replacement and CABG, or closure of atrial septal
defects, were randomised to one of three groups:
• Aprotinin group: n = 48, M/F = 31/17, mean (sd) age = 57 (10) years
• Desmopressin group: n = 50, M/F = 33/17, mean (sd) age = 58 (12) years
• Control group (Placebo): n = 51, M/F = 31/20, mean (sd) age = 54 (12) years
Interventions • Aprotinin group received 2 million kallikrein inactivator units (KIU) of aprotinin before
anaesthesia (time stage 1) given over 20 to 30 minutes. A dose of 2 million KIU was added to the
prime solution of the heart-lung machine (time stage 2). Aprotinin was administered
continuously (time stage 3) at 500,000 KIU/hr (50ml/hr) until the end of the operation (from
skin incision to skin closure), then patients received 50ml of saline (time stage 4).
• Desmopressin group received desmopressin infusions corresponding to 0.3 to 0.4 ug/kg
body weight. Desmopressin was infused in 50ml of physiologic saline solution for 20 to 30
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Casas 1995 (Continued)
minutes, 15 minutes after protamine administration (time stage 4). In other time phases (1-3)
patients received saline solution only.
• Control group received a placebo of saline solution during all four stages.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood
loss (24hrs), re-operation for bleeding, femoral embolism, stroke
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - allocation concealment was by
sealed envelopes
Blinding?
All outcomes
Unclear Double blind
Casati 1999
Methods Method ofrandomisation and allocation concealment were not described
Participants 210 patients undergoing cardiac surgery were randomly assigned to one of three groups:
• Epsilon aminocaproic group: n = 68, M/F = 54/12, mean (sd) age = 58.7 (10) years
• Tranexamic acid group: n = 72, M/F = 57/13, mean (sd) age = 61.9 (9.6) years
• Aprotinin group: n= 70, M/F = 54/13, mean (sd) age = 63.6 (9.6) years
Interventions • EACA group received 5g during 20 minutes after induction of anaesthesia before
sternotomy followed by a continuous infusion of 2g/hr until the end of the operation + 2.5g
added to the pump prime.
• TXA group received 1g over 20 minutes before sternotomy, followed by a continuous
infusion of 400mg/hour during operative period and 500mg added to the pump prime.
• Aprotinin group received 280mg throughout 20 minutes before sternotomy, followed by a
constant infusion of 70mg throughout the operation and 280mg added to the pump prime.
NB: All groups were exposed to cell salvage. Pre-operative autologous blood donation use was evenly
distributed between groups
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
blood loss, mortality, myocardial infarction, deep venous thrombosis, pulmonary embolus, pre-op-
erative autologous donation of blood, neurological complications, re-operation for surgical bleeding
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
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Casati 1999 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Casati 2000
Methods Patients were randomised into treatment groups bymeans of a computer generated random number
sequence. Allocation concealment was not described. Trial was unblinded
Participants 1040 patients undergoing primary elective cardiac operations were randomly assigned to one of
two groups:
• Tranexamic acid group: n = 522, M/F = 415/107, mean (sd) age = 61 (10) years
• Aprotinin group: n = 518, M/F = 412/106, mean (sd) age = 62 (10) years
Interventions • Tranexamic acid group received 1g over 20 minutes before surgical incision followed by a
constant infusion of 400mg/hr during the entire operative period and 500mg was added to the
pump prime.
• Aprotinin group received 280mg for 20 minutes before surgical incision followed by a
constant infusion of 70mg/hr until the end of the operation and 280mg was added to the pump
prime.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, mortality, myocardial infarction, fresh frozen plasma usage, (units), platelet usage
(units), pulmonary embolus
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated random number sequence
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No
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Casati 2001
Methods Method of randomisation was not described. Coded infusion syringes were used and prepared by
a staff member not directly involved with perioperative clinical treatment
Participants 40 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 15/5, mean (sd) age = 64 (13) years
• Control group (Placebo): n = 20, M/F = 17/3, mean (sd) age = 62 (11) years
Interventions • TXA group (off-pump surgery) received a bolus of 1g of TXA over 20 minutes after the
induction of anaesthesia but before skin incision and a continuous infusion of 400mg/hr during
the whole surgical period.
• Control group received an infusion of saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Casati 2002
Methods Coded infusion syringes were used to conceal which medication was placebo and which was TXA.
Method of randomisation was not described
Participants 60 patients undergoing elective thoracic-aorto surgery were randomised to one of two groups:
• Tranexamic acid group: n = 30, M/F = 23/6, mean (sd) age = 59 (13) years
• Control group (Placebo): n = 30, M/F = 19/10, mean (sd) age = 63 (11) years
Interventions • Tranexamic acid group received a bolus of TXA 1g in 20 minutes after the induction of
anaesthesia but before skin incision and a continuous infusion of 400mg/hr during the whole
surgical period and an additional 500mg of TXA was added to the pump prime of CPB.
• Control group received an infusion of saline solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood
loss (24hrs), re-operation for bleeding, mortality, myocardial infarction, pulmonary embolus, pre-
operative aspirin, pre-operative anticoagulant, stroke, hospital length of stay (days)
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Casati 2002 (Continued)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Casati 2004
Methods Randomisation was by means of two seperate computer-generated random number sequences.
Coded syringes were used to administer medication
Participants 102 patients scheduled for cardiac surgery with either ’on-pump’ or ’off-pump’ procedures were
randomised to one of four groups:
• Control group (Placebo) (’Off-pump’ surgery): n = 25, M/F = 21/4, mean (sd) age =61 (11)
years
• Tranexamic acid group (’Off-pump’ surgery): n = 26, M/F = 20/6, mean (sd) age = 64 (12)
years
• Control group (placebo) (’On-pump’ surgery): n = 25, M/F = 21/4, mean (sd) age = 60 (9)
years
• Tranexamic acid group (’On-pump’ surgery): n = 26, M/F = 24/2, mean (sd) age = 64 (9)
years
Interventions • Control group (’Off-pump’ surgery) received an equivalent volume of saline solution
administered as a bolus injection in 20 minutes before skin incision, followed by a continuous
infusion of saline until the completion of surgery.
• Tranexamic acid group (’Off-pump’ surgery) received a bolus injection of 1g of TXA in 20
minutes before skin incision followed by a continuous infusion of 400mg/hr until completion of
surgery.
• Control group (’On-pump’ surgery) received the same treatment as Group 1 plus received an
equivalent volume of saline solution added to the CPB pump.
• Tranexamic acid (’On-pump’ surgery) received the same treatment as Group 2 plus received
500mg of TXA added to the pump prime.
NB: ’On-pump’ surgery patients (Groups 3 & 4) the remaining blood in the cardiopulmonary
bypass (CPB) circuit and that blood aspirated from the surgical field was concentrated with a cell
separator and reinfused. For ’Off-pump’ surgery patients only in cases of significant intra-operative
bleeding was the shed blood concentrated in a cell separator and reinfused. No autotransfusion of
shed mediastinal blood was performed during the post-operative period for any group
ONCAB-Cell Salvage. Only in cases of significant intra-operative bleeding was the shed blood
concentrated in a cell separator and reinfused. No autotransfusion of shed mediastinal blood was
performed during the post-operative period
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Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, number of participants exposed to platelets,
blood loss (24hrs), re-exploration for bleeding, stroke, intra-operative resternotomy, fresh frozen
plasma usage (units), platelet usage (units)
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomnumber sequences
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Cicek 1996a
Methods Method of randomisation and allocation concealment were not described
Participants 75 patients scheduled for elective cardiac operations with cardiopulmonary bypass were randomly
assigned to one of three groups:
• Aprotinin group (High dose): n = 25, M/F = 22/3, mean (sd) age = 44.9 (18.6) years
• Aprotinin group (Post-operative low dose): n = 25, M/F = 19/6, mean (sd) age = 52.9 (12.4)
years
• Control group: n = 25, M/F = 21/4, mean (sd) age = 46.7 (15) years
Interventions • Aprotinin group (High dose) received a bolus of 2 million kallikrein inhibiting units (KIU)
of aprotinin (280mg), plus a maintenance dose of 500,000 KIU/hr (70mg/hr) until the end of
the operation. In addition 2 million KIU (280mg) was added to the oxygenator priming fluid.
• Aprotinin group (Post-operative low dose) received a bolus of 2 million KIU (280mg) at the
end of the procedure before transfer to the intensive care unit.
• Control group did not receive aprotinin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial infarction
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Cicek 1996b
Methods Patients were randomised to receive aprotinin or placebo by means of a random numbers table.
Method of allocation concealment was not described
Participants 57 patients undergoing cardiac operations with cardiopulmonary bypass (CPB) were randomly
assigned to one of two groups:
• Aprotinin group: n = 29, M/F = 21/8, mean (sd) age = 51.6 (15.4) years
• Control group (Placebo): n = 28, M/F = 19/9, mean (sd) age = 48.2 (14.2) years
Interventions • Aprotinin group received a bolus of 2 million kallikrein inhibiting units (KIU) of aprotinin
(280mg) infused over 15 minutes when they arrived in intensive care.
• Control group received an equal volume of normal saline solution at corresponding times to
the aprotinin treated group.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers table
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Cicekcioglu 2006
Methods Method of randomisation and allocation concealment were not described. Data were collected in
a blinded fashion
Participants 44 patients undergoing coronary artery bypass grafting were randomly assigned to one of two
groups:
• Aprotinin group: n = 24, M/F = 19/5, mean (sd) age = 48.6 (12.1) years
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• Control group (Placebo): n = 20, M/F = 18/2, mean (sd) age = 48.3 (9.0) years
Interventions • Aprotinin group (low-dose) administered in two equal doses - bolus of 250,000 KIU 5
minutes before skin incision just after induction of anaesthesia, second dose of 250,000 KIU was
added to the prime pump.
• Control group received saline.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, amount of allogeneic blood
transfused (units), blood loss, mortality, length of hospital stay, post-operative morbidity
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Claeys 2007
Methods Methods of sequence generation and allocation concealment were not described
Participants 40 patients undergoing orthopaedic (hip) surgery were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 5/15, mean (sd) age = 73 (8) years
• Control group (Placebo): n = 20, all females, M/F = 7/13, mean (sd) age = 68 (11) years
Interventions • Tranexamic acid group received single pre-operative dose of 15mg/kg.
• Control group received a placebo of saline.
Outcomes Outcomes reported: Number of patients receiving blood transfusions, blood loss, deep vein throm-
bosis
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
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Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Coffey 1995
Methods Method of randomisation was not described. Pharmacy controlled the randomisation process.
Method of allocation concealment was not clear
Participants 30 patients undergoing cardiac surgery were randomised to either one of two groups:
• Tranexamic acid group: n = 16, M/F = 5/11, mean age = 63.94 years
• Control group (Placebo): n = 14, M/F = 5/9, mean age = 64.75 years
Interventions • Tranexamic acid group received a loading dose of 10mg/kg of TXA over a period of 30
minutes at the time of skin incision followed by a 1mg/kg/hr infusion over 12 hours.
• Control group received an equal volume of saline.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, mortality
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Cohen 1998
Methods Patients were randomised by the hospital pharmacy after stratification and blocking in groups of
six. The pharmacy supplied bags that contained dipyridamole (DIP), aprotinin (APR) or a saline
placebo
Participants 115 patients undergoing cardiac operations for valve replacement or myocardial revascularization,
or a combined procedure were randomised to one of two groups:
• Aprotinin group: n = 56, M/F = 44/12, mean (sd) age = 63 (9) years
• Control group (Placebo): n = 59, M/F = 47/12, mean (sd) age = 61 (8) years
85Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cohen 1998 (Continued)
Interventions • Aprotinin group received a high dose of aprotinin (Full Hammersmith) with a loading dose
of 280mg (2 million KIU) plus a pump prime dose of 280mg and a maintenance dose 70mg/hr
intra-operatively and continued for 1 hour post-operatively.
• Control group received a saline placebo.
NB: All patients were administered dipyridamole (DIP) orally (100mg four times daily for three or
more doses pre-operatively) and intravenously (at a rate of 0.24mg/kghr beginning before anaes-
thesia induction and continuing for 1 hour post-operatively). Autologous blood shed into sterile
cardiotomy reservoirs from chest drains was autotransfused to the patient when drainage exceeded
150ml during the first 4 hours post-operatively
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, mortality, my-
ocardial infarction, autologous shed blood transfused, blood loss (24 hrs),
renal failure, stroke, intensive care unit length of stay (days), hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Colwell 2007
Methods Patients were randomly assigned on the day of surgery to a treatment group in a 1:1 ration from a
computer-generated list managed by an interactive voice response system. Aprotinin and placebo
were provided to the pharmacy in the same packaging and were dispensed by the randomisation
assignment, blinding the patient and staff to the actual treatment group. The primary efficacy
analysis was performed on the intention-to-treat population
Participants 359 patients undergoing orthopaedic surgery (hip arthroplasty) were randomised to one of two
groups:
• Aprotinin group: n = 180, M/F = 61/84, mean (sd) age = 63.4 (12.1) years
• Control group: n = 179, M/F = 81/96, mean (sd) age = 64.4 (12.7) years
Interventions • Aprotinin group - received a test dose of 10,000 KIU, loading dose of 2 million KIU, then
0.5 million KIU per hour until end of surgery.
• Control group received saline.
Outcomes Outcomes reported: Number of patients receiving blood transfusions, volume of blood transfused
(units), blood loss, deep vein thrombosis, renal failure, myocardial infarction, stroke, mortality,
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pulmonary embolism
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated list
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Corbeau 1995
Methods Method of randomisation and allocation concealment were not described. Two patients were ex-
cluded after randomisation. [French language]
Participants 104 adults undergoing either coronary artery bypass grafting (CABG) or aortic valve replacement
(AVR) were randomised to one of three groups:
• Aprotinin group: n = 43 [AVR: n = 20, M/F = 13/7, mean (sd) age = 64 (16) years; CABG:
n = 23, M/F = 20/3, mean (sd) age = 68 (8) years]
• Tranexamic acid group: n = 41 [AVR: n = 19, M/F = 7/12, mean (sd) age = 63 (19) years;
CABG: n = 22, M/F = 19/3, mean (sd) age = 62 (9) years
• Control group: n = 20 [AVR: n = 10, M/F = 7/3, mean (sd) age = 60 (22) years; CABG: n =
10, M/F = 9/1, mean (sd) age = 66 (3) years]
Interventions • Aprotinin group received 2 million kallikrien inactivator units (KIU) of aprotinin (280mg)
after induction of anaesthesia, followed by an infusion of 500,000 KIU/hr (70mg/hr) until chest
closure, with a supplement to the oxygenator prime of 2 million KIU of aprotinin.
• Tranexamic acid group received 15mg/kg of TXA between the injection of heparin (400IU/
kg) and the beginning of extracorporeal circulation, plus 15mg/kg after protamine injection (1.
3mg/100IU of heparin).
• Control group did not receive any antifibrinolytic therapy.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Cosgrove 1992
Methods Methodof randomisation and allocation concealmentwere not described. All subjects were included
in the final analysis
Participants 169 patients undergoing isolated re-operative myocardial revascularisation were randomised to
either one of three groups:
• Aprotinin group (High dose): n = 57, males (87.7%), mean (sd) age = 60.8 (7.8) years
• Aprotinin group (Low dose): n = 56, males (80.4%), mean (sd) age = 61.1 (8.3) years
• Control group (Placebo): n = 56, males (87.5%), mean (sd) age = 63.0 (8.8) years
Interventions • Aprotinin group (High dose) received 70mg of aprotinin in 50ml of 0.9% saline. After
induction of anaesthesia, a loading dose of 200ml of aprotinin solution was given intravenously
over 20 minutes. Immediately after this, a continuous infusion of 50ml/hr was begun and
maintained until the patient left the operating room. An additional 200ml of aprotinin was added
to the prime volume of the cardiopulmonary bypass machine.
• Aprotinin group (Low dose) received 35mg of aprotinin in 50ml of 0.9% saline solution at
corresponding times as Group 1.
• Control group received 50ml of saline solution at corresponding times as Group 1.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, mortality, myocardial infarction, re-operation for bleeding, fresh frozen plasma usage (units),
platelet usage (units)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Cvachovec 2001
Methods Method of randomisation and allocation concealment were not described in the abstract. [Czech
Republic]
Participants 42 patients undergoing total hip arthroplasty were randomly allocated to one of two groups:
• Aprotinin group (Low dose): n = 20, M/F = 10/10
• Control group: n = 22, M/F = 8/14
NB: No age data were reported
Interventions • Aprotinin group (Low dose) received 2 million KIU (280mg) of aprotinin started pre-
operatively and continued in the course of the first hour of surgery.
• Control group did not receive aprotinin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Foreign language paper
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
D’Ambra 1996
Methods A separate random code, using blocks of six, was generated for each site by the statistical department
of Bayer Incorporated. The study medication for each patient was supplied for each patient in a
case pack containing 14 vials. The loading dose vials, pump prime vials, and constant infusion vials
were separately identified and packaged within the pack for each patient. Investigators were blinded
to the identity and lot number of each case pack
Participants 213 patients undergoing cardiac surgery were enrolled and randomised at the five sites to one of
three groups:
• Aprotinin group (High dose): n = 65, M/F = 31/34, mean (sd) age = 59.8 (3.1) years
• Aprotinin group (Low dose): n = 62, M/F = 33/29, mean (sd) age = 59.2 (3.2) years
• Control group (Placebo): n = 64, M/F = 30/34, mean (sd) age = 60.0 (3.1) years
NB: Of the 213 patients enrolled and randomised, 212 were included in the safety analysis and
191 were included in a primary analysis of efficacy
Interventions • Aprotinin group (High dose) received an intravenous loading dose of 280mg of aprotinin (2
million KIU) infused over 20-30 minutes followed by a continuous infusion of 70mg/hr (500,
000 KIU/hr) infused until chest closure. An additional dose of aprotinin equivalent to the loading
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dose was added to the pump prime.
• Aprotinin group (Low dose) received a loading dose of 140mg of aprotinin (1 million KIU)
infused over 20-30 minutes followed by a continuous infusion of 35mg (250,000 KIU/hr) of
aprotinin, infused until chest closure. An additional dose of aprotinin, equivalent to the loading
dose, was added to the pump prime.
• Control group received equivalent volumes of normal saline solution at corresponding times
to the active treatments.
NB: Blood conservation measures were used for all groups. These measures included the reinfusion
of post-operative mediastinal shed blood (cell salvage) and the pre-operative donation of autologous
blood (PAD). Epsilon aminocaproic acid (EACA) and desmopressin (DDAVP) were used to treat
active bleeding after the reversal of heparin
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), mortality, myocardial infarction, re-
operation, renal dysfunction, deep vein thrombosis, cardiovascular complications, cerebrovascular
accident
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random code generated for each site by the sta-
tistical department of Bayer
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
D’Ambrosio 1999
Methods Method of randomisation and allocation concealment were not described
Participants 60 patients undergoing total hip arthroplasty were randomised into one of four groups:
Comparison 1:
• Aprotinin group: n = 15, M/F = 8/7, mean (sd) age = 61.5 (9.2) years
• Control group (Placebo): n = 15, M/F = 9/6, mean (sd) age = 66.7 (7.3) years
Comparison 2:
• Aprotinin group: n = 15, M/F = 7/8, mean (sd) age = 66.6 (9.2) years
• Control group (Placebo): n = 15, M/F = 7/8, mean (sd) age = 60.5 (12.9) years
Interventions Comparison 1:
• Aprotinin group (epidural + general anaesthesia) received 500,000 KIU of aprotinin
administered as a bolus before skin incision and 500,000 KIU continuous infusion until the skin
was sutured.
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• Control group (epidural + general anaesthesia) received saline solution 0.9% in same
manner as aprotinin.
Comparison 2:
• Aprotinin group (general anaesthesia) 500,000 KIU was administered as a bolus before skin
incision and 500,000 KIU continuous until the skin was sutured.
• Control group (placebo) (general anaesthesia) saline solution 0.9% in the same manner as
aprotinin.
NB: All subjects were exposed to pre-operative autologous blood donation and cell savage
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, allogeneic &
autologous blood usage (units)
Notes Quality assessment score (Schulz criteria): 2/7
No transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Daily 1994
Methods Method of randomisation was not described. Epsilon-aminocaproic acid (EACA) and placebo were
delivered to the operating room in numbered, but otherwise identical vials labelled “study drug”
Participants 40 patients undergoing first-time coronary artery bypass grafting without prior sternotomy were
randomised to one of two groups:
• Epsilon aminocaproic acid group: n = 21, M/F 14/7, mean (sd) age = 63 (9) years
• Control group (Placebo): n = 19, M/F = 18/1, mean (sd) age = 67 (10) years
Interventions • Epsilon aminocaproic acid group (EACA) received 10g of EACA in 40ml of saline solution
given after induction of anaesthesia but before the skin incision. Another 40ml was given after
heparin administration in the pump, and a third 40ml dose was given after the administration of
protamine.
• Control group (Placebo) received equivalent volumes of saline solution.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss (12/24hrs), my-
ocardial infarction, stroke (cerebrovascular accident), use of shed mediastinal blood
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Dalmau 1999
Methods Method of randomisation and allocation concealment were not described
Participants 124 patients undergoing orthotopic liver transplantation were randomised to one of three groups:
• Epsilon aminocaproic acid group: n = 42
• Tranexamic acid group: n = 42
• Control group (Placebo) group: n = 40
NB: No age or gender data were reported.
Interventions • Epsilon aminocaproic acid (EACA) group received a continuous infusion of EACA (8g in
480mL normal saline) at 16mg/kg per hour. EACA was infused from induction of anaesthesia to
graft reperfusion.
• Tranexamic acid group (TXA) received a continuous infusion of TXA (5g in 450mL normal
saline) at 10mg/kg per hour. TXA was infused from induction of anaesthesia to graft reperfusion.
• Control group received an equal volume infusion of normal saline. Placebo was infused from
the induction of anaesthesia to graft reperfusion.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), thrombotic events, cryoprecipitate (units)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Dalmau 2000
Methods Drugs were prepared then randomised to patients using a randomisation schedule provided in
sealed envelopes
Participants 132 patients undergoing orthotopic liver transplantation (OLT) were randomly assigned to one of
three groups:
• Epsilon aminocaproic acid group: n = 42, M/F = 26/16, median (range) age = 56 (32-69)
years
• Tranexamic acid group: n = 42, M/F = 31/11, median (range) age = 58 (22-69) years
• Control group (Placebo): n = 40, M/F = 22/18, median (range) age = 60 (18-67) years
Interventions • Epsilon aminocaproic acid (EACA) group received a continuous infusion of EACA (8g in
480ml of normal saline) at a rate of 16mg/kg/hr from the induction of anesthesia until the portal
vein was unclamped.
• Tranexamic acid (TXA) group received a continuous dose infusion of TXA (5g in 450ml of
normal saline) at a rate of 16mg/kg/hour from the induction of anaesthesia until the portal vein
was unclamped.
• Control group received isotonic saline at an equal volume (10ml/kg/hour) from the
induction of anaesthesia until the portal vein was unclamped.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma (units), platelets (units), other arterial thrombosis,
prophylactic DDAVP treatment, DDAVP treatment for bleeding, EACA treatment (clinical fibrol-
ysis)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes were used to con-
ceal treatment allocation
Blinding?
All outcomes
Yes Double blind
Dalmau 2004
Methods Drugs were prepared and then randomised to patients using a randomisation schedule provided in
sealed envelopes. Method of randomisation was not described
Participants 127 patients undergoing orthotopic liver transplantation were randomised to one of two groups:
• Aprotinin group (Low dose): n = 63, M/F = 45/19, mean (sd) age = 54 (9) years
• Tranexamic acid group: n = 64, M/F = 44/19, mean (sd) age = 53 (10) years
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Interventions • Aprotinin group (Low dose) received a bolus of 2 million KIU in 250ml of IV solution in 30
minutes followed by a continuous infusion of 500, 000 KIU/hr. Diluted in normal saline to be
administered at a rate of 100ml/hr after the bolus dose.
• Tranexamic acid (TXA) group received a bolus of 250ml of normal saline in 30 minutes
followed by a continuous infusion of TXA at a dose of 10mg/kg/hr. Diluted in normal saline to
be administered at a rate of 100ml/hour after the bolus dose.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma (units), platelets (units)
, mortality, myocardial infarction, DDAVP pre-operative administration, EACA intra-operative
administration, any thrombosis, re-operation for bleeding, renal failure
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes were used to con-
ceal treatment allocation
Blinding?
All outcomes
Yes Double blind
Defraigne 2000
Methods Randomisation was accomplished using a random number table. Sealed envelopes were used to
conceal treatment allocation
Participants 200 patients undergoing cardiac surgery were randomly allocated to one of four groups:
• Aprotinin group: n = 50, M/F = 34/16, mean (sd) age = 62.8 (13.4) years
• Control group: n = 50, M/F = 36/14, mean (sd) age = 64.2 (11.3) years
• Aprotinin group: n = 50, M/F = 35/15, mean (sd) age = 64 (13.4) years
• Control group: n = 50, M/F = 34/16, mean (sd) age = 60.1 (12.7) years
Interventions • Aprotinin group (Heparin coated CPB circuit with aprotinin administration - HCO-A)
received a loading dose of 280mg (2 million KIU) before surgery and 280mg in the pump prime
and a continuous infusion of 500, 000 KIU/hour IV.
• Control group (Heparin coated CPB circuit without aprotinin - HCO).
• Aprotinin group (Uncoated CPB circuit with aprotinin) received a loading dose of 280mg (2
million KIU) of aprotinin before surgery and 280mg in the prime solution and continuous
infusion of 500,000 KIU/hour IV.
• Control group (Uncoated CPB circuit without aprotinin administration).
Outcomes Outcomes reported:Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage
(units), blood loss
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Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? No Inadequate - sealed envelopes were used to con-
ceal treatment allocation
Blinding?
All outcomes
No Single blind
Del Rossi 1989
Methods Method of randomisation and allocation concealment were not described
Participants 350 patients undergoing elective coronary artery bypass surgery, repair of myocardial aneurysms,
valve replacement or combined procedures were randomly assigned to one of two groups:
• Epsilon aminocaproic acid group: n = 170, M/F = 132/38, mean (sd) age males = 58.9 (2.1)
years; mean (sd) age females = 61.6 (2.8) years
• Control group (Placebo): n = 180, M/F = 144/66, mean (sd) age males = 59.8 (5.6) years;
mean (sd) age females = 60.2 (4.2) years
Interventions • Epsilon aminocaproic acid group received an initial priming dose of 5g of EACA prior to
skin incision, followed by a continuous infusion of 1g/hr over the next 6 to 8 hours.
• Control group received saline solution in the same fashion.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24hrs), mortality, myocardial in-
farction, re-operation for bleeding, stroke, graft failure
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
95Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Deleuze 1991
Methods Pharmaceutical company supplied the study drugs in identical bottles, identifiable only by number.
The method of generating allocation sequences was not described. [French]
Participants 60 coronary patients undergoing at least two aorto-coronary bypass grafts for the first time were
randomised to one of two groups:
• Aprotinin group: n = 30, M/F = 24/6, mean (sd) age = 60.3 (8.0) years
• Control group (Placebo): n = 30, M/F = 25/5, mean (sd) age = 61.3 (8.0) years
Interventions • Aprotinin group received 4 flasks (200ml) of aprotinin intravenously, after the induction of
anaesthesia, over 30 minutes via a central venous catheter, then a continuous infusion of aprotinin
at 50ml/hr until the end of surgery. A further 4 flasks were administered via the extracorporeal
circulation circuit.
• Control group received the equivalent volume of physiological serum over the same time
periods.
NB: One active flask contained 70mg (500,000 KIU) of aprotinin in 50mls of physiological serum.
One placebo flask contained an equivalent quantity of physiological serum
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (48 hrs), re-operation
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
French article - translated
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Demeyere 2006
Methods Method of sequence generation and allocation concealment were not described. [Poster presenta-
tion]
Participants 60 patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotinin group: n=20
• Tranexamic acid group: n = 20
• Control group: n = 20
NB: Demographic data were not reported.
Interventions • Aprotinin group (High dose) received 280mg loading dose, 70mg/hr infusion rate and
280mg in the pump prime.
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• Tranexamic acid group received 100mg loading dose then 1mg/kg/hr infusion.
• Control group received saline.
Outcomes Outcomes reported: Transfusion of blood products, blood loss, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Desai 2009
Methods Methods of sequence generation and allocation concealment were unclear
Participants 75 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group: n = 38
• Control group: n = 37
NB: Demographic data were not reported.
Interventions • Aprotinin group (full-dose) 10,000 KIU test dose, 2 million KIU via central line and 500,
000 KIU/hr IV until the end of surgery.
• Control group received saline.
Outcomes Outcomes reported: Number of patients receiving blood transfusion, blood loss, myocardial in-
farction, renal failure, mortality, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Yes Double blind
Dietrich 1990
Methods Method of randomisation was not described. Aprotinin and placebo were provided by the manu-
facturer (Bayer AG, Leverkusen, FRG) in identical packages, each containing 12 bottles that could
only be identified by the random number. One patient from the aprotinin trial arm was excluded
from the final analysis
Participants 40 patients scheduled for elective primary myocardial revascularisation were randomised to one of
two groups:
• Aprotinin group: n = 20, mean (sd) age = 58 (10) years
• Control group (Placebo): n = 20, mean (sd) age = 55 (8) years
NB: Gender data were not reported.
Interventions • Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin after
induction of anaesthesia and before surgery, over a 15 minute period followed by a continuous
infusion of 500,000 KIU/hr administered by infusion pump for the entire duration of surgery. An
additional bolus of 2 million KIU of aprotinin was added to the pump prime of the heart-lung
machine.
• Control group received an equal volume of saline solution.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic whole blood usage
(ml/units), fresh frozen plasma usage (units), platelet usage (units), blood loss, re-operation for
bleeding
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Dietrich 1992
Methods Method of randomisation and allocation concealment were not described. No exclusions reported
Participants 1784 adult patients undergoing primary coronary artery bypass grafting, valve replacement (or
combined procedures), and cardiac reoperations, were randomly assigned to one of two groups:
• Aprotinin group: n = 902, M/F = 667/239, mean (sd) age = 60 (10) years
• Control group: n = 882, M/F = 653/229, mean (sd) age = 59 (11) years
Interventions • Aprotinin group received a loading dose of 2 million KIU of aprotinin after induction of
anaesthesia and before surgery, over a 15-minute period, followed by a continuous infusion of 500,
000 KIU/hr administered by an infusion pump during the entire course of surgery. An additional
bolus of 2 million KIU of aprotinin was added to the pump prime of the heart-lung machine.
• Control group received no aprotinin.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage,
blood loss (36 hrs), mortality, intensive care unit length of stay (days), re-operation, renal failure,
hypotension
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Dietrich 1995
Methods Patients were independently randomised, using a table of random numbers, to either aprotinin or
control group. Aprotinin and placebo were provided by the manufacturer (Bayer AG, Leverkusen,
Germany) in identical packages each containing 14 bottles, that could only be identified by the
random number. No loss to follow-up reported
Participants 30 male patients scheduled for elective primary coronary revascularisation were randomly assigned
to one of two groups:
• Aprotinin group: n = 15, mean (sd) age = 62.93 (6.77) years
• Control group (Placebo): n = 15, mean (sd) age = 62.07 (10.01) years
Interventions • Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin over a 15-
minute period at the start of surgery, followed by a continuous infusion of 500,000 KIU/hr
throughout the course of surgery. An additional bolus of 2 million KIU was added to the prime of
the heart-lung machine.
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• Control group received an equal volume of saline.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, complications, re-operation, mortality
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Table of random numbers
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Dietrich 2008
Methods Computer-generated randomisation list and central allocation were used
Participants 220 patients undergoing cardiac surgery were randomly allocated to one of two groups:
• Aprotinin group: n = 110, M/F = 82/28, mean (sd) age= 67.3 (10.6) years
• Tranexamic acid group (n = 110), M/F = 72/38, mean (sd) age = 69.8 (10.3) years
Interventions • Aprotonin group received a 1ml test dose, then 1 million KIU IV over 10 minutes, then
continuous infusion of 500,000 KIU/hr for the duration of surgery, additional 2 million KIU
added to CPB circuit priming fluid.
• Tranexamic acid group received a 2g bolus dose, followed by a continuous infusion of 1g/hr,
additional bolus added to CPB circuit priming fluid.
Outcomes Outcomes reported: Number of patients receiving blood transfusion, volume of blood transfused
(units), mortality, renal failure, length of hospital stay (days)
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation list
Allocation concealment? Yes Adequate
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Blinding?
All outcomes
Yes Double blind
Dignan 2001
Methods Study drug was administered by the anesthesiologist as an infusion in a blinded fashion. Allocation
concealment was not described
Participants 200 participants undergoing elective cardiac surgery were randomly assigned to one of two groups:
• Aprotinin group (Low dose): n = 101, M/F = 75/26, mean (range) age = 62.8 (35-80) years
• Control group (Placebo): n = 99, M/F = 77/22, mean (range) age = 65.2 (40-81) years
Interventions • Aprotinin group received 1 million KIU of aprotinin in total (140mg) - 500,000KIU before
skin incision and 500,000 KIU during the initiation of CPB.
• Control group received the same volume of normal saline.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic whole blood usage
(units/mls), fresh frozen plasma usage (units), platelet usage (units),
blood loss, re-operation for bleeding, acute renal failure, stroke
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Diprose 2005
Methods Computer generated random numbers determined patient allocation to one of three treatment
groups. Sealed envelopes were used to conceal treatment allocation
Participants 186 patients undergoing elective cardiac surgery were randomly assigned to one of three groups:
• Aprotinin group (High dose): n = 63, M/F = 52/8, median (interquartile range) age = 62
(55-69) years
• Tranexamic acid group: n = 62, M/F = 49/11, median (interquartile range) age = 65 (58.5-
73.5) years
• Control group (Placebo): n = 61, M/F = 52/8, median (interquartile range) age = 65(60-70)
years
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Diprose 2005 (Continued)
Interventions • Aprotinin group received 2 million KIU (280mg) in 200ml volume at the start of surgery, 2
million KIU of aprotinin was added to the pump prime, and a continuous infusion of 500,000
KIU/hr was given throughout the operation.
• Tranexamic acid group received 5g in 200ml normal saline, 200ml of normal saline added to
the pump prime, and a continuous infusion of 50ml/hour of normal saline throughout the
operation.
• Control group received normal saline as an IV bolus into the pump prime and a continuous
infusion of 50ml/hour of normal saline per hour throughout the operation.
NB: All groups received intra-operative cell salvage (Compact A; Dideco, Sorin Biomedica, Italy)
and each group received a test dose of 5ml of study solution
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, mortality, myocardial infarction, re-operation for bleeding, renal failure, respiratory
failure
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated random numbers deter-
mined patient allocation
Allocation concealment? No Inadequate
Blinding?
All outcomes
Yes Double blind
Dorman 2008
Methods Method of sequence generation and allocation concealment were not described
Participants 60 patients undergoing cardiac surgery were randomly allocated to one of two groups:
• Aprotinin group: n = 30, M/F = 25/5, mean (SEM) age = 62.0 (2.0) years
• Epsilon aminocaproic acid group: n = 30, M/F = 20/10, mean (SEM) age = 60.0 (2.0) years
Interventions • Aprotonin group received 1 million KIU IV at the start of surgery with an additional 1
million KIU in the CPB circuit, and a continuous infusion of 250,000 KIU per hour until the
end of surgery.
• Epsilon aminocaproic acid group received 5g IV concurrent with systemic heparinization
and an additional 5g in the CPB circuit, and another 5g administered IV immediately after
discontinuation of CPB.
Outcomes Outcomes reported: Number of patients receiving blood transfusion, volume blood transfused
(units), blood loss
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Dorman 2008 (Continued)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Dryden 1997
Methods Method of randomisation was not described. The “study drug” was mixed by independent Intensive
Care Unit (ICU) personnel
Participants 41 patients undergoing re-operative cardiac valve surgery were randomised to one of two groups:
• Tranexamic acid group: n = 22, M/F = 9/13, mean (sd) age = 63 (12.6) years
• Control group (Placebo): n = 19, M/F = 8/11, mean (sd) age = 64 (18) years
Interventions • Tranexamic acid group received 10g of TXA in 500ml of normal saline infused after the
induction of anaesthesia as an intravenous bolus over 30 minutes prior to skin incision.
• Control group received normal saline solution in the same volume.
Outcomes Outcomes reported:Allogeneic blood usage (mls), blood loss, total platelets transfused, total plasma
transfused, mortality, hospital length of stay (days), hospital complications, re-operation for active
bleeding
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
No Single blind
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Eberle 1998
Methods Different treatment solutions were identical in appearance. Method of randomisation was not
described
Participants 40 patients undergoing cardiac surgery were randomised to one of three groups:
• Epsilon aminocaproic acid group: n = 20, mean (sd) age = 61(10) years
• Aprotinin group: n = 20, mean (sd) age = 60 (10) years
• Non-randomised historical control group: n = 10, mean (sd) age = 57 (14) years
NB: No gender data were reported.
Interventions • Epsilon aminocaproic acid group received a test dose of 1 mL followed after 10 minutes by a
loading dose of 200mL of solution given over 30 minutes. EACA was infused continuously at a
rate of 50ml/hour until the start of CPB. EACA-10g both as loading and pump prime dose at 2.
5g/hour as an infusion.
• Aprotinin group received the same volume regimen as EACA. 2 million KIU (280mg) for
loading and pump prime followed by an infusion of 500,000 KIU/hour (70mg/hr) from CPB
weaning until 4 hours after heparin reversal.
• Control group did not receive either EACA or aprotinin treatment.
NB: Both EACA and aprotinin groups received cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial Infarction
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Ehrlich 1998
Methods Each bottle of aprotinin provided by the pharmaceutical company was placed in a box with bottles
of normal saline solution. These bottles were indistinguishable from one another. An assistant, who
was only involved in randomisation of the medication, arranged these bottles into 50 pairs. Each
pair consisted of two bottles of aprotinin or two bottles of saline solution. Each of these pairs was
randomly assigned a number from 1 to 50. Each patient was randomly assigned a number and
then given the corresponding bottles. After the study was completed, the randomisation code was
broken and the data were analysed
Participants 50 patients undergoing thoracic aortic operations with the use of profound hypothermic circulatory
arrest were randomly assigned to one of two groups:
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Ehrlich 1998 (Continued)
• Aprotinin group: n = 25, M/F = 9/16, mean (range) age = 70 (58-80) years
• Control group (Placebo): n = 25, M/F = 7/18, mean (range) age = 70 (60-78) years
Interventions • Aprotinin group received 1 million KIU of aprotinin (140mg) before the onset of
cardiopulmonary bypass.
• Control group received an equal volume of 0.9% saline solution as a placebo.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, mortality (30-day), myocardial
infarction, renal dysfunction/renal failure, re-operation for bleeding, neurological deficit, stroke
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Ekback 2000
Methods Method of randomisation and allocation concealment were not described
Participants 40 patients undergoing elective adult surgery and were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 9/11, mean (sd) age = 66.4 (9.0) years
• Control group (Placebo): n = 20, M/F = 11/9, mean (sd) age = 65.6 (8.8) years
Interventions • Tranexamic acid group received a bolus dose of 10mg/kg before surgical incision. A
continuous infusion of 1.0mg/kg/hr during 10 hours was then started immediately after the first
bolus dose. A second bolus dose of 1.0mg/kg was given three hours later to counteract potential
dilutive effects of intra-operative autotransfusion.
• Control group received physiological saline as a placebo.
NB: All study participants underwent pre-operative autologous blood donation (2 units autologous
blood donated) on two occasions within a four week period. Both trial arms were equally exposed
to cell salvage
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, deep vein throm-
bosis
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
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Ekback 2000 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Ellis 2001
Methods Randomisation was carried out using a computer generated randomisation table. Allocation con-
cealment was not described
Participants 30 patients were randomly assigned to one of three groups:
• Tranexamic acid group: n = 10, M/F = 4/6, mean (sd) age = 71(5) years
• Desmopressin group: n = 10, M/F = 2/8, mean (sd) age = 72 (6) years
• Control group (Placebo): n = 10, M/F = 3/7, mean (sd) age = 72 (8) years
Interventions • Tranexamic acid group received TXA 30 minutes before deflating the limb tourniquet an IV
bolus dose (15mg/kg) administered over a 30 minute period, thereafter a constant IV infusion of
TXA (10mg/kg/hr) was administered until 12 hours after final deflation of the limb tourniquet.
• Desmopressin group 30 minutes before deflating the limb tourniquet an IV bolus dose of
DDAVP (0.3micrograms/kg) was infused over a 30 minute period, thereafter a constant IV
infusion of saline was administered until 12 hours after final deflation of the limb tourniquet.
• Control group received an equal volume of saline.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogenic blood usage (units)
, hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisationwas carried out using a computer
generated randomisation table
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Engel 2001
Methods Method of randomisation and allocation concealment was not described
Participants 36 patients were randomised to one of three groups:
• Tranexamic acid group: n = 12, M/F = 4/8, mean (sd) age = 71 (9) years
• Aprotinin group: n = 12, M/F = 3/9, mean (sd) age = 71 (9) years
• Control group: n = 12, M/F = 4/8, mean (sd) age = 66 (11) years
Interventions • Tranexamic acid group received 15mg/kg of TXA followed by a repeat dose of 10mg/kg after
3 hours.
• Aprotinin group received 1 million KIU (140mg) of aprotinin immediately before deflating
the tourniquet followed by an infusion of 500,000 KIU per hour for 4 hours.
• Control group received no antifibrinolytic treatment.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Unblinded
Englberger 2002a
Methods Bottles of aprotinin and saline (placebo solution) were numbered continuously. Blinding of bottles
was performed by personal otherwise not involved in the study. Method of randomisation was not
described
Participants 47 patients undergoing elective ’off-pump’ cardiac surgery were randomly allocated to one of two
groups:
• Aprotonin group (Low dose): n = 22, M/F = 16/6, mean (sd) age = 63.9 (10.8) years
• Control group (Placebo): n = 25, M/F = 19/6, mean (sd) age = 66.4 (9.0) years
Interventions • Aprotonin group received a loading dose of 2 million KIU (280mg) of aprotinin at the
beginning of surgery followed by a continuous infusion of 500,000 KIU/hr throughout surgery
(70mg/hr).
• Control group received the same volume of saline solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, number of patients exposed to
fresh frozen plasma, blood loss, mortality, myocardial infarction, re-operation for bleeding, number
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Englberger 2002a (Continued)
of patients exposed to autotransfusion, volume of blood autotransfused, hospital length of stay
(days), neurological deficit, renal dysfunction
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Englberger 2002b
Methods Method of randomisation and allocation concealment were not described
Participants 29 patients undergoing elective cardiac surgery were randomly allocated to one of two groups:
• Aprotinin group (Low dose - pump prime): n = 15, M/F = 13/2, mean (sd) age = 60.3 (10)
years
• Control group: n = 14, M/F = 10/4, mean (sd) age = 61.5 (7.5) years
Interventions • Aprotonin group received 2 million KIU of aprotinin (280mg) added to the pump prime
only.
• Control group - treatment details were not reported.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, fresh frozen plasma usage (units), blood loss,
mortality, myocardial infarction, re-operation for bleeding, neurological deficit, renal dysfunction,
hospital length of stay (days), number of patients exposed to autotransfusion, volume of blood
autotransfused
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Unclear Unclear
Fauli 2005
Methods Method of randomisation was not described. All patients received pre-prepared infusions of similar
volume and appearance provided by the pharmaceutical company
Participants 60 patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 20, M/F = 15/5, mean (sd) age = 52.5 (10.1) years
• Aprotinin group (Low dose): n = 20, M/F = 17/3, mean (sd) age = 57.7 (4.6) years
• Control group (Placebo): n = 20, M/F = 14/6, mean (sd) age = 56.5 (6.5) years
Interventions • Aprotinin group (High dose) received a loading dose of 280mg of aprotinin, followed by a
continuous infusion of 70mg/hr of aprotinin until closure of sternotomy, and 280mg of aprotinin
was added to the pump prime.
• Aprotinin group (Low dose) received 280mg of aprotinin added to the pump prime.
• Control group (Placebo) received the same volume of saline.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24hrs), hospital length of stay
(days)
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Feindt 1994
Methods Method of randomisation and allocation concealment were not described
Participants 20 patients undergoing aortocoronary bypass surgery were randomly allocated to one of two groups:
• Aprotinin group (High-dose): n = 10, M/F = NR, mean (sd) age = 62.3 (1.2) years
• Control group (Placebo): n = 10, M/F = NR, mean (sd) age = 66.4 (2.4) years
Interventions • Aprotonin group received high-dose (2 million units kallikrein inhibitor at the induction of
anaesthesia, 2 million units added to the priming volume of the heart-lung machine and 500,000
U/h during the operation).
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• Control group - treatment details were not reported.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood transfusion, post-operative
blood loss, mortality, parameters of thrombin activation and fibrinolysis
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind - studywas described as being dou-
ble blind
Fergusson 2008
Methods The research pharmacist at each centre randomly assigned patients to receive one of three antifib-
rinolytic agents with the use of a voice-activated automated centralised program. An independent
biostatistician generated the randomisation scheme using a computer-generated randomisation list.
Researchers, patients, members of the clinical teams, and members of the data and safety monitor-
ing committee were all unaware of study-group assignment
Participants 2331 high-risk cardiac surgical patients were randomly allocated to one of three groups:
• Aprotinin group: n = 781, M/F = 543/238, mean (sd) age = 67.0 (10.8) years
• Tranexamic acid group: n = 770, M/F = 562/208, mean (sd) age = 66.9 (11.4) years
• Epsilon aminocaproic acid: n = 780, M/F = 569/211, mean (sd) age = 66.6 (10.8) years
Interventions • Aprotonin group received high-dose aprotinin with a test dose of 40,000 KIU administered
during a 10 minute period after the insertion of a central venous line and induction of anaesthesia.
In the absence of of anaphylaxis, the remainder of the loading dose (1.96 million KIU), after
which a maintenance infusion of 500,000 KIU per hour was initiated and maintained during
surgery. An additional dose of 2 million KIU was added to the cardiopulmonary-bypass circuit.
• Tranexamic acid group received a 30mg/kg loading dose, a 16mg/kg maintenance dose, then
2 mg/kg added to the bypass circuit.
• Epsilon aminocaproic acid group received a 10g loading dose, then a 2g maintenance
infusion.
Outcomes Outcomes reported:Number of patients transfused allogeneic blood, massive post-operative bleed-
ing, re-operation for bleeding, myocardial infarction, stroke, mortality,
renal failure, length of stay (days).
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
110Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fergusson 2008 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation list
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Findlay 2001
Methods Method of randomisation and allocation concealment were not described
Participants 63 patients undergoing orthotopic liver transplantation were randomised to one of two groups:
• Aprotinin group: n = 33, mean (sd) age = 50 (9) years
• Control group (Placebo): n = 30, mean (sd) age = 52 (10) years
NB: Gender data were not reported.
Interventions • Aprotinin group received a loading dose of 1 million KIU over 30 minutes (after a test dose
of 10,000 KIU) followed by an infusion of 250,000 KIU/hr until skin closure.
• Control group received an equivalent infusion of normal saline.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet
usage (units), mortality, re-operation for bleeding, hepatic artery thrombosis, hospital length of
stay (days), intensive care unit length of stay (hours)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Fraedrich 1989
Methods Method of randomisation and allocation concealment were not described
Participants 80 male patients undergoing primary coronary bypass surgery were randomised to one of two
groups:
• Aprotinin group: n =40, mean age = 60.6 years
• Control group: n = 40, mean age = 58.2 years
NB: Four patients, two from the intervention and two from the control group were excluded.
Aprotinin group excluded two patients: one allergic reaction, one severe cardiac failure. Control
group excluded two patients: one surgical bleeding, one lethal cardiac failure
Interventions • Aprotinin group received a loading dose of 280mg of aprotinin prior to sternotomy,
followed by a continuous intravenous infusion of 70mg/hr until skin closure. An additional
280mg of aprotinin was added to the prime volume of the membrane oxygenator.
• Control group was not treated with aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage, plasma usage, blood loss, volume of re-transfused
mediastinal blood
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Garcia-Enguita 1998
Methods Method of randomisation and allocation concealment were not described. [Abstract only]
Participants 30 patients undergoing elective orthopaedic surgery were randomly allocated to one of two groups:
• Aprotinin group (Low dose): n = 15
• Control group (Placebo): n = 15
NB: Gender and age data were reported.
Interventions • Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin before the
induction of anaesthesia administered over 30 minutes followed by 500,000 KIU/hr for the
duration of surgery.
• Control group received 200ml of normal saline over 30 minutes followed by 50mL/hr of
saline.
Outcomes Outcomes reported: Allogenic blood usage (units), blood loss.
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Garcia-Enguita 1998 (Continued)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol was not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Garcia-Huete 1997
Methods Method of randomisation and allocation concealment were not described
Participants 80 consecutive patients undergoing elective orthotopic liver transplantation were randomised to
one of two groups:
• Aprotinin group: n = 39, M/F = 24/15, mean (range) age = 50 (15-64) years
• Control group (Placebo): n = 41, M/F = 27/14, mean (range) age = 50 (17-65) years
Interventions • Aprotinin group received an initial dose of 2 million kallikrein inactivator units (KIU) of
aprotinin in the induction phase of anaesthesia followed by an infusion of 500,000 KIU/hr of
aprotinin until the end of the procedure.
• Control group received an equal volume of saline solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, mortality, allergic reactions, re-operation for bleeding, re-transplantation
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
113Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Garneti 2004
Methods Patients were randomised using a list of randomnumbers. Allocation concealment was not described
Participants 50 patients undergoing total hip arthroplasty were randomised to one of two groups:
• Tranexamic acid group: n = 25), mean (sd) age = 69.6 (11.99) years
• Control group (Placebo): n = 25, mean (sd) age = 67.6 (11.4) years
Interventions • Tranexamic acid group received 10mg/kg of intravenous TXA as a bolus at time of
anaesthesia.
• Control group received a similar volume of normal saline as a bolus at time of anaesthesia.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (48hrs), deep vein thrombosis, pulmonary embolus
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes List of random numbers
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Gherli 1992
Methods Method of randomisation and allocation concealment were not described.[Italian]
Participants 31 patients undergoing cardiopulmonary bypass were randomly divided into one of three groups:
• Aprotinin group (High dose): n = 9, M/F = 7/2, mean (range) age = 61.5 (44-71) years
• Aprotinin group (Low dose): n = 9, M/F = 8/1, mean (range) age = 58.2 (47-71) years
• Control group: n = 13, M/F = 10/3, mean (range) age = 60.4 (52-66) years
Interventions • Aprotinin group (High dose) received 2 million kallikrein inactivator units (KIU) of
aprotinin over 15 minutes, followed by a continuous infusion of 1 million KIU/hr of aprotinin.
An additional 2 million KIU of aprotinin was added to the pump prime.
• Aprotinin group (Low dose) received 1 million kallikrein inactivator units (KIU) of
aprotinin over 15 minutes, followed by a continuous infusion of 500,000 KIU/hr of aprotinin.
An additional 1 million KIU of aprotinin was added to the pump prime.
• Control group did not receive aprotinin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial infarction, renal failure, blood products used, haemoglobin levels
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Gherli 1992 (Continued)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Gill 2009
Methods Patients were allocated according to a computer-generated randomisation schedule
Participants 10 patients undergoing orthopaedic (hip) surgery were randomised to one of two groups:
• Tranexamic acid group: n = 5, mean (range) age = 66.6 (53-83) years
• Control group (Placebo): n = 5, mean (range) age = 61.4 (36-73) years
Interventions • Tranexamic acid group received 10mg/kg bolus before anaesthesia then 1mg/kg/hr at start of
surgery until wound closure.
• Control group (placebo) received saline.
Outcomes Outcomes reported: Number of patients receiving blood transfusion, blood loss, volume blood
transfused (units)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation schedule
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Golanski 2000
Methods Method of randomisation and allocation concealment were not described. [Polish]
Participants 54 patients undergoing elective cardiac surgery were randomly allocated to one of two groups:
• Aprotinin group (Low dose): n = 30, M/F = 29/1, mean (sd) age = 56.2 (10.5) years
• Control group: n = 24, M/F = 22/2, mean (sd) age = 54.7 (8.1) years
Interventions • Aprotinin group received an infusion of 3 million kallikrein inactivator units (KIU) of
aprotinin intra-operatively.
• Control did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, mortality, myocardial infarction
Notes Quality assessment score (Schulz criteria): 0/7
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Good 2003
Methods Coded ampoules of TXA or saline placebo prepared by the drug company were randomised in
blocks of 10 (five saline, five TXA) by means of computer generated numbers. Four patients were
withdrawn from the final analysis before the randomisation code was broken
Participants 55 patients undergoing total knee replacement surgery were randomised to one of two groups:
• Tranexamic acid group: n = 27, M/F = 9/18, median (IQR) age = 72 (46-83) years
• Control group (Placebo): n = 24, M/F = 6/18, median (IQR) age = 72 (50-84) years
Interventions • Tranexamic acid group received 10mg/kg of intravenous TXA at the end of the surgical
procedure, just before the release of the tourniquet (maximum dose of 1000mg). The dose of
TXA was repeated after 3 hours.
• Control group received saline placebo solution at corresponding times as the TXA group.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis, infection
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
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Good 2003 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated numbers
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Gott 1998
Methods Method of randomisation and allocation concealment were not described
Participants 400 cardiac surgery patients were randomly allocated to one of three groups:
• Aprotinin group: n = 109
• Control/standard: n = 112
• Leukocyte depletion: n= 112
• Heparin-bonded circuitry: n = 67
NB: No demographic data were reported.
Interventions • Aprotonin group received low-dose - standard treatment plus a half-Hammersmith
aprotonin protocol.
• Control - standard treatment.
• Leukocyte depletion - based on the standard CPB protocol with addition of leukocyte
filtration of arterial line and cardioplegia delivery line.
• Heparin-bonded circuitry, membrane oxygenator and a centrifugal pump.
Outcomes Outcomes reported: Total amount of allogeneic blood transfused (units), mortality, length of
hospital stay, renal dysfunction, lung function
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Green 1995
Methods Study was described as an open label randomised controlled trial conducted in two phases. Patients
were assigned to groups by means of computer generated table of random numbers
Participants 84 consecutive patients undergoing primary coronary artery bypass graft surgery or re-operations
were randomly assigned to one of two groups:
• Aprotinin group: n = 48, M/F = 39/9, mean (sd) age = 62 (9) years
• Control group: n = 36, M/F = 31/5, mean (sd) age = 63 (8) years
Two aprotinin dose regimens were studied:
• Dosage level 1 - Aprotinin group: n = 24, M/F = 20/4, mean (sd) age = 64 (8) years
• Dosage level 1 - Control group: n = 18, M/F 16/2, mean (sd) age = 63 (8) years
• Dosage level 2 - Aprotinin group: n = 24, M/F=19/5, mean (sd) age = 60 (9) years
• Dosage level 2 - Control group: n = 18, M/F=15/3, mean (sd) age = 64 (8) years
Interventions • Phase 1, patients assigned to recombinant (r) aprotinin (treatment group) received 2mg/kg
(14,300 kallikrein inactivation units/kg) as an intravenous bolus given in 20 minutes after the
induction of anaesthesia, an intravenous infusion of 0.5mg/kg/hr until the patient left the
operating room, and 1 mg/kg added to each litre of lactated Ringers solution for priming of the
membrane oxygenator.
• Phase 2, each dose was doubled. Studies of dosage level 1 were performed in Chicago (42
patients) and studies of dosage level 2 were conducted both in Chicago (26 patients) and in
Temple, Texas (16 patients). Patients were stratified according to centre, surgeon, and type of
surgery.
The study also compared patients who underwent primary operations (n = 60) with those patients
who underwent re-operations (n = 24)
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, blood loss, overall erythrocyte
loss, autotransfusion device erythrocytes, myocardial infarction, mortality, renal function (BUN +
creatinine levels), pre-operative and post-operative haemoglobin levels
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were assigned to groups by means of
computer generated table of random numbers
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No
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Greilich 2001
Methods Method of randomisation and allocation concealment were not described
Participants 72 patients undergoing elective cardiac surgery were randomised to one of three groups:
• Epsilon aminocaproic acid group: n = 23, mean (sd) age = 63 (8) years
• Aprotinin group: n =24, mean (sd) age = 64 (9) years
• Control group (Placebo) (n = 25), mean (sd) age = 62 (7) years
Interventions • Epsilon aminocaproic acid group received 100mg/kg loading dose, 5g added to the pump
prime, and 30mg/kg/hr as a continuous infusion.
• Aprotinin group received 2 million KIU of aprotinin added to the pump prime, and 500,
000 KIU/hr (70mg/hour) as a continuous infusion.
• Control group received 200ml normal saline as a loading dose, 200ml of normal saline
added to the pump prime, and 50ml/hr of saline as a continuous infusion.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, intensive care
unit length of stay (days), mechanical ventilation (hours)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Greilich 2003
Methods Method of randomisation and allocation concealment were not described
Participants 60 male patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 20, mean (sd) age = 64 (9) years
• Epsilon aminocaproic acid (n = 20), mean (sd) age = 62 (9) years
• Control group (Placebo) (n = 20), mean (sd) age = 63 (8) years
Interventions • Aprotinin group (High dose) received 2 million KIU (280mg) of aprotinin as a loading dose
and a continuous infusion of 500,000 KIU/hr of aprotinin. An additional 2 million KIU
(280mg) of aprotinin was added to the pump prime solution.
• Epsilon aminocaproic acid group received 100mg/kg of EACA as a loading dose and a
continuous infusion of 30mg/kg/hr. An additional 5g of EACA was added to the pump prime.
• Control group (placebo) received normal saline in equivalent volumes.
NB: All groups were exposed to cell salvage.
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Greilich 2003 (Continued)
Outcomes Outcomes reported: Allogeneic blood usage (units), platelet usage (units), blood loss, plasma levels
of Interleukin-6 and Interleukin-8 during and after CPB
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Greilich 2004
Methods Method of randomisation and allocation concealment were not described
Participants 36 male patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 12, mean (sd) age = 62 (8) years
• Epsilon aminocaproic acid group: n = 12, mean (sd) age = 64 (9) years
• Control group (Placebo): n = 12, mean (sd) age = 65 (8) years
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin
and a continuous infusion of 500,000 KIU/hr. An additional 2 million KIU of aprotinin was
added to the pump prime.
• Epsilon aminocaproic acid group received a loading dose of 100mg/kg of EACA and a
continuous infusion of 30mg/kg/hr. An additional 5g of EACA was added to the pump prime.
• Control group received normal saline solution using similar volumes as aprotinin and EACA
treatments.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24hrs), biochemical markers of
plasmin activity (D-dimer), biochemical markers of platelet (CD62P), activation, biochemical
markers of leukocyte (CD11b) activation, biochemical markers of leukocyte-platelet conjugate
formation
Notes Quality assessment score (Schulz criteria):3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
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Greilich 2004 (Continued)
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Greilich 2009
Methods A table of random numbers was used to generate the allocation sequence. Central (pharmacy)
allocation was used
Participants 78 male patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotonin group: n = 26, mean (sd) age = 65 (9) years
• EACA group: n = 25, mean (sd) age = 62 (8) years
• Control group (Placebo): n = 27, mean (sd) age = 62 (7) years
Interventions • Aprotonin group received full-dose - loading dose 2 million KIU over 15 minutes plus 2
million added to pump prime and infusion of 500,000 KIU/hr until patient arrival at ICU.
• EACA group - high dose - 100mg/kg initial loading dose, 5g in pump prime solution,
30mg/kg/hr.
• Control group received saline.
Outcomes Outcomes reported: Number of patients transfused allogeneic blood, mortality, stroke, myocardial
infarction, renal failure, length of hospital stay (days)
Notes Quality assessment score (Schulz criteria):7/7
Transfusion protocol was used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes A table of random numbers was used to generate
the allocation sequence
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Groh 1993
Methods Method of randomisation and allocation concealment was not described
Participants 20 patients undergoing orthotopic liver transplantation were randomised to one of two groups:
• Aprotinin group: n = 9, mean (range) age = 51 (28-66) years
• Control group (Placebo): n = 9, mean (range) age = 49 (31-59) years
NB: Two patients were excluded from the final analysis
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Groh 1993 (Continued)
Interventions • Aprotinin group received a loading dose of 2 million KIU of aprotinin after the induction of
anaesthesia, followed by a continuous infusion of 500,000 KIU/hr of aprotinin until the end of
the procedure.
• Control group received an unspecified placebo.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage
(units)
Notes Quality assessment score (Schulz criteria):3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Harder 1991
Methods Method of randomisation was not described. The randomisation code was only known by the
hospital pharmacy. Allocation concealment was by means of coded vials collected from the hospital
pharmacy in the morning before the operation. No exclusions were reported
Participants 80male patients scheduled for elective coronary artery bypass graftingwith cardiopulmonary bypass
were randomised to one of two groups:
• Aprotinin group:n = 40, mean (sd) age = 57.6 (8.8) years
• Control group (Placebo): n = 40, mean (sd) age = 57.0 (8.8) years
Interventions • Aprotinin group received a bolus of 200ml (2 million KIU) of aprotinin just after the Swan-
Ganz pulmonary artery catheter was introduced, followed by a continuous infusion of 500,000
KIU/hr (50ml) via an infusion pump. An additional 2 million KIU of aprotinin was added to the
pump prime. The total amount of aprotinin delivered by infusion was 4 million KIU before and
during bypass.
• Control group received saline solution in equivalent volumes.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
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Harder 1991 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Hardy 1993
Methods Randomisation was performed by the pharmacy department with each successive block of four
patients being randomised (random allocation of two patients to Group A and two patients to
Group C). Method used to generate allocation sequences was not described
Participants 44 patients scheduled for repeat myocardial revascularisation, repeat value surgery, or a combined
procedure (primary or repeat) were randomised to one of two groups:
• Aprotinin group: n = 22, M/F = 16/6, mean (sd) age = 62 (9) years
• Control group (Placebo): n = 19, M/F = 12/12, mean (sd) age = 58 (11) years
NB: Three patients in the control group were excluded: one patient died in the operating room
and one died upon arrival in the ICU. The third patient was excluded when the surgeon proceeded
to a single valve replacement instead of the planned combined procedure
Interventions • Aprotinin group received a bolus of 200,000 KIU of aprotinin after the induction of
anaesthesia, but before skin incision, over a period of 20 minutes, followed by an infusion of 100,
000 KIU/hr during the entire surgical procedure and in the intensive care unit (ICU), for a total
dose of 1 million KIU.
• Control group received an equal volume of sodium chloride 0.9% throughout surgery and
recovery.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), mortality, re-exploration for bleeding
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
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Hardy 1993 (Continued)
Blinding?
All outcomes
Yes Double blind
Hardy 1997
Methods Each successive block of four patients was randomised by the Department of Pharmacy (random
allocation of two patients to the treatment group and two patients to the control group). Method
used to generate allocation sequences was not described
Participants 52 patients undergoing primary or repeat myocardial revascularisation, or repeat valve surgery were
randomised to one of two groups:
• Aprotinin group: n = 26, M/F = 15/11, mean (sd) age = 59 (11) years
• Control group (placebo) (n = 26), M/F = 19/7, mean (sd) age = 59 (10) years
Interventions • Aprotinin group received 1 million KIU of aprotinin added to the priming solution of the
cardiopulmonary bypass circuit.
• Control group (placebo) received an equal volume of sodium chloride 0.9% added to the
priming solution of the cardiopulmonary bypass circuit.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, re-operation, blood loss, haemoglobin concentrations, coagulation factors
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Hardy 1998
Methods Study participants were randomised by the pharmacy department. Each successive block of nine
patients were randomised to ensure a comparable number of patients in all groups and a similar
distribution of patients over time. All bags were coded by theDepartment of Pharmacy and identical
volumes of solution were infused
Participants 134 patients undergoing scheduled elective coronary artery bypass graft surgery were randomised
to one of three groups:
• Control group (Placebo): n = 45, M/F = 38/7
• Tranexamic acid group: n = 43, M/F = 27/16
124Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hardy 1998 (Continued)
• Epsilon aminocaproic acid group: n = 46, M/F = 35/11
NB: Age data were not reported
Interventions • Control group (placebo) received a bolus plus an infusion of placebo solution (0.9% normal
saline solution).
• Tranexamic acid group received a 10g bolus of TXA over 20 minutes, followed by a placebo
infusion. The placebo consisted of 0.9% normal saline solution.
• Epsilon aminocaproic acid group received a 15g bolus over 20 minutes, followed by an
infusion of 1g/hr.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units),
fresh frozen plasma usage (units), platelet usage (units), blood loss, mortality, myocardial infarction,
cerebrovascular accident, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Adequate
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Harley 2002
Methods Method of randomisation and allocation concealment were not described
Participants 35 patients undergoing elective orthopaedic surgery were randomised to one of two groups:
• Epsilon aminocaproic acid group: n = 26, M/F = 10/16, mean (sd) age = 69 (11) years
• Control group (Placebo): n = 29, M/F = 11/18, mean (sd) age = 69 (10) years
Interventions • Epsilon aminocaproic acid group received a loading dose of 150mg/kg administered as a
bolus dose over 20 minutes on the patients arrival in OR. An hourly EACA infusion of 12.5mg/
kg was subsequently administered for an additional 5 hours.
• Control group received a placebo of saline solution
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis, pulmonary embolus
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
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Harley 2002 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Harmon 2004
Methods A computer-generated randomisation sequence was used to allocate patients. The sequence was
concealed (numbered containers) until treatment was assigned
Participants 36 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group (High dose): n = 17, M/F = 17/3, mean (sd) age = 63.4 (5.4) years
• Control group (Placebo): n = 18, M/F = 14/4, mean (sd) age = 60.1 (9.5) years
NB: One patient was excluded from the final analysis
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin
after the induction of anaesthesia and a continuous infusion of 500,000 KIU/hr of aprotinin
during surgery. An additional 2 million KIU was added to the CPB circuit prime.
• Control group (placebo) receive an unspecified solution.
Outcomes Outcomes reported: Cognitive deficit, number of patients exposed to allogeneic blood, blood loss,
hospital length of stay (days), serious adverse events
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation
Allocation concealment? Yes Adequate
Blinding?
All outcomes
No Single blind
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Havel 1992
Methods Patients were randomly allocated to receive the test compound or a placebo by use of sealed
envelopes. Method of randomisation was not described
Participants 20 male patients undergoing orthotopic heart transplantation were randomised to one of two
groups:
• Aprotinin group (Low dose): n = 10
• Control group (Placebo): n = 10
NB: Demographic data not reported.
Interventions • Aprotinin group received 280mg of aprotinin over 20 minutes after anaesthesia prior to
surgery. In addition 280mg was added to the priming volume of the heart lung machine.
• Control group received a corresponding volume of normal saline solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - used sealed envelopes to conceal
treatment allocation
Blinding?
All outcomes
Yes Double blind
Havel 1994
Methods Method used to generate random sequences was not described. Bottles of aprotinin and placebo
were indistinguishable from each other. The preparation of each patient was individually packaged
with 12 bottles each; each individual bottle, as well as the carton, was marked with a label carrying
the patient number (the randomisation number). Each study package contained a total of 12 bottles,
of which eight carried the label “Infusion” and four the label “Pump”
Participants 45 male patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 15, mean (sd) age = 60 (8) years
• Aprotinin group (Low dose): n = 15, mean (sd) age = 59 (8) years
• Control group (Placebo): n = 15, mean (sd) age = 60 (9) years
Interventions • Aprotinin group (High dose) received 2 million KIU of aprotinin as a bolus over 30 minutes
after the institution of anaesthesia but before skin incision, followed by a continuous infusion of 2
million KIU/hr of aprotinin over 4 hours, and an additional 2 million KIU of aprotinin was
added to the pump prime.
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Havel 1994 (Continued)
• Aprotinin group (Low dose) received 2 million KIU of aprotinin added to the pump prime
only.
• Control group received 0.9% saline solution.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, graft patency rates
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Hayashida 1997
Methods Patients were randomised by means of computer-generated randomisation table. Method of allo-
cation concealment was not described
Participants 167 patients undergoing primary isolated coronary artery bypass graft surgery were randomised to
one of three groups:
• Aprotinin group (Minimal dose): n = 55, M/F = 43/12, mean (sd) age = 64.4 (8.8) years
• Aprotinin group (Low dose): n = 55, M/F = 35/20, mean (sd) age = 63.2 (8.2) years
• Control group: n = 57, M/F = 41/16, mean (sd) age = 61.2 (9.8) years
Interventions • Aprotinin group (Minimal dose) received 1 million KIU of aprotinin in the
cardiopulmonary bypass priming solution.
• Aprotinin group (Low dose) received 30,000 KIU/kg of aprotinin in the priming solution
and a continuous infusion of aprotinin at a rate of 7,500 KIU/kg every hour during
cardiopulmonary bypass. The mean dose of aprotinin in the low dose group was 2.7 million KIU
(range 1.4 million KIU to 4.0 million KIU).
• Control group received no aprotinin treatment.
NB: All groups were exposed to pre-operative autologous blood donation (PAD)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), all blood product requirements (units), blood loss, mortality,
myocardial infarction, allergic reaction, parameters of clotting and fibrinolysis, renal function, early
graft pattency rates
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation table
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Hayes 1996
Methods Method of randomisation and allocation concealment were not described
Participants 40 patients scheduled for total hip replacement surgery were randomly allocated to one of two
groups:
• Aprotinin group: n = 20, M/F = 8/12, mean (sd) age = 70.0 (7.9) years
• Control group: n = 20, M/F = 7/13, mean (sd) age = 72.9 (10.3) years
Interventions • Aprotinin group received 2 million KIU of aprotinin intravenously over 20 minutes prior to
surgical incision.
• Control group received an equal volume of infusion consisting of 0.9% normal saline.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, haemoglobin levels, coagulation
parameters, complications
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Hei 2005
Methods Method of randomisation and allocation concealment were not described. [Chinese language]
Participants 40 patients with severe hepatitis undergoing liver transplantation were randomly assigned to one
of two groups:
• Aprotinin group: n = 20
• Control group (Placebo): n = 20
Demographic data: M/F = 38/2, age range = 31-67 years.
Interventions • Aprotinin group received a continuous infusion of 400,000 KIU of aprotinin commenced at
the induction of anaesthesia and ceased at the end of surgery.
• Control group received normal saline at the same volumes as the aprotinin regimen.
Outcomes Outcomes reported:Allogeneic blood usage (units), fresh frozen plasma usage, platelet usage, blood
loss
Notes Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Hekmat 2004
Methods Randomisation was based on a computer-generated code and sealed in sequentially numbered,
opaque envelopes
Participants 120 patients undergoing elective cardiac surgery were randomly assigned to one of two groups:
• Aprotinin group (High dose): n = 60, M/F = 51/9, mean (sd) age = 63 (8) years
• Tranexamic acid group: n = 60, M/F = 51/7, mean (sd) age = 63 (8) years
Interventions • Aprotinin group (High dose - “Full Hammersmith” regimen) received a loading dose of 2
million kallikrein inactivation units (KIU) of aprotinin, 2 million KIU of aprotinin added to the
CPB pump prime, and a continuous infusion of 500,000 KIU/hr during CPB.
• Tranexamic acid group received 500mg of TXA as a loading dose, 500mg added to the CPB
pump prime, and 1g was given post CPB (a total of 2g of TXA).
NB: Cell Salvage was used during surgery in both groups using a cell saver (Brat2, Cobe Cardio-
vascular Inc, Arvada, CO.)
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet
usage (units), blood loss, mortality, myocardial Infarction, hospital length of stay (days), intensive
care unit length of stay (days), intubation time (hours), number of patients requiring Intra-aortic
balloon pump (IABP) therapy
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Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated code
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Hendrice 1995
Methods Method of randomisation and allocation concealment were not described
Participants 26 patients undergoing primary coronary artery bypass surgery were randomly allocated to one of
two groups:
• Aprotinin group: n = 12, mean (sd) age = 59.8 (7.9) years
• Control group: n = 14, mean (sd) age = 58.1 (17.3) years
Nb: Gender data not provided.
Interventions • Aprotinin group received a loading dose of 2 million kallikrein inactivation units (KIU) of
aprotinin over a period of 30 minutes, followed by an infusion of 500,000 KIU until the end of
surgery. A supplement of 2 million KIU of aprotinin was administered to the priming of the
extracorporeal circuit.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage, blood loss (24 hrs), haemoglobin levels, coagulation
factors
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Methods Concealment of treatment allocationwas bymeans of a ticket drawn from an envelope containing an
equal number of treatment and placebo tickets. The method used to generate allocation sequences
was not described
Participants 29 patients undergoing total knee arthroplasty were randomly allocated to one of two groups:
• Tranexamic acid group: n = 15, M/F = 2/13, mean (range) age = 70 (56-82) years
• Control group (Placebo): n = 13, M/F = 3/10, mean (range) age = 70 (63-78) years
Interventions • Tranexamic acid group received a bolus of 15mg/kg of TXA 2-5 minutes before deflation of
limb tourniquet.
• Control group received an equal volume of sodium chloride solution (0.9%).
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial infarction, deep vein thrombosis, pulmonary embolus, minor non-throm-
boembolic complications
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate
Blinding?
All outcomes
Yes Double blind
Hiipala 1997
Methods A ticket indicating the group was drawn and enclosed in an envelope. The envelopes were opened
after the study was completed. Injection syringes were prepared by a person outside the surgical
team
Participants 75 patients scheduled for 77 total knee arthroplasties were randomly allocated to one of two groups:
• Tranexamic acid group: n = 39, M/F = 4/35, mean (sd) age = 70 (7) years
• Control group (Placebo): n = 38, M/F = 8/30, mean (sd) age = 69 (5) years
NB: Three patients were excluded from the final analysis for miscellaneous reasons
Interventions • Tranexamic acid group received 15mg/kg of TXA before the removal of the limb tourniquet,
followed by two 10mg/kg additional doses.
• Control group received equal volumes of normal saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, mortality, deep vein thrombosis, pulmonary embolus,
non-thrombotic complications.
132Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hiipala 1997 (Continued)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate
Blinding?
All outcomes
Yes Double blind
Hill 1998
Methods Patients were randomised according to a computer-generated sequence. Method of allocation con-
cealment was not described
Participants 20 adult patients scheduled for first-time myocardial revascularisation were randomly assigned to
one of two groups:
• Aprotinin group: n = 10, mean (sd) age = 64 (7.9) years
• Control group: n = 10, mean (sd) age = 62 (7.9) years
NB: Gender data not reported.
Interventions • Aprotinin group received 280mg of aprotinin (2 million KIU) intravenously as a loading
dose followed by 70mg (500,000 KIU) of aprotinin per hour as a constant intravenous infusion
until chest closure. In addition 280mg of aprotinin (2 million KIU) was added to the “pump
prime”.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage (units), interleukin-10 (IL-10) levels
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated sequence
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Horrow 1990
Methods Patients were randomised using a random number table. Sealed envelopes ensured that only the
pharmacist, who prepared the encoded infusions, knew whether a patient received drug or placebo
Participants 49 patients undergoing cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 18, mean (sd) age = 66 (10)
• Control group (Placebo): n = 20, mean (sd) age = 62 (9) years
Interventions • Tranexamic acid group received a 10mg/kg infusion of TXA over a 20-minute period
followed by an infusion of 1mg/kg for 10 hours.
• Control group received equivalent infusions of saline (100ml total volume).
NB: Both groups received cell salvage.
Outcomes Outcomes reported: Allogeneic blood usage (units), number of participants exposed to fresh frozen
plasma, number of participants exposed to platelets, blood loss (12 hrs), deep vein thrombosis,
pulmonary embolus, stroke, number of patients receiving cell salvage, volume of cell salvage auto-
transfused
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? No Inadequate
Blinding?
All outcomes
Yes Double blind
Horrow 1991
Methods A table of random numbers determined patient allocation to one of four groups. Coded infusion
bags and sealed envelopes prepared by a pharmacist not involved in the study provided double
blinded conditions
Participants 163 adult patients undergoing coronary revascularisation, valve replacement, both procedures, or
repair of atrial septal defect, were randomly allocated to one of four groups:
• Control group (Placebo): n = 44, mean (sd) age = 64 (10) years
• Tranexamic acid group: n = 37, mean (sd) age = 65 (11) years
• Desmopressin group: n = 38, mean (sd) age = 63 (11) years
• Tranexamic acid + Desmopressin group: n = 40, mean (sd) age = 63 (9) years
NB: Gender data were not reported.
Interventions • Control group received saline solutions.
• Tranexamic acid group received tranexamic acid beginning after induction of anaesthesia but
before skin incision (loading dose - 10mg/kg over 30 minutes) followed by a 12 hour infusion of
1mg/kg/hr.
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• Desmopressin group received desmopressin acetate (0.3ug/kg over 20 minutes) beginning
after extracorporeal circulation following completion of protamine infusion.
• Tranexamic acid + Desmopressin group received both tranexamic acid and desmopressin in
an identical fashion to groups 2 and 3.
NB: All patients received cell salvaged autologous blood if available
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss (12hrs), myocardial infarction,
stroke, deep venous thrombosis, re-operation for bleeding, rash, ventricular dysfunction, pulmonary
oedema, ventricular tachycardia
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Table of random numbers
Allocation concealment? No Inadequate
Blinding?
All outcomes
No Single blind
Horrow 1995
Methods Coded infusion bags for both loading and infusion doses and sealed envelopes prepared by a
pharmacist provided allocation concealment. Randomisation was determined by a table of random
numbers
Participants 148 patients undergoing elective cardiac operations were randomised to one of six groups:
• Control group (Placebo): n = 27, M/F = 23/4, mean (sd) age = 63 (10.4) years
• Tranexamic acid group (Quarter dose): n = 24; M/F = 18/6; mean (sd) age = 67 (9.8) years
• Tranexamic acid group (Half dose): n = 22, M/F = 19/3, mean (sd) age = 61 (9.4) years
• Tranexamic acid group (Whole dose): n = 21, M/F = 18/3, mean (sd) age = 66 (9.2) years
• Tranexamic acid group (Double dose): n = 27, M/F = 22/5, mean (sd) age = 63 (10.4) years
• Tranexamic acid group (Fourfold dose): n = 27, M/F = 21/6, mean (sd) age = 65 (10.4) years
Interventions • Control group received saline infusions.
• Tranexamic acid group (Quarter dose) received a loading dose of 2.5mg/kg of TXA after the
induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion
of 0.25mg/kg/hr of TXA.
• Tranexamic acid group (Half dose) received a loading dose of 5.0mg/kg of TXA after the
induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion
of 0.5mg/kg/hr of TXA.
• Tranexamic acid group (Whole dose) received a loading dose of 10mg/kg of TXA after the
induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion
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of 1.0mg/kg/hr of TXA.
• Tranexamic acid group (Double dose) received a loading dose of 20mg/kg of TXA after the
induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion
of 2.0mg/kg/hr of TXA.
• Tranexamic acid group (Fourfold dose) received a loading dose of 40mg/kg of TXA after the
induction of anaesthesia over a period of 30 minutes followed by a 12 hour continuous infusion
of 4.0mg/kg/hr of TXA.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood
loss (12 hrs), mortality, hypotension
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Table of random numbers
Allocation concealment? No Inadequate
Blinding?
All outcomes
Yes Double blind
Husted 2003
Methods Randomisation was performed by computer. The drugs were packed in numbered envelopes by a
person not connected with the surgical procedure and handled by the anaesthetist. The randomi-
sation code was not broken until the study was completed
Participants 40 patients undergoing primary total hip arthroplasty were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 7/13, mean age = 65 years
• Control group (Placebo): n = 20, M/F = 6/14, mean age = 67 years
Interventions • Tranexamic acid group received a bolus dose of 10mg/kg of TXA (maximum 1g) during 10
minutes about 15 minutes before the incision, followed by a continuous infusion of 1mg/kg/hr
dissolved in 1 litre of saline for 10 hours (maximum 1g over 10 hours).
• Control group received saline as a bolus injection of 20ml about 15 minutes before the
operation followed by a continuous infusion of 1 litre of saline during 10 hours.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis, pulmonary embolus, infection, haemoglobin levels
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was performed by computer
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Ickx 2006
Methods Method of randomisation and allocation concealment were not described
Participants 51 patients undergoing primary liver transplantation were randomised to one of two groups:
• Aprotinin group (Low dose): n = 24, M/F = 20/4, mean (sd) age = 50 (10) years
• Tranexamic acid group (n = 27), M/F = 25/2, mean (sd) age = 53 (7) years
Interventions • Aprotinin group (Low dose) received 280mg of aprotinin as a slow bolus over 30 minutes
followed by a continuous infusion of 70mg/hr. The infusion was initiated during the anhepatic
phase, 30 minutes before the expected reperfusion time, and maintained until 2 hours after
reperfusion.
• Tranexamic acid group received a slow bolus of 40mg/kg of TXA over 30 minutes followed
by a continuous infusion at a rate of 40mg/kg/hr. The infusion was initiated during the anhepatic
phase, 30 minutes before the expected reperfusion time, and maintained until 2 hours after
reperfusion.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, number of patients exposed
to fresh frozen plasma, number of patients exposed to platelets, allogeneic blood usage (units),
mortality, hospital length of stay (days), intensive care unit length of stay (days)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Methods Method of randomisation and allocation concealment were not described. Exclusions or loss to
follow-up were not reported. [Abstract]
Participants 240 patients undergoing cardiac surgery were randomised to one of four groups:
• Tranexamic acid group: n = 70
• Aprotinin group (Low dose): n = 70
• Aprotinin group (High dose): n = 70
• Control group: n = 70
NB: Demographic data were not reported.
Interventions • Tranexamic acid group received 15mg/kg of TXA before the injection of heparin prior to
cardiopulmonary bypass (CPB).
• Aprotinin group (Low dose) received 500,000 KIU of aprotinin during 20 minutes after
induction, followed by a continuous infusion of 500,000 KIU/hr until the end of CPB.
• Aprotinin group (High dose) received 2 million KIU of aprotinin over a 45 minute period
after induction followed by a continuous infusion of 500,000 KIU/hr until the end of CPB, the
priming volume of the CPB circuit included 2 million KIU of aprotinin.
• Control group received no antifibrinolytic treatment.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, blood loss, haematocrit values
Notes Quality assessment score (Schulz criteria): 0/7 (Abstract)
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Jamieson 1997
Methods Method of randomisation and allocation concealment were not described
Participants 50 patients undergoing re-operative cardiac surgery were randomised to one of two groups:
• Aprotinin group (High dose): n = 24, M/F = 11/13, median (range) age = 54 (34-77) years
• Control group (Placebo): n = 36, M/F = 12/12, median (range) age = 53 (28-78) years
Interventions • Aprotinin group (High dose) received a loading dose of 280mg of aprotinin infused after
induction of anaesthesia, 280mg in the cardiopulmonary prime solution, and 70mg/hr of
aprotinin for a period of 6 hours.
• Control group received a placebo of normal saline.
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NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss, mortality, hospital length of
stay (days), total blood products transfused
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Jansen 1999
Methods Randomisation was performed using a computer-generated random number list. Method of allo-
cation concealment was not described
Participants 42 patients undergoing unilateral bicondylar cemented total knee arthroplasty were randomised to
one of two groups:
• Tranexamic acid group: n = 21, M/F = 5/16, mean (range) age = 70.7 (62-80) years
• Control group (Placebo) (n = 21), M/F = 3/18, mean (range) age = 71.0 (64-84) years
Interventions • Tranexamic acid group received 15mg/kg of intravenous TXA before inflation of the
tourniquet and surgery and repeated every 8 hours for 3 days.
• Control group received an equivalent volume of normal saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep venous thrombosis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was performed using a com-
puter-generated random number list
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Yes Double blind
Janssens 1994
Methods Method of randomisation and allocation concealment were not described
Participants 40 patients undergoing primary total hip replacement were randomised to one of two groups:
• Aprotinin group: n = 20, M/F = 10/10, mean (sd) age = 64.9 (13.2) years
• Control group (Placebo): n = 20, mean (sd) age = 65.3 (15.3) years
Interventions • Aprotinin group received a bolus injection of 2 million KIU of aprotinin over 30 minutes
after the induction of anaesthesia, followed by an infusion of 500,000 KIU/hr until the end of
surgery with a maximum dose of 3.5 million KIU of aprotinin.
• Control group received the same volume of normal saline according to the same protocol as
aprotinin.
Outcomes Outcomes reported: Blood loss, number of patients exposed to allogeneic/autologous blood, allo-
geneic blood usage (units), autologous blood usage (units), hospital length of stay (days), deep vein
thrombosis
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Jares 2003
Methods Method of randomisation and allocation concealment were not described
Participants 47 patients undergoing ’off pump’ coronary artery bypass graft surgery were randomised to one of
two groups:
• Tranexamic acid group: n = 22, M/F = 20/2
• Control group: n = 25, M/F = 15/10
NB: No age data were reported.
Interventions • Tranexamic acid group received 1g of TXA 10 minutes before surgical incision followed by a
continuous infusion at a rate of 200mg/hr until the end of the procedure.
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• Control group did not receive antifibrinolytic treatment.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, pulmonary em-
bolus, aspirin use <5 days, re-operation for bleeding, stroke
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No No blinding
Jeserschek 2003
Methods Method of randomisation and allocation concealment were not described
Participants 18 patients undergoing elective orthopaedic surgery were randomised to one of two groups:
• Aprotinin group (Low dose): n = 9, M/F = 3/6, mean (sd) age = 67 (12.0) years
• Control group (Placebo): n = 9, M/F = 5/4, mean (sd) age = 72.7 (7.8) years
Interventions • Aprotinin group (Low dose) received at the begining of the operation 1 million KIU of
aprotinin (140mg) as a loading dose followed by a continuous infusion of 500,000 KIU/hr.
• Control group received the same volume of normal saline.
NB: Both groups were exposed to intra-operative cell salvage
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Yes Double blind
Jimenez 2007
Methods Patients were assigned to treatment group by independent pharmacists using a list of pseudo-
randomised numbers to receive coded infusions of either TXA or placebo. The cose was revealed
once recruitment, data collection, and laboratory analyses were completed
Participants 50 patients undergoing cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 24, M/F = 12/12, mean (95%CI) age = 66 (63-70) years
• Control group (Placebo): n = 26, M/F = 15/11, mean (95% CI) age = 67 (62-71) years
Interventions • Tranexamic acid group received 2g before and after surgery.
• Control group received saline.
Outcomes Outcomes reported: Number of patients receiving blood transfusion, volume of blood transfused
(units), blood loss, mortality, hospital length of stay, mechanical ventilation hours, inflammatory
response, d-dimer levels
Notes Quality assessment score (Schulz criteria): 7/7
Use of a transfusion protocol was not reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomised number list
Allocation concealment? Yes Adeaquate
Blinding?
All outcomes
Yes Double blind
Johansson 2005
Methods Patients were randomised by computer in blocks of 10. Coded ampoules were prepared by the
pharmaceutical company. All personnel and patients were blinded as to the treatment until the
randomisation code was broken which took place after all patients had been evaluated
Participants 119 patients undergoing total hip arthroplasty were randomised to one of two groups:
• Tranexamic acid group: n = 47, M/F = 25/22, mean (sd) age = 69 (7) years
• Control group (Placebo): n = 53, M/F = 28/25, mean (sd) age = 68 (8) years
NB: Before the randomisation code was broken 19 patients were excluded due to violation of the
study protocol
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Interventions • Tranexamic acid group received a bolus infusion of 15mg/kg of TXA mixed in 100ml of
normal saline immediately before the start of the operation.
• Control group received normal saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer randomisation
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Kahveci 1996
Methods Method of randomisation and allocation concealment were not described. [Turkish language]
Participants 28 patients undergoing coronary artery bypass surgery or cardiac valvular surgery were randomised
to one of two groups:
• Aprotinin group (Low dose): n = 14, M/F = 6/8, mean (sd) age = 45.5 (12.8) years
• Control group: n = 14, M/F = 8/6, mean (sd) age = 48 (10.5) years
Interventions • Aprotinin group (Low dose) received a bolus of 2 million KIU of aprotinin (280 mg) before
the induction of anaesthesia followed by a continuous infusion of 500,000 KIU/hr.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), blood loss
Notes Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Unclear Unclear
Kalangos 1994
Methods Method of randomisation and allocation concealment were not described. No exclusions were
reported
Participants 165 adult patients undergoing elective primary aortocoronary bypass operations were randomised
to one of three groups:
• Aprotinin group (High dose): n = 55, M/F = 47/8, mean (sd) age = 58.2 (5.6) years
• Aprotinin group (Low dose): n = 55, M/F = 44/11, mean (sd) age = 57.7 (6.6) years
• Control (Placebo): n = 55, M/F = 49/6, mean (sd) age = 60.5 (6.8) years
Interventions • Aprotinin group (High dose) received an intravenous bolus of 2 million KIU of aprotinin at
induction of anaesthesia. Another 2 million KIU of aprotinin was added to the pump prime
volume. A continuous infusion of 500,000 KIU/hr of aprotinin was maintained until the end of
the operation.
• Aprotinin group (Low dose) received 25,000 KIU/kg added to the pump prime solution
(mean dosage 1.78 million KIU; range 1.375 million KIU to 2.3 million KIU) and saline was
administered at all other corresponding times.
• Control group received identical volumes of saline at all corresponding times.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial infarction, creatine phosphokinase - myocardial band (CK-MB) levels
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Karski 1995
Methods Randomisation was performed by the pharmacy department. The method used to generate alloca-
tion sequences was not described
Participants 150 patients undergoing cardiac operations were randomised to one of three groups:
• Tranexamic acid group (TA-10): n = 50, mean (sd) age = 59 (21.2) years
• Tranexamic acid group (TA-20): n = 50, mean (sd) age = 63 (7.0) years
• Control group (Placebo): n = 50, mean (sd) age = 58 (14.1) years
NB: Gender data were not reported.
Interventions • Tranexamic acid group (TA-10) received an infusion of 10g of TXA intravenously over 20
minutes after induction of anaesthesia and a placebo infusion (0.9% normal saline) over the
subsequent 5 hours.
• Tranexamic acid group (TA-20) received 10g of TXA over 20 minutes and then a further
10g infused over 5 hours.
• Control group received a placebo bolus (0.9% normal saline) and a placebo infusion (0.9%
normal saline) over 5 hours.
NB: All groups were exposed to cell salvage (autotransfusion). Patients with defined ’excessive bleed-
ing’ were treated with 10-40g of intravenous epsilon aminocaproic acid (EACA) or desmopressin
(DDAVP)
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
No Single blind
Karski 2005
Methods A computer-generated randomisation code in blocks of four was used to assign patients to treatment
or control in a double-blinded fashion. The hospital pharmacy prepared identical bags of solution
Participants 312 patients undergoing cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 147, M/F = 128/19, mean (sd) age = 59.9 (8.9) years
• Control group (Placebo): n = 165, M/F = 147/18, mean (sd) age = 60 (8.3) years
Interventions • Tranexamic acid group received 100mg/kg of TXA in 100ml solution over 20 minutes after
the induction of anaesthesia.
145Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Karski 2005 (Continued)
• Control group received 5% dextrose.
Outcomes Outcomes reported: Number of patinets exposed to allogeneic blood, number of patients exposed
to fresh frozen plasma, number of patients exposed to platelets, mortality, myocardial infarction,
stroke, cardiac arrest, atrial fibrillation
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol not specified
NB:Open-labeled tranexamic acidwas administered to 4 patients in the TXA group and 24 patients
in the control group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation code
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Kaspar 1997
Methods Study infusions were prepared by the hospital pharmacy using a computer generated randomisation
schedule
Participants 32 consecutive patients undergoing orthotopic liver transplantation were randomly allocated to
one of two groups:
• Tranexamic acid group: n = 16
• Control group (Placebo): n = 16
NB: Demographic data were not reported.
Interventions • Tranexamic acid group received a continuous small dose infusion of TXA (1g in 500ml of
normal saline) at a dose of 2mg/kg/hr.
• Control group received an equal volume of normal saline.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma (units), platelets (units),
mortality, hepatic arterial thrombosis, epsilon aminocaproic acid ’rescue’, cryoprecipitate
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
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Kaspar 1997 (Continued)
Adequate sequence generation? Yes Computer generated randomisation schedule
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Katoh 1997
Methods Method of randomisation and allocation concealment were not described
Participants 93 patients undergoing either coronary artery bypass grafting or heart valve operations were ran-
domly divided into one of three groups:
• Tranexamic acid group (TA-1): n = 31, M/F = 22/9, mean (sd) age = 63.7 (8.3) years
• Tranexamic acid group (TA-2): n = 31, M/F = 21/10, mean (sd) age = 62.9 (9.5) years
• Control group: n = 31, M/F = 22/9, mean (sd) age = 64.7 (11.7) years
Interventions • Tranexamic acid group (TA-1) received an infusion of tranexamic acid (TXA) of 100mg/kg
intravenously (IV) over 20 minutes soon after induction of anaesthesia and before
cardiopulmonary bypass (CPB).
• Tranexamic acid group (TA-2) received a 100mg/kg dose of TXA intravenously (IV) over 20
minutes soon after induction of anaesthesia and before CPB, and an additional dose of 50mg/kg
infused IV over 20 minutes soon after being weaned from CPB.
• Control group did not receive tranexamic acid.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, mortality, myocardial infarction, stroke, pulmonary embolism, deep vein thrombosis
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Katsaros 1996
Methods Method of randomisation was not described. Allocation concealment was by coded infusions. One
patient was eliminated from the study due to improper data collection
Participants 211 patients scheduled for open heart operations were randomised to one of two groups:
• Tranexamic acid group: n = 104, M/F = 68/36, mean (sd) age = 65 (9.3) years
• Control group (Placebo): n = 106, M/F = 80/26, mean (sd) age = 63 (12.3) years
Interventions • Tranexamic acid group received 10g of TXA (diluted to 250ml with normal saline solution)
intravenously over 20 minutes. No incision was made until the completion of the infusions.
• Control group received 250ml of normal saline solution.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, bood loss (24hrs), mortality,
myocardial infarctions, deep vein thrombosis, pulmonary embolus,
re-operation for bleeding, cerebrovascular accident, renal failure, central nervous system complica-
tions
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Katzel 1998
Methods Method of randomisation and allocation concealment were not described. [German language]
Participants 24 male patients undergoing thoracic surgery for malignant lung disease were randomised to one
of two groups:
• Aprotinin group (Low dose): n = 12, mean (sd) age = 57.1 (8.2) years
• Control group (Placebo): n = 12, mean (sd) age = 59.4 (9.0) years
Interventions • Aprotinin group (Low dose) received a bolus of 280mg of aprotinin (2 million KIU)
followed by 500,000 KIU of aprotinin during surgery until 1 hour after surgery.
• Control group was infused with isotonic saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, blood loss, transient ischaemic
attack
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Katzel 1998 (Continued)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Kazemi 2010
Methods Methods of sequence generation and allocation concealment were not described
Participants 64 patients undergoing orthopaedic surgery were randomised to one of two groups:
• Tranexamic acid group: n = 32, M/F = 23/9, mean (sd) age = 46.6 (16.2) years
• Control group: n = 32, M/F = 20/12, mean (sd) age = 45.4 (17.2) years
Interventions • Tranexamic acid group received 15mg/kg given five minutes pre-operatively.
• Control group received saline.
Outcomes Outcomes reported: Volume of blood transfused (units), blood loss, deep vein thrombosis, length
of stay (days)
Notes Transfusion protocol was used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Kikura 2006
Methods Method of randomisation and allocation concealment were not described
Participants 100 patients undergoing cardiac surgery were randomised to one of two groups:
• Epsilon aminocaproic acid: n = 50, M/F = 38/12, mean (sd) age = 63 (10) years
• Control group (Placebo): n = 50, M/F = 40/10, mean (sd) age = 62 (11) years
Interventions • Epsilon aminocaproic acid group received 100mg/kg of EACA as a loading dose over 20-30
minutes, after endotracheal intubation, followed by a continuous infusion of 1g/hr of EACA
during the operation, and a loading dose of 10g given into the CPB circuit prime solution. The
infusion was discontinued on completion of surgery.
• Control group (placebo) received identical appearing normal saline in identical volumes at
the same times as EACA treatment.
NB: Both groups were exposed to intra-operative cell salvage
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, blood
loss (24hrs)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Kipfer 2003
Methods Method of randomisation and allocation concealment were not described
Participants 30 adult patients undergoing elective cardiac surgery were randomised into one of two groups:
• Aprotinin group (Low dose): n = 15, M/F = 12/3, mean (sd) age = 62.3 (7) years
• Control group: n = 15, M/F = 12/3, mean (sd) age = 61.3 (7) years
Interventions • Aprotinin group (Low dose - pump prime) received 2 million KIU (280mg) of aprotinin
added to the prime volume of the CPB.
• Control group did not receive aprotonin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units),
blood loss, fresh frozen plasma,myocardial infarction,mortality,myocardial infarction, retransfused
mediastinal shed blood, re-operation for bleeding, renal dysfunction, neurological deficit, hospital
length of stay (days)
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Kipfer 2003 (Continued)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Klein 1998
Methods Method of randomisation and allocation concealment were not described
Participants 109 patients undergoing elective cardiac surgery were randomised to one of three groups:
• Aprotinin group (High dose + ASA): n = 40), M/F = 33/7, mean (sd) age = 64.0 (6.3) years
• Aprotinin group (High dose): n = 38, M/F = 34/4, mean (sd) age = 62.1 (7.3) years
• Control group (Placebo): n = 31, M/F = 28/3, mean (sd) age = 63.0 (9.3) years
Interventions • Aprotinin group (High dose + ASA) received a loading dose of 2 million KIU (280mg)
followed by a continuous infusion of 500,000 KIU/hr until chest closure for a 6 hour maximum
period. In addition, 2 million KIU of aprotinin was added to the pump prime. Patients
underwent a minimum 10-day run-in period on ASA (100mg/day) until surgery.
• Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) followed by
a continuous infusion of 500,000 KIU/hr until chest closure for a 6 hour maximum period. In
addition, 2 million KIU of aprotinin was added to the pump prime.
• Control group received an unspecified placebo.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, fresh frozen plasma, myocardial
infarction
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Yes Double blind
Kluger 2003
Methods Patients underwent permuted block randomisation using random number tables. All patients re-
ceived four syringes, labelled A,B,C,and D. Patients, clinicians, and investigators were all blinded
to group allocation
Participants 90 patients undergoing cardiac surgery were randomised to one of three groups:
• Epsilon aminocaproic acid group (Post-heparin): n = 30, M/F = 24/6, mean (sd) age = 65 (8.
1) years
• Epsilon aminocaproic acid group (Pre-incision): n = 28, M/F = 23/5, mean (sd) age = 66 (8.
1) years
• Control group (Placebo): n = 30, M/F = 22/8, mean (sd) age = 67 (6.5) years
NB: Two patients were excluded from the final analysis.
Interventions • Epsilon aminocaproic acid group (Post-heparin) received an initial bolus of normal saline
prior to skin incision, followed by a normal saline infusion. Three minutes after heparin
administration patients received a bolus of 150mg/kg of EACA over 10 minutes and then an
infusion of 15mg/kg/hr.
• Epsilon aminocaproic acid group (Pre-incision) received a bolus of 150mg/kg of EACA over
10 minutes after the induction of anaesthesia but before skin incision, followed by an infusion of
15mg/kg/hr. Three minutes after heparin administration, to maintain blinding, this group
received a bolus of normal saline over 10 minutes, followed by a resumption of the EACA
infusion until the termination of CPB.
• Control group received normal saline boluses and infusions throughout.
NB: All groups were exposed to acute normovolaemic haemodilution (ANH)
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, number of patients exposed
to fresh frozen plasma and platelets, mortality, myocardial infarction,
re-operation for bleeding, stroke.
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Koster 2004
Methods Allocation of patients was blinded to the surgeon. Method of randomisation was not described
Participants 200 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Aprotinin group (Low dose + heparin): n = 100, M/F = 56/44, mean (sd) age = 64 (15) years
• Control group (Heparin alone): n = 100, M/F = 57/43, mean (sd) age = 66 (17) years
Interventions • Aprotinin group (Low dose + heparin) received a bolus of 1 million KIU of aprotinin
immediately before initiation of CPB and a continuous infusion of 250,000 KIU/hr during the
period of CPB. In addition, 1 million KIU of aprotinin was added to the CPB pump prime.
• Control group received standard care without aprotinin treatment.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma, blood loss, duration of
ventilation (hours)
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Kratzer 1997
Methods Method of randomisation was by means of a random number generator. Method used to conceal
treatment allocation was not described. [German language]
Participants 18 patients undergoing orthotopic liver transplantation were randomised to one of two groups:
• Aprotinin group: n = 9, mean age 47.9 years
• Control group (Placebo): n = 9, mean age 49.4 years
NB: Gender data were not reported.
Interventions • Aprotinin group received an intravenous bolus of 2 million KIU (280mg) of aprotinin at
induction of anaesthesia and a continuous infusion of 500,000 KIU/hr of aprotinin until the end
of the operation.
• Control group received physiological saline solution.
Outcomes Outcomes reported: Allogeneic blood usage (units), coagulation parameters, blood loss
Notes Transfusion protocol used
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Kratzer 1997 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Kreisler 2005
Methods Randomisation was accomplished through the use of a computer-generated table of random num-
bers. Method used to conceal treatment allocation was not described
Participants 71 patients undergoing cardiac surgery were randomised to one of three groups:
• Epsilon aminocaproic acid: n = 22, M/F = 17/5, mean (sd) age = 63.4 (7.2) years
• Heparin-coated CPB circuit: n = 20, 17/3, mean (sd) age = 59.6 (10.4) years
• Control group (Placebo): n = 25, M/F = 17/8, mean (sd) age = 61.4 (8.8) years
Interventions • Epsilon aminocaproic acid group received non-heparin coated circuits and EACA. A loading
dose of 75mg/kg of EACA was given over 10 minutes after the induction of anaesthesia and prior
to skin incision followed by a maintenance infusion of EACA of 12.5mg/kg/hr continued for 2
hours after the arrival of the patient in the intensive care unit. An additional 5g of EACA was
added to the CPB priming fluid.
• Heparin coated (bonded) CPB circuit group were treated with tip-to-tip heparin-coated
CPB circuits, including the cardiotomy reservoir, arterial filter, aortic and venous cannulas, and a
placebo infusion of normal saline.
• Control group received non-heparin coated circuits and a 0.9% normal saline load and
maintenance infusion given in the same manner as EACA-treated patients.
NB: All groups were exposed to cell savage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, number of patients exposed
to platelets, hospital length of stay (days), intensive care length of stay (hours), cell saver volume
autotransfused
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated table of random numbers
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Yes Double blind
Kuepper 2003
Methods Group assignment was by sealed envelopes. Sealed envelopes were opened after induction of anaes-
thesia by the unblinded investigator who was not part of the operating team
Participants 120 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Aprotinin group (Low dose): n = 60, M/F = 40/20, mean (sd) age = 65.5 (7.8) years
• Control group: n = 59, M/F = 40/19, mean (sd) age = 65.6 (8.8) years
Interventions • Aprotonin group (Low dose) received a single loading dose of 2 million KIU (280mg) of
aprotinin given after the induction of anaesthesia but before skin incision.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, fresh frozen plasma, platelets (units)
, mortality
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion threshold for RBC not reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate
Blinding?
All outcomes
No Single blind
Kuitunen 2005
Methods Study drugs were prepared by the hospital pharmacy. Randomisation was carried out using closed
envelopes
Participants 60 patients undergoing primary coronary artery bypass graft surgery were randomised to one of
three groups:
• Aprotinin group (High dose): n = 20, mean (sd) age = 61 (8.9) years
• Tranexamic acid group: n = 20, mean (sd) age = 63 (8.9) years
• Control group (Placebo): n = 20, mean (sd) age = 65 (8.9) years
Interventions • Aprotinin group (High dose) received 2 million KIU (280mg) of aprotinin after the
induction of anaesthesia, followed by an infusion of 500,000 KIU/hr (70mg/hr) until the end of
surgery. In addition, 2 million KIU (280mg) of aprotinin was added to the pump prime of the
155Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kuitunen 2005 (Continued)
CPB circuit.
• Tranexamic acid group received 15mg/kg after the induction of anaesthesia, followed by an
infusion of 15mg/kg until the end of surgery. In addition, 15mg/kg was added to the pump prime
of the CPB circuit.
• Control group received normal saline.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, number of patients exposed
to fresh frozen plasma, number of participants exposed to platelets,
blood loss (16hrs), mortality, myocardial infarction, re-operation for bleeding, stroke
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Closed envelopes
Allocation concealment? No Inadequate
Blinding?
All outcomes
Yes Double blind
Kuitunen 2006
Methods Method of randomisation and allocation concealment were not described
Participants 30 patients undergoing elective primary cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 15, M/F = 12/3, mean (sd) age = 57 (16) years
• Control group: n = 15, M/F = 11/4, mean (sd) age = 61 (11) years
Interventions • Tranexamic acid group received 1g after administration of 15ml/kg of 6% HES in the
immediate post-operative period.
• Control group received saline after administration of 15ml/kg of 6% HES in the immediate
post-operative period.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood transfusion, number of pa-
tients exposed to fresh frozen plasma and platelets, blood loss (24hrs), re-operation for bleeding
Notes Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Kunt 2005
Methods Method of randomisation and allocation concealment were not described
Participants 86 patients undergoing routine cardiac surgery were randomised to one of two groups:
• Aprotinin group: n = 40, M/F = 30/10, mean (sd) age = 63 (12) years
• Control group: n = 46, mean (sd) age = 60 (7) years
Interventions • Aprotinin group received 500,000 KIU (70mg) of aprotinin in the pump prime only.
• Control group received “no aprotinin.”
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24 hrs), mortality, hospital length
of stay (days), intensive care unit length of stay (hours), re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Kyriss 2001
Methods Randomisation carried out using a computer-generated random list. Allocation concealment not
specified
Participants 38 patients undergoing elective thoracic surgery were randomised to one of two groups:
• Aprotinin group (Low dose): n = 18, M/F = 12/6, mean age = 51.8 years
• Control group (Placebo): n =20, M/F = 12/8, mean age = 50.8 years
Interventions • Aprotonin group (Low dose) received a test dose of 10,000 KIU during induction of
anaesthesia followed by an initial bolus dose of 2 million KIU (280mg) of aprotinin over 20
minutes and a continuous infusion of 500,000 KIU/hr during the surgical procedure.
• Control group received a corresponding volume of saline solution.
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Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, fresh frozen plasma, blood loss, mortality, blood loss, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 5/7
No transfusion protocol
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random list
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Landymore 1997
Methods Method of randomisation was not described. The study drugs were prepared by pharmacy, given
an identification number, and then sent to the operating room
Participants 148 patients undergoing primary myocardial revascularisation were randomised to one of three
groups:
• Aprotinin group (Low dose): n = 48
• Epsilon-aminocaproic acid group: n = 44
• Tranexamic acid group: n = 56
• Control group: n = 50 (not included in randomisation process)
NB: Demographic data were not reported.
Interventions • Aprotinin group (Low dose) received a loading dose of 200,000 KIU of aprotinin
administered before cardiopulmonary bypass (CPB), followed by a maintenance dose of 200,000
KIU/hr of aprotinin continued until the termination of CPB.
• Epsilon-aminocaproic acid group received a loading dose of 5g administered before CPB,
followed by a maintenance dose of 1g/hr of EACA continued until the termination of CPB.
• Tranexamic acid group received a loading dose of 10mg/kg of TXA administered before
CPB, followed by a maintenance dose of 1mg/kg/hr of TXA continued until the termination of
CPB.
• Control group did not receive antifibrinolytic treatment.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, thrombosis, deep vein thrombosis,
pulmonary embolus
Notes Quality assessment score (Schulz criteria):2/7
Transfusion protocol used
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Lass 1995
Methods Method of randomisation and allocation concealment were not described. Four aprotinin (7.8%)
and eight control (14.5%) patients were excluded from the final analysis
Participants 110 male patients undergoing elective primary coronary bypass surgery were randomised to one of
two groups:
• Aprotinin group (High dose): n = 55
• Control (Placebo): n = 55
NB: Demographic data were not reported.
Interventions • Aprotinin group (High dose) received 2 million KIU of aprotinin as a loading dose before
sternotomy followed by an infusion of 500,000 KIU/hr until the end of surgery. An additional 2
million KIU was added to the priming volume.
• Control group received saline solution as a matching placebo in identical form by the same
administration scheme.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, graft patency, blood loss, mortality, myocardial infarction, acute heart failure, post-operative
complications, re-operation
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Later 2009
Methods Allocated according to a computer-generated randomisation sequence, allocation concealed by use
of sealed, opaque envelopes
Participants 298 patients undergoing cardiac surgery were randomised to one of three groups:
• Aprotonin group: n = 96, M/F = 73/23, mean (sd) age = 66.5 (10.7) years
• Tranexamic acid group: n = 99, M/F = 73/26, mean (sd) age = 64.1 (13.0) years
• Control group: n = 103, M/F = 68/35, mean (sd) age = 65 (11.2) years
Interventions • Aporinin group (high dose) received 2 million KIU pre-CPB, 2 million KIU at pump prime,
and 500,000 KIU/hr during CPB.
• Tranexamic acid group received 1g loading dose, 500mg added to CBP system prime, and a
continuous infusion of 400mg/hr.
• Control group received saline.
Outcomes Outcomes reported: Number of patienst exposed to allogeneic blood, myocardial infarction, renal
failure, hospital length of stay (days), re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Computer-generated randomisation sequence
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Laub 1994
Methods Method of randomisation and allocation concealment were not described
Participants 47 patients undergoing isolated coronary revascularisation were randomised to one of two groups:
• Aprotinin group: n = 16, M/F = 12/4, mean (sd) age = 65.3 (11.2) years
• Control group (Placebo): n = 16, M/F = 13/3, mean (sd) age = 63.6 (10) years
NB: The study group consisted of 32 patients in total. Fifteen of the originally enrolled patients
were not included in the final analysis due to: adverse reactions while receiving the study medication
(n = 2), inability to obtain or a technically inadequate CT scan (n = 7), refusal to come for follow-
up examinations (n = 4), or died (n = 2)
Interventions • Aprotinin group received 500 KIU of aprotinin as a test dose after the induction of
anaesthesia, followed by 2 million KIU (280mg) of aprotinin as a bolus. An infusion of 0.5
million KIU of aprotinin was commenced after the bolus was given and 2 million KIU of
aprotinin was added to the pump prime.
• Control group received an identical volume of placebo.
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Laub 1994 (Continued)
NB: Autologous blood salvage with reinfusion of washed RBCs was used for all patients. Shed
mediastinal and pleural blood was filtered and reinfused using an autotransfusion system
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, volume of allogeneic blood
transfused, blood loss, volume of platelets and fresh frozen plasma, re-operation for bleeding, post-
operative Hb levels, graft occlusions, any blood product usage, haematologic variables, coagulation
profiles, renal function
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Lavee 1993
Methods Method of randomisation and allocation concealment were not described
Participants 30 patients undergoing various cardiopulmonary bypass procedures were randomised to one of two
groups:
• Aprotinin group (Low dose): n = 15, M/F = 13/2, mean (sd) age = 62 (11) years
• Control group (Placebo): n = 11, M/F = 11/4, mean (sd) age = 60 (9) years
Interventions • Aprotinin group received 2 million KIU of aprotinin added to the priming volume of the
oxygenator. No additional aprotinin doses were given to the patients.
• Control group received an equivalent volume of placebo solution (saline solution 0.9%)
added to the priming volume of the oxygenator.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24hrs), platelets (units), platelet
aggregation
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
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Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Leijdekkers 2006
Methods Patients were randomised to receive either placebo or aprotinin using a standard randomisation list
stored in the pharmacy department, only to be opened after the study was closed for inclusion
Participants 35 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotonin group: n = 16, M/F = 14/2, mean (sd) age = 68 (9.5) years
• Control group: n = 19, M/F = 14/5, mean (sd) age = 68 (6.8) years
Interventions • Aporinin group received 2 million KIU starting dose followed by 500,000 KIU/hr during
surgery.
• Control group received saline.
Outcomes Outocmes reported: Volume blood transfused (units), blood loss, mortality, re-operation for bleed-
ing
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation list
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Lemay 2004
Methods Method of randomisation was not described. Study drugs were prepared by the hospital pharmacist.
Patient caregivers and the investigator collecting the data were blinded to the solution used
Participants 40 patients undergoing total hip replacement were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 12/8, mean (sd) age = 59.7 (10.3) years
• Control group (Placebo): n = 19, M/F = 13/6, mean (sd) age = 53.6 (12.8) years
NB: One patient was excluded from the final analysis.
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Interventions • Tranexamic acid group received TXA immediately before surgery. After a test dose of 1ml of
TXA, patients received a dose of 10mg/kg of intravenous TXA followed by an infusion of TXA of
1mg/kg/hr until skin closure.
• Control group received an equivalent volume of physiologic saline.
NB: Pre-operative autologous donation of 3 units was offered to all patients
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis, changes in haemoglobin levels
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Lemmer 1994
Methods Metho used to generate allocation sequences was not described. Aprotinin and an identically ap-
pearing placebo was supplied by Bayer AG, Leverkusen, Germany. Enrolled patients were stratified
as to whether they were undergoing primary procedures (n = 151 patients: Lemmer 1) or repeat
procedures (n = 65 patients: Lemmer 2)
Participants 151 patients undergoing isolated primary coronary artery bypass graft operations were randomised
to one of two groups:
• Aprotinin group: n = 74, M/F = 51/16, mean age = 64 years
• Control group (Placebo): n = 74, M/F = 61/13, mean age = 62 years
65 patients undergoing repeat coronary artery bypass graft operations were randomised to one of
two groups:
• Aprotinin group (High dose): n = 29, M/F = 21/2, mean age = 66 years
• Control group (Placebo): n = 36, M/F = 29/3, mean age = 65 years
Interventions • Aprotinin group received a loading dose of 280mg of aprotinin followed by a continuous
infusion of 70mg/hr, and 280mg of aprotinin was added to the oxygenator prime solution. The
continuous infusion was discontinued on the patients’ arrival to the intensive care unit.
• Control group received identical volumes of 0.9% sodium chloride solution.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma (units), platelets (units), blood loss, mortality,
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Lemmer 1994 (Continued)
myocardial infarction, re-operation for bleeding, allergic reactions, renal failure, renal failure +
dialysis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used.
Of the 151 patients undergoing primary CABG, 141 (74 in the aprotinin treated group and 67 in
the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated from
efficacy analysis before the random code was broken.
Of the 65 patients undergoing repeat CABG surgery 55 (23 in the aprotinin treated group and
32 in the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated
from efficacy analysis before the random code was broken
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Lemmer 1996
Methods Method of randomisation and allocation concealment were not described
Participants 704 first time coronary artery bypass grafting patients were randomised to one of four groups:
• Control group (Placebo): n = 178, M/F = 151/27, mean (sd) age = 62.5 (10.67) years
• Aprotinin group (High dose): n = 173, M/F = 145/28, mean (sd) age = 61.3 (10.5) years
• Aprotinin group (Low dose): n = 180, M/F = 155/25, mean (sd) age = 61.7 (10.7) years
• Aprotinin group (Pump prime dose): n = 173, M/F = 151/22, mean (sd) age = 62.1 (10.5)
years
Interventions • Control group received equivalent volumes of 0.9% sodium chloride at the same time
periods.
• Aprotinin group (High dose) received a loading dose of 280mg of aprotinin, a continuous
infusion dose of 70mg/hr until the end of the operation, and 280mg of aprotinin was added to
the pump prime solution.
• Aprotinin group (Low dose) received a loading dose of 140mg of aprotinin, a continuous
infusion dose of 35mg/hr until the end of the operation, and 140mg of aprotinin was added to
the pump prime solution.
• Aprotinin group (Pump prime dose) received a loading dose of placebo (0.9% sodium
chloride), a continuous infusion of placebo until the end of the operation, and 280mg of
aprotinin was added to the pump prime.
NB: All groups were exposed to cell salvage autotransfusion.
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Outcomes Outcomes reported: Total blood product exposures per patient, number of patients exposed to
allogeneic blood, allogeneic blood usage (units), platelet (units), fresh frozen plasma (units), cryo-
precipitate (units), blood loss, re-operation for diffuse bleeding, myocardial infarction
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Lemmer˙1 1994
Methods Refer to Lemmer 1994
Participants 151 patients undergoing isolated primary coronary artery bypass graft operations were randomised
to one of two groups:
• Aprotinin group: n = 74, M/F = 51/16, mean age = 64 years
• Control group (Placebo): n = 74, M/F = 61/13, mean age = 62 years
Interventions • Aprotinin group received a loading dose of 280mg of aprotinin followed by a continuous
infusion of 70mg/hr, and 280mg of aprotinin was added to the oxygenator prime solution. The
continuous infusion was discontinued on the patients’ arrival to the intensive care unit.
• Control group received identical volumes of 0.9% sodium chloride solution.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma (units), platelets (units), blood loss, mortality,
myocardial infarction, re-operation for bleeding, allergic reactions, renal failure, renal failure +
dialysis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used.
Of the 151 patients undergoing primary CABG, 141 (74 in the aprotinin treated group and 67 in
the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated from
efficacy analysis before the random code was broken
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Lemmer˙2 1994
Methods Refer to Lemmer 1994
Participants 65 patients undergoing repeat coronary artery bypass graft operations were randomised to one of
two groups:
• Aprotinin group (High dose): n = 29, M/F = 21/2, mean age = 66 years
• Control group (Placebo): n = 36, M/F = 29/3, mean age = 65 years
Interventions • Aprotinin group (High dose) received a loading dose of 280mg of aprotinin followed by a
continuous infusion of 70mg/hr, and 280mg of aprotinin was added to the oxygenator prime
solution. The continuous infusion was discontinued on the patients arrival to the intensive care
unit.
• Control group received an identical volume of 0.9% sodium chloride solution.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma (units), platelets (units), blood loss, mortality,
myocardial infarction, re-operation for bleeding.
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used.
Of the 65 patients undergoing repeat CABG surgery 55 (23 in the aprotinin treated group and
32 in the placebo treated group) fulfilled the criteria for efficacy analysis. Patients were eliminated
from efficacy analysis before the random code was broken
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Yes
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Lentschener 1997
Methods Generation of allocation sequences was by means of computer-generated random codes. Method
of allocation concealment was not described
Participants 97 patients scheduled for elective liver resection performed through subcostal incision were ran-
domly assigned to one of two groups:
• Aprotinin group: n = 48, M/F = 23/24, mean (sd) age = 53 (15) years
• Control group (Placebo): n = 49, M/F = 26/21, mean (sd) age = 54 (15) years
Interventions • Aprotinin group received a loading dose of 2 million KIU over 20 minutes after the
induction of anaesthesia, followed by a continuous infusion of 500,000 KIU/hr administered by
infusion pump until skin closure. An additional bolus of 500,000 KIU of aprotinin was infused
for every three units of RBC transfused.
• Control group received equivalent volumes of the placebo (0.9% saline solution) at the
respective times.
Outcomes Outcomes reported: Blood loss, number of patients exposed to allogeneic blood transfusion, fresh
frozen plasma transfused, platelet units transfused
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random codes
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Lentschener 1999
Methods Patients were randomised in a double blind fashion by using a computer generated random code.
Randomisation was both stratified by the number of fused levels and blocked in groups of four
before the induction of anesthesia. Allocation concealment was not described
Participants 72 patients undergoing posterior lumbar spine fusion were randomly assigned to one of two groups:
• Aprotinin group: n = 35, M/F = 18/17, mean (sd) age = 46 (9) years
• Control group (Placebo): n = 37, M/F = 19/18, mean (sd) age = 51 (11) years
Interventions • Aprotinin group received a loading dose of 2 million KIU (280mg) over 20 minutes after
induction of anaesthesia, followed by a continuous infusion of 500,000 KIU/hr administered by
infusion pump until skin closure. An additional bolus of 500,000 KIU of aprotinin was infused
every three units of RBC transfused.
• Control group received equivalent volumes of the placebo (0.9% saline solution) at the
respective times.
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Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood (units),
autologous transfusion, blood loss (24hrs), post-operative total autologous units (total)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated random code
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Levy 1995
Methods Method of randomisation and allocation concealment were not described. Eleven medical centres
participated. Study performed efficacy and safety analysis. Exclusions defined by protocol
Participants 287 patients undergoing repeat coronary artery bypass graft surgery were randomly assigned to one
of four groups:
• Aprotinin group (High dose): n = 73 (safety analysis), n = 61 (efficacy analysis), M/F = 55/6;
mean (sd) age = 64 (7.8) years
• Aprotinin group (Low dose): n = 70 (safety analysis), n = 59 (efficacy analysis), M/F = 52/7;
mean (sd) age = 65+/-7.7 years
• Aprotinin group (Pump-prime): n = 72 (safety analysis), n = 68 (efficacy analysis), M/F =
62/6; mean (sd) age = 66 (8.2) years
• Control group (Placebo): n = 72 (safety analysis), n = 65 (efficacy analysis), M/F = 59/6;
mean (sd) age = 64 (8.0) years
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin, plus an
additional 2 million KIU was added to the cardiopulmonary bypass (CPB) circuit prime,
followed by a continuous infusion of 500,000 KIU/hr during surgery.
• Aprotinin group (Low dose) received a loading dose of 1 million KIU of aprotinin, plus 1
million KIU was added to the CPB circuit prime, followed by a continuous infusion of 250,000
KIU/hr during surgery.
• Aprotinin group (Pump-prime) received 2 million KIU of aprotinin added to the CPB
circuit prime.
• Control group received equivalent volumes of 0.9% sodium chloride.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss
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Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Li 2005
Methods Method of randomisation and allocation concealment were not described
Participants 70 patients undergoing elective cardiac surgery were randomised to one of four groups:
• Control group: n = 10, M/F = 9/1, mean (sd) age = 59 (9) years
• Platelet-rich plasmapheresis + acute normovolaemic haemodilution + cell salvage group: n =
20, M/F = 17/3, mean (sd) age = 59 (6) years
• Aprotinin group: n = 22, M/F = 9/1, mean (sd) age = 61 (7) years
• Combined group: n = 18, M/F = 16/2, mean (sd) age 62 (8) years
Interventions • Control received standard care with no active intervention.
• PRP+ ANH + CS group: After the induction of anaesthesia, blood was withdrawn via the 9-
French central venous catheter at a rate of 35-45ml/min and collected in the 125mL centrifugal
bowl of an autotransfusion unit (Cell Saver 5, Haemonetics Corp., Braintree, MA). No systemic
heparin was administered at this time but calcium in the blood was sequested with citrate by
mixing the blood and ACD (adenosine, citrate, dextrose) agent (Perfect, Beijing, China) at a
volume ratio of 8:1. The withdrawn blood volume was replaced with a mixing (1:2) of plasma
substitute (Gelofusion) and crystalloid (Lactate Ringer Injection) at a volume ratio of 1:2-3 to
maintain a steady PCWP. The withdrawn blood was centrifuged at 2400 rpm to separate the
RBC’s from the plasma and platelets. After removing the RBC’s the plasma was continuously
centrifuged at 2400 rpm to separate the PRP from the platelet-poor plasma. An average of 30
minutes and three to four passes were required to complete blood withdrawal and separation of
the PRP and PPP. A volume of blood was withdrawn to obtain approximately 300ml of PRP from
each study patient. In addition, the autotransfusion device at the same machine (Cell saver 5,
Haemonetics Corp., Braintree, MA) was also used to retrieve RBC’s that were lost throughout the
course of the operation. Saline (0.9% NaCl) was used to irrigate all the sponges with blood in the
surgical field and then suctioned to the cell saver for further washing. Autologous RBC’s both
obtained during initial blood withdrawal and obtained via the autotransfusion device during the
operation were reinfused as necessary. After reversal of heparin, the autologous PPP and PRP were
reinfused back to the patients as were any remaining autologous RBC’s.
• Aprotinin group (High dose) received a loading dose of 2 million KIU before CPB and 2
million KIU added to the pump prime and a continuous infusion of 1 million KIU/hr
administered until skin closure or until a total dose of 5 million KIU was achieved.
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• Combined group (PRP + ANH +CS + Aprotinin) received treatment combining
interventions of Group 2 and Group 3.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients receiving fresh frozen plasma, number of patients receiving platelets, blood
loss
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Liu 1993
Methods Allocation sequences were generated by a computer generated random list. The trial drug and
placebo were supplied in identical packs. Exclusions or loss to follow-up were reported
Participants 40 patients undergoing elective myocardial revascularisation were randomised to one of two groups:
• Aprotinin group: n = 20, M/F = 13/7, mean (sd) age = 64.7 (2.0) years
• Control group (Placebo): n = 20, M/F = 17/3, mean (sd) age = 66.7 (1.3) years
Interventions • Aprotinin group received a loading dose of 1 million KIU of aprotinin intravenously after
the induction of anaesthesia, 1 million KIU in the priming volume of the heart-lung machine and
250,000 KIU/hr after the loading dose to the end of skin closure, or up to 1 million KIU of
aprotinin if the operation exceeded 4 hours in duration.
• Control group received a corresponding volume of placebo (substance used was not
specified).
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma, blood loss, total post-operative autotransfusion from the chest drainage,
mortality, re-operation for bleeding, allergic reaction, hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Yes Allocation sequences were generated by a com-
puter generated random list
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Liu 1998
Methods Method of randomisation and allocation concealment were not described
Participants 60 patients undergoing open heart surgery were randomly assigned to one of three groups:
• Epsilon aminocaproic group: n = 20, mean (sd) age = 65 (9) years
• Epsilon aminocaproic + platelet-rich plasmapheresis group: n = 20, mean (sd) age = 67 (12)
years
• Control group: n = 20, mean (sd) age = 64 (11) years
NB: Gender data were not reported.
Interventions • Epsilon aminocaproic acid group received 150mg/kg before CPB.
• Epsilon aminocaproic + platelet-rich plasmapheresis group received 150mg/kg of EACA
before CPB and platelet-rich plasma (PRP) at 10ml/kg salvaged from each patient with a plasma
saver before CPB which was then reinfused. PRP was reinfused at the end of CPB after protamine
administration.
• Control group received standard care.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), platelets
usage (units), blood loss
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Llau 1998
Methods Method of randomisation and allocation concealment were not described. [Abstract]
Participants 20 patients undergoing elective orthopaedic surgery were randomly allocated to one of two groups:
• Aprotinin group (Low dose): n = 10, mean (sd) age = 68 (8) years
• Control group (Placebo): n = 10, mean (sd) age = 67 (7) years
Interventions • Aprotinin group (Low dose) received 2 million KIU of aprotinin 30 minutes immediately
after the induction of anaesthesia.
• Control group received normal saline in the same volume and time as aprotinin,
immediately after the induction of anaesthesia.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis, change in haematocrit levels - baseline to 24 hrs post-operative,
change in haemoglobin levels - baseline to 24 hrs post-operative
Notes Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Locatelli 1990
Methods Method of randomisation and allocation concealment were not described. [Italian language]
Participants 38 patients undergoingmyocardial revascularisationwere randomly allocated to one of three groups:
• Aprotinin group (High dose): n = 12
• Aprotinin group (Low dose): n = 13
• Control group: n = 13
NB: Demographic data were not reported.
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin previous
to median sternotomy, followed by a continuous infusion of 500,000 KIU/hr until the end of the
operation. An additional 2 million KIU of aprotinin was added to the pump prime.
• Aprotinin group (Low dose) received a continuous infusion of 500,000 KIU/hr of aprotinin
until the end of the operation.
• Control group did not receive aprotinin.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (28 hrs), adverse reactions
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Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Luo 1998
Methods Method of randomisation and allocation concealment were not described
Participants 20 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotonin group: n = 10, M/F = 7/3, mean (sd) age = 36.9 (15.97) years
• Control group: n = 10, M/F = 7/3, mean (sd) age = 42.8 (13.31) years
Interventions • Aprotinin group received 3 million KIU of aprotinin.
• Control group did not receive aprotinin. no intervention.
Outcomes Outcomes reported: volume of blood transfused, duration of CPB.
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not reported.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Methods Method of randomisation and allocation concealment were not described. [Italian language]
Participants 99 patients undergoing coronary artery bypass graft surgery and valvular cardiac surgery were
randomised to one of three groups:
• Aprotinin group (High dose): n = 33, mean (sd) age = 64.0 (8.51) years
• Aprotinin group (Low dose): n = 33, mean (sd) age = 63.5 (8.37) years
• Control group: n = 33, mean (sd) age = 62.9 (9.7) years
NB: Gender data were not reported.
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin
intravenously (IV) over a period of 30 minutes, followed by 500,000 KIU/hr until the
termination of the operation. An additional 2 million KIU was added to pump prime.
• Aprotinin group (Low dose) received 2 million KIU added to the pump prime.
• Control group did not receive aprotinin.
NB: All groups were exposed to acute normovolemic haemodilution and cell salvage
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), allergic reactions
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used.
Four patients were excluded from the study due to surgical bleeding (one from the control group,
one from the high-dose aprotinin group, and two from the low-dose aprotinin group). One patient
from the low-dose aprotinin group died and was excluded from analysis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
MacGillivray 2010
Methods Tranexamic acid or placebo for infusion was prepared by the institution’s pharmacy in two identical
50mLbags (identified only by randomnumber)with the constituents unknown to the administering
anesthesiologist or surgeon. Method of randomisation was not described
Participants 60 patients undergoing orthopaedic (knee) surgery were randomised to one of three groups:
• Tranexamic acid group #1: n = 20, M/F = 7/13, mean (sd) age = 62 (4.3) years
• Tranexamic acid group #2: n = 20, M/F = 8/12, mean (sd) age = 65 (4.3) years
• Control group: n = 20, M/F = 5/15, mean (sd) age = 66 (7.3) years
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MacGillivray 2010 (Continued)
Interventions • Tranexamic acid group #1 received two doses of 10mg/kg. Patients received the first infusion
over 10 minutes before deflation of the first tourniquet and the second (over 10 minutes) 3 hours
after the first.
• Tranexamic acid group #2 received two doses of 15mg/kg. Patients received the first infusion
over 10 minutes before deflation of the first tourniquet and the second (over 10 minutes) 3 hours
after the first.
• Control group received normal saline. Patients received the first infusion of saline over 10
minutes before deflation of the first tourniquet and the second (over 10 minutes) 3 hours after the
first.
NB: Patients received re-infusion of autotransfused blood from the intra-articular drains
Outcomes Outcomes reported:number of patients exposed to allogeneic blood transfusion, blood loss, number
of allogeneic units transfused, adverse events
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Maddali 2007
Methods A computer-generated randomisation code was used to allocate participants. Allocation was con-
cealed by using sequentially-numbered, sealed opaque envelopes
Participants 222 patients undergoing cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 111, M/F = 80/31, mean (sd) age = 57.1 (8.9) years
• Control group: n = 111, M/F = 72/38, mean (sd) age = 58.2 (8.3) years
Interventions • Tranexamic acid group received loading dose of 10mg/kg before incision, then a continuous
infusion of 1mg/kg/hr until end of CPB.
• Control group received saline.
Outcomes Outcomes reported: Volume blood transfused, blood loss, mortality, stroke, re-operation for bleed-
ing
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation code
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Maineri 2000
Methods Method of randomisation and allocation concealment were not described
Participants 48 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Epsilon aminocaproic acid group: n = 24, mean (sd) age = 59.9 (10) years
• Tranexamic acid group (n = 24), mean (sd) age = 64.2 (9) years
NB: Gender data were not reported.
Interventions • Epsilon aminocaproic acid group received 10g of EACA as a standard dose in 30 minutes
following the induction of anaesthesia, and a maintenance infusion of 2g/hr was given
throughout the operation.
• Tranexamic acid group received a loading dose of 20mg/kg of TXA given in 60 minutes,
followed by a maintenance infusion of 2mg/kg/hr.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, pulmonary embolus, post -operative Hct, stroke
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Methods Randomisation of patients was performed with the help of a computer -generated random number
sequence programme. To ensure proper blinding the three studied solutions were prepared by the
pharmacy as bottles
Participants 60 patients undergoing elective cardiac surgery (off pump CABG) were randomly assigned to one
of three groups:
• Aprotinin group: n = 20, M/F = 1/5, mean (sd) age = 56.4 (9.1) years
• Tranexamic acid group: n = 20, M/F = 17/3, mean (sd) age = 57.5 (8.4) years
• Control group (Placebo): n = 20, M/F = 19/1, mean (sd) age = 57.7 (8.4) years
Interventions • Aprotinin group received 2 million KIU of aprotinin after skin incision, followed by a
continuous infusion of 3 million KIU throughout surgery at a rate of 500,000 KIU/hr.
• Tranexamic acid group received 1.5g of TXA (15mg/kg) after skin incision followed by a
continuous infusion of 1g throughout surgery at a rate of 2mg/kg/hr.
• Control group received normal saline at the same time and volumes as aprotinin and TXA.
NB: Loading dose was administered over 20 minutes in all groups. Infusion dose was infused at a
rate of 50ml/hr in all groups
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss (24hrs), myocardial infarction,
number of patients exposed to fresh frozen plasma, number of patients exposed to platelets, re-
operation for bleeding, renal dysfunction, hospital length of stay (days), renal dysfunction, neuro-
logical deficit
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer -generated random number sequence
programme
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Marcel 1996
Methods Patients were randomised by a computer program. Method of allocation concealment was not
described
Participants 44 consecutive patients undergoing orthotopic liver transplantation were randomised to one of two
groups:
• Aprotinin group: n = 21
• Control group (Placebo): n = 23
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NB: Demographic data were not reported.
Interventions • Aprotinin group received 200,000 KIU per hour via an intravenous infusion which was
started immediately after the induction of anaesthesia.
• Control group received normal saline.
Outcomes Outcomes reported:Allogeneic blood usage (units), fresh frozen plasma usage (units), platelet usage
(units), blood loss (24hrs)
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomised by a computer program
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Mehr-Aein 2007
Methods Method of randomisation was not reported. Concealment of allocation was achieved by using
pharmacy prepared coded infusion syringes
Participants 66 patients undergoing cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 33, mean (sd) age = 44 (10) years
• Control group: n = 33, mean (sd) age = 45 (10) years
NDB: Gender data were not reported.
Interventions • Tranexamic acid group received loading dose of 15mg/kg at beginning of surgery, same dose
before infusion of heparin at end of surgery, and again after protamine infusion.
• Control group received saline.
Outcomes Outcomes reported: Number of patient exposed to allogeneic blood transfusion, volume of blood
transfused (units), blood loss, re-operation for bleeding, mortality, myocardial infarction, renal
failure, length of hospital stay (days)
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Mengistu 2008
Methods Method of randomisation and allocation concealment were not described
Participants 50 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group: n = 25, M/F = 20/5, mean (sd) age = 69 (9) years
• Tranexamic acid group: n = 25, M/F = 18/7, mean (sd) age = 70 (9) years
Interventions • Aprotinin group received 2 million KIU pre-CPB, 2 million KIU at pump prime, and 500,
000 KIU/hr until arrival at ICU.
• Tranexamic group received 2g administered after induction of anaesthesia and 6mg/kg/hr
given continuously until arrival at ICU, and 1g added to CBP system prime.
Outcomes Outcomes reported: number of patients exposed to allogeneic blood transfusion, volume of allo-
geneic blood transfused, blood loss
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Menichetti 1996
Methods Method of randomisation and allocation concealment were not described
Participants 96 consecutive patients undergoing coronary artery bypass surgery were randomised to one of four
groups:
• Aprotinin group: n = 24, M/F = 12/12, mean (sd) age = 60.4 (5.1) years
• Epsilon aminocaproic acid group: n = 24, M/F = 14/10, mean (sd) age = 56.6 (6.7) years
• Tranexamic acid group: n = 24, M/F = 12/12, mean (sd) age = 55.2 (8.6) years
• Control group: n = 24, M/F = 13/11, mean (sd) age = 61.0 (9.7) years
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Interventions • Aprotinin group received a loading dose of 2 million KIU of aprotinin followed by a
continuous infusion of 500,000 KIU/hr. An additional 2 million KIU of aprotinin was added to
the CPB prime solution.
• Epsilon aminocaproic acid group received 80mg bolus of EACA intravenously and after 30
minutes a continuous infusion of 30 mg/kg of EACA. An additional 80mg/kg of EACA was
added to the CPB prime solution.
• Tranexamic acid group received a 10mg/kg bolus of TXA followed by a continuous infusion
of 3mg/kg/hr. An additional 10mg/kg of TXA was added to the CPB prime solution.
• Control group received usual care.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss (24hrs), re-oper-
ation for bleeding, haemoglobin levels, activated clotting times (ACT),
prothrombin times, activated partial thromboplastin times (APTT), plasminogen levels, factor VIII
levels, TAT complex/values
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Misfeld 1998
Methods Method of randomisation and allocation concealment were not described
Participants 42 patients undergoing elective cardiac surgery were randomised to one of three groups:
• Aprotinin group: n = 14, M/F = 14/0, mean (sd) age = 63 (6) years
• Tranexamic acid group: n = 14, M/F = 14/0, mean (sd) age = 56 (7) years
• Control group: n = 14, M/F = 11/3, mean (sd) age = 59 (10) years
Interventions • Aprotinin group received a test dose of 30,000 KIU at anesthesia induction and 1 million
KIU of aprotinin was added to the pump prime. After protamine administration further
aprotinin was administered in a dose of 200,000 KIU/hr for another 5 hours.
• Tranexamic acid group received 10mg/kg as a bolus after heparinization followed by a
continuous intravenous infusion of 1mg/kg/hr over 10 hours.
• Control treatment was not specified.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (6 hrs), mortality, change in haemoglobin levels - baseline to 24 hrs post-operative
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Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Mohr 1992
Methods Method of randomisation and allocation concealment were not described. No loss to follow-up
reported
Participants 50 patients undergoing primary coronary artery bypass graft surgery (CABG), repeat CABG, valve
replacement, or valve replacement + CABG surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 17, M/F = 14/3, mean (sd) age = 58 (10) years
• Aprotinin group (Low dose): n = 17, M/F = 14/3, mean (sd) age = 62 (10) years
• Control group (Placebo): n = 16, M/F = 11/5, mean (sd) age = 63 (11) years
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU of aprotinin for 20
minutes before sternotomy. An additional 2 million KIU of aprotinin was added to the priming
volume of the bubble oxygenator, and a continuous infusion of 500,000 KIU/hr was given after
the loading dose throughout surgery until skin closure or a total of 6 million KIU of aprotinin
was achieved.
• Aprotinin group (Low dose) received placebo (saline 0.9%) as a loading dose, 2 million KIU
of aprotinin in the pump prime, and placebo in the continuous infusion phase.
• Control group received equal volumes of placebo solution (0.9% saline) at the respective
times.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), re-operation for bleeding, post-operative platelet counts, platelet aggregation
evaluation by scanning electron microscopy
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
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Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Mongan 1998
Methods Patients were randomised using a computer-generated random sequence. Method used to conceal
treatment allocation was not described
Participants 150 patients undergoing primary coronary artery bypass graft surgery were randomised to one of
two groups:
• Aprotinin group (High dose): n = 75, M/F = 61/14, mean (sd) age = 62 (10) years
• Tranexamic acid (n = 75), M/F = 59/16, mean (sd) age = 61 (11) years
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg in 200ml)
administered before skin incision and a continuous infusion of 500,000 KIU/hr (3 million KIU
in 300ml) limited to the subsequent 6 hours. An additional 2 million KIU (280mg in 200ml) was
added to the pump prime.
• Tranexamic acid group received a loading dose of 1g (15mg/kg) administered before skin
incision and a continuous infusion of 1g infused at 50ml/hr (2mg/kg/hr in 300ml) limited to the
subsequent 6 hours. Normal saline solution (300ml) was added to the pump prime.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, mortality, myocardial infarction, re-operation for bleeding, stroke
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random sequence
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Moran 2000
Methods Patients were randomly assigned by a computer-generated code. Method used to conceal treatment
allocation was not described
Participants 42 patients undergoing coronary artery bypass surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 12, M/F = 11/1, mean (sd) age = 58.0 (8.4) years
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• Aprotinin group (Low dose): n = 12, M/F = 12/4, mean (sd) age = 59.6 (10.7) years
• Control group (placebo) (n = 14), M/F = 11/3, mean (sd) age = 59.7 (8.6) years
NB: Four patients were excluded from the final efficacy analysis. All 42 patients were included in
the safety analysis
Interventions • Aprotinin group (High dose) received a total dose of 6 million KIU (840mg) of aprotinin.
Prior to anaesthesia 2 million KIU (280mg) of aprotinin was administered and another 2 million
KIU (280mg) was added to the pump prime. An additional 2 million KIU (280mg) was
administered after the completion of CPB.
• Aprotinin group (Low dose) received a total dose of 4 million KIU (560mg) of aprotinin.
Prior to anaesthesia 2 million KIU (280mg) of aprotinin was administered and another 2 million
KIU (280mg) was added to the pump prime.
• Control group received 600ml of normal saline solution.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss (24hrs), mortality,
myocardial infarction, re-operation for bleeding, stroke
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated code
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Murkin 1994
Methods Method of allocation concealment was not described. Randomisation was by means of computer-
generated random code
Participants 54 patients undergoing first-time coronary artery bypass or valvular heart operations requiring
cardiopulmonary bypass (CPB) were randomised to one of two groups:
• Aprotinin group: n = 29, M/F = 22/7, mean (sd) age = 62 (9.7) years
• Control group (Placebo): n = 25, M/F = 16/9, mean (sd) age = 65.8 (7.5) years
NB:Three of the 57 enrolled patientswere deemed ineligible because of cancellation of the operation
(n = 2) and non-use of CPB (n = 1). All 54 remaining patients were included for analysis
Interventions • Aprotinin group received 2 million KIU of aprotinin (200ml) as a loading dose including an
initial 5 ml dose given after establishment of full monitoring and anaesthesia, 2 million KIU of
aprotinin was added to the CPB pump prime, and a continuous infusion of 500,000 KIU/hr of
aprotinin was given throughout the operation and for 1 hour after the patient had returned to the
intensive care unit (ICU). The maximum dose of aprotinin was 7 million KIU.
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• Control group received equal volumes of placebo (substance not specified).
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss (36hrs), myocardial infarction,
pulmonary embolic events, hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random code
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Murkin 1995
Methods Randomisation was by means of computer generated codes. Method of allocation concealment was
not described
Participants 53 consecutive patients undergoing revision total hip arthroplasty or primary bilateral total hip
arthroplasty were randomly assigned to one of two groups:
• Aprotinin group: n = 29, M/F = 9/20, mean (sd) age = 66.9 (15) years
• Control group (Placebo): n = 24, M/F = 11/13, mean (sd) age = 65.5 (16.6) years
Interventions • Aprotinin group received 2 million KIU (200ml) of aprotinin over 15 minutes followed by
an infusion of 500,000 KIU (50ml) per hour. Those patients weighing less than 60kg and more
than 80kg received a loading dose of 2.8ml/kg (10,000 KIU/ml) and an infusion of 0.7ml/kg/hr.
• Control group received an equivalent volume of 0.9% saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, cerebrovascular accident, deep vein thrombosis,
hospital length of stay (days).
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated codes
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Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Murkin 2000
Methods Labels on all medication vials were the same except for the patient executive number. Patients were
stratified on the basis of whether or not pre-operative autologous blood donations had been made
Participants 301 undergoing elective primary unilateral total hip replacement were randomised to one of four
groups:
• Aprotinin group (Low dose): n = 69, M/F = 34/35, mean age = 63.7 years
• Aprotinin group (Medium dose): n = 68, M/F = 27/41, mean age = 65.5 years
• Aprotinin group (High dose): n = 75, M/F = 46/29, mean age = 63.4 years
• Control group (Placebo): n = 68, M/F = 32/36, mean age = 63.2 years
Interventions • Aprotinin group (Low dose) received a loading dose of 500,000 KIU (70mg) of aprotinin.
• Aprotinin group (Medium dose) received a loading dose of 1 million KIU (140mg) of
aprotinin and a continuous infusion of 250,000 KIU/hr.
• Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin
and a continuous infusion of 500,000 KIU/hr.
• Control group received an unspecified placebo.
NB: Epsilon aminocaproic acid and desmopressin were used if deemed necessary. Data regarding
the use of these two drugs to minimise blood loss were not reported. All groups used pre-operative
autologous donation
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, myocardial in-
farction, mortality, deep venous thrombosis, pre-operative autologous blood donation
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Murphy 2006
Methods Allocation was generated by a card system and concealed in sealed, opaque envelopes
Participants 100 off-pump coronary artery bypass grafting surgical patients were randomly allocated to one of
two groups:
• Tranexamic acid group: n = 50, M/F = 42/8, mean (sd) age = 64.9 (7.0) years
• Control group (Placebo): n = 50, M/F = 37/13, mean (sd) age = 65.8 (8.7) years
Interventions • Tranexamic acid group received 2g as an intravenous bolus before sternotomy.
• Control group received a bolus of normal saline.
NB: All patients underwent peri-operative cell salvage with autotransfusion of washed salvaged red
blood cells at the completion of the operative procedure
Outcomes Outcomes reported: number of patients exposed to allogeneic blood transfusion, blood loss, mor-
tality, stroke, renal dysfunction, myocardial infarction, length of stay
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Niskanen 2005
Methods Patients were randomised into two groups by an envelope method in a double-blind manner. The
randomisation and preparation of the drug were done in the absence of other personnel by two
anaesthesia nurses not engaged in the study. The code was broken after the last patient had been
treated
Participants 40 patients undergoing cemented hip arthroplasty were randomised to one of two groups:
• Tranexamic acid group: n = 19, M/F = 6/13, mean (sd) age = 66 (9.1) years
• Control group (Placebo): n = 20, M/F = 7/13, mean (sd) age = 65 (8.2) years
NB: One patient was excluded from the final analysis.
Interventions • Tranexamic acid group received 10mg/kg of intravenous TXA over 5-10 minutes,
immediately before the operation. The next two doses were given 8 hours and 16 hours after the
first injection.
• Control group received corresponding doses of saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, deep vein thrombosis
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Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Norman 2009
Methods Patients were allocated according to a randomisation schedule based on study accession number.
Pharmacy controlled allocation
Participants 20 undergoing extrapleural pneumonectomy for mesothelioma were randomised to one of two
groups:
• Aprotinin group: n = 11, M/F = 0/9, mean (sd) age = 63.5 (6.2) years
• Control group (Placebo): n = 9, M/F = 8/3, mean (sd) age = 62 (7.6) years
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU infused over 1 hour,
followed by maintenance infusion of 500,000 KIU/hr until ICU admission.
• Control group received a saline placebo.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood transfusion, blood loss, mor-
tality
Notes Quality assessment score (Schulz criteria): 7/7
Use of transfusion protocol not reported
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation schedule based on study acces-
sion number
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Nurözler 2008
Methods Patients were allocated according to a list of random treatment codes. Method used to conceal
treatment allocation was not described
Participants 51 undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group: n = 25, M/F = 19/6, mean (sd) age = 63.1 (8.8) years
• Control group (Placebo): n = 26, M/F = 18/8, mean (sd) age = 64.6 (6.7) years
Interventions • Aprotinin group (low dose) received bolus 1 million KIU infused over 30 minutes, then
continuous infusion of 500,000 KIU/hr until end of surgery.
• Control group received a saline placebo.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood transfusion, volume blood
transfused (units), blood loss, re-operation for bleeding, myocardial infarction, stroke, length of
hospital stay (days)
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes List of random treatment codes
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Nuttall 2000
Methods Patients were randomly assigned by a computer-generated random number sequence. Method used
to conceal treatment allocation was not described
Participants 168 patients undergoing cardiac surgery were randomised to one of four groups:
• Aprotinin group (High dose): n = 40, M/F = 28/12, median (range) age = 70.5 (45-86) years
• Tranexamic acid group: n = 45, M/F = 31/14, median (range) age = 71 (43-83) years
• Tranexamic acid + acute normovolaemic haemodilution (ANH) group: n = 32, M/F = 28/4,
median (range) age = 67.5 (42-91) years
• Control group (Placebo): n = 43, M/F = 35/8, median (range) age = 63 (29-83) years
NB: Eight patients were excluded from the final analysis.
Interventions • Aprotinin group (High dose) received a test dose of 1.4mg (1ml) followed by a loading dose
of 280mg of aprotinin over 20-30 minutes. In addition, patients received a continuous infusion
of 70mg/hr (50ml/hr) of aprotinin and 280mg (200ml) was added to the pump prime.
• Tranexamic acid group received a loading dose of 10mg/kg and a continuous infusion of
1mg/kg/hr commenced after central venous cannulation and continued for 2 hours into
treatment in intensive care.
• Tranexamic acid + ANH group received a loading dose of 10mg/kg and a continuous
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infusion of 1mg/kg/hr commenced after central venous cannulation and continued for 2 hours
into treatment in intensive care. In addition, patients received intra-operative autologous blood
(12.5% of whole blood volume withdrawn before CPB and within 10 mins after central venous
cannulation).
• Control group received a normal saline infusion.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, mortality, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated random number sequence
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Okita 1996
Methods Method of randomisation and allocation concealment were not described
Participants 60 patients undergoing aortic surgery under deep hypothermic circulatory arrest were randomly
allocated to one of two groups:
• Aprotinin group: n = 39, M/F = 26/13, mean (sd) age = 63.5 (8.9) years
• Control group: n = 21, M/F = 16/5, mean (sd) age = 67.9 (9.4) years
Interventions • Aprotinin group received 2 million KIU of aprotinin administered in the pump prime only.
• Control group did not receive aprotinin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage, blood
loss (24 hrs), mortality, myocardial infarction, stroke, renal failure,
respiratory failure + pneumonia.
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
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Okita 1996 (Continued)
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Orpen 2006
Methods A pharmacist not involved with the study carried out randomisation in the pharmacy by a sealed
envelope method and prepared the contents of the administered solution. The operating team was
blinded to the contents of the administered solution for every patient although allowance was made
for the code to be broken should an adverse drug reaction occur
Participants 30 patients undergoing total knee arthroplasty were randomised to one of two groups:
• Tranexamic acid group: n = 15, M/F = 8/7, mean (95%CI) age = 73 (70-78) years
• Control group: n = 14, M/F = 3/11, mean (95%CI) age = 69 (63-74) years
NB: One patient was excluded from the final analysis.
Interventions • Tranexamic acid group received 15mg/kg of TXA intravenously at the time that cement
mixing commenced.
• Control group received an equivalent volume of normal saline given intravenously at the
time that cement mixing commenced.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, deep vein throm-
bosis, change in haemoglobin levels
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Palmer 2003
Methods A computer generated randomisation schedule was used to randomly assign patients into the
treatment groups. The vials used for each group were only identifiable by the patient study number
Participants 95 patients undergoing elective neurological surgery were divided into two subsets:
Meningioma subset: n = 56
• Aprotinin group: n = 30, M/F = 7/23, mean (sd) age = 58.4 (13.0) years
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Palmer 2003 (Continued)
• Control group (Placebo): n = 26, M/F = 9/17, mean (sd) age = 58.5 (2.8) years
Vestibular Schwannoma subset: n = 39
• Aprotinin group: n = 17, M/F =11/6, mean (sd) age = 48.6 (10.9) years
• Control group (Placebo): n = 17, M/F = 11/16, mean (sd) age = 54.1 (12.0) years
Interventions • Aprotinin group (Low dose) received a loading dose of 30,000 KIU/kg of aprotinin infused
over 15-20 minutes administered before the start of surgery and followed by a continuous
infusion of 10,000 KIU/kg/hr until the patient was transferred to the Intensive Care Unit.
• Control group received 0.9% sodium chloride solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, mortality (7-day & 30-day)
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation schedule
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Parvizi 2007
Methods Patients were allocated according to a computer-generated randomisation list. Adequacy of alloca-
tion concealment was unclear
Participants 162 undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group: n = 81), M/F = 49/32, mean (sd) age = 52.6 (13.8) years
• Control group (Placebo): n = 81, M/F = 49/32, mean (sd) age = 54.1 (11.4) years
Interventions • Aprotinin group received 500,000 KIU infused before and 500,000 KIU during CPB.
• Control group received a saline placebo.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood transfusion, volume of blood
transfused, blood loss, myocardial infarction, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
191Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Parvizi 2007 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation list
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Penta de Peppo 1995
Methods Method of randomisation and allocation concealment were not described
Participants 60 consecutive patients undergoing elective open-heart surgery were randomised to one of four
groups:
• Control group: n = 15, M/F = 13/2, mean (sd) age = 63 (7) years
• Epsilon aminocaproic acid group: n = 15, M/F = 13/2, mean (sd) age = 62 (7) years
• Tranexamic acid group: n = 15, M/F = 12/3, mean (sd) age = 60 (12) years
• Aprotinin group (High dose): n = 15, M/F = 12/3, mean (sd) age = 64 (10) years
Interventions • Control group received no antifibrinolytic treatment.
• Epsilon aminocaproic acid group received 10g of EACA intravenously (IV) at the induction
of anaesthesia followed by an infusion of 2g/hr for 5 hours.
• Tranexamic acid group received 10mg/kg of TXA IV within 30 minutes after the induction
of anaesthesia, followed by an infusion of 1mg/kg per hour for 10 hours.
• Aprotinin group (High dose) received 2 million KIU of aprotinin IV at the induction of
anaesthesia followed by an infusion of 500,000 KIU/hr during surgery and 2 million KIU of
aprotinin added to the extracorporeal circuit.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, re-operation for bleeding,
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Petsatodis 2006
Methods Patients were randomised using an envelope technique. Method of allocation concealment was not
described
Participants 50 patients undergoing total hip arthroplasty were randomised to one of two groups:
• Aprotinin group: n = 25, mean (sd) age = 58.4 (12.5) years
• Control group (Placebo): n = 25, mean (sd) age = 59.6 (10.9) years
Interventions • Aprotinin group received a bolus of 20,000 KIU/kg of aprotinin at the time of anaesthesia
followed by an infusion of 50,000 KIU/hr.
• Control group received normal saline in the same volumes.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Pinosky 1997
Methods Method of randomisation and allocation concealment were not described
Participants 59 patients undergoing cardiac surgery were randomly assigned to one of three groups:
• Epsilon aminocaproic acid group: n = 20, M/F = 12/8, mean (sd) age = 62.6 (9.4) years
• Tranexamic acid group: n = 20, M/F = 12/18, mean (sd) age = 62.6 (9.4) years
• Control group (Placebo): n = 19, M/F = 15/4, mean (sd) age = 60.6 (10.9) years
Interventions • Epsilon aminocaproic acid group received an intravenous loading dose of 150mg/kg and a
continuous infusion of 10mg/kg/hr for 6 hours. EACA was given immediately following the
induction of anaesthesia.
• Tranexamic acid group received a loading dose of 15mg/kg followed by a continuous infusion
of 1mg/kg/hr for 6 hours. TXA was given immediately following the induction of anaesthesia.
• Control group received a bolus of normal saline and a continuous infusion of normal saline
for 6 hours.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, aspirin use,
number of patients exposed to platelets and fresh frozen plasma
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Pinosky 1997 (Continued)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Pleym 2003
Methods Randomisation was by mean of a computer programme. Study medications were delivered in
identical 50mL syringes
Participants 79 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 40, M/F = 34/6, mean (sd) age = 63.6 (9.9) years
• Control group (Placebo): n = 39, M/F = 32/7, mean (sd) age = 62 (9.2) years
Interventions • Tranexamic acid group received 30mg/kg of TXA as a bolus injection given over 5 minutes
immediately before the start of CPB.
• Control group received a bolus injection of the corresponding volume of 0.9% sodium
chloride solution given 5 minutes immediately before the start of CPB.
NB: Both groups were exposed to post-operative cell salvage, tranexamic acid, and desmopressin
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, re-operation for bleeding, fresh frozen plasma usage (units), platelet usage (units)
, pulmonary embolus, retransfused mediastinal shed blood, post-operative TXA, post-operative
DDAVP, ASA 75mg/day, ASA 160mg/day
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer programme
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Porte 2000
Methods The trial drug was provided double-blind by the manufacturer in blocks of 12 identical case packs.
Each case pack contained all bottles for one patient, identifiable only by the sequence number.
Each block of 12 case packs contained four packs of each dosage group, randomly assigned to the
sequence numbers 1 to 12. Patients received the next available case pack of each block. Centres were
provided with sealed cards with the randomisation codes to enable an individual patient’s code to
be broken in an emergency. A separate set of the sealed randomisation cards was kept at the Central
Data Centre. At the end of the study all cards with randomisation codes were sent to the Central
Data Centre
Participants 141 patients undergoing orthotopic liver transplantation were randomised to one of three groups:
• Aprotinin group (High dose): n = 46, M/F = 34/12, median (range) age = 52 (18-66) years
• Aprotinin group (Low dose): n = 43, M/F = 34/19, median (range) age = 49 (18-69) years
• Control group (Placebo): n = 48, M/F = 36/12, median (range) age = 53 (19-68) years
NB: Four patients were excluded from the final analysis.
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU (280mg) of aprotinin
over 20 minutes before and during the induction of anaesthesia, followed by a continuous
infusion of 1 million KIU/hr (140mg/hr) until 2 hours after graft reperfusion. An additional dose
of 1 million KIU was administered 30 minutes before graft reperfusion.
• Aprotinin group (Low dose) received a loading dose of 2 million KIU (280mg) of aprotinin
over 20 minutes before and during the induction of anaesthesia, followed by a continuous
infusion of 500,000 KIU/hr until 2 hours after graft reperfusion.
• Control group received 0.9% normal saline in an identical time schedule and volume.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, number of patients exposed to
platelets and cryoprecipitate
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Poston 2006
Methods Study drug or placebowas delivered to the operating room in unlabeled bottles tomaintain blinding.
Method of randomisation was not specified
Participants 70 patients undergoing ’off-pump’ coronary artery bypass graft surgery were randomised to one of
two groups:
• Aprotinin group (Low dose): n = 29
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Poston 2006 (Continued)
• Control group (Placebo): n = 31
NB: Demographic data were not reported.
Interventions • Aprotinin group (Low dose) received 10,000 KIU of aprotinin as a test dose followed by 2
million KIU (280mg) of aprotinin as a bolus before sternotomy, and 500,000 KIU/hr (70mg/hr)
of aprotinin as a continuous infusion until the end of surgery.
• Control group received normal saline.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units),
fresh frozenplasmausage (units), platelet usage (units),myocardial infarction, deep vein thrombosis,
stroke, hospital length of stay (days), Intensive Care Unit length of stay (days)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Prendergast˙1 1996
Methods Method of randomisation and allocation concealment were not described
Participants 38 patients undergoing primary sternotomy for heart transplantation were randomised to one of
two groups:
• Aprotinin group: n = 18, M/F = 15/3, mean (sd) age = 45.4 (10.2) years
• Control group: n = 20, M/F = 14/6, mean (sd) age = 49.3 (6.7) years
Interventions • Aprotinin group received 200ml of aprotinin as a loading dose intravenously followed by a
continuous infusion of aprotinin of 50ml/hr until the end of the operation. In addition, 200ml of
aprotinin was added to the cardiopulmonary bypass circuit.
• Control group did not receive aprotinin.
NB: Precise dose of aprotinin (KIU or mg) was not reported.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24hrs), haemoglobin levels, crea-
tinine levels
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not specified
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Prendergast˙1 1996 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Prendergast˙2 1996
Methods Method of randomisation and allocation concealment were not described
Participants 32 patients undergoing re-operative heart transplantation were randomised to one of two groups:
• Aprotinin group: n = 16, M/F = 14/2, mean (sd) age = 54.4 (6.9) years
• Control group: n = 16, M/F = 13/3, mean (sd) age = 55 (10.6) years
Interventions • Aprotinin received a 200ml loading dose of aprotinin intravenously followed by a
continuous infusion of 50ml/hr until the end of the operation. In addition, 200ml of aprotinin
was added to the cardiopulmonary bypass circuit.
• Control group received no aprotinin.
NB: Precise dose of aprotinin (KIU or mg) was not reported.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24 hrs), haemoglobin levels, crea-
tinine levels
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Pugh 1995
Methods Method of randomisation and allocation concealment were not described
Participants 75 patients scheduled for routine primary cardiac surgery were randomly allocated to one of three
groups:
• Control group: n = 23, M/F = 16/7, mean (sd) age (+/-SD) = 66 (9.3) years
• Tranexamic acid group: n = 22, M/F = 17/5, mean (sd) age = 58 (10) years
• Aprotinin group: n = 21, M/F = 15/6, mean (sd) age = 62 (9.7) years
NB: Nine patients were withdrawn from the trial: two from the control group, three from the
tranexamic acid group, and four from the aprotinin group
Interventions • Control group received neither trial drug nor placebo preparation.
• Tranexamic acid group received 2.5g of TXA before skin incision, with a further 2.5g of
TXA added to the cardiopulmonary bypass (CPB) solution.
• Aprotinin group received 1 million KIU of aprotinin before skin incision, with a further 1
million KIU added to the priming solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patinets exposed to fresh frozen plasma, blood loss,
re-operation for bleeding.
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Ranaboldo 1997
Methods Allocation concealment was by the use of identical coded bottles containing active drug or placebo.
The method of randomisation was not described
Participants 136 patients undergoing elective aortic surgery were randomised to one of two groups:
• Aprotinin group: n = 66, M/F = 55/11, median age = 68 years
• Control group (Placebo) group: n = 62, M/F = 45/17, median age = 70 years
NB: Eight patients were excluded from the final analysis. Four deaths occurred within 7 days of
surgery (two in each group). Four patients were found at operation not to be suitable for the planned
reconstructive surgery
Interventions • Aprotinin group received 2 million KIU of aprotinin as a loading dose over a 20 minute
period, followed by a maintenance infusion of 500,000 KIU/hr.
• Control group received equal volumes of 0.9% normal saline.
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Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), mortality (30 day), myocardial infarction, stroke, pulmonary embolus, deep
vein thrombosis, chest infection, hepatitis, sepsis, renal failure, urinary tract infection
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Rao 1999
Methods Method of randomisation and allocation concealment were not described
Participants 30 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Epsilon aminocaproic acid group: n = 15, M/F = 13/2, mean age = 53 years
• Control group: n = 15, M/F = 13/2, mean age = 55 years
Interventions • Epsilon aminocaproic acid group received 100mg/kg of EACA as a loading dose slowly after
the induction of anaesthesia and a continuous infusion of EACA at 1g/hr for a further 6 hours.
• Control group received no EACA treatment.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24 hrs), myocardial infarction,
fresh frozen plasma usage (units), platelet usage (units), ASA treatment until surgery (185mg), ASA
treatment until surgery (375mg), stroke, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Blinding?
All outcomes
Unclear Unclear
Ray 1997
Methods Method of randomisation and allocation concealment were not described
Participants 106 patients undergoing aortic or mitral valve replacement or both were randomly assigned to one
of two groups:
• Aprotinin group: n = 54, M/F = 35/19, median age = 54 years
• Control group (Placebo): n = 52, M/F = 28/24, median age = 58 years
Interventions • Aprotinin group received 2 million KIU of aprotinin (280mg) over 20 minutes after the
induction of anaesthesia followed by 500,000 KIU/hr (70mg/hr) until the patient was returned to
the post-operative ward. In addition, 2 million KIU (280mg) was added to the oxygenator prime.
• Control group received an equivalent volume of normal saline.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, re-operation, platelet usage
(units), fresh frozen plasma usage (units)
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Ray 1999
Methods Method of randomisation and allocation concealment were not described
Participants 150 patients in elective adult cardiac surgery were randomly assigned to one of three groups:
• Aprotinin group (High dose): n = 50
• Aprotinin group (Low dose): n = 50
• Control group (Placebo): n = 50
NB: Gender or age data were not reported.
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Ray 1999 (Continued)
Interventions • Aprotinin group (High dose) received a loading dose of 2 million KIU over 20 minutes after
the induction of anaesthesia followed by 500,000 KIU/hr (70mg/hr) until the patient was
returned to the post-operative ward. In addition, 2 million KIU (280mg) was added to the pump
prime.
• Aprotinin group (Low dose) received a loading dose of 140mg (1 million KIU) infused over
20 minutes after the induction of anaesthesia and a pump prime dose of 140mg (1 million KIU).
• Control group received a volume of saline solution equivalent to the volume admitted in the
low dose aprotinin.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Ray 2001
Methods Method of randomisation and allocation concealment were not described
Participants 100 patients undergoing elective cardiac surgery were randomly assigned to one of two groups:
• Epsilon aminocaproic acid group: n = 51
• Aprotinin group: n = 49
NB: Gender or age data were not reported.
Interventions • Epsilon aminocaproic acid group received a test dose of 250mg at least 10 minutes before
the loading dose of 5g given over a 20 minute period after the induction of anaesthesia and 1.25g/
hr continuous infusion until 4 hours after bypass. In addition, 5g of EACA was added to the
pump prime before cross clamping.
• Aprotinin group received a test dose of 10,000 KIU before the loading dose (1 million KIU)
given over a 20 minute period after the induction of anaesthesia and 1 million KIU was added to
the pump prime.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, re-operation for bleeding,
aspirin use within 10 days, Intensive Care Unit length of stay (hours), neurologic events
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol was not used
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Ray 2001 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Ray 2005
Methods Method of randomisation and allocation concealment were not described. Allocation of the ran-
domised drug was performed by a nurse not otherwise connected with the study
Participants 45 patients undergoing elective primary total hip arthroplasty were randomly allocated to one of
three groups:
• Aprotinin group: n = 15, mean (interquartile range) age = 69 (58-74) years
• Epsilon aminocaproic acid group: n = 15, mean (interquartile range) age = 72 (59-77) years
• Control group (Placebo): n = 15, mean (interquartile range) age = 72 (59-77) years
Interventions • Aprotinin group received a 10,000 KIU test dose of aprotinin followed by a bolus of 2
million KIU given over 30 minutes after the induction of anaesthesia followed by a continuous
infusion of 500,000 KIU/hr for 3 hours.
• Epsilon aminocaproic acid group received 10g of EACA in 250mL of IV saline given over 30
minutes after the induction of anaesthesia followed by 5g in 250mL of IV saline over 3 hours.
• Control group received normal saline in the same manner as the other trial arms.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), deep vein thrombosis, pre-operative apirin use
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Rhydderch 1993
Methods Methods of sequence generation and allocation concealment were unclear
Participants 43 undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group (n = 20), M/F = 14/6, mean (SD) age = 42 (15) years
• Control group (placebo) (n = 23), M/F = 15/8, mean (SD) age = 37 (17) years
Interventions • Aprotinin group received 2 million KIU added to the pump prime.
• Control group received a saline placebo.
Outcomes Outcomes reported: Volume blood transfused, re-operation for bleeding.
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Rocha 1994
Methods Method of randomisation and allocation concealment were not described
Participants 109 of 122 eligible patients scheduled for coronary artery bypass graft surgery, valvular surgery, or
mixed cardiac surgery were randomised to one of four groups:
• Aprotinin group: n = 28, M/F = 16/12, mean (sd) age = 58.9 (10.0) years
• Desmopressin group: n = 25, M/F = 14/11, mean (sd) age = 56.6 (8.8) years
• Desmopressin group: n = 28, M/F = 20/8, mean (sd) age = 57.3 (7.6) years
• Control group: n = 28, M/F = 22/6, mean (sd) age = 56.3 (10.1) years
Interventions • Aprotinin group received a bolus infusion of 2 million KIU of aprotinin within 30 minutes
after the induction of anaesthesia followed by a continuous infusion of 500,000 KIU/hr of
aprotinin until the patient left the operating room. In addition, a bolus of 2 million KIU of
aprotinin was added to the pump prime by replacement of crystalloid.
• Desmopressin group received 0.3ug/kg of desmopressin (DDAVP) in 50ml of saline
solution over a period of 20 minutes, given intravenously on completion of cardiopulmonary
bypass (CPB) and immediately after administration of protamine.
• Desmopressin group received two doses of DDAVP (2 x 0.3ug/ml) and an additional dose 6
hours after surgery.
• Control group did not receive aprotinin or DDAVP.
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Rocha 1994 (Continued)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage, blood
loss (72hrs), mortality, thrombosis
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
No Single blind
Rodrigus 1996
Methods Method of randomisation and allocation concealment were not described
Participants 99 adult patients undergoing elective primary coronary artery bypass graft, or valvular surgery, with
cardiopulmonary bypass were randomised to one of two groups:
• Aprotinin group: n = 46, M/F = 39/7, mean (sd) age = 60.4 (8.8) years
• Control group (Placebo): n = 47, M/F = 34/13, mean (sd) age = 59 (7.8) years
NB: Six of the 99patients randomisedwere excluded from the study.Ninety-three patients remained
in the study for analysis
Interventions • Aprotinin group received aprotinin as an infusion of 2 million KIU in 200ml of normal
saline after induction, followed by a continuous infusion of 500,000 KIU/hr and 2 million KIU
in the priming volume of the extracorporeal circuit.
• Control group received the same volume of normal saline.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), blood loss (24hrs), mortality, myocardial
infarction [definite & possible], re-operation for bleeding, atrial fibrillation
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
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Rodrigus 1996 (Continued)
Blinding?
All outcomes
Yes Double blind
Rossi 1997
Methods Method of randomisation and allocation concealment were not described
Participants 43 patients scheduled for elective primary myocardial revascularisation were randomly allocated to
one of two groups:
• Aprotinin group: n = 21, mean (sd) age = 58 (8) years
• Control group (n = 22), mean (sd) age = 56 (12) years
NB: Gender data were not reported.
Interventions • Aprotinin group received 2 million KIU of aprotinin in the cardiopulmonary bypass prime.
• Control group did not receive aprotinin.
NB: Both groups were exposed to acute normovolaemic haemodilution (ANH)
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss (24hrs), re-oper-
ation for bleeding, side effects
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Royston 1987
Methods Patients were randomly allocated to receive test compound by means of sealed envelopes. Method
of randomisation was not described
Participants 22 patients undergoing repeat cardiac surgery through previous median sternotomy wound were
randomised to one of two groups:
• Aprotinin group: n = 11, mean (sd) age = 53 (15) years
• Control group: n = 11, mean (sd) age = 57 (13) years
NB: Gender data were not reported.
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Royston 1987 (Continued)
Interventions • Aprotinin group received a loading dose of 280mg of aprotinin via central venous access over
20 minutes before the opening of the previous median sternotomy wound, followed by a
continuous infusion of 70mg/hr until skin closure at the end of the operation. An additional
280mg of aprotinin was added to the prime volume of the oxygenator.
• Control group did not receive aprotinin.
NB: Both groups were exposed to acute normovolaemic haemodilution (ANH)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), mortality, total haemoglobin loss,
time for wound closure (mins), platelet counts.
Notes Quality assessment score (Schulz criteria):3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Unclear Unclear
Sadeghi 2007
Methods Patients were randomised using a random number technique. The correct treatment option was
assured by means of coded infusion syringes prepared by hospital pharmacy not involved otherwise
in the study
Participants 67 undergoing orthopaedic surgery for hip fractures were randomised to one of two groups:
• Tranexamic acid group: n = 32, M/F = 17/15, mean (sd) age = 51.81 (25.7) years
• Control group (Placebo): n = 35, M/F = 24/11, mean (sd) age = 44.4 (26.16) years
Interventions • Tranexamic acid group received a bolus of 15mg/kg at the beginning of surgery.
• Control group received saline solution.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood transfusion, mortality, blood
loss, volume blood transfused (units), length of hospital stay (days)
Notes Quality assessment score (Schulz criteria):7/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
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Sadeghi 2007 (Continued)
Adequate sequence generation? Yes Random number technique
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Samama 2002
Methods Centres were provided with sealed envelopes with the randomisation codes to enable an individual
patient’s code to be broken in an emergency. A separate set of sealed randomisation tables were kept
at the central data centre. To maintain masking, all patients received identical volumes of solution
and an identical number of bottles for the identical dose and for the continuous infusion, regardless
of treatment group
Participants 58 patients undergoing elective orthopaedic surgery were randomised to one of three groups:
• Aprotinin group (High dose): n = 18, mean (sd) age = 44 (17) years
• Aprotinin group (Low dose): n = 22, mean (sd) age = 48 (19) years
• Control group (Placebo): n = 18, mean (sd) age = 44 (22) years
NB: Gender data were not reported.
Interventions • Aprotinin group (High dose) received a loading dose of 4 million KIU (560mg) given over
20 minutes before and during the induction of anaesthesia followed by a continuous infusion of 1
million KIU until skin closure.
• Aprotinin group (Low dose) received a loading dose of 2 million KIU (280mg) given over 20
minutes before and during the induction of anaesthesia followed by a continuous infusion of 500,
000 KIU until skin closure.
• Control group received saline in an identical time schedule and volume.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis, pulmonary embolus, trauma cases, cell salvage used, autologous
transfusion
Notes Quality assessment score (Schulz criteria):6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation codes
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
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Santamaria 2000
Methods Method of randomisation and allocation concealment were not described
Participants 84 patients undergoing elective coronary artery bypass graft surgery were randomly allocated to
one of two groups:
• Aprotinin group (High dose): n = 28, M/F = 27/1, mean (range) age = 58 (38-78) years
• Aprotinin group (Low dose): n = 28, M/F = 24/4, mean (range) age = 61 (40-75) years
• Control group (Placebo): n = 28, M/F = 24/4, mean (range) age = 59 (41-76) years
Interventions • Aprotinin group (High dose) received a bolus of 2 million KIU as a loading dose followed by
a continuous infusion of 500,000 KIU/hr during CPB. In addition, 2 million KIU (280mg) of
aprotinin was added to the pump prime.
• Aprotonin group (Low dose - pump prime only) received a bolus of saline as a loading dose
followed by a continuous infusion of saline during CPB. Two million KIU (280mg) of aprotinin
was added to the prime solution.
• Control group received a bolus of saline. Saline was added to the priming solution and a
continuous infusion of saline was administered during CPB.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial infarction, stroke, hypertension, A-V block
Notes Quality assessment score (Schulz criteria):4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Santos 2006
Methods Groups were randomised by means of sequentially numbered sealed envelopes opened by a nurse in
the operating room. Only the nurse, who prepared the infusions, knew whether a patient received
drug or placebo. Study drugs were delivered in identical volumes. Staff in the operating room and
in the intensive care unit were not aware of the treatment
Participants 65 patients undergoing primary coronary artery bypass graft surgery were randomised to one of
two groups:
• Tranexamic acid group: n = 29, M/F = 18/11, mean (sd) age = 62 (9.2) years
• Control group (placebo) (n = 31), M/F = 25/6, mean (sd) age = 59 (8.7) years
NB: Five patients were excluded from the final analysis.
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Santos 2006 (Continued)
Interventions • Tranexamic acid group received a loading dose of 10mg/kg of TXA before skin incision,
followed by a continuous infusion of 1mg/kg/hr for 5 hours.
• Control group received a bolus of normal saline solution in an identical syringe and a
continuous infusion of normal saline for 5 hours.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), blood loss, mortality, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Schmartz 2003
Methods Sixty patients were divided into three groups by means of computerised randomisation. Allocation
concealment was not specified
Participants 60 male patients undergoing primary elective cardiac surgery were randomised to one of three
groups:
• Aprotinin group (High dose): n = 20, mean (sd) age = 62 (9) years
• Aprotinin group (Low dose): n = 20, mean (sd) age = 59 (11) years
• Control group (Placebo): n = 20, mean (sd) age = 61 (11) years
Interventions • Aprotonin group (High dose) received a loading dose of 2 million KIU (280mg) followed by
a continuous infusion of 500,000 KIU/hr. In addition, 2 million KIU (280mg) of aprotinin was
added to the pump prime.
• Aprotinin group (Low dose) received a loading dose of 1 million KIU (140mg) followed by a
continuous infusion of 250,000 KIU/hr. In addition, 1 million KIU (140mg) of aprotinin was
added to the pump prime.
• Control group received an unspecified placebo.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood markers of inflammation during and
after CPB
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol not used
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Schmartz 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computerised randomisation
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blinding
Schweizer 2000
Methods Concealment of treatment allocation was not described. Patients were allocated randomly in a
double-blind manner. Method of randomisation was not described
Participants 60 patients undergoing elective coronary artery bypass graft surgery, aortic valve replacement and
mitral valve replacement and repair were randomised to one of two groups:
• Aprotinin group (Low dose): n = 28), M/F = 21/7, mean (range) age = 66 (35-85) years
• Control group (Placebo): n = 29, M/F = 21/8, mean (range) age = 64 (33-81) years
Interventions • Aprotinin group (Low dose) received a mean dose of 4.1 million KIU of aprotinin,
consisting of a loading dose of 280mg (2 million KIU) over 30 minutes, 140mg (1 million KIU)
added to the pump prime and a continuous infusion of 500,000 KIU/hr from the start of surgery
until skin closure.
• Control group received a similar volume of normal saline.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, mortality, myocardial infarction,
re-operation for bleeding
Notes Quality assessment score (Schulz criteria):3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Shore-Lesserson 1996
Methods Patients were randomly assigned to treatment or placebo by computer generated table. The phar-
macist who prepared the infusions knew whether the patient received active treatment or placebo
in the event of an adverse response
Participants 31 patients undergoing repeat open heart surgery were randomised to one of two groups:
• Tranexamic acid group: n = 17, M/F = 10/7, mean (sd) age = 68 (13) years
• Control group (Placebo): n = 13, M/F = 10/3, mean (sd) age = 63 (6) years
NB: One patient from the placebo group was withdrawn from the study due to excessive post-
operative bleeding and requiring intra-aortic balloon counter pulsation
Interventions • Tranexamic acid group received an initial dose of TXA, 20mg/kg over 20 minutes, followed
by a continuous infusion of 2mg/kg/hr. This infusion was terminated at the completion of the
surgical procedure.
• Control group received an equal volume of saline.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage,
fresh frozen plasma usage, platelet usage, blood loss, mortality, myocardial infarction, pulmonary
complications, re-operation, renal impairment, cerebral ischemia, embolic stroke
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated table
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Sorin 1999
Methods Method of randomisation and allocation concealment were not described. [Abstract]
Participants 42 patients undergoing total knee replacement were randomly assigned to one of two groups:
• Tranexamic acid group: n = 21
• Control group (Placebo): n = 21
NB: Demographic data were not reported.
Interventions • Tranexamic acid group received 15mg/kg of TXA 30 minutes before surgery and
subsequently every 8 hours over the following 3 days.
• Control group received an equal volume of saline.
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Sorin 1999 (Continued)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, deep vein thrombosis
Notes Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Speekenbrink 1995
Methods Method of randomisation and allocation concealment were not described
Participants 60 patients scheduled for elective primary coronary artery bypass grafting were randomly assigned
to one of four groups:
• Aprotinin group: n = 15, M/F = 13/2, mean (sd) age = 62 (10) years
• Tranexamic acid group: n = 15, M/F = 14/1, mean (sd) age = 61 (11) years
• Dipyridamole group: n = 15, M/F = 13/2, mean (sd) age = 60 (9) years
• Control group: n = 15, M/F = 14/1, mean (sd) age = 57 (12) years
Interventions • Aprotinin group received single dose of 2 million KIU of aprotinin added to the pump
prime.
• Tranexamic acid group received a bolus of 10mg/kg over 20 minutes and continued at a rate
of 1mg/kg up to total dose of 1,000 mg.
• Dipyridamole (Persantin) group received 100mg four times a day (oral), 36 hours before the
operation. After induction of anaesthesia treatment was continued with intravenous dipyridamole
at a rate of 0.24mg/kg/hr for 24 hours.
• Control group received usual care.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), blood loss (6hrs), myocardial infarction, haemorrhage from
chest
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
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Speekenbrink 1995 (Continued)
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Speekenbrink 1996
Methods Study medications were supplied in boxes containing 12 bottles with 50mL solution. The ran-
domisation code was kept by supplied. The codes were broken after data acquisition were complete
and verified
Participants 115 patients scheduled for elective coronary artery bypass graft surgery were randomised to one of
three groups:
• Control group (Placebo): n = 37, M/F = 29/8, mean (sd) age = 57 (8) years
• Aprotinin group (Low dose): n = 37, M/F = 33/4, mean (sd) age = 62 (9) years
• Aprotinin group (High dose): n = 38, M/F = 30/8, mean (sd) age = 62 (9) years
Interventions • Control group received equivalent volumes of normal saline.
• Aprotinin group (Low dose) received 500,000 KIU of aprotinin in the prime solution.
• Aprotinin group (High dose) received 2 million KIU of aprotinin over 30 minutes followed
by an infusion of 500,000 KIU/hr. In addition, 500,000 KIU of aprotinin was added to the
prime solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), mortality, myocardial infarction, renal failure, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Three patients were excluded from the final analysis: Two from the placebo group (one for excessive
postoperative bleeding caused by a broken suture and one for a small left ventricular aneurysm
requiring resection), one from the high dose aprotinin group who had dense pericardial adhesions
resembling those found in reoperation
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Stammers 1997
Methods Method of randomisation was not described. All drugs were drawn up by a pharmacist and placed
in a 500mL glass bottle which was labelled with the patient’s name, registration number and date.
No other clinician knew of the treatment received by the patient
Participants 20 patients undergoing first time coronary artery bypass grafting were randomly assigned to one of
two groups:
• Aprotinin group: n = 8, M/F = 6/2, mean (sd) age = 66.3 (5.8) years
• Control group (Placebo): n = 12, M/F = 10/2, mean (sd) age = 63.9 (9.2) years
Interventions • Aprotinin group received a loading dose of 2 million KIU (280mg) of aprotinin
administered intravenously immediately following the induction of anaesthesia, 2 million KIU of
aprotinin placed in the priming volume of the extracorporeal circuit, and a constant infusion of
500,000 KIU/hr (70mg/hr) until chest closure.
• Control group received an equal volume of saline administered in the same manner.
Outcomes Outcomes reported: Allogeneic blood usage, Intensive care ventilator time (hrs), renal failure,
neurological injury, hospital length of stay (days), blood loss (24hrs)
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Stewart 2001
Methods Randomisation using numbers chosen randomly from a computer generated table. Study drug and
placebo bottles were identifiable only by the random number
Participants 30 patients undergoing elective orthognathic surgery (maxillary Le Fort I and mandibular sagittal
split osteotomies) were randomised to one of two groups:
• Aprotinin group (Low dose): n = 15
• Control group (Placebo): n = 15
NB: Gender and age data were not reported.
Interventions • Aprotinin group (Low dose) received a loading dose of 280mg (2 million KIU) given after
the induction of anaesthesia and before the operation started for over 20 minutes, followed by a
continuous infusion at a rate of 500,000 KIU/hr was infused until the end of the procedure.
• Control group received normal saline at the same time and volumes as aprotinin.
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Stewart 2001 (Continued)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated table
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Swart 1994
Methods Method of randomisation was not described. Intervention and placebo solutions were supplied by
Bayer AG (Germany)
Participants 50 patients undergoing primary coronary artery bypass surgery and 50 patients undergoing valve
surgery were randomised to one of two groups:
• Aprotinin group: n = 49, M/F = 33/16, mean (range) age = 53.1 (18-78) years
• Control group (Placebo) (n = 49), M/F = 32/17, mean (range) age = 51.6 (18-76) years
Interventions • Aprotinin group received 2 million KIU of aprotinin at the start of the operation, infused
over a period of 30 minutes followed by a continuous infusion of aprotinin at 500,000 KIU/hr
for 4 hours or until the end of the operation. In addition, 2 million KIU was added to the
priming solution of the extracorporeal circuit.
• Control group received similar volumes of saline.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss (48hrs), mortality,
biochemistry and haematology values
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
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Swart 1994 (Continued)
Blinding?
All outcomes
Yes Double blind
Tabuchi 1994
Methods Method of randomisation was not described. The study solution was prepared by the pharmacy
department according to a randomised code, which was kept blind to all clinicians and investigators
until all data were obtained
Participants 40 patients undergoing elective coronary artery bypass grafting were randomised to one of two
groups:
• Aprotinin group: n = 19, mean (sd) age = 60.9 (8.7) years
• Control group (Placebo): n = 17, mean (sd) age = 60.2 (8.6) years
NB: Gender data were not reported. Four patients were excluded from the final analysis; three from
the placebo group for surgical bleeding requiring repeat thoracotomy, and one from the aprotinin
group for haemothorax
Interventions • Aprotinin group received 325mg of aspirin orally 10 hours before operation and 2 million
KIU of aprotinin (280mg) added to the pump prime solution.
• Control group received 325mg of aspirin orally 10 hours before operation and 200ml of
placebo solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelet usage (units), re-operation for bleeding, haemothorax
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Taggart 2003
Methods A pre-determined randomisation scheme was generated by the pharmaceutical company supplying
the trial drug. Sealed code break cards were available if necessary. The study was analysed on an
intention-to-treat (ITT) basis and included those patients who received open-label aprotinin
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Taggart 2003 (Continued)
Participants 74 patients undergoing cardiac surgery with total arterial grafting were randomised to one of two
groups:
• Aprotinin group (High dose): n = 37, M/F = 33/3, mean (sd) age = 60 (8) years
• Control group (Placebo): n = 34, M/F = 32/2, mean (sd) age = 61 (8) years
NB: Four patients were excluded from the final analysis.
Interventions • Aprotinin group (High dose) received a 5mL (1.4mg/mL) test dose of aprotinin after the
induction of anaesthesia and before sternotomy. The remaining 195mL of the loading dose was
administered over 20-30 minutes using an infusion pump. After the completion of the loading
dose, a maintenance infusion of 50ml/hr was continued for 4 hours. A further 200mL was added
to the pump prime of the bypass circuit.
• Control group received an unspecified solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of participants exposed to fresh frozen plasma and platelets, blood loss, myocardial
infarction, re-operation for bleeding, hospital length of stay
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
NB: Nine patients in the control group (placebo) received open-label aprotinin whilst two patients
in the aprotinin group received open-label aprotinin
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
No Single blind
Taghaddomi 2009
Methods Table of random numbers was used to generate the allocation sequence. An independent anesthe-
siologist prepared coded infusions with tranexamic acid and placebo and was not directly involved
in the clinical treatment of randomised patients. Both operating room staff and the intensive care
unit staff were blinded regarding the study group
Participants 100 patients undergoing cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 50, M/F = 38/12, mean (sd) age = 54.7 (10.9) years
• Control group (Placebo): n = 50, M/F = 34/16, mean (sd) age = 60.3 (10.2) years
Interventions • Tranexamic acid group received a bolus of 1g was given 20 minutes before incision then a
maintenance dose of 400mg/hr during the entire surgical procedure.
• Control group received normal saline.
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Taghaddomi 2009 (Continued)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood transfusion, blood loss, stroke,
renal failure, myocardial infarction
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Table of random numbers
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Tanaka 2001
Methods Ampoules containing either tranexamic acid or placebo were numbered and placed in envelopes at
random by a pharmacologist
Participants 99 patients undergoing elective knee arthroplasty were randomised to one of four groups:
• Control group (Placebo): n = 26, M/F = 9/17, mean (range) age = 65 (58-70) years
• Tranexamic acid group (Pre-operative TXA): n = 24, M/F = 7/17, mean (range) age = 65
(59-70) years
• Tranexamic acid group (Intra-operative TXA): n = 22, M/F = 7/15, mean (range) age = 65
(60-71) years
• Tranexamic acid group (Pre-and-intra-operative TXA): n = 27, M/F = 8/19, mean (range)
age = 65 (59-69) years
Interventions • Control group received saline twice, 10 minutes before surgery and on deflation of the
tourniquet.
• Tranexamic acid group (Pre-operative TXA) received 20mg/kg of TXA 10 minutes before
surgery and saline 10 minutes before the deflation of the tourniquet.
• Tranexamic acid group (Intra-operative TXA) received saline 10 minutes before surgery and
20mg/kg of TXA 10 minutes before deflation of the tourniquet.
• Tranexamic acid group (Pre-and-intra-operative TXA) received 10mg of TXA 10 minutes
before surgery and 10mg/kg 10 minutes before deflation of the tourniquet.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol not used
Risk of bias
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Tanaka 2001 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Tassani 2000
Methods Study performed in a double blind, placebo controlled manner. Method of randomisation and
allocation concealment were not described
Participants 20 patients undergoing elective cardiac surgery were randomly assigned to one of two groups:
• Aprotinin group: n = 10
• Control group (Placebo): n = 10
NB: Gender and age data were not reported.
Interventions • Aprotinin group received a loading dose of 2 million KIU of aprotinin, a priming dose of 2
million KIU, and a continuous infusion of 500,000 KIU/hr during surgery.
• Control group received an unspecified placebo.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Thorpe 1994
Methods Method of randomisation and allocation concealment were not described
Participants 17 patients undergoing elective knee replacement surgery were randomly allocated to one of two
groups:
• Aprotinin group: n = 8
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Thorpe 1994 (Continued)
• Control group: n = 9
NB: Demographic data were not reported.
Interventions • Aprotinin group received 0.5 million KIU of aprotinin over 20 minutes immediately before
inflation of the tourniquet, another 0.5 million KIU of aprotinin over 20 minutes before
deflation of the tourniquet followed by an infusion of 1 million KIU over the next 2 hours.
• Control group did not receive aprotinin.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, femoral thrombosis
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Trinh-Duc 1992
Methods Method of randomisation and allocation concealment were not described. [French language]
Participants 60 patients undergoing cardiac surgery were randomised to one of two groups:
• Aprotinin group (High dose): n = 29, M/F = 19/10, mean (sd) age = 54.89 (14.92) years
• Epsilon aminocaproic acid group (n = 27), M/F = 20/7, mean (sd) age = 61.07 (10.65) years
NB: Four patients were excluded from the final analysis.
Interventions • Aprotinin group received 2 million KIU (280mg) of aprotinin after the induction of
anaesthesia followed by a continuous infusion of 500,000 KIU/hr of aprotinin until skin closure.
In addition, 2 million KIU (280mg) of aprotinin was added to the pump prime.
• Epsilon aminocaproic acid group received 5g of EACA as a bolus after the induction of
anaesthesia followed by a continuous infusion of 2g/hr until skin closure. In addition, 5g of
EACA was added to the pump prime.
NB: Both groups received cell salvage and acute normovolaemic haemodilution (ANH)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), blood loss (48hrs), mortality,
minor stroke, respiratory problems, severe hypotension.
Notes Transfusion protocol not used
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Trinh-Duc 1992 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Troianos 1999
Methods Method of randomisation and allocation concealment were not described
Participants 72 patients undergoing primary coronary artery bypass surgery were randomised to one of two
groups:
• Epsilon aminocaproic acid group: n = 38, M/F = 27/11, mean (sd) age = 66 (9) years
• Control group (Placebo): n = 36, M/F = 24/12, mean (sd) age = 65 (9) years
Interventions • Epsilon aminocaproic acid group received a bolus dose of 0.5ml/kg of EACA administered
immediately after systemic heparization (125mg/kg), and an infusion of EACA commenced at 0.
05ml/kg/hr (12.5mg/kg/hr) and continued until after the administration of protamine and before
the patient left the operating room.
• Control group received saline solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma and platelets, blood loss (6hrs & 48hrs), re-
exploration for bleeding, haemoglobin loss
Notes Quality assessment score (Schulz criteria): 3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Turkoz 2001
Methods Method of randomisation and allocation concealment were not described
Participants 30 patients undergoing elective cardiac surgery were allocated randomly to one of three groups:
• Aprotonin group (High dose): n = 10, M/F = 9/1, mean (sd) age = 60.2 (3.4) years
• Methylprednisolone group: n = 10, M/F = 8/2, mean (sd) age = 58.3 (3.0) years
• Control group: n = 10, M/F = 9/1, mean (sd) age = 63.8 (1.9) years
Interventions • Aprotinin group (High dose) received a loading dose of 280mg (2 million KIU) of aprotinin
followed by a continuous infusion of 70mg/hr (500,000 KIU/hr) administered during the
operation. In addition, 280mg (2million KIU) of aprotinin was added to the pump prime.
• Methylprednisolone group received 30mg/kg of methylprednisolone intravenously 5
minutes before surgery.
• Control group received standard care.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss.
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Uozaki 2001
Methods Method of randomisation and allocation concealment were not described
Participants 14 patients undergoing elective cardiac surgery were allocated to one of two groups:
• Tranexamic acid group: n = 14, M/F = 5/1, mean (sd) age = 72.3 (4.1) years
• Control group: n = 7, M/F = 3/3, mean (sd) age = 63.3 (5.3) years
Interventions • Tranexamic acid group received 50mg/kg of intravenous TXA before skin incision and after
the start of CPB.
• Control group did not receive TXA treatment.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss (24hrs), re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol not used
Risk of bias
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Uozaki 2001 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Urban 2001
Methods Patients were randomised by means of a random number generator. Method used to conceal
treatment allocation was not described
Participants 60 patients undergoing complex reconstructive spinal surgery were randomised to one of three
groups:
• Aprotinin group: n = 20, mean (sd) age = 47.2 years
• Epsilon aminocaproic acid group: n = 17, mean (sd) age = 46.6 years
• Control group: n = 18, mean (sd) age = 47.3 years
NB: Gender data were not reported. Five patients were excluded from the final analysis
Interventions • Aprotinin group received 1 million KIU of aprotinin as a loading dose over 30 minutes
followed by 250,000 KIU/hr.
• Epsilon aminocaproic acid group received a 5g loading dose over 30 minutes followed by
15mg/kg/hr.
• Control group received no antifibrinolytic treatment.
NB: All groups were exposed to cell salvage and pre-operative autologous blood donation (PAD)
Outcomes Outcomes reported: Allogeneic & autologous blood usage (units), blood loss, respiratory compli-
cations
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number generator
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Utada 1997
Methods Method of randomisation and allocation concealment were not described. [Japanese language]
Participants 21 patients undergoing primary total hip replacement were randomised to one of two groups:
• Aprotinin group (Low dose): n = 11, M/F = 1/10, mean (sd) age = 63 (11) years
• Control group (Placebo): n = 10, M/F = 2/8, mean (sd) age = 64 (5) years
Interventions • Aprotinin group (Low dose) received 2 million KIU (280mg) of aprotinin as a continuous
infusion throughout the surgical procedure.
• Control group received normal saline solution.
Outcomes Outcomes reported: Allogeneic blood usage (units), blood loss, changes in haemoglobin levels
Notes Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Van der Linden 2005
Methods Random assignment was conducted using unmasked envelopes, each containing a card indicating
treatment with aprotinin or placebo. A nurse, assigned to another department of the hospital
was responsible for the preparation of placebo and treatment solutions, which were identical in
appearance and packing
Participants 75 patients scheduled for urgent or acute isolated coronary artery bypass graft surgery were ran-
domised to one of two groups:
• Aprotinin group (High dose): n = 37, M/F = 31/6, mean (sd) age = 66.4 (10) years
• Control group (Placebo): n = 38, M/F = 25/13, mean (sd) age = 68.3 (10) years
Interventions • Aprotinin group (High dose) received a 1 ml test dose of aprotinin after the induction of
anaesthesia then received 2 million KIU (280 mg) of aprotinin as a bolus before the start of
surgery. Another 2 million KIU of aprotinin was added to the pump prime and a continuous
infusion of 500,000 KIU/hr was infused during surgery.
• Control group received an equal volume of saline solution at the same time periods as the
aprotinin regimen.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), platelets usage (units), mortality, myocardial infarction, stroke,
atrial fibrillation, number of patients receiving TXA treatment
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Van der Linden 2005 (Continued)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Van Oeveren 1987
Methods Method of randomisation and allocation concealment were not described
Participants 22 patients undergoing coronary artery bypass graft surgery were randomised to one of two groups:
• Aprotinin group: n = 11, mean (sd) age = 56.2 (3.9) years
• Control group: n = 11, mean (sd) age = 57.5 (5.1) years
Interventions • Aprotinin group received an infusion of 2 million KIU (280mg) of aprotinin over 20-30
minutes and a continuous infusion of 500,000 KIU/hr until the end of the operation. In
addition, for each litre of transfused whole blood given during the operation, an additional 500,
000 KIU of aprotinin was administered by a separate bolus infusion.
• Control group did not receive aprotinin.
Outcomes Outcomes reported: Allogeneic blood usage, blood loss, biochemical markers.
Notes Quality assessment score (Schulz criteria): 0/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Vander-Salm 1996
Methods Random assignment was by means of a random number table and drug preparation was performed
by the hospital pharmacy
Participants 103 patients undergoing coronary artery bypass graft surgery or valvular surgery were randomly
assigned to one of two groups:
• Epsilon aminocaproic acid group: n = 51, M/F = 35/16, mean (sd) age = 64.7 (12.1) years
• Control group (Placebo): n = 52, M/F = 40/12, mean (sd) age = 64.2 (12.4) years
Interventions • Epsilon aminocaproic acid group received 10mg of EACA intravenously before skin
incision, 10g of EACA after heparin administration, and 10g of EACA at discontinuation of
cardiopulmonary bypass (CPB) but before protamine administration.
• Control group received saline solution in the same volumes and with the same timing as the
EACA treated group.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma, blood loss (12hrs & 24hrs), mortality, cere-
brovascular accident, re-operation for bleeding
Notes Quality assessment score (Schulz criteria): 7/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Vanek 2005
Methods An envelope method with random numbers was used to randomise patients. An independent
pharmacologist not directly involved in the clinical treatment of randomised patients prepared
coded infusions with the study drug and placebo
Participants 91 patients undergoing cardiac surgery were randomised to one of three groups:
• Tranexamic acid group: n = 32, M/F = 16/16, mean (95% CI) age = 68.4 (64.6-72.2) years
• Aprotinin group: n = 29, M/F = 20/9, mean (95% CI) age = 67.3 (64.2-70.4) years
• Control group: n = 30, M/F = 22/8, mean (95% CI) age = 68.9 (65.8-72.0) years
Interventions • Tranexamic acid group received 1g TXA before skin incision and a continuous infusion of
200mg/hr during the whole surgical procedure.
• Aprotinin group received 1 million KIU of aprotinin before skin incision and a continuous
infusion of 250,000 KIU/hr during the whole surgical procedure.
• Control group received normal saline 0.9% before skin incision and a continuous infusion
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Vanek 2005 (Continued)
during the whole surgical procedure.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, blood loss, number of patients
exposed to fresh frozen plasma
Notes Quality assessment score (Schulz criteria): 6/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Vedrinne 1992
Methods Method of randomisation and allocation concealment were not described
Participants 90 consecutive patients undergoing cardiac surgery were randomly allocated to one of three groups:
• Aprotinin group: n = 30, M/F = 23/7, mean (sd) age = 58 (8) years
• Auto-transfusion group: n = 30, M/F = 20/10, mean (sd) age = 57 (7) years
• Control group: n = 30, M/F = 24/6, mean (sd) age = 59 (10) years
Interventions • Aprotinin group received 2 million KIU of aprotinin at the induction of anaesthesia infused
over 20-30 minutes (10,000 KIU/ml of pure aprotinin without additives) followed by a
continuous infusion of 500,000 KIU/hr of aprotinin administered throughout the operation. In
addition, 2 million KIU of aprotinin was added to the priming solution of the extracorporeal
circuit.
• Auto-transfusion group had 400 ml of autologous blood withdrawn into citrate-phosphate-
dextrose during electrocardiographic and haemodynamic monitoring. Blood was withdrawn after
the induction of anaesthesia and before skin incision. Withdrawn blood was concomitantly
replaced by 500ml of 4% albumin. Autologous blood was kept at room temperature (18-20
degrees) and was transfused after the completion of cardiopulmonary bypass, but before the
patients were transferred to the Intensive Care Unit (ICU).
• Control group patients underwent routine management without autologous transfusion or
aprotinin treatment.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, number of patients exposed to fresh frozen plasma and platelets,
blood loss (6hrs & 48hrs), re-operation for bleeding, haemoglobin loss
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
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Vedrinne 1992 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Veien 2002
Methods Patients were randomised using a computer generated randomisation table to treatment groups.
Method of allocation concealment was not described
Participants 30 patients undergoing elective orthopaedic surgery were randomly assigned to one of two groups:
• Tranexamic acid group: n = 15, M/F = 4/11, mean (sd) age = 70.5 (9.5) years
• Control group: n = 15, M/F = 1/14, mean (sd) age = 69.5 (9.0) years
Interventions • Tranexamic acid group received 10mg/kg of TXA administered just before the release of the
tourniquet, and 10mg/kg of TXA given 3 hours later in the recovery room. Although a maximum
of 1g was given each time.
• Control group received standard care without TXA treatment.
NB: All groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, cell salvage autologous blood returned, thrombo-embolic events
Notes Quality assessment score (Schulz criteria):3/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Computer generated randomisation table
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Wei 2006
Methods Method of allocation concealment and randomisation were not described
Participants 112 patients undergoing ’off-pump’ coronary artery bypass graft surgery were randomised to one
of two groups:
• Aprotinin group: n = 36, M/F = 28/8, mean (sd) age = 61.4 (7.5) years
• Tranexamic acid group: n = 36, M/F = 28/8, mean (sd) age = 62.8 (7.9) years
• Control group (Placebo): n = 40, M/F = 32/8, mean (sd) age = 60.7 (8.0) years
Interventions • Aprontinin group received 1 million KIU loading dose at beginning of surgery, followed by
continuous infusion of 500000 KIU per hour during surgery.
• Tranexamic acid group received a loading dose of 0.75g of TXA over 20 minutes at the
beginning of surgery followed by a continuous infusion of 0.25g/hr throughout surgery.
• Control group received the same volume of saline solution.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, fresh frozen plasma usage (units), number of patients exposed to fresh frozen plasma, blood loss
(24hrs), hospital length of stay (days), Intensive Care Unit length of stay (days)
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Results for aprotinin versus control and TXA versus control - reported in separate publications
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Wendel 1995
Methods Method of randomisation was not described. Aprotinin and placebo were provided by the manu-
facturer in identical bottles that differed only in the random numbers on their labels
Participants 40 patients undergoing aorto-coronary artery bypass graft surgery were randomised to one of two
groups:
• Aprotinin group: n = 20, mean (sd) age = 62.4 (7.4) years
• Control group (Placebo): n = 20, mean (sd) age = 60.6 (7.7) years
NB: Gender data were not reported.
Interventions • Aprotinin group received 30,000 KIU/kg of aprotinin as a loading dose over 20 minutes,
followed by a continuous infusion of 7,000 KIU/kg/per/hr. In addition, 30,000 KIU/kg of
aprotinin was added to the priming solution after 5 minutes of extracorporeal circulation (ECC).
• Control group received physiologic saline solution.
229Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Wendel 1995 (Continued)
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss, myocardial infarction, infarctional biomarkers
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol not specified
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Wong 2000
Methods The randomisation and preparation of study drugs was performed by the hospitals department of
pharmacy. There was no attempt to stratify the randomisation process
Participants 80 patients undergoing elective cardiac surgery were randomised to one of two groups:
• Tranexamic acid group: n = 40, mean (sd) age = 66.0 (10.9) years
• Aprotinin group (High dose): n = 40, mean (sd) age = 65.4 (8.6) years
NB: Gender data were not reported.
Interventions • Tranexamic acid group received a bolus of 10g of TXA over 20 minutes after the induction
of anaesthesia and before skin incision. Normal saline 0.9% was used during the other time
periods similar to the aprotinin regimen. A test dose of 1mL was given.
• Aprotinin group (High dose) received an infusion of 2 million KIU (280mg) of aprotinin
infused over 20 minutes after the induction of anaesthesia and before skin incision, followed by a
continuous infusion of 500,000 KIU/hr administered throughout the operation until skin
closure. In addition, 2 million KIU (280mg) was added to the pump prime.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), myocardial infarction, mortality, fresh frozen plasma usage, platelet usage
(units), re-operation for bleeding, stroke
Notes Quality assessment score (Schulz criteria): 5/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
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Wong 2000 (Continued)
Adequate sequence generation? Unclear Unclear
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
Wong 2008
Methods A computer-generated randomisation list was used for sequence generation. The randomisation
schedule was kept inaccessible throughout the study period. Patient assignments were placed into
sequentially numbered opaque sealed envelopes. A research pharmacist, not involved with care
of the patient prepared the placebo and treatment medications that were identical in appearance.
The research personnel, anaesthesiologists, surgeons, and operating room staff were blinded to the
randomisation
Participants 151 patients undergoing orthopaedic (spinal) surgery were randomised to one of two groups:
• Tranexamic acid group: n = 73, M/F = 21/52, mean (sds) age = 56.8 (16.2) years
• Control group (Placebo): n = 74, M/F = 26/48, mean (sd) age = 50.0 (16.2) years
Interventions • Tranexamic acid group received a bolus of 10mg/kg IV, then maintenance infusion of 1mg/
kg/hr until skin closure.
• Control group received the same volume of saline solution.
Outcomes Outcomes reported:number of patients exposed to allogeneic blood transfusion, blood loss, volume
blood transfused (units), deep vein thrombosis
Notes Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomisation list
Allocation concealment? Yes Adequate
Blinding?
All outcomes
Yes Double blind
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Wu 2006
Methods Method of randomisation was not described. Sealed envelopes were used to conceal treatment
allocation
Participants 217 patients undergoing liver tumor resection were randomised to one of two groups:
• Tranexamic acid group: n = 106, M/F = 77/29, mean (range) age = 62 (22-88) years
• Control group (Placebo): n = 108, M/F = 80/28, mean (range) age = 57 (28-84) years
NB: Three patients were excluded from the final analysis.
Interventions • Tranexamic acid group received 500mg of intravenous TXA administered just before the
operation, then received 250mg of intravenous TXA every 6 hours for 3 days.
• Control group group received a similar volume of normal saline at the same time intervals as
the TXA drug regimen.
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss, hospital length
of stay (days), wound infection
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? No Inadequate - sealed envelopes
Blinding?
All outcomes
Yes Double blind
Yamasaki 2004
Methods Randomisation was carried out by a person not involved in the operation using a ticket drawn from
an envelope containing an equal number of tranexamic acid and placebo tickets
Participants 40 patients undergoing cementless total hip arthroplasty were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 19/1, mean (sd) age = 55.5 (14.2) years
• Control group: n = 20, M/F = 18/2, mean (sd) age = 61.2 (6.9) years
Interventions • Tranexamic acid group received 1,000mg of TXA administered intravenously 5 minutes
before the start of the operation.
• Control group did not receive TXA treatment.
NB: Both groups received pre-operatively donated autologous blood (PAD)
Outcomes Outcomes reported: Number of patients exposed to allogeneic blood, blood loss (24hrs), thrombo-
embolic events
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Yamasaki 2004 (Continued)
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol not used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Adequate
Allocation concealment? No Inadequate
Blinding?
All outcomes
Unclear Unclear
Yassen 1993
Methods Method of randomisation and allocation concealment were not described
Participants 20 patients undergoing orthotopic liver transplantation were randomly allocated to one of two
groups:
• Tranexamic acid group: n = 10, M/F = 5/5, mean (sd) age = 44.8 (12.2) years
• Control group (Placebo): n = 10, M/F = 4/6, mean (sd) age = 49.6 (14.2) years
Interventions • Tranexamic acid group received 10mg/kg loading dose of TXA at the start of the anhepatic
phase of the operation, followed by an infusion of 3mg/kg/hr until the patient was transferred to
the Intensive Care Unit (ICU).
• Control group received a similar volume of normal saline as a bolus followed by an infusion.
NB: Both groups were exposed to cell salvage.
Outcomes Outcomes reported: Allogeneic blood usage (units), fresh frozen plasma usage (units), platelets
usage (units), blood loss, any thrombosis
Notes Quality assessment score (Schulz criteria): 2/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
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Zabeeda 2002
Methods Method of randomisation and allocation concealment were not described. The surgeon was blinded
with respect to whether tranexamic acid or placebo was infused
Participants 50 patients undergoing coronary artery bypass graft surgery were randomised to one of two groups:
• Tranexamic acid group: n = 25, M/F = 20/5, mean (sd) age = 65.6 (9) years
• Control group (Placebo): n = 25, M/F = 18/7, mean (sd) age = 65 (13) years
Interventions • Tranexamic acid group received 10mg/kg of TXA for more than 15 minutes in a volume of
10ml after the induction of anaesthesia followed by a continuous infusion of 1mg/kg/hr in a
volume of 10ml for the duration of the procedure.
• Control group received a 10ml bolus of 0.9% saline solution followed by a continuous
infusion of saline (10ml/hr).
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage (units)
, blood loss (24hrs), stroke, mediastinal infection, pre-operative aspirin use
Notes Quality assessment score (Schulz criteria): 4/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Yes Double blind
Zhang 2007
Methods Methods of sequence generation and allocation concealmentwere not described. [Chinese language]
Participants 102 patients undergoing orthopaedic knee surgery were randomised to one of two groups:
• Tranexamic acid group: n = 51
• Control group (Placebo): n = 51
NB: Randomised subjects were aged between 59-77 years of age. Gender: M/F = 43/59
Interventions • Tranexamic acid group received 1g in 250ml saline IV infused before deflation of
tourniquet, then IV administration of 1g 3 hours later.
• Control group received saline.
Outcomes Outcomes reported: Volume blood transfused (units), blood loss, deep vein thrombosis
Notes Use of transfusion protocol is not reported
Risk of bias
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Zhang 2007 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Unclear
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
Zohar 2004
Methods Patients were randomly allocated to treatment groups using a computer generated randomisation
table. Method used to conceal treatment allocation was not described
Participants 40 patients undergoing total knee replacement were randomised to one of two groups:
• Tranexamic acid group: n = 20, M/F = 6/14, mean (sd) age = 73 (8) years
• Control group: n = 20, M/F = 7/13, mean (sd) age = 73 (7) years
Interventions • Tranexamic acid group received 15mg/kg of TXA as an intravenous bolus 30 minutes before
the limb tourniquet was deflated administered over 30 minutes. Thereafter a constant infusion of
10mg/kg/hr was administered until 12 hours after final deflation of the limb tourniquet.
• Control group received usual care with no TXA treatment.
Outcomes Outcomes reported:Number of patients exposed to allogeneic blood, allogeneic blood usage, blood
loss (12hrs), thrombo-embolic events (30-day), hospital length of stay (days)
Notes Quality assessment score (Schulz criteria): 1/7
Transfusion protocol used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated randomisation table
Allocation concealment? Unclear Unclear
Blinding?
All outcomes
Unclear Unclear
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Fejer 1998 Study was excluded on the basis there was uncertainty regarding the age of study participants. As the study
involved thoracolumbar transpedicular (TLT) fixation of the spine for spondylolisthesis subjects less than 18 years
of age may have been included
Langdown 2000 Study did not report the number of patients randomised to each trial arm rather reported the total number of
patients randomised. Study was excluded on the basis there was uncertainty regarding the number of patients in
each trial arm
Montesano 1996 Abstract refers to patients as being randomly selected but methods section of paper states study was retrospective.
Study was excluded on the basis there was uncertainty regarding trial design
Zufferey 2010 Patients undergoing surgery for hip fractures - not elective
Characteristics of ongoing studies [ordered by study ID]
Myles 2008
Trial name or title ATACAS trial
Methods Multi-centre, randomised, blinded 2x2 factorial trial.
Participants N=4600, patients undergoing elective CABG surgery.
Interventions Patients will be allocated to one of four groups
(1) Aspirin
(2) Tranexamic acid
(3) Tranexamic acid plus aspirin
(4) Placebo
Outcomes Mortality
Myocardial infarction
Stroke
Pulmonary embolism
Renal failure
Bowel infarction
Re-operation for bleeding
Blood transfusion
Starting date
Contact information
Notes
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Verma 2010
Trial name or title
Methods Single-centre, randomised, double-blinded control study
Participants Patient undergoing corrective spinal surgery.
Interventions Patients will be allocated to one of three groups
(1) Tranexamic acid
(2) EACA
(3) Saline
Outcomes Perioperative blood loss
Renal failure
Starting date
Contact information
Notes ClinicalTrials.gov ID: NCT00958581
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D A T A A N D A N A L Y S E S
Comparison 1. Aprotinin versus Control (Blood Transfusion & Blood Loss)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 108 11172 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.60, 0.72]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
108 11172 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.60, 0.72]
2.1 Cardiac surgery 84 9497 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.63, 0.73]
2.2 Orthopaedic surgery 15 1146 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.52, 0.89]
2.3 Thoracic surgery 3 78 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.14, 0.59]
2.4 Vascular surgery 2 188 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.97, 1.03]
2.5 Liver surgery 2 177 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.37, 0.90]
2.6 Neuro surgery 1 56 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.40, 1.35]
2.7 Orthognathic surgery 1 30 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.02, 0.77]
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
108 11172 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.60, 0.72]
3.1 Transfusion Protocol 87 9974 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.59, 0.71]
3.2 No Transfusion Protocol 21 1198 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.61, 0.84]
4 No. Exposed to Allogeneic
Blood - Dose
107 12116 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.62, 0.73]
4.1 Prime Dose 16 1251 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.71, 0.96]
4.2 Low Dose 50 3601 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.55, 0.77]
4.3 High Dose 61 7264 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.61, 0.71]
5 No. Exposed to Allogeneic
Blood - Dose (Cardiac Surgery)
83 10423 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.65, 0.74]
5.1 Prime Dose 15 1191 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.69, 0.96]
5.2 Low Dose 29 2372 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.60, 0.80]
5.3 High Dose 58 6860 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.62, 0.72]
6 Trial Methodological Quality -
Allocation Concealment
108 11172 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.60, 0.72]
6.1 Allocation concealment -
Yes
33 2755 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.53, 0.79]
6.2 Allocation concealment -
Unclear
63 7489 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.64, 0.75]
6.3 Allocation concealment -
No
12 928 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.54, 0.75]
7 Units of Allogeneic Blood
Transfused - Transfused
Patients
40 3563 Mean Difference (IV, Random, 95% CI) -0.98 [-1.29, -0.66]
8 Units of Allogeneic Blood
Transfused - All Patients
74 7820 Mean Difference (IV, Random, 95% CI) -1.02 [-1.26, -0.79]
9 Blood loss - Intra-operative 16 883 Mean Difference (IV, Random, 95% CI) -191.87 [-280.45, -
103.28]
9.1 Cardiac surgery 7 470 Mean Difference (IV, Random, 95% CI) -148.18 [-240.21, -
56.14]
9.2 Orthopaedic surgery 5 201 Mean Difference (IV, Random, 95% CI) -151.05 [-317.63,
15.52]
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9.3 Thoracic surgery 2 40 Mean Difference (IV, Random, 95% CI) -577.06 [-893.71, -
260.41]
9.4 Liver surgery 2 137 Mean Difference (IV, Random, 95% CI) -1200.40 [-2943.39,
542.59]
9.5 Vascular surgery 1 35 Mean Difference (IV, Random, 95% CI) -102.00 [-1004.32,
796.32]
10 Blood loss - Post-operative 87 7896 Mean Difference (IV, Random, 95% CI) -345.88 [-383.47, -
308.29]
10.1 Cardiac surgery 75 7371 Mean Difference (IV, Random, 95% CI) -369.62 [-408.95, -
330.29]
10.2 Orthopaedic surgery 7 318 Mean Difference (IV, Random, 95% CI) -113.58 [-223.69, -
3.46]
10.3 Thoracic surgery 2 83 Mean Difference (IV, Random, 95% CI) -359.31 [-460.15, -
258.48]
10.4 Orthognathic surgery 1 30 Mean Difference (IV, Random, 95% CI) -513.0 [-717.21, -
308.79]
10.5 Liver surgery 1 44 Mean Difference (IV, Random, 95% CI) -105.0 [-194.36, -
15.64]
10.6 Vascular surgery 1 50 Mean Difference (IV, Random, 95% CI) -203.00 [-404.93, -
1.07]
11 Blood loss - Post-operative -
Dose (Cardiac Surgery)
75 8181 Mean Difference (IV, Random, 95% CI) -367.69 [-403.50, -
331.87]
11.1 Prime Dose 15 1158 Mean Difference (IV, Random, 95% CI) -343.08 [-458.13, -
228.04]
11.2 Low Dose 24 2038 Mean Difference (IV, Random, 95% CI) -274.58 [-316.48, -
232.67]
11.3 High Dose 52 4985 Mean Difference (IV, Random, 95% CI) -418.59 [-470.96, -
366.22]
12 Blood loss - Total 17 1789 Mean Difference (IV, Random, 95% CI) -415.95 [-520.38, -
311.51]
12.1 Cardiac surgery 7 1359 Mean Difference (IV, Random, 95% CI) -448.86 [-612.82, -
284.91]
12.2 Orthopaedic surgery 10 430 Mean Difference (IV, Random, 95% CI) -399.09 [-562.81, -
235.37]
Comparison 2. Tranexamic Acid versus Control (Blood Transfusion & Blood Loss)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 65 4842 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.53, 0.70]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
65 4842 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.53, 0.70]
2.1 Cardiac surgery 34 3006 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.57, 0.81]
2.2 Orthopaedic surgery 27 1381 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.39, 0.62]
2.3 Liver surgery 2 296 Risk Ratio (M-H, Random, 95% CI) Not estimable
2.4 Vascular surgery 1 59 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.33, 0.96]
2.5 Gynaecological surgery 1 100 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.75, 3.01]
239Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
65 4842 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.53, 0.70]
3.1 Transfusion Protocol 56 4125 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.48, 0.67]
3.2 No Transfusion Protocol 9 717 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.61, 0.96]
4 No. Exposed to Allogeneic
Blood - Dose (Cardiac Surgery)
36 3191 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.58, 0.80]
4.1 Total dose < 2.0 grams 19 1123 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.58, 0.84]
4.2 Total dose 2.0 - 10.0
grams
18 2068 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.52, 0.86]
5 Trial Methodological Quality -
Allocation Concealment
65 4842 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.53, 0.70]
5.1 Allocation concealment -
Yes
28 2110 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.51, 0.69]
5.2 Allocation concealment -
Unclear
24 1503 Risk Ratio (M-H, Random, 95% CI) 0.53 [0.37, 0.76]
5.3 Allocation concealment -
No
13 1229 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.62, 0.86]
6 Units Allogeneic Blood
Transfused - Transfused
Patients
13 481 Mean Difference (IV, Random, 95% CI) -0.34 [-0.80, 0.11]
7 Units of Allogeneic Blood
Transfused - All Patients
23 1814 Mean Difference (IV, Random, 95% CI) -0.87 [-1.20, -0.53]
8 Blood loss - Intra-operative 17 1173 Mean Difference (IV, Random, 95% CI) -121.41 [-180.19, -
62.63]
8.1 Cardiac surgery 4 244 Mean Difference (IV, Random, 95% CI) -166.76 [-331.24, -
2.27]
8.2 Orthopaedic surgery 12 829 Mean Difference (IV, Random, 95% CI) -115.52 [-187.88, -
43.16]
8.3 Gynaecological surgery 1 100 Mean Difference (IV, Random, 95% CI) -164.00 [-366.45,
34.45]
8.4 Head & neck surgery 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
9 Blood loss - Post-operative 35 2501 Mean Difference (IV, Random, 95% CI) -247.17 [-294.76, -
199.58]
9.1 Cardiac surgery 22 1597 Mean Difference (IV, Random, 95% CI) -272.87 [-328.85, -
216.89]
9.2 Orthopaedic surgery 12 804 Mean Difference (IV, Random, 95% CI) -228.52 [-321.76, -
135.27]
9.3 Gynaecological surgery 1 100 Mean Difference (IV, Random, 95% CI) -63.0 [-118.89, -7.
11]
9.4 Head & neck surgery 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
10 Blood loss - Post-operative -
Dose (Cardiac Surgery)
22 1597 Mean Difference (IV, Random, 95% CI) -272.87 [-328.85, -
216.89]
10.1 Total dose < 2.0 grams 12 619 Mean Difference (IV, Random, 95% CI) -245.03 [-329.76, -
160.29]
10.2 Total dose 2.0 - 10.0
grams
10 978 Mean Difference (IV, Random, 95% CI) -297.94 [-364.49, -
231.39]
11 Blood loss - Total 28 1712 Mean Difference (IV, Random, 95% CI) -414.06 [-525.19, -
302.92]
11.1 Cardiac surgery 6 391 Mean Difference (IV, Random, 95% CI) -300.47 [-470.74, -
130.21]
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11.2 Orthopaedic surgery 20 1201 Mean Difference (IV, Random, 95% CI) -446.19 [-554.61, -
337.78]
11.3 Liver surgery 1 20 Mean Difference (IV, Random, 95% CI) -6552.0 [-14329.54,
1225.54]
11.4 Gynaecological surgery 1 100 Mean Difference (IV, Random, 95% CI) -243.0 [-460.02, -
25.98]
11.5 Head & neck surgery 0 0 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 3. Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 16 1035 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.99]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
16 1035 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.99]
2.1 Cardiac Surgery 11 649 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.52, 0.93]
2.2 Orthopaedic Surgery 4 304 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.08]
2.3 Liver Surgery 1 82 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.80, 1.08]
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
16 1035 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.99]
3.1 Transfusion Protocol 15 1005 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.65, 0.98]
3.2 No Transfusion Protocol 1 30 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.36, 4.97]
4 Trial Methodological Quality -
Allocation Concealment
16 1035 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.67, 0.99]
4.1 Allocation concealment -
Yes
5 452 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.58, 1.16]
4.2 Allocation concealment -
Unclear
9 455 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.46, 1.03]
4.3 Allocation concealment -
No
2 128 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.81, 1.08]
5 Units of Allogeneic Blood
Transfused - Transfused
Patients
3 119 Mean Difference (IV, Random, 95% CI) 0.22 [-0.34, 0.79]
6 Units of Allogeneic Blood
Transfused - All Patients
6 432 Mean Difference (IV, Random, 95% CI) -1.30 [-2.14, -0.45]
7 Blood loss - Intra-operative 5 353 Mean Difference (IV, Random, 95% CI) -156.63 [-276.92, -
36.33]
7.1 Cardiac surgery 2 79 Mean Difference (IV, Random, 95% CI) -213.58 [-310.03, -
117.13]
7.2 Orthopaedic surgery 3 274 Mean Difference (IV, Random, 95% CI) -40.66 [-236.71,
155.38]
8 Blood loss - Post-operative 14 1174 Mean Difference (IV, Random, 95% CI) -207.49 [-276.43, -
138.54]
8.1 Cardiac surgery 12 946 Mean Difference (IV, Random, 95% CI) -200.27 [-273.44, -
127.09]
8.2 Orthopaedic surgery 2 228 Mean Difference (IV, Random, 95% CI) -285.06 [-452.73, -
117.39]
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9 Blood loss - Total 2 92 Mean Difference (IV, Random, 95% CI) -299.69 [-522.54, -
76.84]
9.1 Orthopaedic surgery 2 92 Mean Difference (IV, Random, 95% CI) -299.69 [-522.54, -
76.84]
Comparison 4. Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 21 4185 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.81, 1.01]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
21 4185 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.81, 1.01]
2.1 Cardiac surgery 18 3983 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.76, 0.99]
2.2 Liver surgery 2 178 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.11]
2.3 Orthopaedic surgery 1 24 Risk Ratio (M-H, Random, 95% CI) 11.00 [0.67, 179.29]
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
21 4185 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.81, 1.01]
3.1 Transfusion Protocol 20 4155 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.80, 1.01]
3.2 No Transfusion Protocol 1 30 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.67, 1.27]
4 Trial Methodological Quality -
Allocation Concealment
21 4185 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.81, 1.01]
4.1 Allocation concealment -
Yes
4 1871 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.69, 0.92]
4.2 Allocation concealment -
Unclear
13 1832 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.88, 1.07]
4.3 Allocation concealment -
No
4 482 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.62, 1.39]
5 Units Allogeneic Blood
Transfused - Transfused
Patients
6 207 Mean Difference (IV, Random, 95% CI) -0.07 [-0.44, 0.30]
6 Units Allogeneic Blood
Transfused - All Patients
10 992 Mean Difference (IV, Random, 95% CI) -0.24 [-0.45, -0.04]
7 Blood loss 14 1041 Mean Difference (IV, Random, 95% CI) -136.44 [-198.40, -
74.47]
7.1 Cardiac surgery -
Post-operative
13 831 Mean Difference (IV, Random, 95% CI) -145.81 [-209.99, -
81.62]
7.2 Cardiac surgery - Total 1 210 Mean Difference (IV, Random, 95% CI) 6.0 [-171.38, 183.
38]
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Comparison 5. Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 12 2200 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.76, 0.89]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
12 2200 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.76, 0.89]
2.1 Cardiac surgery 10 2125 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.76, 0.89]
2.2 Orthopaedic surgery 2 75 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.48, 1.40]
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
12 2200 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.76, 0.89]
3.1 Transfusion Protocol 9 2014 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.76, 0.89]
3.2 No Transfusion Protocol 3 186 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.47, 1.31]
4 Trial Methodological Quality -
Allocation Concealment
12 2200 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.76, 0.89]
4.1 Allocation concealment -
Yes
3 1651 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.71, 1.05]
4.2 Allocation concealment -
Unclear
8 504 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.58, 0.99]
4.3 Allocation concealment -
No
1 45 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.49, 1.55]
5 Units of Allogeneic Blood
Transfused - Transfused
Patients
2 63 Mean Difference (IV, Random, 95% CI) -0.18 [-0.63, 0.28]
6 Units of Allogeneic Blood
Transfused - All Patients
5 329 Mean Difference (IV, Random, 95% CI) -0.21 [-0.55, 0.14]
7 Blood loss 8 499 Mean Difference (IV, Random, 95% CI) -106.01 [-212.50, 0.
47]
7.1 Cardiac surgery -
Post-operative
7 454 Mean Difference (IV, Random, 95% CI) -111.43 [-220.64, -
2.21]
7.2 Orthopaedic surgery -
Total
1 45 Mean Difference (IV, Random, 95% CI) 100.0 [-515.06, 715.
06]
Comparison 6. Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 8 2003 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.21]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
8 2003 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.21]
2.1 Cardiac surgery 6 1852 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.79, 1.46]
2.2 Orthopaedic surgery 1 67 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.03, 1.94]
2.3 Liver surgery 1 84 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.64, 1.02]
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
8 2003 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.21]
3.1 Transfusion Protocol 8 2003 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.21]
243Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4 Trial Methodological Quality -
Allocation Concealment
8 2003 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.77, 1.21]
4.1 Allocation concealment -
Yes
1 1550 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.93, 1.07]
4.2 Allocation concealment -
Unclear
5 302 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.68, 1.98]
4.3 Allocation concealment -
No
2 151 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.22, 1.84]
5 Units of Allogeneic Blood
Transfused - Transfused
Patients
4 133 Mean Difference (IV, Random, 95% CI) -0.34 [-0.74, 0.07]
6 Units of Allogeneic Blood
Transfused - All Patients
3 268 Mean Difference (IV, Random, 95% CI) -0.28 [-0.59, 0.03]
7 Blood loss 7 469 Mean Difference (IV, Random, 95% CI) -4.20 [-147.29, 138.
89]
7.1 Cardiac surgery -
Post-operative
6 402 Mean Difference (IV, Random, 95% CI) -4.36 [-163.35, 154.
63]
7.2 Orthopaedic surgery -
Total
1 67 Mean Difference (IV, Random, 95% CI) -9.0 [-270.16, 252.
16]
7.3 Gynaecological surgery -
Total
0 0 Mean Difference (IV, Random, 95% CI) Not estimable
Comparison 7. Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 No. Exposed to Allogeneic Blood 29 5566 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.81, 0.99]
2 No. Exposed to Allogeneic
Blood - Type of Surgery
29 5469 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.80, 0.98]
2.1 Cardiac surgery 24 5192 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.76, 0.96]
2.2 Orthopaedic surgery 3 99 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.32, 3.48]
2.3 Liver surgery 2 178 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.11]
3 No. Exposed to Allogeneic
Blood - Transfusion Protocol
29 5429 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.81, 0.98]
3.1 Transfusion Protocol 25 5213 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.80, 0.99]
3.2 No Transfusion Protocol 4 216 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.65, 1.12]
4 Units of Allogeneic Blood
Transfused - Transfused
Patients
7 251 Mean Difference (IV, Random, 95% CI) -0.11 [-0.42, 0.21]
5 Units of Allogeneic Blood
Transfused - All Patients
14 1254 Mean Difference (IV, Random, 95% CI) -0.25 [-0.42, -0.09]
6 Trial Methodological Quality -
Allocation Concealment
29 5566 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.81, 0.99]
6.1 Allocation concealment -
Yes
6 2742 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.71, 0.95]
6.2 Allocation concealment -
Unclear
18 2297 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.86, 1.04]
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6.3 Allocation concealment -
No
5 527 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.67, 1.28]
Comparison 8. Adverse Events and Other Outcomes (Active versus Control)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-operation for bleeding 85 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Aprotinin versus Control 61 6117 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.34, 0.62]
1.2 Tranexamic Acid versus
Control
27 2386 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.55, 1.17]
1.3 Epsilon Aminocaproic
Acid versus Control
8 922 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.11, 0.99]
2 Mortality 92 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Aprotinin versus Control 63 8876 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.63, 1.06]
2.2 Tranexamic Acid versus
Control
30 2917 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.33, 1.10]
2.3 Epsilon Aminocaproic
Acid versus Control
8 988 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.44, 2.57]
3 Myocardial Infarction (MI) 71 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Aprotinin versus Control 49 7137 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.69, 1.11]
3.2 Tranexamic Acid versus
Control
21 2186 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.41, 1.52]
3.3 Epsilon aminocaproic
Acid versus Control
7 896 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.48, 1.63]
4 Stroke (CVA) 45 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Aprotinin versus Control 23 3122 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.44, 1.52]
4.2 Tranexamic Acid versus
Control
18 2027 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.49, 3.07]
4.3 Epsilon Aminocaproic
Acid versus Control
8 936 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.16, 2.36]
5 Deep Vein Thrombosis (DVT) 40 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Aprotinin versus Control 16 1456 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.47, 1.29]
5.2 Tranexamic Acid versus
Control
23 1472 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.35, 1.43]
5.3 Epsilon Aminocaproic
Acid versus Control
4 304 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.20, 3.03]
6 Pulmonary Embolism (PE) 20 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Aprotinin versus Control 4 585 Risk Ratio (M-H, Random, 95% CI) 1.49 [0.42, 5.29]
6.2 Tranexamic Acid versus
Control
14 1006 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.23, 1.99]
6.3 Epsilon Aminocaproic
Acid versus Control
3 274 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.06, 2.13]
7 Other Thrombosis 19 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Aprotinin versus Control 9 736 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.25, 2.15]
7.2 Tranexamic Acid versus
Control
9 484 Risk Ratio (M-H, Random, 95% CI) 2.10 [0.49, 8.99]
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7.3 Epsilon Aminocaproic
Acid versus Control
2 264 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.15, 1.72]
8 Coronary artery graft occlusion 2 728 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.10, 5.67]
8.1 Aprotinin versus Control 2 728 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.10, 5.67]
9 Renal Failure / Dysfunction 34 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Aprotinin versus Control 27 5185 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.79, 1.54]
9.2 Tranexamic Acid versus
Control
9 912 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.33, 2.37]
9.3 Epsilon Aminocaproic
Acid versus control
2 235 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.14, 1.22]
10 Hospital Length of Stay 31 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Aprotinin versus Control 23 2017 Mean Difference (IV, Random, 95% CI) -0.25 [-0.71, 0.20]
10.2 Tranexamic Acid versus
Control
10 772 Mean Difference (IV, Random, 95% CI) -0.34 [-0.82, 0.13]
10.3 Epsilon Aminocaproic
Acid versus Control
2 228 Mean Difference (IV, Random, 95% CI) 0.58 [-3.17, 4.33]
Comparison 9. Adverse Events and Other Outcomes (Active versus Active)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-operation for bleeding -
Aprotinin versus Tranexamic
Acid
17 4010 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.51, 0.93]
2 Re-operation for bleeding -
Aprotinin versus Epsilon
Aminocaproic Acid
6 2075 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.49, 1.00]
3 Re-operation for bleeding -
Tranexamic Acid versus Epsilon
Aminocaproic Acid
5 1853 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.73, 1.39]
4 Mortality - Aprotinin versus
Tranexamic Acid
17 4130 Risk Ratio (M-H, Random, 95% CI) 1.35 [0.94, 1.93]
5 Mortality - Aprotinin versus
Epsilon Aminocaproic Acid
5 1891 Risk Ratio (M-H, Random, 95% CI) 1.51 [0.99, 2.30]
6 Mortality - Tranexamic Acid
versus Epsilon Aminocaproic
Acid
5 1958 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.59, 1.47]
7 Mortality - Aprotinin versus
Lysine Analogues
19 5127 Risk Ratio (M-H, Random, 95% CI) 1.39 [1.02, 1.89]
8 Myocardial Infarction -
Aprotinin versus Tranexamic
Acid
13 3574 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.71, 1.42]
9 Myocardial Infarction -
Aprotinin versus Epsilon
Aminocaproic Acid
4 1676 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.90, 2.22]
10 Myocardial Infarction -
Tranexamic Acid versus Epsilon
Aminocaproic Acid
3 1687 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.80, 2.23]
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11 Myocardial infarction -
Aprotinin versus Lysine
Analogues
15 4466 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.82, 1.50]
12 Stroke (CVA) - Aprotinin
versus Tranexamic Acid
6 2030 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.52, 1.47]
13 Stroke (CVA) - Aprotinin
versus Epsilon Aminocaproic
Acid
2 1578 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.60, 1.85]
14 Stroke (CVA) - Tranexamic
Acid versus Epsilon
Aminocaproic Acid
3 1658 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.78, 2.29]
15 Deep Vein Thrombosis (DVT)
- Aprotinin versus Tranexamic
Acid
3 265 Risk Ratio (M-H, Random, 95% CI) 0.50 [0.05, 4.81]
16 Deep Vein Thrombosis (DVT)
- Aprotinin versus Epsilon
Aminocaproic Acid
4 300 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.51]
17 Deep Vein Thrombosis (DVT)
- Tranexamic Acid versus
Epsilon Aminocaproic Acid
3 303 Risk Ratio (M-H, Random, 95% CI) Not estimable
18 Pulmonary Embolism (PE) -
Aprotinin versus Tranexamic
Acid
2 241 Risk Ratio (M-H, Random, 95% CI) Not estimable
19 Pulmonary Embolism (PE)
- Aprotinin versus Epsilon
Aminocaproic Acid
3 270 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.10, 18.42]
20 Pulmonary Embolism (PE) -
Tranexamic Acid versus Epsilon
Aminocaproic Acid
3 284 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.01, 7.59]
21 Other Thrombosis - Aprotinin
versus Tranexamic Acid
3 287 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.10, 2.68]
22 Other Thrombosis - Aprotinin
versus Epsilon Aminocaproic
Acid
1 92 Risk Ratio (M-H, Random, 95% CI) Not estimable
23 Other Thrombosis -
Tranexamic Acid versus Epsilon
Aminocaproic Acid
2 184 Risk Ratio (M-H, Random, 95% CI) 2.0 [0.39, 10.34]
24 Renal Failure / Dysfunction -
Aprotinin versus Tranexamic
Acid
6 2238 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.79, 1.31]
25 Renal Failure / Dysfunction
- Aprotinin versus Epsilon
Aminocaproic Acid
2 1595 Risk Ratio (M-H, Random, 95% CI) 1.33 [0.59, 2.99]
26 Renal Failure / Dysfunction -
Tranexamic Acid versus Epsilon
Aminocaproic Acid
1 1540 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.76, 1.27]
27 Hospital Length of Stay -
Aprotinin versus Tranexamic
Acid
6 2174 Mean Difference (IV, Random, 95% CI) -0.05 [-0.92, 0.83]
247Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
28 Hospital Length of Stay -
Aprotinin versus Epsilon
Aminocaproic Acid
2 1605 Mean Difference (IV, Random, 95% CI) -0.49 [-1.74, 0.77]
29 Hospital Length of Stay -
Tranexamic Acid versus Epsilon
Aminocaproic Acid
1 1550 Mean Difference (IV, Random, 95% CI) -0.64 [-1.82, 0.54]
Comparison 10. Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-operation for bleeding 78 8895 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.44, 0.71]
1.1 Aprotinin versus Control 56 5827 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.34, 0.63]
1.2 Tranexamic Acid versus
Control
26 2328 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.54, 1.17]
1.3 Epsilon Aminocaproic
Acid versus Control
7 740 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.11, 1.17]
2 Mortality 76 11240 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.65, 1.07]
2.1 Aprotinin versus Control 55 8174 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.64, 1.10]
2.2 Tranexamic Acid versus
Control
23 2342 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.26, 1.28]
2.3 Epsilon Aminocaproic
Acid versus Control
6 724 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.50, 5.43]
3 Myocardial Infarction 65 9472 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.71, 1.09]
3.1 Aprotinin versus Control 46 6658 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.71, 1.14]
3.2 Tranexamic Acid versus
Control
19 2100 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.37, 1.47]
3.3 Epsilon Aminocaproic
Acid versus Control
6 714 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.48, 1.63]
4 Stroke 38 4850 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.55, 1.63]
4.1 Aprotinin versus Control 18 2127 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.40, 1.67]
4.2 Tranexamic Acid versus
Control
17 1969 Risk Ratio (M-H, Random, 95% CI) 1.44 [0.53, 3.91]
4.3 Epsilon Aminocaproic
Acid versus Control
7 754 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.16, 3.10]
5 Deep Vein Thrombosis (DVT) 7 1046 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.31, 2.87]
5.1 Aprotinin versus Control 3 624 Risk Ratio (M-H, Random, 95% CI) 1.29 [0.36, 4.58]
5.2 Tranexamic Acid versus
Control
4 422 Risk Ratio (M-H, Random, 95% CI) 0.37 [0.04, 3.47]
6 Pulmonary Embolism 7 921 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.14, 2.74]
6.1 Tranexamic Acid versus
Control
6 569 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.04, 3.15]
6.2 Aprotinin versus Control 1 352 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.14, 7.10]
7 Other Thrombosis 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Aprotinin versus Control 4 426 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.11, 3.36]
7.2 Tranexamic Acid versus
Control
1 100 Risk Ratio (M-H, Random, 95% CI) Not estimable
8 Renal Failure / Dysfunction 30 5912 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.71, 1.33]
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8.1 Aprotinin versus Control 24 4947 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.76, 1.51]
8.2 Tranexamic Acid versus
Control
9 912 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.33, 2.37]
8.3 Epsilon Aminocaproic
Acid versus control
1 53 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.11, 1.14]
9 Hospital Length of Stay 19 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Aprotinin versus Control 17 1756 Mean Difference (IV, Random, 95% CI) -0.22 [-0.73, 0.29]
9.2 Tranexamic Acid versus
Control
5 434 Mean Difference (IV, Random, 95% CI) -0.08 [-0.34, 0.18]
Analysis 1.1. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 1 No.
Exposed to Allogeneic Blood.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bailey 1994 119/129 25/25 1.6 % 0.94 [ 0.87, 1.01 ]
Vanek 2005 1/29 6/30 0.2 % 0.17 [ 0.02, 1.35 ]
Mansour 2004 1/20 12/20 0.2 % 0.08 [ 0.01, 0.58 ]
Dietrich 1990 7/19 15/20 0.9 % 0.49 [ 0.26, 0.93 ]
Cohen 1998 17/56 37/59 1.1 % 0.48 [ 0.31, 0.75 ]
Tabuchi 1994 10/19 12/17 1.0 % 0.75 [ 0.44, 1.26 ]
Harmon 2004 3/17 4/18 0.3 % 0.79 [ 0.21, 3.04 ]
Palmer 2003 11/30 13/26 0.9 % 0.73 [ 0.40, 1.35 ]
Poston 2006 10/29 18/31 0.9 % 0.59 [ 0.33, 1.07 ]
Bidstrup 2000 13/30 23/30 1.1 % 0.57 [ 0.36, 0.89 ]
Stewart 2001 1/15 9/15 0.2 % 0.11 [ 0.02, 0.77 ]
Speekenbrink 1996 55/75 29/37 1.5 % 0.94 [ 0.75, 1.16 ]
Hardy 1993 17/22 16/19 1.4 % 0.92 [ 0.68, 1.24 ]
Murkin 2000 12/212 10/68 0.7 % 0.38 [ 0.17, 0.85 ]
Bidstrup 1993 9/43 24/47 0.8 % 0.41 [ 0.22, 0.78 ]
Greilich 2009 18/26 17/27 1.2 % 1.10 [ 0.75, 1.62 ]
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(. . . Continued)
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lemmer˙2 1994 7/23 23/32 0.8 % 0.42 [ 0.22, 0.82 ]
Harder 1991 30/40 29/40 1.4 % 1.03 [ 0.80, 1.34 ]
Dietrich 1995 11/15 15/15 1.3 % 0.74 [ 0.54, 1.02 ]
Ranaboldo 1997 66/66 62/62 1.6 % 1.00 [ 0.97, 1.03 ]
Taggart 2003 14/36 26/34 1.1 % 0.51 [ 0.32, 0.80 ]
Norman 2009 2/8 8/8 0.5 % 0.29 [ 0.10, 0.85 ]
Deleuze 1991 8/30 8/30 0.6 % 1.00 [ 0.43, 2.31 ]
Liu 1993 3/20 12/20 0.4 % 0.25 [ 0.08, 0.75 ]
Lemmer˙1 1994 28/74 35/67 1.2 % 0.72 [ 0.50, 1.05 ]
Capdevila 1998 12/12 11/11 1.5 % 1.00 [ 0.85, 1.17 ]
D’Ambra 1996 73/127 31/64 1.4 % 1.19 [ 0.88, 1.59 ]
Swart 1994 33/49 42/49 1.5 % 0.79 [ 0.63, 0.98 ]
Colwell 2007 20/175 39/177 1.1 % 0.52 [ 0.32, 0.85 ]
Bidstrup 1989 8/40 35/37 0.9 % 0.21 [ 0.11, 0.39 ]
Hardy 1997 23/26 23/26 1.5 % 1.00 [ 0.82, 1.22 ]
Englberger 2002a 2/21 8/23 0.3 % 0.27 [ 0.07, 1.15 ]
Wendel 1995 10/20 15/18 1.1 % 0.60 [ 0.37, 0.97 ]
Jeserschek 2003 7/9 8/9 1.2 % 0.88 [ 0.58, 1.33 ]
Maccario 1994 5/61 6/32 0.4 % 0.44 [ 0.14, 1.32 ]
Parvizi 2007 48/81 52/81 1.4 % 0.92 [ 0.72, 1.18 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Lemmer 1996 173/487 87/157 1.5 % 0.64 [ 0.53, 0.77 ]
Petsatodis 2006 17/25 25/25 1.4 % 0.69 [ 0.52, 0.90 ]
Fraedrich 1989 16/38 26/38 1.2 % 0.62 [ 0.40, 0.95 ]
Lentschener 1997 8/48 19/49 0.8 % 0.43 [ 0.21, 0.89 ]
Ray 1997 7/53 19/52 0.7 % 0.36 [ 0.17, 0.79 ]
Kipfer 2003 4/15 5/15 0.4 % 0.80 [ 0.27, 2.41 ]
Kalangos 1994 60/110 48/55 1.5 % 0.63 [ 0.51, 0.76 ]
Alderman 1998 152/401 213/395 1.5 % 0.70 [ 0.60, 0.82 ]
Lentschener 1999 5/35 12/37 0.6 % 0.44 [ 0.17, 1.12 ]
Englberger 2002b 2/15 7/14 0.3 % 0.27 [ 0.07, 1.07 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Li 2005 5/40 12/30 0.6 % 0.31 [ 0.12, 0.79 ]
Lass 1995 25/51 37/47 1.3 % 0.62 [ 0.45, 0.85 ]
Bidstrup 1990 15/26 16/18 1.3 % 0.65 [ 0.45, 0.94 ]
Gherli 1992 4/18 10/13 0.6 % 0.29 [ 0.12, 0.72 ]
Isetta 1993 55/140 46/70 1.4 % 0.60 [ 0.46, 0.78 ]
Murkin 1994 16/29 22/25 1.3 % 0.63 [ 0.44, 0.90 ]
Cicek 1996b 11/29 18/28 1.0 % 0.59 [ 0.34, 1.01 ]
Speekenbrink 1995 12/15 11/15 1.2 % 1.09 [ 0.73, 1.62 ]
Cosgrove 1992 55/113 44/56 1.5 % 0.62 [ 0.49, 0.78 ]
Rossi 1997 1/21 4/22 0.2 % 0.26 [ 0.03, 2.16 ]
Hayashida 1997 66/110 46/57 1.5 % 0.74 [ 0.61, 0.91 ]
Desai 2009 12/38 16/37 0.9 % 0.73 [ 0.40, 1.33 ]
Dietrich 1992 549/902 730/882 1.6 % 0.74 [ 0.69, 0.78 ]
Okita 1996 28/39 15/21 1.3 % 1.01 [ 0.72, 1.40 ]
Cicek 1996a 17/50 15/25 1.0 % 0.57 [ 0.34, 0.94 ]
Greilich 2001 7/24 13/25 0.8 % 0.56 [ 0.27, 1.16 ]
Nuro¨zler 2008 17/25 23/26 1.4 % 0.77 [ 0.57, 1.04 ]
Vedrinne 1992 14/30 23/30 1.2 % 0.61 [ 0.40, 0.94 ]
Dignan 2001 37/101 58/99 1.3 % 0.63 [ 0.46, 0.85 ]
Kyriss 2001 3/18 10/20 0.4 % 0.33 [ 0.11, 1.02 ]
Basora 1999 23/36 20/21 1.4 % 0.67 [ 0.52, 0.87 ]
Katzel 1998 1/12 6/12 0.2 % 0.17 [ 0.02, 1.18 ]
Mohr 1992 23/34 16/16 1.4 % 0.69 [ 0.54, 0.88 ]
Rodrigus 1996 36/46 26/47 1.4 % 1.41 [ 1.05, 1.91 ]
Llau 1998 0/10 3/10 0.1 % 0.14 [ 0.01, 2.45 ]
Ray 2005 2/15 3/15 0.2 % 0.67 [ 0.13, 3.44 ]
Boldt 1991 1/10 0/10 0.1 % 3.00 [ 0.14, 65.90 ]
Engel 2001 5/12 3/12 0.4 % 1.67 [ 0.51, 5.46 ]
Corbeau 1995 15/43 12/20 1.0 % 0.58 [ 0.34, 1.00 ]
Rocha 1994 22/28 26/28 1.5 % 0.85 [ 0.68, 1.05 ]
Cicekcioglu 2006 3/24 4/20 0.3 % 0.63 [ 0.16, 2.47 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
D’Ambrosio 1999 1/30 0/30 0.1 % 3.00 [ 0.13, 70.83 ]
Laub 1994 4/16 7/16 0.5 % 0.57 [ 0.21, 1.58 ]
Pugh 1995 21/21 23/23 1.6 % 1.00 [ 0.92, 1.09 ]
Murkin 1995 18/29 17/24 1.2 % 0.88 [ 0.60, 1.29 ]
Cvachovec 2001 8/20 16/22 0.9 % 0.55 [ 0.30, 1.00 ]
Thorpe 1994 1/8 6/9 0.2 % 0.19 [ 0.03, 1.24 ]
Klein 1998 4/36 6/29 0.4 % 0.54 [ 0.17, 1.72 ]
Levy 1995 109/188 49/65 1.5 % 0.77 [ 0.64, 0.93 ]
Ray 1999 23/100 21/50 1.1 % 0.55 [ 0.34, 0.89 ]
Santamaria 2000 6/56 11/28 0.6 % 0.27 [ 0.11, 0.66 ]
Menichetti 1996 2/24 18/24 0.3 % 0.11 [ 0.03, 0.43 ]
Locatelli 1990 11/25 9/13 0.9 % 0.64 [ 0.36, 1.13 ]
Tassani 2000 4/10 5/10 0.5 % 0.80 [ 0.30, 2.13 ]
Carrera 1994 42/51 50/51 1.6 % 0.84 [ 0.74, 0.96 ]
Blauhut 1994 3/14 9/14 0.5 % 0.33 [ 0.11, 0.98 ]
Green 1995 6/48 12/36 0.6 % 0.38 [ 0.16, 0.90 ]
Wei 2006 6/36 8/40 0.5 % 0.83 [ 0.32, 2.17 ]
Garcia-Huete 1997 13/39 20/41 1.0 % 0.68 [ 0.40, 1.18 ]
Havel 1992 3/10 7/10 0.5 % 0.43 [ 0.15, 1.20 ]
Later 2009 48/96 73/103 1.4 % 0.71 [ 0.56, 0.89 ]
Alajmo 1989 9/22 8/12 0.9 % 0.61 [ 0.32, 1.17 ]
Baele 1992 35/58 45/57 1.4 % 0.76 [ 0.60, 0.98 ]
Amar 2003 11/23 13/24 1.0 % 0.88 [ 0.50, 1.55 ]
Van der Linden 2005 17/37 27/38 1.2 % 0.65 [ 0.43, 0.97 ]
Diprose 2005 8/60 27/60 0.8 % 0.30 [ 0.15, 0.60 ]
Alvarez 1995 5/49 7/51 0.5 % 0.74 [ 0.25, 2.19 ]
Samama 2002 12/40 11/18 0.9 % 0.49 [ 0.27, 0.89 ]
Kuitunen 2005 11/20 12/20 1.0 % 0.92 [ 0.54, 1.56 ]
Royston 1987 4/11 11/11 0.7 % 0.39 [ 0.19, 0.82 ]
Casas 1995 12/47 29/51 1.0 % 0.45 [ 0.26, 0.77 ]
Total (95% CI) 6259 4913 100.0 % 0.66 [ 0.60, 0.72 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 2695 (Aprotinin), 3067 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 961.52, df = 107 (P<0.00001); I2 =89%
Test for overall effect: Z = 9.54 (P < 0.00001)
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Analysis 1.2. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 2 No.
Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Alajmo 1989 9/22 8/12 0.9 % 0.61 [ 0.32, 1.17 ]
Alderman 1998 152/401 213/395 1.5 % 0.70 [ 0.60, 0.82 ]
Alvarez 1995 5/49 7/51 0.5 % 0.74 [ 0.25, 2.19 ]
Baele 1992 35/58 45/57 1.4 % 0.76 [ 0.60, 0.98 ]
Bailey 1994 119/129 25/25 1.6 % 0.94 [ 0.87, 1.01 ]
Basora 1999 23/36 20/21 1.4 % 0.67 [ 0.52, 0.87 ]
Bidstrup 1989 8/40 35/37 0.9 % 0.21 [ 0.11, 0.39 ]
Bidstrup 1990 15/26 16/18 1.3 % 0.65 [ 0.45, 0.94 ]
Bidstrup 1993 9/43 24/47 0.8 % 0.41 [ 0.22, 0.78 ]
Bidstrup 2000 13/30 23/30 1.1 % 0.57 [ 0.36, 0.89 ]
Blauhut 1994 3/14 9/14 0.5 % 0.33 [ 0.11, 0.98 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Boldt 1991 1/10 0/10 0.1 % 3.00 [ 0.14, 65.90 ]
Carrera 1994 42/51 50/51 1.6 % 0.84 [ 0.74, 0.96 ]
Casas 1995 12/47 29/51 1.0 % 0.45 [ 0.26, 0.77 ]
Cicek 1996a 17/50 15/25 1.0 % 0.57 [ 0.34, 0.94 ]
Cicek 1996b 11/29 18/28 1.0 % 0.59 [ 0.34, 1.01 ]
Cicekcioglu 2006 3/24 4/20 0.3 % 0.63 [ 0.16, 2.47 ]
Cohen 1998 17/56 37/59 1.1 % 0.48 [ 0.31, 0.75 ]
Corbeau 1995 15/43 12/20 1.0 % 0.58 [ 0.34, 1.00 ]
Cosgrove 1992 55/113 44/56 1.5 % 0.62 [ 0.49, 0.78 ]
D’Ambra 1996 73/127 31/64 1.4 % 1.19 [ 0.88, 1.59 ]
Deleuze 1991 8/30 8/30 0.6 % 1.00 [ 0.43, 2.31 ]
Desai 2009 12/38 16/37 0.9 % 0.73 [ 0.40, 1.33 ]
Dietrich 1990 7/19 15/20 0.9 % 0.49 [ 0.26, 0.93 ]
Dietrich 1992 549/902 730/882 1.6 % 0.74 [ 0.69, 0.78 ]
Dietrich 1995 11/15 15/15 1.3 % 0.74 [ 0.54, 1.02 ]
Dignan 2001 37/101 58/99 1.3 % 0.63 [ 0.46, 0.85 ]
Diprose 2005 8/60 27/60 0.8 % 0.30 [ 0.15, 0.60 ]
Englberger 2002a 2/21 8/23 0.3 % 0.27 [ 0.07, 1.15 ]
Englberger 2002b 2/15 7/14 0.3 % 0.27 [ 0.07, 1.07 ]
Fraedrich 1989 16/38 26/38 1.2 % 0.62 [ 0.40, 0.95 ]
Gherli 1992 4/18 10/13 0.6 % 0.29 [ 0.12, 0.72 ]
Green 1995 6/48 12/36 0.6 % 0.38 [ 0.16, 0.90 ]
Greilich 2001 7/24 13/25 0.8 % 0.56 [ 0.27, 1.16 ]
Greilich 2009 18/26 17/27 1.2 % 1.10 [ 0.75, 1.62 ]
Harder 1991 30/40 29/40 1.4 % 1.03 [ 0.80, 1.34 ]
Hardy 1993 17/22 16/19 1.4 % 0.92 [ 0.68, 1.24 ]
Hardy 1997 23/26 23/26 1.5 % 1.00 [ 0.82, 1.22 ]
Harmon 2004 3/17 4/18 0.3 % 0.79 [ 0.21, 3.04 ]
Havel 1992 3/10 7/10 0.5 % 0.43 [ 0.15, 1.20 ]
Hayashida 1997 66/110 46/57 1.5 % 0.74 [ 0.61, 0.91 ]
Isetta 1993 55/140 46/70 1.4 % 0.60 [ 0.46, 0.78 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kalangos 1994 60/110 48/55 1.5 % 0.63 [ 0.51, 0.76 ]
Kipfer 2003 4/15 5/15 0.4 % 0.80 [ 0.27, 2.41 ]
Klein 1998 4/36 6/29 0.4 % 0.54 [ 0.17, 1.72 ]
Kuitunen 2005 11/20 12/20 1.0 % 0.92 [ 0.54, 1.56 ]
Lass 1995 25/51 37/47 1.3 % 0.62 [ 0.45, 0.85 ]
Later 2009 48/96 73/103 1.4 % 0.71 [ 0.56, 0.89 ]
Laub 1994 4/16 7/16 0.5 % 0.57 [ 0.21, 1.58 ]
Lemmer 1996 173/487 87/157 1.5 % 0.64 [ 0.53, 0.77 ]
Lemmer˙1 1994 28/74 35/67 1.2 % 0.72 [ 0.50, 1.05 ]
Lemmer˙2 1994 7/23 23/32 0.8 % 0.42 [ 0.22, 0.82 ]
Levy 1995 109/188 49/65 1.5 % 0.77 [ 0.64, 0.93 ]
Li 2005 5/40 12/30 0.6 % 0.31 [ 0.12, 0.79 ]
Liu 1993 3/20 12/20 0.4 % 0.25 [ 0.08, 0.75 ]
Locatelli 1990 11/25 9/13 0.9 % 0.64 [ 0.36, 1.13 ]
Maccario 1994 5/61 6/32 0.4 % 0.44 [ 0.14, 1.32 ]
Mansour 2004 1/20 12/20 0.2 % 0.08 [ 0.01, 0.58 ]
Menichetti 1996 2/24 18/24 0.3 % 0.11 [ 0.03, 0.43 ]
Mohr 1992 23/34 16/16 1.4 % 0.69 [ 0.54, 0.88 ]
Murkin 1994 16/29 22/25 1.3 % 0.63 [ 0.44, 0.90 ]
Nuro¨zler 2008 17/25 23/26 1.4 % 0.77 [ 0.57, 1.04 ]
Parvizi 2007 48/81 52/81 1.4 % 0.92 [ 0.72, 1.18 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Poston 2006 10/29 18/31 0.9 % 0.59 [ 0.33, 1.07 ]
Pugh 1995 21/21 23/23 1.6 % 1.00 [ 0.92, 1.09 ]
Ray 1997 7/53 19/52 0.7 % 0.36 [ 0.17, 0.79 ]
Ray 1999 23/100 21/50 1.1 % 0.55 [ 0.34, 0.89 ]
Rocha 1994 22/28 26/28 1.5 % 0.85 [ 0.68, 1.05 ]
Rodrigus 1996 36/46 26/47 1.4 % 1.41 [ 1.05, 1.91 ]
Rossi 1997 1/21 4/22 0.2 % 0.26 [ 0.03, 2.16 ]
Royston 1987 4/11 11/11 0.7 % 0.39 [ 0.19, 0.82 ]
Santamaria 2000 6/56 11/28 0.6 % 0.27 [ 0.11, 0.66 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Speekenbrink 1995 12/15 11/15 1.2 % 1.09 [ 0.73, 1.62 ]
Speekenbrink 1996 55/75 29/37 1.5 % 0.94 [ 0.75, 1.16 ]
Swart 1994 33/49 42/49 1.5 % 0.79 [ 0.63, 0.98 ]
Tabuchi 1994 10/19 12/17 1.0 % 0.75 [ 0.44, 1.26 ]
Taggart 2003 14/36 26/34 1.1 % 0.51 [ 0.32, 0.80 ]
Tassani 2000 4/10 5/10 0.5 % 0.80 [ 0.30, 2.13 ]
Van der Linden 2005 17/37 27/38 1.2 % 0.65 [ 0.43, 0.97 ]
Vanek 2005 1/29 6/30 0.2 % 0.17 [ 0.02, 1.35 ]
Vedrinne 1992 14/30 23/30 1.2 % 0.61 [ 0.40, 0.94 ]
Wei 2006 6/36 8/40 0.5 % 0.83 [ 0.32, 2.17 ]
Wendel 1995 10/20 15/18 1.1 % 0.60 [ 0.37, 0.97 ]
Subtotal (95% CI) 5329 4168 81.8 % 0.68 [ 0.63, 0.73 ]
Total events: 2431 (Aprotinin), 2728 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 329.48, df = 83 (P<0.00001); I2 =75%
Test for overall effect: Z = 10.18 (P < 0.00001)
2 Orthopaedic surgery
Amar 2003 11/23 13/24 1.0 % 0.88 [ 0.50, 1.55 ]
Capdevila 1998 12/12 11/11 1.5 % 1.00 [ 0.85, 1.17 ]
Colwell 2007 20/175 39/177 1.1 % 0.52 [ 0.32, 0.85 ]
Cvachovec 2001 8/20 16/22 0.9 % 0.55 [ 0.30, 1.00 ]
D’Ambrosio 1999 1/30 0/30 0.1 % 3.00 [ 0.13, 70.83 ]
Engel 2001 5/12 3/12 0.4 % 1.67 [ 0.51, 5.46 ]
Jeserschek 2003 7/9 8/9 1.2 % 0.88 [ 0.58, 1.33 ]
Lentschener 1999 5/35 12/37 0.6 % 0.44 [ 0.17, 1.12 ]
Llau 1998 0/10 3/10 0.1 % 0.14 [ 0.01, 2.45 ]
Murkin 1995 18/29 17/24 1.2 % 0.88 [ 0.60, 1.29 ]
Murkin 2000 12/212 10/68 0.7 % 0.38 [ 0.17, 0.85 ]
Petsatodis 2006 17/25 25/25 1.4 % 0.69 [ 0.52, 0.90 ]
Ray 2005 2/15 3/15 0.2 % 0.67 [ 0.13, 3.44 ]
Samama 2002 12/40 11/18 0.9 % 0.49 [ 0.27, 0.89 ]
Thorpe 1994 1/8 6/9 0.2 % 0.19 [ 0.03, 1.24 ]
Subtotal (95% CI) 655 491 11.4 % 0.68 [ 0.52, 0.89 ]
Total events: 131 (Aprotinin), 177 (Control)
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H,Random,95%
CI
M-
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CI
Heterogeneity: Tau2 = 0.14; Chi2 = 45.47, df = 14 (P = 0.00003); I2 =69%
Test for overall effect: Z = 2.77 (P = 0.0055)
3 Thoracic surgery
Katzel 1998 1/12 6/12 0.2 % 0.17 [ 0.02, 1.18 ]
Kyriss 2001 3/18 10/20 0.4 % 0.33 [ 0.11, 1.02 ]
Norman 2009 2/8 8/8 0.5 % 0.29 [ 0.10, 0.85 ]
Subtotal (95% CI) 38 40 1.1 % 0.29 [ 0.14, 0.59 ]
Total events: 6 (Aprotinin), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00066)
4 Vascular surgery
Okita 1996 28/39 15/21 1.3 % 1.01 [ 0.72, 1.40 ]
Ranaboldo 1997 66/66 62/62 1.6 % 1.00 [ 0.97, 1.03 ]
Subtotal (95% CI) 105 83 2.9 % 1.00 [ 0.97, 1.03 ]
Total events: 94 (Aprotinin), 77 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
5 Liver surgery
Garcia-Huete 1997 13/39 20/41 1.0 % 0.68 [ 0.40, 1.18 ]
Lentschener 1997 8/48 19/49 0.8 % 0.43 [ 0.21, 0.89 ]
Subtotal (95% CI) 87 90 1.7 % 0.58 [ 0.37, 0.90 ]
Total events: 21 (Aprotinin), 39 (Control)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 2.44 (P = 0.015)
6 Neuro surgery
Palmer 2003 11/30 13/26 0.9 % 0.73 [ 0.40, 1.35 ]
Subtotal (95% CI) 30 26 0.9 % 0.73 [ 0.40, 1.35 ]
Total events: 11 (Aprotinin), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
7 Orthognathic surgery
Stewart 2001 1/15 9/15 0.2 % 0.11 [ 0.02, 0.77 ]
Subtotal (95% CI) 15 15 0.2 % 0.11 [ 0.02, 0.77 ]
Total events: 1 (Aprotinin), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.22 (P = 0.026)
Total (95% CI) 6259 4913 100.0 % 0.66 [ 0.60, 0.72 ]
Total events: 2695 (Aprotinin), 3067 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 961.52, df = 107 (P<0.00001); I2 =89%
Test for overall effect: Z = 9.54 (P < 0.00001)
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Analysis 1.3. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 3 No.
Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Alajmo 1989 9/22 8/12 0.9 % 0.61 [ 0.32, 1.17 ]
Alderman 1998 152/401 213/395 1.5 % 0.70 [ 0.60, 0.82 ]
Alvarez 1995 5/49 7/51 0.5 % 0.74 [ 0.25, 2.19 ]
Amar 2003 11/23 13/24 1.0 % 0.88 [ 0.50, 1.55 ]
Bailey 1994 119/129 25/25 1.6 % 0.94 [ 0.87, 1.01 ]
Basora 1999 23/36 20/21 1.4 % 0.67 [ 0.52, 0.87 ]
Bidstrup 1989 8/40 35/37 0.9 % 0.21 [ 0.11, 0.39 ]
Bidstrup 1990 15/26 16/18 1.3 % 0.65 [ 0.45, 0.94 ]
Bidstrup 1993 9/43 24/47 0.8 % 0.41 [ 0.22, 0.78 ]
Blauhut 1994 3/14 9/14 0.5 % 0.33 [ 0.11, 0.98 ]
Boldt 1991 1/10 0/10 0.1 % 3.00 [ 0.14, 65.90 ]
Capdevila 1998 12/12 11/11 1.5 % 1.00 [ 0.85, 1.17 ]
Carrera 1994 42/51 50/51 1.6 % 0.84 [ 0.74, 0.96 ]
Casas 1995 12/47 29/51 1.0 % 0.45 [ 0.26, 0.77 ]
Cicek 1996a 17/50 15/25 1.0 % 0.57 [ 0.34, 0.94 ]
Cicek 1996b 11/29 18/28 1.0 % 0.59 [ 0.34, 1.01 ]
Cicekcioglu 2006 3/24 4/20 0.3 % 0.63 [ 0.16, 2.47 ]
Cohen 1998 17/56 37/59 1.1 % 0.48 [ 0.31, 0.75 ]
Colwell 2007 20/175 39/177 1.1 % 0.52 [ 0.32, 0.85 ]
Corbeau 1995 15/43 12/20 1.0 % 0.58 [ 0.34, 1.00 ]
D’Ambra 1996 73/127 31/64 1.4 % 1.19 [ 0.88, 1.59 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Deleuze 1991 8/30 8/30 0.6 % 1.00 [ 0.43, 2.31 ]
Desai 2009 12/38 16/37 0.9 % 0.73 [ 0.40, 1.33 ]
Dietrich 1990 7/19 15/20 0.9 % 0.49 [ 0.26, 0.93 ]
Dietrich 1992 549/902 730/882 1.6 % 0.74 [ 0.69, 0.78 ]
Dietrich 1995 11/15 15/15 1.3 % 0.74 [ 0.54, 1.02 ]
Dignan 2001 37/101 58/99 1.3 % 0.63 [ 0.46, 0.85 ]
Diprose 2005 8/60 27/60 0.8 % 0.30 [ 0.15, 0.60 ]
Engel 2001 5/12 3/12 0.4 % 1.67 [ 0.51, 5.46 ]
Englberger 2002a 2/21 8/23 0.3 % 0.27 [ 0.07, 1.15 ]
Englberger 2002b 2/15 7/14 0.3 % 0.27 [ 0.07, 1.07 ]
Garcia-Huete 1997 13/39 20/41 1.0 % 0.68 [ 0.40, 1.18 ]
Gherli 1992 4/18 10/13 0.6 % 0.29 [ 0.12, 0.72 ]
Green 1995 6/48 12/36 0.6 % 0.38 [ 0.16, 0.90 ]
Greilich 2001 7/24 13/25 0.8 % 0.56 [ 0.27, 1.16 ]
Greilich 2009 18/26 17/27 1.2 % 1.10 [ 0.75, 1.62 ]
Harder 1991 30/40 29/40 1.4 % 1.03 [ 0.80, 1.34 ]
Hardy 1993 17/22 16/19 1.4 % 0.92 [ 0.68, 1.24 ]
Hardy 1997 23/26 23/26 1.5 % 1.00 [ 0.82, 1.22 ]
Harmon 2004 3/17 4/18 0.3 % 0.79 [ 0.21, 3.04 ]
Hayashida 1997 66/110 46/57 1.5 % 0.74 [ 0.61, 0.91 ]
Isetta 1993 55/140 46/70 1.4 % 0.60 [ 0.46, 0.78 ]
Kalangos 1994 60/110 48/55 1.5 % 0.63 [ 0.51, 0.76 ]
Katzel 1998 1/12 6/12 0.2 % 0.17 [ 0.02, 1.18 ]
Kipfer 2003 4/15 5/15 0.4 % 0.80 [ 0.27, 2.41 ]
Klein 1998 4/36 6/29 0.4 % 0.54 [ 0.17, 1.72 ]
Kuitunen 2005 11/20 12/20 1.0 % 0.92 [ 0.54, 1.56 ]
Lass 1995 25/51 37/47 1.3 % 0.62 [ 0.45, 0.85 ]
Later 2009 48/96 73/103 1.4 % 0.71 [ 0.56, 0.89 ]
Laub 1994 4/16 7/16 0.5 % 0.57 [ 0.21, 1.58 ]
Lemmer 1996 173/487 87/157 1.5 % 0.64 [ 0.53, 0.77 ]
Lemmer˙1 1994 28/74 35/67 1.2 % 0.72 [ 0.50, 1.05 ]
0.1 0.2 0.5 1 2 5 10
Favours Aprotinin Favours Control
(Continued . . . )
259Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lemmer˙2 1994 7/23 23/32 0.8 % 0.42 [ 0.22, 0.82 ]
Lentschener 1997 8/48 19/49 0.8 % 0.43 [ 0.21, 0.89 ]
Lentschener 1999 5/35 12/37 0.6 % 0.44 [ 0.17, 1.12 ]
Levy 1995 109/188 49/65 1.5 % 0.77 [ 0.64, 0.93 ]
Li 2005 5/40 12/30 0.6 % 0.31 [ 0.12, 0.79 ]
Llau 1998 0/10 3/10 0.1 % 0.14 [ 0.01, 2.45 ]
Locatelli 1990 11/25 9/13 0.9 % 0.64 [ 0.36, 1.13 ]
Maccario 1994 5/61 6/32 0.4 % 0.44 [ 0.14, 1.32 ]
Mansour 2004 1/20 12/20 0.2 % 0.08 [ 0.01, 0.58 ]
Menichetti 1996 2/24 18/24 0.3 % 0.11 [ 0.03, 0.43 ]
Mohr 1992 23/34 16/16 1.4 % 0.69 [ 0.54, 0.88 ]
Murkin 1994 16/29 22/25 1.3 % 0.63 [ 0.44, 0.90 ]
Murkin 1995 18/29 17/24 1.2 % 0.88 [ 0.60, 1.29 ]
Murkin 2000 12/212 10/68 0.7 % 0.38 [ 0.17, 0.85 ]
Nuro¨zler 2008 17/25 23/26 1.4 % 0.77 [ 0.57, 1.04 ]
Palmer 2003 11/30 13/26 0.9 % 0.73 [ 0.40, 1.35 ]
Parvizi 2007 48/81 52/81 1.4 % 0.92 [ 0.72, 1.18 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Poston 2006 10/29 18/31 0.9 % 0.59 [ 0.33, 1.07 ]
Pugh 1995 21/21 23/23 1.6 % 1.00 [ 0.92, 1.09 ]
Ranaboldo 1997 66/66 62/62 1.6 % 1.00 [ 0.97, 1.03 ]
Ray 1997 7/53 19/52 0.7 % 0.36 [ 0.17, 0.79 ]
Rossi 1997 1/21 4/22 0.2 % 0.26 [ 0.03, 2.16 ]
Royston 1987 4/11 11/11 0.7 % 0.39 [ 0.19, 0.82 ]
Samama 2002 12/40 11/18 0.9 % 0.49 [ 0.27, 0.89 ]
Santamaria 2000 6/56 11/28 0.6 % 0.27 [ 0.11, 0.66 ]
Speekenbrink 1996 55/75 29/37 1.5 % 0.94 [ 0.75, 1.16 ]
Stewart 2001 1/15 9/15 0.2 % 0.11 [ 0.02, 0.77 ]
Swart 1994 33/49 42/49 1.5 % 0.79 [ 0.63, 0.98 ]
Tabuchi 1994 10/19 12/17 1.0 % 0.75 [ 0.44, 1.26 ]
Taggart 2003 14/36 26/34 1.1 % 0.51 [ 0.32, 0.80 ]
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Van der Linden 2005 17/37 27/38 1.2 % 0.65 [ 0.43, 0.97 ]
Vanek 2005 1/29 6/30 0.2 % 0.17 [ 0.02, 1.35 ]
Vedrinne 1992 14/30 23/30 1.2 % 0.61 [ 0.40, 0.94 ]
Wei 2006 6/36 8/40 0.5 % 0.83 [ 0.32, 2.17 ]
Subtotal (95% CI) 5599 4375 81.0 % 0.65 [ 0.59, 0.71 ]
Total events: 2394 (Aprotinin), 2715 (Control)
Heterogeneity: Tau2 = 0.13; Chi2 = 924.12, df = 86 (P<0.00001); I2 =91%
Test for overall effect: Z = 8.72 (P < 0.00001)
2 No Transfusion Protocol
Baele 1992 35/58 45/57 1.4 % 0.76 [ 0.60, 0.98 ]
Bidstrup 2000 13/30 23/30 1.1 % 0.57 [ 0.36, 0.89 ]
Cosgrove 1992 55/113 44/56 1.5 % 0.62 [ 0.49, 0.78 ]
Cvachovec 2001 8/20 16/22 0.9 % 0.55 [ 0.30, 1.00 ]
D’Ambrosio 1999 1/30 0/30 0.1 % 3.00 [ 0.13, 70.83 ]
Fraedrich 1989 16/38 26/38 1.2 % 0.62 [ 0.40, 0.95 ]
Havel 1992 3/10 7/10 0.5 % 0.43 [ 0.15, 1.20 ]
Jeserschek 2003 7/9 8/9 1.2 % 0.88 [ 0.58, 1.33 ]
Kyriss 2001 3/18 10/20 0.4 % 0.33 [ 0.11, 1.02 ]
Liu 1993 3/20 12/20 0.4 % 0.25 [ 0.08, 0.75 ]
Norman 2009 2/8 8/8 0.5 % 0.29 [ 0.10, 0.85 ]
Okita 1996 28/39 15/21 1.3 % 1.01 [ 0.72, 1.40 ]
Petsatodis 2006 17/25 25/25 1.4 % 0.69 [ 0.52, 0.90 ]
Ray 1999 23/100 21/50 1.1 % 0.55 [ 0.34, 0.89 ]
Ray 2005 2/15 3/15 0.2 % 0.67 [ 0.13, 3.44 ]
Rocha 1994 22/28 26/28 1.5 % 0.85 [ 0.68, 1.05 ]
Rodrigus 1996 36/46 26/47 1.4 % 1.41 [ 1.05, 1.91 ]
Speekenbrink 1995 12/15 11/15 1.2 % 1.09 [ 0.73, 1.62 ]
Tassani 2000 4/10 5/10 0.5 % 0.80 [ 0.30, 2.13 ]
Thorpe 1994 1/8 6/9 0.2 % 0.19 [ 0.03, 1.24 ]
Wendel 1995 10/20 15/18 1.1 % 0.60 [ 0.37, 0.97 ]
Subtotal (95% CI) 660 538 19.0 % 0.71 [ 0.61, 0.84 ]
Total events: 301 (Aprotinin), 352 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 49.74, df = 20 (P = 0.00024); I2 =60%
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Test for overall effect: Z = 4.02 (P = 0.000058)
Total (95% CI) 6259 4913 100.0 % 0.66 [ 0.60, 0.72 ]
Total events: 2695 (Aprotinin), 3067 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 961.52, df = 107 (P<0.00001); I2 =89%
Test for overall effect: Z = 9.54 (P < 0.00001)
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Analysis 1.4. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 4 No.
Exposed to Allogeneic Blood - Dose.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 4 No. Exposed to Allogeneic Blood - Dose
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Prime Dose
Bailey 1994 49/51 25/25 1.4 % 0.97 [ 0.89, 1.05 ]
Englberger 2002b 2/15 7/14 0.2 % 0.27 [ 0.07, 1.07 ]
Hardy 1997 23/26 23/26 1.3 % 1.00 [ 0.82, 1.22 ]
Hayashida 1997 31/55 46/57 1.2 % 0.70 [ 0.54, 0.91 ]
Kalangos 1994 31/55 48/55 1.2 % 0.65 [ 0.50, 0.83 ]
Kipfer 2003 4/15 5/15 0.4 % 0.80 [ 0.27, 2.41 ]
Lemmer 1996 56/159 87/157 1.2 % 0.64 [ 0.49, 0.82 ]
Levy 1995 49/68 49/65 1.3 % 0.96 [ 0.78, 1.17 ]
Maccario 1994 3/29 6/32 0.3 % 0.55 [ 0.15, 2.01 ]
Mohr 1992 15/17 16/16 1.3 % 0.89 [ 0.72, 1.09 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Okita 1996 28/39 15/21 1.1 % 1.01 [ 0.72, 1.40 ]
Rossi 1997 1/21 4/22 0.1 % 0.26 [ 0.03, 2.16 ]
Santamaria 2000 3/28 11/28 0.3 % 0.27 [ 0.09, 0.87 ]
Speekenbrink 1995 12/15 11/15 1.0 % 1.09 [ 0.73, 1.62 ]
Speekenbrink 1996 28/37 29/37 1.2 % 0.97 [ 0.75, 1.24 ]
Tabuchi 1994 10/19 12/17 0.8 % 0.75 [ 0.44, 1.26 ]
Subtotal (95% CI) 649 602 14.2 % 0.83 [ 0.71, 0.96 ]
Total events: 345 (Aprotinin), 394 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 59.49, df = 15 (P<0.00001); I2 =75%
Test for overall effect: Z = 2.47 (P = 0.014)
2 Low Dose
Alajmo 1989 9/22 8/12 0.7 % 0.61 [ 0.32, 1.17 ]
Alvarez 1995 5/49 7/51 0.4 % 0.74 [ 0.25, 2.19 ]
Amar 2003 11/23 13/24 0.8 % 0.88 [ 0.50, 1.55 ]
Bailey 1994 47/53 25/25 1.3 % 0.90 [ 0.80, 1.00 ]
Basora 1999 23/36 20/21 1.2 % 0.67 [ 0.52, 0.87 ]
Blauhut 1994 3/14 9/14 0.4 % 0.33 [ 0.11, 0.98 ]
Capdevila 1998 12/12 11/11 1.3 % 1.00 [ 0.85, 1.17 ]
Cicek 1996a 9/25 15/25 0.7 % 0.60 [ 0.33, 1.11 ]
Cicek 1996b 11/29 18/28 0.8 % 0.59 [ 0.34, 1.01 ]
Cicekcioglu 2006 3/24 4/20 0.3 % 0.63 [ 0.16, 2.47 ]
Cosgrove 1992 29/56 44/56 1.2 % 0.66 [ 0.49, 0.88 ]
Cvachovec 2001 8/20 16/22 0.8 % 0.55 [ 0.30, 1.00 ]
D’Ambra 1996 32/62 31/64 1.1 % 1.07 [ 0.75, 1.51 ]
D’Ambrosio 1999 1/30 0/30 0.1 % 3.00 [ 0.13, 70.83 ]
Dignan 2001 37/101 58/99 1.1 % 0.63 [ 0.46, 0.85 ]
Engel 2001 5/12 3/12 0.3 % 1.67 [ 0.51, 5.46 ]
Englberger 2002a 2/21 8/23 0.2 % 0.27 [ 0.07, 1.15 ]
Garcia-Huete 1997 13/39 20/41 0.8 % 0.68 [ 0.40, 1.18 ]
Gherli 1992 2/9 10/13 0.3 % 0.29 [ 0.08, 1.02 ]
Hardy 1993 17/22 16/19 1.1 % 0.92 [ 0.68, 1.24 ]
Havel 1992 3/10 7/10 0.4 % 0.43 [ 0.15, 1.20 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hayashida 1997 35/55 46/57 1.2 % 0.79 [ 0.62, 1.00 ]
Isetta 1993 28/70 46/70 1.1 % 0.61 [ 0.44, 0.85 ]
Jeserschek 2003 7/9 8/9 1.0 % 0.88 [ 0.58, 1.33 ]
Katzel 1998 1/12 6/12 0.1 % 0.17 [ 0.02, 1.18 ]
Kyriss 2001 3/18 10/20 0.3 % 0.33 [ 0.11, 1.02 ]
Lemmer 1996 62/168 87/157 1.2 % 0.67 [ 0.52, 0.85 ]
Lentschener 1997 8/48 19/49 0.6 % 0.43 [ 0.21, 0.89 ]
Lentschener 1999 5/35 12/37 0.5 % 0.44 [ 0.17, 1.12 ]
Levy 1995 27/59 49/65 1.1 % 0.61 [ 0.44, 0.83 ]
Liu 1993 3/20 12/20 0.4 % 0.25 [ 0.08, 0.75 ]
Llau 1998 0/10 3/10 0.1 % 0.14 [ 0.01, 2.45 ]
Locatelli 1990 7/13 9/13 0.7 % 0.78 [ 0.42, 1.45 ]
Mansour 2004 1/20 12/20 0.1 % 0.08 [ 0.01, 0.58 ]
Murkin 1995 18/29 17/24 1.0 % 0.88 [ 0.60, 1.29 ]
Murkin 2000 12/212 10/68 0.6 % 0.38 [ 0.17, 0.85 ]
Nuro¨zler 2008 17/25 23/26 1.1 % 0.77 [ 0.57, 1.04 ]
Palmer 2003 11/30 13/26 0.7 % 0.73 [ 0.40, 1.35 ]
Parvizi 2007 48/81 52/81 1.2 % 0.92 [ 0.72, 1.18 ]
Petsatodis 2006 17/25 25/25 1.2 % 0.69 [ 0.52, 0.90 ]
Poston 2006 10/29 18/31 0.8 % 0.59 [ 0.33, 1.07 ]
Pugh 1995 21/21 23/23 1.4 % 1.00 [ 0.92, 1.09 ]
Ranaboldo 1997 66/66 62/62 1.4 % 1.00 [ 0.97, 1.03 ]
Ray 1999 14/50 21/50 0.8 % 0.67 [ 0.38, 1.16 ]
Ray 2005 2/15 3/15 0.2 % 0.67 [ 0.13, 3.44 ]
Samama 2002 8/22 11/18 0.7 % 0.60 [ 0.31, 1.16 ]
Stewart 2001 1/15 9/15 0.1 % 0.11 [ 0.02, 0.77 ]
Thorpe 1994 1/8 6/9 0.1 % 0.19 [ 0.03, 1.24 ]
Vanek 2005 1/29 6/30 0.1 % 0.17 [ 0.02, 1.35 ]
Wei 2006 6/36 8/40 0.4 % 0.83 [ 0.32, 2.17 ]
Subtotal (95% CI) 1899 1702 35.6 % 0.65 [ 0.55, 0.77 ]
Total events: 722 (Aprotinin), 969 (Control)
Heterogeneity: Tau2 = 0.23; Chi2 = 721.10, df = 49 (P<0.00001); I2 =93%
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 5.01 (P < 0.00001)
3 High Dose
Alderman 1998 152/401 213/395 1.3 % 0.70 [ 0.60, 0.82 ]
Baele 1992 35/58 45/57 1.2 % 0.76 [ 0.60, 0.98 ]
Bailey 1994 23/25 25/25 1.3 % 0.92 [ 0.80, 1.06 ]
Bidstrup 1989 8/40 35/37 0.7 % 0.21 [ 0.11, 0.39 ]
Bidstrup 1990 15/26 16/18 1.0 % 0.65 [ 0.45, 0.94 ]
Bidstrup 1993 9/43 24/47 0.7 % 0.41 [ 0.22, 0.78 ]
Bidstrup 2000 13/30 23/30 0.9 % 0.57 [ 0.36, 0.89 ]
Boldt 1991 1/10 0/10 0.1 % 3.00 [ 0.14, 65.90 ]
Carrera 1994 42/51 50/51 1.3 % 0.84 [ 0.74, 0.96 ]
Casas 1995 12/47 29/51 0.8 % 0.45 [ 0.26, 0.77 ]
Cicek 1996a 8/25 15/25 0.7 % 0.53 [ 0.28, 1.03 ]
Cohen 1998 17/56 37/59 0.9 % 0.48 [ 0.31, 0.75 ]
Colwell 2007 20/175 39/177 0.9 % 0.52 [ 0.32, 0.85 ]
Corbeau 1995 15/43 12/20 0.8 % 0.58 [ 0.34, 1.00 ]
Cosgrove 1992 26/57 44/56 1.1 % 0.58 [ 0.42, 0.80 ]
D’Ambra 1996 41/65 31/64 1.1 % 1.30 [ 0.95, 1.78 ]
Deleuze 1991 8/30 8/30 0.5 % 1.00 [ 0.43, 2.31 ]
Desai 2009 12/38 16/37 0.8 % 0.73 [ 0.40, 1.33 ]
Dietrich 1990 7/19 15/20 0.7 % 0.49 [ 0.26, 0.93 ]
Dietrich 1992 549/902 730/882 1.4 % 0.74 [ 0.69, 0.78 ]
Dietrich 1995 11/15 15/15 1.1 % 0.74 [ 0.54, 1.02 ]
Diprose 2005 8/60 27/60 0.6 % 0.30 [ 0.15, 0.60 ]
Fraedrich 1989 16/38 26/38 1.0 % 0.62 [ 0.40, 0.95 ]
Gherli 1992 2/9 10/13 0.3 % 0.29 [ 0.08, 1.02 ]
Greilich 2001 7/24 13/25 0.6 % 0.56 [ 0.27, 1.16 ]
Greilich 2009 18/26 17/27 1.0 % 1.10 [ 0.75, 1.62 ]
Harder 1991 30/40 29/40 1.2 % 1.03 [ 0.80, 1.34 ]
Harmon 2004 3/17 4/18 0.3 % 0.79 [ 0.21, 3.04 ]
Isetta 1993 27/70 46/70 1.1 % 0.59 [ 0.42, 0.83 ]
Kalangos 1994 29/55 48/55 1.2 % 0.60 [ 0.46, 0.79 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Klein 1998 4/36 6/29 0.3 % 0.54 [ 0.17, 1.72 ]
Kuitunen 2005 11/20 12/20 0.8 % 0.92 [ 0.54, 1.56 ]
Lass 1995 25/51 37/47 1.1 % 0.62 [ 0.45, 0.85 ]
Later 2009 48/96 73/103 1.2 % 0.71 [ 0.56, 0.89 ]
Laub 1994 4/16 7/16 0.4 % 0.57 [ 0.21, 1.58 ]
Lemmer 1996 55/160 87/157 1.2 % 0.62 [ 0.48, 0.80 ]
Lemmer˙1 1994 28/74 35/67 1.0 % 0.72 [ 0.50, 1.05 ]
Lemmer˙2 1994 7/23 23/32 0.7 % 0.42 [ 0.22, 0.82 ]
Levy 1995 33/61 49/65 1.2 % 0.72 [ 0.55, 0.94 ]
Li 2005 5/40 12/30 0.5 % 0.31 [ 0.12, 0.79 ]
Locatelli 1990 4/12 9/13 0.5 % 0.48 [ 0.20, 1.16 ]
Maccario 1994 2/32 6/32 0.2 % 0.33 [ 0.07, 1.53 ]
Menichetti 1996 2/24 18/24 0.3 % 0.11 [ 0.03, 0.43 ]
Mohr 1992 8/17 16/16 0.9 % 0.49 [ 0.30, 0.80 ]
Murkin 1994 16/29 22/25 1.1 % 0.63 [ 0.44, 0.90 ]
Norman 2009 2/8 8/8 0.4 % 0.29 [ 0.10, 0.85 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Ray 1997 7/53 19/52 0.6 % 0.36 [ 0.17, 0.79 ]
Ray 1999 9/50 21/50 0.7 % 0.43 [ 0.22, 0.84 ]
Rocha 1994 22/28 26/28 1.2 % 0.85 [ 0.68, 1.05 ]
Rodrigus 1996 36/46 26/47 1.1 % 1.41 [ 1.05, 1.91 ]
Royston 1987 4/11 11/11 0.6 % 0.39 [ 0.19, 0.82 ]
Samama 2002 4/18 11/18 0.4 % 0.36 [ 0.14, 0.93 ]
Santamaria 2000 3/28 11/28 0.3 % 0.27 [ 0.09, 0.87 ]
Speekenbrink 1996 27/38 29/37 1.2 % 0.91 [ 0.70, 1.18 ]
Swart 1994 33/49 42/49 1.2 % 0.79 [ 0.63, 0.98 ]
Taggart 2003 14/36 26/34 0.9 % 0.51 [ 0.32, 0.80 ]
Tassani 2000 4/10 5/10 0.4 % 0.80 [ 0.30, 2.13 ]
Van der Linden 2005 17/37 27/38 1.0 % 0.65 [ 0.43, 0.97 ]
Vedrinne 1992 14/30 23/30 1.0 % 0.61 [ 0.40, 0.94 ]
Wendel 1995 10/20 15/18 0.9 % 0.60 [ 0.37, 0.97 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 3663 3601 50.2 % 0.66 [ 0.61, 0.71 ]
Total events: 1622 (Aprotinin), 2357 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 173.52, df = 60 (P<0.00001); I2 =65%
Test for overall effect: Z = 10.02 (P < 0.00001)
Total (95% CI) 6211 5905 100.0 % 0.67 [ 0.62, 0.73 ]
Total events: 2689 (Aprotinin), 3720 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 1011.26, df = 126 (P<0.00001); I2 =88%
Test for overall effect: Z = 10.19 (P < 0.00001)
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Analysis 1.5. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 5 No.
Exposed to Allogeneic Blood - Dose (Cardiac Surgery).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 5 No. Exposed to Allogeneic Blood - Dose (Cardiac Surgery)
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Prime Dose
Bailey 1994 49/51 25/25 1.9 % 0.97 [ 0.89, 1.05 ]
Englberger 2002b 2/15 7/14 0.2 % 0.27 [ 0.07, 1.07 ]
Hardy 1997 23/26 23/26 1.7 % 1.00 [ 0.82, 1.22 ]
Hayashida 1997 31/55 46/57 1.5 % 0.70 [ 0.54, 0.91 ]
Kalangos 1994 31/55 48/55 1.6 % 0.65 [ 0.50, 0.83 ]
Kipfer 2003 4/15 5/15 0.3 % 0.80 [ 0.27, 2.41 ]
Lemmer 1996 56/159 87/157 1.6 % 0.64 [ 0.49, 0.82 ]
Levy 1995 49/68 49/65 1.7 % 0.96 [ 0.78, 1.17 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Maccario 1994 3/29 6/32 0.2 % 0.55 [ 0.15, 2.01 ]
Mohr 1992 15/17 16/16 1.7 % 0.89 [ 0.72, 1.09 ]
Rossi 1997 1/21 4/22 0.1 % 0.26 [ 0.03, 2.16 ]
Santamaria 2000 3/28 11/28 0.3 % 0.27 [ 0.09, 0.87 ]
Speekenbrink 1995 12/15 11/15 1.2 % 1.09 [ 0.73, 1.62 ]
Speekenbrink 1996 28/37 29/37 1.6 % 0.97 [ 0.75, 1.24 ]
Tabuchi 1994 10/19 12/17 0.9 % 0.75 [ 0.44, 1.26 ]
Subtotal (95% CI) 610 581 16.4 % 0.81 [ 0.69, 0.96 ]
Total events: 317 (Aprotinin), 379 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 62.42, df = 14 (P<0.00001); I2 =78%
Test for overall effect: Z = 2.50 (P = 0.012)
2 Low Dose
Alajmo 1989 9/22 8/12 0.7 % 0.61 [ 0.32, 1.17 ]
Alvarez 1995 5/49 7/51 0.3 % 0.74 [ 0.25, 2.19 ]
Bailey 1994 47/53 25/25 1.9 % 0.90 [ 0.80, 1.00 ]
Basora 1999 23/36 20/21 1.5 % 0.67 [ 0.52, 0.87 ]
Blauhut 1994 3/14 9/14 0.3 % 0.33 [ 0.11, 0.98 ]
Cicek 1996a 9/25 15/25 0.7 % 0.60 [ 0.33, 1.11 ]
Cicek 1996b 11/29 18/28 0.9 % 0.59 [ 0.34, 1.01 ]
Cicekcioglu 2006 3/24 4/20 0.2 % 0.63 [ 0.16, 2.47 ]
Cosgrove 1992 29/56 44/56 1.5 % 0.66 [ 0.49, 0.88 ]
D’Ambra 1996 32/62 31/64 1.3 % 1.07 [ 0.75, 1.51 ]
Dignan 2001 37/101 58/99 1.4 % 0.63 [ 0.46, 0.85 ]
Englberger 2002a 2/21 8/23 0.2 % 0.27 [ 0.07, 1.15 ]
Gherli 1992 2/9 10/13 0.2 % 0.29 [ 0.08, 1.02 ]
Hardy 1993 17/22 16/19 1.4 % 0.92 [ 0.68, 1.24 ]
Havel 1992 3/10 7/10 0.3 % 0.43 [ 0.15, 1.20 ]
Hayashida 1997 35/55 46/57 1.6 % 0.79 [ 0.62, 1.00 ]
Isetta 1993 28/70 46/70 1.3 % 0.61 [ 0.44, 0.85 ]
Lemmer 1996 62/168 87/157 1.6 % 0.67 [ 0.52, 0.85 ]
Levy 1995 27/59 49/65 1.4 % 0.61 [ 0.44, 0.83 ]
Liu 1993 3/20 12/20 0.3 % 0.25 [ 0.08, 0.75 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Locatelli 1990 7/13 9/13 0.7 % 0.78 [ 0.42, 1.45 ]
Mansour 2004 1/20 12/20 0.1 % 0.08 [ 0.01, 0.58 ]
Nuro¨zler 2008 17/25 23/26 1.4 % 0.77 [ 0.57, 1.04 ]
Parvizi 2007 48/81 52/81 1.6 % 0.92 [ 0.72, 1.18 ]
Poston 2006 10/29 18/31 0.8 % 0.59 [ 0.33, 1.07 ]
Pugh 1995 21/21 23/23 1.9 % 1.00 [ 0.92, 1.09 ]
Ray 1999 14/50 21/50 0.8 % 0.67 [ 0.38, 1.16 ]
Vanek 2005 1/29 6/30 0.1 % 0.17 [ 0.02, 1.35 ]
Wei 2006 6/36 8/40 0.4 % 0.83 [ 0.32, 2.17 ]
Subtotal (95% CI) 1209 1163 27.1 % 0.69 [ 0.60, 0.80 ]
Total events: 512 (Aprotinin), 692 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 125.74, df = 28 (P<0.00001); I2 =78%
Test for overall effect: Z = 4.99 (P < 0.00001)
3 High Dose
Alderman 1998 152/401 213/395 1.8 % 0.70 [ 0.60, 0.82 ]
Baele 1992 35/58 45/57 1.6 % 0.76 [ 0.60, 0.98 ]
Bailey 1994 23/25 25/25 1.8 % 0.92 [ 0.80, 1.06 ]
Bidstrup 1989 8/40 35/37 0.7 % 0.21 [ 0.11, 0.39 ]
Bidstrup 1990 15/26 16/18 1.2 % 0.65 [ 0.45, 0.94 ]
Bidstrup 1993 9/43 24/47 0.7 % 0.41 [ 0.22, 0.78 ]
Bidstrup 2000 13/30 23/30 1.0 % 0.57 [ 0.36, 0.89 ]
Boldt 1991 1/10 0/10 0.0 % 3.00 [ 0.14, 65.90 ]
Carrera 1994 42/51 50/51 1.9 % 0.84 [ 0.74, 0.96 ]
Casas 1995 12/47 29/51 0.9 % 0.45 [ 0.26, 0.77 ]
Cicek 1996a 8/25 15/25 0.7 % 0.53 [ 0.28, 1.03 ]
Cohen 1998 17/56 37/59 1.1 % 0.48 [ 0.31, 0.75 ]
Corbeau 1995 15/43 12/20 0.9 % 0.58 [ 0.34, 1.00 ]
Cosgrove 1992 26/57 44/56 1.4 % 0.58 [ 0.42, 0.80 ]
D’Ambra 1996 41/65 31/64 1.4 % 1.30 [ 0.95, 1.78 ]
Deleuze 1991 8/30 8/30 0.5 % 1.00 [ 0.43, 2.31 ]
Desai 2009 12/38 16/37 0.8 % 0.73 [ 0.40, 1.33 ]
Dietrich 1990 7/19 15/20 0.7 % 0.49 [ 0.26, 0.93 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dietrich 1992 549/902 730/882 2.0 % 0.74 [ 0.69, 0.78 ]
Dietrich 1995 11/15 15/15 1.4 % 0.74 [ 0.54, 1.02 ]
Diprose 2005 8/60 27/60 0.6 % 0.30 [ 0.15, 0.60 ]
Fraedrich 1989 16/38 26/38 1.1 % 0.62 [ 0.40, 0.95 ]
Gherli 1992 2/9 10/13 0.2 % 0.29 [ 0.08, 1.02 ]
Greilich 2001 7/24 13/25 0.6 % 0.56 [ 0.27, 1.16 ]
Greilich 2009 18/26 17/27 1.2 % 1.10 [ 0.75, 1.62 ]
Harder 1991 30/40 29/40 1.5 % 1.03 [ 0.80, 1.34 ]
Harmon 2004 3/17 4/18 0.2 % 0.79 [ 0.21, 3.04 ]
Isetta 1993 27/70 46/70 1.3 % 0.59 [ 0.42, 0.83 ]
Kalangos 1994 29/55 48/55 1.5 % 0.60 [ 0.46, 0.79 ]
Klein 1998 4/36 6/29 0.3 % 0.54 [ 0.17, 1.72 ]
Kuitunen 2005 11/20 12/20 0.9 % 0.92 [ 0.54, 1.56 ]
Lass 1995 25/51 37/47 1.4 % 0.62 [ 0.45, 0.85 ]
Later 2009 48/96 73/103 1.6 % 0.71 [ 0.56, 0.89 ]
Laub 1994 4/16 7/16 0.4 % 0.57 [ 0.21, 1.58 ]
Lemmer 1996 55/160 87/157 1.5 % 0.62 [ 0.48, 0.80 ]
Lemmer˙1 1994 28/74 35/67 1.2 % 0.72 [ 0.50, 1.05 ]
Lemmer˙2 1994 7/23 23/32 0.7 % 0.42 [ 0.22, 0.82 ]
Levy 1995 33/61 49/65 1.5 % 0.72 [ 0.55, 0.94 ]
Li 2005 5/40 12/30 0.4 % 0.31 [ 0.12, 0.79 ]
Locatelli 1990 4/12 9/13 0.4 % 0.48 [ 0.20, 1.16 ]
Maccario 1994 2/32 6/32 0.2 % 0.33 [ 0.07, 1.53 ]
Menichetti 1996 2/24 18/24 0.2 % 0.11 [ 0.03, 0.43 ]
Mohr 1992 8/17 16/16 0.9 % 0.49 [ 0.30, 0.80 ]
Murkin 1994 16/29 22/25 1.3 % 0.63 [ 0.44, 0.90 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Ray 1997 7/53 19/52 0.5 % 0.36 [ 0.17, 0.79 ]
Ray 1999 9/50 21/50 0.7 % 0.43 [ 0.22, 0.84 ]
Rocha 1994 22/28 26/28 1.6 % 0.85 [ 0.68, 1.05 ]
Rodrigus 1996 36/46 26/47 1.4 % 1.41 [ 1.05, 1.91 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Royston 1987 4/11 11/11 0.6 % 0.39 [ 0.19, 0.82 ]
Santamaria 2000 3/28 11/28 0.3 % 0.27 [ 0.09, 0.87 ]
Speekenbrink 1996 27/38 29/37 1.5 % 0.91 [ 0.70, 1.18 ]
Swart 1994 33/49 42/49 1.6 % 0.79 [ 0.63, 0.98 ]
Taggart 2003 14/36 26/34 1.0 % 0.51 [ 0.32, 0.80 ]
Tassani 2000 4/10 5/10 0.4 % 0.80 [ 0.30, 2.13 ]
Van der Linden 2005 17/37 27/38 1.2 % 0.65 [ 0.43, 0.97 ]
Vedrinne 1992 14/30 23/30 1.1 % 0.61 [ 0.40, 0.94 ]
Wendel 1995 10/20 15/18 1.0 % 0.60 [ 0.37, 0.97 ]
Subtotal (95% CI) 3462 3398 56.5 % 0.67 [ 0.62, 0.72 ]
Total events: 1596 (Aprotinin), 2299 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 164.59, df = 57 (P<0.00001); I2 =65%
Test for overall effect: Z = 9.67 (P < 0.00001)
Total (95% CI) 5281 5142 100.0 % 0.69 [ 0.65, 0.74 ]
Total events: 2425 (Aprotinin), 3370 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 392.72, df = 101 (P<0.00001); I2 =74%
Test for overall effect: Z = 10.73 (P < 0.00001)
0.1 0.2 0.5 1 2 5 10
Favours Aprotinin Favours Control
271Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 6 Trial
Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 6 Trial Methodological Quality - Allocation Concealment
Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Bailey 1994 119/129 25/25 1.6 % 0.94 [ 0.87, 1.01 ]
Bidstrup 1989 8/40 35/37 0.9 % 0.21 [ 0.11, 0.39 ]
Bidstrup 1993 9/43 24/47 0.8 % 0.41 [ 0.22, 0.78 ]
Bidstrup 2000 13/30 23/30 1.1 % 0.57 [ 0.36, 0.89 ]
Capdevila 1998 12/12 11/11 1.5 % 1.00 [ 0.85, 1.17 ]
Cohen 1998 17/56 37/59 1.1 % 0.48 [ 0.31, 0.75 ]
Colwell 2007 20/175 39/177 1.1 % 0.52 [ 0.32, 0.85 ]
D’Ambra 1996 73/127 31/64 1.4 % 1.19 [ 0.88, 1.59 ]
Deleuze 1991 8/30 8/30 0.6 % 1.00 [ 0.43, 2.31 ]
Dietrich 1990 7/19 15/20 0.9 % 0.49 [ 0.26, 0.93 ]
Dietrich 1995 11/15 15/15 1.3 % 0.74 [ 0.54, 1.02 ]
Englberger 2002a 2/21 8/23 0.3 % 0.27 [ 0.07, 1.15 ]
Greilich 2009 18/26 17/27 1.2 % 1.10 [ 0.75, 1.62 ]
Harder 1991 30/40 29/40 1.4 % 1.03 [ 0.80, 1.34 ]
Hardy 1993 17/22 16/19 1.4 % 0.92 [ 0.68, 1.24 ]
Hardy 1997 23/26 23/26 1.5 % 1.00 [ 0.82, 1.22 ]
Harmon 2004 3/17 4/18 0.3 % 0.79 [ 0.21, 3.04 ]
Lemmer˙1 1994 28/74 35/67 1.2 % 0.72 [ 0.50, 1.05 ]
Lemmer˙2 1994 7/23 23/32 0.8 % 0.42 [ 0.22, 0.82 ]
Liu 1993 3/20 12/20 0.4 % 0.25 [ 0.08, 0.75 ]
Mansour 2004 1/20 12/20 0.2 % 0.08 [ 0.01, 0.58 ]
Murkin 2000 12/212 10/68 0.7 % 0.38 [ 0.17, 0.85 ]
Norman 2009 2/8 8/8 0.5 % 0.29 [ 0.10, 0.85 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palmer 2003 11/30 13/26 0.9 % 0.73 [ 0.40, 1.35 ]
Poston 2006 10/29 18/31 0.9 % 0.59 [ 0.33, 1.07 ]
Ranaboldo 1997 66/66 62/62 1.6 % 1.00 [ 0.97, 1.03 ]
Speekenbrink 1996 55/75 29/37 1.5 % 0.94 [ 0.75, 1.16 ]
Stewart 2001 1/15 9/15 0.2 % 0.11 [ 0.02, 0.77 ]
Swart 1994 33/49 42/49 1.5 % 0.79 [ 0.63, 0.98 ]
Tabuchi 1994 10/19 12/17 1.0 % 0.75 [ 0.44, 1.26 ]
Taggart 2003 14/36 26/34 1.1 % 0.51 [ 0.32, 0.80 ]
Vanek 2005 1/29 6/30 0.2 % 0.17 [ 0.02, 1.35 ]
Wendel 1995 10/20 15/18 1.1 % 0.60 [ 0.37, 0.97 ]
Subtotal (95% CI) 1553 1202 32.2 % 0.64 [ 0.53, 0.79 ]
Total events: 654 (Aprotinin), 692 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 665.70, df = 32 (P<0.00001); I2 =95%
Test for overall effect: Z = 4.30 (P = 0.000017)
2 Allocation concealment - Unclear
Alderman 1998 152/401 213/395 1.5 % 0.70 [ 0.60, 0.82 ]
Basora 1999 23/36 20/21 1.4 % 0.67 [ 0.52, 0.87 ]
Bidstrup 1990 15/26 16/18 1.3 % 0.65 [ 0.45, 0.94 ]
Blauhut 1994 3/14 9/14 0.5 % 0.33 [ 0.11, 0.98 ]
Boldt 1991 1/10 0/10 0.1 % 3.00 [ 0.14, 65.90 ]
Carrera 1994 42/51 50/51 1.6 % 0.84 [ 0.74, 0.96 ]
Cicek 1996a 17/50 15/25 1.0 % 0.57 [ 0.34, 0.94 ]
Cicek 1996b 11/29 18/28 1.0 % 0.59 [ 0.34, 1.01 ]
Cicekcioglu 2006 3/24 4/20 0.3 % 0.63 [ 0.16, 2.47 ]
Corbeau 1995 15/43 12/20 1.0 % 0.58 [ 0.34, 1.00 ]
Cosgrove 1992 55/113 44/56 1.5 % 0.62 [ 0.49, 0.78 ]
Cvachovec 2001 8/20 16/22 0.9 % 0.55 [ 0.30, 1.00 ]
D’Ambrosio 1999 1/30 0/30 0.1 % 3.00 [ 0.13, 70.83 ]
Desai 2009 12/38 16/37 0.9 % 0.73 [ 0.40, 1.33 ]
Dietrich 1992 549/902 730/882 1.6 % 0.74 [ 0.69, 0.78 ]
Dignan 2001 37/101 58/99 1.3 % 0.63 [ 0.46, 0.85 ]
Engel 2001 5/12 3/12 0.4 % 1.67 [ 0.51, 5.46 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Englberger 2002b 2/15 7/14 0.3 % 0.27 [ 0.07, 1.07 ]
Fraedrich 1989 16/38 26/38 1.2 % 0.62 [ 0.40, 0.95 ]
Garcia-Huete 1997 13/39 20/41 1.0 % 0.68 [ 0.40, 1.18 ]
Gherli 1992 4/18 10/13 0.6 % 0.29 [ 0.12, 0.72 ]
Green 1995 6/48 12/36 0.6 % 0.38 [ 0.16, 0.90 ]
Greilich 2001 7/24 13/25 0.8 % 0.56 [ 0.27, 1.16 ]
Hayashida 1997 66/110 46/57 1.5 % 0.74 [ 0.61, 0.91 ]
Isetta 1993 55/140 46/70 1.4 % 0.60 [ 0.46, 0.78 ]
Jeserschek 2003 7/9 8/9 1.2 % 0.88 [ 0.58, 1.33 ]
Kalangos 1994 60/110 48/55 1.5 % 0.63 [ 0.51, 0.76 ]
Katzel 1998 1/12 6/12 0.2 % 0.17 [ 0.02, 1.18 ]
Kipfer 2003 4/15 5/15 0.4 % 0.80 [ 0.27, 2.41 ]
Klein 1998 4/36 6/29 0.4 % 0.54 [ 0.17, 1.72 ]
Kyriss 2001 3/18 10/20 0.4 % 0.33 [ 0.11, 1.02 ]
Lass 1995 25/51 37/47 1.3 % 0.62 [ 0.45, 0.85 ]
Laub 1994 4/16 7/16 0.5 % 0.57 [ 0.21, 1.58 ]
Lemmer 1996 173/487 87/157 1.5 % 0.64 [ 0.53, 0.77 ]
Lentschener 1997 8/48 19/49 0.8 % 0.43 [ 0.21, 0.89 ]
Lentschener 1999 5/35 12/37 0.6 % 0.44 [ 0.17, 1.12 ]
Levy 1995 109/188 49/65 1.5 % 0.77 [ 0.64, 0.93 ]
Li 2005 5/40 12/30 0.6 % 0.31 [ 0.12, 0.79 ]
Llau 1998 0/10 3/10 0.1 % 0.14 [ 0.01, 2.45 ]
Locatelli 1990 11/25 9/13 0.9 % 0.64 [ 0.36, 1.13 ]
Maccario 1994 5/61 6/32 0.4 % 0.44 [ 0.14, 1.32 ]
Menichetti 1996 2/24 18/24 0.3 % 0.11 [ 0.03, 0.43 ]
Mohr 1992 23/34 16/16 1.4 % 0.69 [ 0.54, 0.88 ]
Murkin 1994 16/29 22/25 1.3 % 0.63 [ 0.44, 0.90 ]
Murkin 1995 18/29 17/24 1.2 % 0.88 [ 0.60, 1.29 ]
Nuro¨zler 2008 17/25 23/26 1.4 % 0.77 [ 0.57, 1.04 ]
Okita 1996 28/39 15/21 1.3 % 1.01 [ 0.72, 1.40 ]
Parvizi 2007 48/81 52/81 1.4 % 0.92 [ 0.72, 1.18 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Petsatodis 2006 17/25 25/25 1.4 % 0.69 [ 0.52, 0.90 ]
Pugh 1995 21/21 23/23 1.6 % 1.00 [ 0.92, 1.09 ]
Ray 1997 7/53 19/52 0.7 % 0.36 [ 0.17, 0.79 ]
Ray 1999 23/100 21/50 1.1 % 0.55 [ 0.34, 0.89 ]
Ray 2005 2/15 3/15 0.2 % 0.67 [ 0.13, 3.44 ]
Rocha 1994 22/28 26/28 1.5 % 0.85 [ 0.68, 1.05 ]
Rodrigus 1996 36/46 26/47 1.4 % 1.41 [ 1.05, 1.91 ]
Rossi 1997 1/21 4/22 0.2 % 0.26 [ 0.03, 2.16 ]
Santamaria 2000 6/56 11/28 0.6 % 0.27 [ 0.11, 0.66 ]
Speekenbrink 1995 12/15 11/15 1.2 % 1.09 [ 0.73, 1.62 ]
Tassani 2000 4/10 5/10 0.5 % 0.80 [ 0.30, 2.13 ]
Thorpe 1994 1/8 6/9 0.2 % 0.19 [ 0.03, 1.24 ]
Vedrinne 1992 14/30 23/30 1.2 % 0.61 [ 0.40, 0.94 ]
Wei 2006 6/36 8/40 0.5 % 0.83 [ 0.32, 2.17 ]
Subtotal (95% CI) 4233 3256 56.5 % 0.69 [ 0.64, 0.75 ]
Total events: 1866 (Aprotinin), 2105 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 179.31, df = 62 (P<0.00001); I2 =65%
Test for overall effect: Z = 9.14 (P < 0.00001)
3 Allocation concealment - No
Alajmo 1989 9/22 8/12 0.9 % 0.61 [ 0.32, 1.17 ]
Alvarez 1995 5/49 7/51 0.5 % 0.74 [ 0.25, 2.19 ]
Amar 2003 11/23 13/24 1.0 % 0.88 [ 0.50, 1.55 ]
Baele 1992 35/58 45/57 1.4 % 0.76 [ 0.60, 0.98 ]
Casas 1995 12/47 29/51 1.0 % 0.45 [ 0.26, 0.77 ]
Diprose 2005 8/60 27/60 0.8 % 0.30 [ 0.15, 0.60 ]
Havel 1992 3/10 7/10 0.5 % 0.43 [ 0.15, 1.20 ]
Kuitunen 2005 11/20 12/20 1.0 % 0.92 [ 0.54, 1.56 ]
Later 2009 48/96 73/103 1.4 % 0.71 [ 0.56, 0.89 ]
Royston 1987 4/11 11/11 0.7 % 0.39 [ 0.19, 0.82 ]
Samama 2002 12/40 11/18 0.9 % 0.49 [ 0.27, 0.89 ]
Van der Linden 2005 17/37 27/38 1.2 % 0.65 [ 0.43, 0.97 ]
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Study or subgroup Aprotinin Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 473 455 11.2 % 0.63 [ 0.54, 0.75 ]
Total events: 175 (Aprotinin), 270 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 15.50, df = 11 (P = 0.16); I2 =29%
Test for overall effect: Z = 5.22 (P < 0.00001)
Total (95% CI) 6259 4913 100.0 % 0.66 [ 0.60, 0.72 ]
Total events: 2695 (Aprotinin), 3067 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 961.52, df = 107 (P<0.00001); I2 =89%
Test for overall effect: Z = 9.54 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 1.7. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 7 Units of
Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 7 Units of Allogeneic Blood Transfused - Transfused Patients
Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alderman 1998 152 0.99 (1.67) 213 1.92 (2.63) -0.93 [ -1.37, -0.49 ]
Basora 1999 23 2.11 (1.75) 20 2.4 (1.18) -0.29 [ -1.17, 0.59 ]
Bidstrup 1990 15 1.39 (0.52) 16 3.04 (1.98) -1.65 [ -2.66, -0.64 ]
Bidstrup 2000 13 3 (1.74) 23 2.86 (2.08) 0.14 [ -1.13, 1.41 ]
Blauhut 1994 3 1.67 (0.58) 9 2.44 (1.13) -0.77 [ -1.76, 0.22 ]
Carrera 1994 42 4.25 (1.45) 50 5.51 (2.93) -1.26 [ -2.18, -0.34 ]
Casas 1995 12 2.54 (1.81) 29 3.25 (1.96) -0.71 [ -1.96, 0.54 ]
Colwell 2007 20 1.6 (0.5) 39 1.95 (0.89) -0.35 [ -0.71, 0.01 ]
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Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Corbeau 1995 15 2.29 (1.49) 12 2.83 (1.45) -0.54 [ -1.65, 0.57 ]
Cosgrove 1992 55 7.07 (11.64) 44 5.22 (6.57) 1.85 [ -1.79, 5.49 ]
D’Ambra 1996 73 3.39 (3.58) 31 2.68 (4.2) 0.71 [ -0.98, 2.40 ]
Dietrich 1990 7 1.47 (1.26) 15 3.72 (3.21) -2.25 [ -4.12, -0.38 ]
Dietrich 1992 549 5.16 (6.17) 730 8.05 (7.67) -2.89 [ -3.65, -2.13 ]
Dietrich 1995 12 2.75 (1.86) 15 6.53 (4.66) -3.78 [ -6.36, -1.20 ]
Dignan 2001 37 2.18 (1.77) 58 2.51 (1.3) -0.33 [ -0.99, 0.33 ]
Diprose 2005 8 2.1 (1.42) 27 3.73 (4.47) -1.63 [ -3.58, 0.32 ]
Engel 2001 5 1.4 (0.55) 3 2 (0) 0.0 [ 0.0, 0.0 ]
Fraedrich 1989 16 1.92 (1.13) 26 4.56 (2.2) -2.64 [ -3.65, -1.63 ]
Harder 1991 30 2 (1.05) 29 2.21 (0.91) -0.21 [ -0.71, 0.29 ]
Hardy 1993 17 3.88 (2.58) 16 3.09 (2.18) 0.79 [ -0.84, 2.42 ]
Jeserschek 2003 7 3.71 (1.5) 8 5.25 (2.76) -1.54 [ -3.75, 0.67 ]
Katzel 1998 1 1 (0) 6 2.67 (1.03) 0.0 [ 0.0, 0.0 ]
Klein 1998 4 3 (2) 6 2.67 (2.16) 0.33 [ -2.28, 2.94 ]
Lemmer 1996 173 2.45 (0.82) 87 3.25 (2.56) -0.80 [ -1.35, -0.25 ]
Lemmer˙1 1994 28 2.91 (3.54) 35 4.02 (1.95) -1.11 [ -2.57, 0.35 ]
Lemmer˙2 1994 7 1.31 (7.26) 23 4.59 (3.99) -3.28 [ -8.90, 2.34 ]
Levy 1995 109 2 (2.15) 49 3.4 (4.03) -1.40 [ -2.60, -0.20 ]
Li 2005 5 0.35 (0.59) 8 1.14 (0.39) -0.79 [ -1.37, -0.21 ]
Mohr 1992 23 2.09 (1.02) 15 3.44 (1.97) -1.35 [ -2.43, -0.27 ]
Murkin 1994 16 3.4 (2.4) 22 5.3 (2.81) -1.90 [ -3.56, -0.24 ]
Murkin 1995 18 2 (0.85) 17 2.9 (1.65) -0.90 [ -1.78, -0.02 ]
Parvizi 2007 55 2.56 (0.27) 61 4.34 (0.37) -1.78 [ -1.90, -1.66 ]
Petsatodis 2006 17 2.29 (0.99) 25 3.8 (1.66) -1.51 [ -2.31, -0.71 ]
Speekenbrink 1995 12 2.91 (1.94) 11 4.27 (3.15) -1.36 [ -3.52, 0.80 ]
Speekenbrink 1996 55 1.64 (1.13) 29 1.91 (2.57) -0.27 [ -1.25, 0.71 ]
Stewart 2001 1 2 (0) 9 2.33 (1.12) 0.0 [ 0.0, 0.0 ]
Tabuchi 1994 10 2.66 (1.53) 12 3.26 (1.66) -0.60 [ -1.93, 0.73 ]
Tassani 2000 4 1.5 (1.58) 5 1.2 (1.9) 0.30 [ -1.97, 2.57 ]
Van der Linden 2005 17 2.61 (1.07) 27 3.94 (3.15) -1.33 [ -2.62, -0.04 ]
-10 -5 0 5 10
Favours aprotinin Favours control
(Continued . . . )
277Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vedrinne 1992 14 1.78 (0.53) 23 2.43 (1.02) -0.65 [ -1.15, -0.15 ]
Total (95% CI) 1680 1883 -0.98 [ -1.29, -0.66 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 197.82, df = 36 (P<0.00001); I2 =82%
Test for overall effect: Z = 6.15 (P < 0.00001)
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Analysis 1.8. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 8 Units of
Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 8 Units of Allogeneic Blood Transfused - All Patients
Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Alajmo 1989 22 0.71 (1.33) 11 1.36 (1.62) -0.65 [ -1.76, 0.46 ]
Alvarez 2001 26 1 (1.8) 29 1.9 (2) -0.90 [ -1.90, 0.10 ]
Amar 2003 23 1.8 (1.5) 24 1.8 (2.5) 0.0 [ -1.17, 1.17 ]
Apostolakis 2008 29 0 (0) 30 0.03 (0.183) 0.0 [ 0.0, 0.0 ]
Basora 1999 23 2.11 (1.75) 212 2.29 (1.26) -0.18 [ -0.92, 0.56 ]
Bert 2008 25 0.44 (0.77) 25 1.3 (1.34) -0.86 [ -1.47, -0.25 ]
Bidstrup 1990 26 0.8 (0.8) 18 2.7 (2.1) -1.90 [ -2.92, -0.88 ]
Bidstrup 2000 30 1.3 (1.88) 30 2.19 (2.19) -0.89 [ -1.92, 0.14 ]
Blauhut 1994 14 0.36 (0.74) 14 1.57 (1.5) -1.21 [ -2.09, -0.33 ]
Carrera 1994 51 3.5 (2.1) 51 5.4 (3) -1.90 [ -2.91, -0.89 ]
Cicek 1996a 50 1.25 (1.22) 25 2.55 (1.09) -1.30 [ -1.84, -0.76 ]
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Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cicek 1996b 29 0.45 (0.5) 28 1.7 (0.9) -1.25 [ -1.63, -0.87 ]
Cicekcioglu 2006 24 0.91 (0.75) 20 0.91 (0.76) 0.0 [ -0.45, 0.45 ]
Colwell 2007 175 0.18 (0.52) 177 0.43 (0.91) -0.25 [ -0.40, -0.10 ]
Corbeau 1995 43 0.8 (1.4) 20 1.7 (1.8) -0.90 [ -1.79, -0.01 ]
Cosgrove 1992 113 3.44 (8.83) 56 4.1 (6.2) -0.66 [ -2.96, 1.64 ]
Cvachovec 2001 20 1.58 (0.32) 22 1.63 (0.67) -0.05 [ -0.36, 0.26 ]
D’Ambra 1996 127 1.95 (3.19) 64 1.3 (3.2) 0.65 [ -0.31, 1.61 ]
Defraigne 2000 100 2.13 (2.57) 100 3.01 (3.28) -0.88 [ -1.70, -0.06 ]
Desai 2009 38 0.39 (0.64) 37 0.66 (0.78) -0.27 [ -0.59, 0.05 ]
Dietrich 1990 19 0.54 (1.03) 20 2.79 (3.21) -2.25 [ -3.73, -0.77 ]
Dietrich 1992 902 3.14 (5.43) 882 6.66 (7.61) -3.52 [ -4.13, -2.91 ]
Dietrich 1995 15 2.2 (2.01) 15 6.5 (4.66) -4.30 [ -6.87, -1.73 ]
Dignan 2001 101 0.8 (1.5) 99 1.47 (1.59) -0.67 [ -1.10, -0.24 ]
Diprose 2005 60 0.28 (0.87) 60 1.68 (3.51) -1.40 [ -2.32, -0.48 ]
Ehrlich 1998 25 1.2 (2) 25 3.5 (3) -2.30 [ -3.71, -0.89 ]
Fauli 2005 40 1.55 (1.4) 20 3.2 (3.2) -1.65 [ -3.12, -0.18 ]
Fraedrich 1989 38 0.81 (1.2) 38 3.12 (2.81) -2.31 [ -3.28, -1.34 ]
Garcia-Enguita 1998 15 2.3 (2.1) 15 4.2 (1.9) -1.90 [ -3.33, -0.47 ]
Garcia-Huete 1997 39 13 (8) 41 14.4 (9.7) -1.40 [ -5.29, 2.49 ]
Golanski 2000 29 1.7 (1.5) 24 2.9 (1) -1.20 [ -1.88, -0.52 ]
Greilich 2009 26 2.5 (2.7) 27 1.8 (2) 0.70 [ -0.58, 1.98 ]
Harder 1991 40 1.5 (1.26) 40 1.6 (1.26) -0.10 [ -0.65, 0.45 ]
Hardy 1993 22 3 (2.8) 19 2.6 (2.3) 0.40 [ -1.16, 1.96 ]
Hayashida 1997 110 2.85 (2.22) 57 4.3 (2.26) -1.45 [ -2.17, -0.73 ]
Hayes 1996 20 1.1 (0.9) 20 1.2 (1.2) -0.10 [ -0.76, 0.56 ]
Hei 2005 20 2.94 (1.72) 20 7.04 (5.28) -4.10 [ -6.53, -1.67 ]
Hendrice 1995 12 0 (0) 14 1.35 (0.33) 0.0 [ 0.0, 0.0 ]
Hill 1998 10 1.1 (0.47) 10 2.8 (0.66) -1.70 [ -2.20, -1.20 ]
Janssens 1994 20 1.8 (1.24) 20 3.4 (1.31) -1.60 [ -2.39, -0.81 ]
Kahveci 1996 14 0.28 (0.45) 14 0.42 (0.64) -0.14 [ -0.55, 0.27 ]
Kalangos 1994 110 2.87 (0.88) 55 4.3 (1.5) -1.43 [ -1.86, -1.00 ]
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Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Katzel 1998 12 1 (0) 12 1.3 (1.56) 0.0 [ 0.0, 0.0 ]
Koster 2004 100 0.1 (0.05) 100 0.2 (0.1) -0.10 [ -0.12, -0.08 ]
Kuepper 2003 60 2.1 (1.7) 59 3.3 (3.3) -1.20 [ -2.15, -0.25 ]
Kunt 2005 40 1.2 (0.52) 46 3.33 (1.13) -2.13 [ -2.49, -1.77 ]
Laub 1994 16 0.42 (0.68) 16 0.99 (1.47) -0.57 [ -1.36, 0.22 ]
Lavee 1993 15 2.1 (1.1) 15 3.6 (1.8) -1.50 [ -2.57, -0.43 ]
Leijdekkers 2006 16 0.44 (0.7) 19 2 (7.9) -1.56 [ -5.13, 2.01 ]
Lemmer 1996 487 0.87 (1.27) 157 1.8 (2.5) -0.93 [ -1.34, -0.52 ]
Lemmer˙1 1994 74 1.1 (2.58) 67 2.1 (2.46) -1.00 [ -1.83, -0.17 ]
Lemmer˙2 1994 23 0.4 (3.84) 32 3.3 (3.96) -2.90 [ -4.98, -0.82 ]
Maccario 1994 61 0.17 (0.56) 32 0.5 (1.14) -0.33 [ -0.75, 0.09 ]
Marcel 1996 21 2.1 (2) 23 3 (4.4) -0.90 [ -2.89, 1.09 ]
Mohr 1992 34 1.41 (1.21) 16 3.44 (1.97) -2.03 [ -3.08, -0.98 ]
Murkin 1994 29 1.9 (3.23) 25 4.7 (3) -2.80 [ -4.46, -1.14 ]
Nuro¨zler 2008 25 1.7 (1.4) 26 2.9 (1.8) -1.20 [ -2.08, -0.32 ]
Okita 1996 39 11.64 (9.07) 21 12.27 (8.5) -0.63 [ -5.25, 3.99 ]
Parvizi 2007 81 2.56 (0.27) 81 4.34 (0.37) -1.78 [ -1.88, -1.68 ]
Poston 2006 29 1.8 (2.1) 31 2.3 (2) -0.50 [ -1.54, 0.54 ]
Prendergast˙1 1996 18 0.2 (0.5) 20 0.5 (1.1) -0.30 [ -0.83, 0.23 ]
Prendergast˙2 1996 16 1.3 (1.2) 16 2.2 (2.1) -0.90 [ -2.09, 0.29 ]
Rhydderch 1993 20 2 (1.7) 23 3.3 (2.3) -1.30 [ -2.50, -0.10 ]
Schmartz 2003 40 1.62 (0.68) 20 2.21 (0.91) -0.59 [ -1.04, -0.14 ]
Schweizer 2000 26 1.4 (0.7) 28 2.6 (1.4) -1.20 [ -1.78, -0.62 ]
Speekenbrink 1995 15 2.33 (2.1) 15 3.13 (3.3) -0.80 [ -2.78, 1.18 ]
Speekenbrink 1996 75 1.2 (1.21) 37 1.5 (2.4) -0.30 [ -1.12, 0.52 ]
Stammers 1997 8 0.58 (1.19) 12 2.27 (1.67) -1.69 [ -2.94, -0.44 ]
Tabuchi 1994 19 1.4 (1.74) 17 2.3 (2.06) -0.90 [ -2.15, 0.35 ]
Turkoz 2001 10 1.9 (0.5) 10 2 (0.9) -0.10 [ -0.74, 0.54 ]
Utada 1997 11 3.2 (1.4) 10 2.8 (1.4) 0.40 [ -0.80, 1.60 ]
Van der Linden 2005 37 1.2 (1.5) 38 2.8 (3.2) -1.60 [ -2.73, -0.47 ]
Vedrinne 1992 30 0.83 (0.97) 30 1.86 (1.37) -1.03 [ -1.63, -0.43 ]
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Study or subgroup Aprotinin Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wei 2006 36 1.67 (0.56) 40 1.33 (0) 0.0 [ 0.0, 0.0 ]
Total (95% CI) 4198 3622 -1.02 [ -1.26, -0.79 ]
Heterogeneity: Tau2 = 0.77; Chi2 = 1627.35, df = 69 (P<0.00001); I2 =96%
Test for overall effect: Z = 8.41 (P < 0.00001)
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Analysis 1.9. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 9 Blood
loss - Intra-operative.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 9 Blood loss - Intra-operative
Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Desai 2009 38 794 (465) 37 1034 (659) 6.7 % -240.00 [ -498.74, 18.74 ]
Dietrich 1990 19 363 (159) 20 636 (322) 10.4 % -273.00 [ -431.20, -114.80 ]
Fauli 2005 40 958.5 (385.12) 20 829 (421) 8.0 % 129.50 [ -90.24, 349.24 ]
Harmon 2004 17 568 (355) 18 840 (296) 8.1 % -272.00 [ -489.20, -54.80 ]
Hendrice 1995 12 225 (121) 14 401 (207) 11.8 % -176.00 [ -304.24, -47.76 ]
Koster 2004 100 261 (107) 100 355 (127) 15.3 % -94.00 [ -126.55, -61.45 ]
Leijdekkers 2006 16 2362 (1340) 19 2466 (1370) 0.9 % -104.00 [ -1004.32, 796.32 ]
Subtotal (95% CI) 242 228 61.1 % -148.18 [ -240.21, -56.14 ]
Heterogeneity: Tau2 = 6875.87; Chi2 = 13.63, df = 6 (P = 0.03); I2 =56%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Orthopaedic surgery
Amar 2003 23 1200 (1000) 24 1000 (900) 2.3 % 200.00 [ -344.67, 744.67 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hayes 1996 20 725 (150) 20 768 (235) 12.0 % -43.00 [ -165.18, 79.18 ]
Janssens 1994 20 793 (332) 20 1113 (494) 6.6 % -320.00 [ -580.85, -59.15 ]
Murkin 1995 29 996 (436.2) 24 1318 (710.35) 5.0 % -322.00 [ -647.53, 3.53 ]
Utada 1997 11 1573 (462) 10 1760 (623) 2.9 % -187.00 [ -659.90, 285.90 ]
Subtotal (95% CI) 103 98 28.8 % -151.05 [ -317.63, 15.52 ]
Heterogeneity: Tau2 = 13580.14; Chi2 = 6.62, df = 4 (P = 0.16); I2 =40%
Test for overall effect: Z = 1.78 (P = 0.076)
3 Thoracic surgery
Katzel 1998 12 324 (159) 12 856 (563) 4.9 % -532.00 [ -863.00, -201.00 ]
Norman 2009 8 769 (630.4) 8 1832 (1436.39) 0.6 % -1063.00 [ -2149.99, 23.99 ]
Subtotal (95% CI) 20 20 5.5 % -577.06 [ -893.71, -260.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 3.57 (P = 0.00035)
4 Liver surgery
Hei 2005 20 3107 (1281) 20 5342 (3013) 0.4 % -2235.00 [ -3669.87, -800.13 ]
Lentschener 1997 48 1217 (966) 49 1653 (1221) 3.2 % -436.00 [ -873.67, 1.67 ]
Subtotal (95% CI) 68 69 3.6 % -1200.40 [ -2943.39, 542.59 ]
Heterogeneity: Tau2 = 1325289.21; Chi2 = 5.52, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.35 (P = 0.18)
5 Vascular surgery
Leijdekkers 2006 16 2362 (1340) 19 2466 (1370) 0.9 % -104.00 [ -1004.32, 796.32 ]
Subtotal (95% CI) 16 19 0.9 % -104.00 [ -1004.32, 796.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
Total (95% CI) 449 434 100.0 % -191.87 [ -280.45, -103.28 ]
Heterogeneity: Tau2 = 13085.01; Chi2 = 40.04, df = 16 (P = 0.00077); I2 =60%
Test for overall effect: Z = 4.24 (P = 0.000022)
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Analysis 1.10. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 10
Blood loss - Post-operative.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 10 Blood loss - Post-operative
Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Alajmo 1989 22 486 (220) 11 830 (405) 0.9 % -344.00 [ -600.38, -87.62 ]
Alvarez 2001 26 890 (430) 29 1340 (560) 0.9 % -450.00 [ -712.41, -187.59 ]
Asimakopoulos 2000 8 371 (62) 10 848 (126) 1.6 % -477.00 [ -566.13, -387.87 ]
Baele 1992 58 699 (429) 57 1198 (1124) 0.8 % -499.00 [ -810.98, -187.02 ]
Basora 1999 36 498.15 (372.58) 21 863.1 (755.5) 0.7 % -364.95 [ -710.24, -19.66 ]
Bidstrup 1989 40 309 (133) 37 573 (166) 1.6 % -264.00 [ -331.53, -196.47 ]
Bidstrup 1990 26 352 (138) 18 1393 (979) 0.5 % -1041.00 [ -1496.37, -585.63 ]
Bidstrup 2000 30 368.7 (164.3) 30 837.3 (404.9) 1.3 % -468.60 [ -624.96, -312.24 ]
Blauhut 1994 14 269 (142.18) 14 453 (192.56) 1.4 % -184.00 [ -309.38, -58.62 ]
Boldt 1991 10 260 (160) 10 390 (230) 1.2 % -130.00 [ -303.65, 43.65 ]
Boldt 1994 20 465 (195) 20 515 (155) 1.5 % -50.00 [ -159.17, 59.17 ]
Carrera 1994 51 431.8 (343) 51 895.2 (568) 1.2 % -463.40 [ -645.51, -281.29 ]
Cicek 1996a 50 265 (165.68) 25 411 (151) 1.6 % -146.00 [ -220.92, -71.08 ]
Cicek 1996b 29 410.5 (174.8) 28 696.2 (247.7) 1.5 % -285.70 [ -397.35, -174.05 ]
Cicekcioglu 2006 24 547.8 (170.6) 20 660.6 (213.4) 1.5 % -112.80 [ -228.58, 2.98 ]
Cohen 1998 56 780 (262) 59 1497 (360) 1.5 % -717.00 [ -831.66, -602.34 ]
Corbeau 1995 43 834 (448) 20 1416 (559) 0.9 % -582.00 [ -861.19, -302.81 ]
Cosgrove 1992 113 792.35 (1269.74) 56 1121 (683) 0.8 % -328.65 [ -623.28, -34.02 ]
Defraigne 2000 100 587 (328.82) 100 1060.5 (503.84) 1.5 % -473.50 [ -591.42, -355.58 ]
Deleuze 1991 30 380 (125) 30 852 (522) 1.2 % -472.00 [ -664.07, -279.93 ]
Desai 2009 38 603 (330) 37 810 (415) 1.3 % -207.00 [ -376.97, -37.03 ]
Dietrich 1990 19 738 (411) 20 1431 (760) 0.6 % -693.00 [ -1073.91, -312.09 ]
Dietrich 1992 902 678 (419) 882 1037 (671) 1.6 % -359.00 [ -411.04, -306.96 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dietrich 1995 15 597 (312.4) 15 1496 (785.51) 0.5 % -899.00 [ -1326.80, -471.20 ]
Dignan 2001 99 455 (298.5) 99 689 (298.5) 1.6 % -234.00 [ -317.16, -150.84 ]
Englberger 2002b 15 850 (231) 14 1227 (582) 0.7 % -377.00 [ -703.51, -50.49 ]
Fauli 2005 40 526 (675.83) 20 1157 (783) 0.6 % -631.00 [ -1033.02, -228.98 ]
Feindt 1994 10 279 (29) 10 664 (108) 1.6 % -385.00 [ -454.31, -315.69 ]
Fraedrich 1989 38 652 (382) 38 1204 (705) 1.0 % -552.00 [ -806.94, -297.06 ]
Gherli 1992 18 280 (145.09) 13 660 (185) 1.4 % -380.00 [ -500.86, -259.14 ]
Golanski 2000 29 660 (221) 24 1215 (587) 1.0 % -555.00 [ -803.24, -306.76 ]
Greilich 2009 26 685 (505) 27 1002 (627) 0.8 % -317.00 [ -622.96, -11.04 ]
Hardy 1993 22 565 (589) 19 631 (423) 0.8 % -66.00 [ -377.05, 245.05 ]
Harmon 2004 17 520 (287) 18 769 (303) 1.2 % -249.00 [ -444.46, -53.54 ]
Hayashida 1997 110 391.5 (167.32) 57 535 (294.44) 1.6 % -143.50 [ -226.09, -60.91 ]
Hendrice 1995 12 328 (84) 14 699 (261) 1.4 % -371.00 [ -515.74, -226.26 ]
Kalangos 1994 110 752 (159.15) 55 1378 (375) 1.5 % -626.00 [ -729.47, -522.53 ]
Kipfer 2003 15 964 (355) 15 1193 (526) 0.8 % -229.00 [ -550.14, 92.14 ]
Klein 1998 36 597 (266) 29 772 (299) 1.4 % -175.00 [ -314.26, -35.74 ]
Koster 2004 100 564 (425) 100 744 (497) 1.4 % -180.00 [ -308.17, -51.83 ]
Kuepper 2003 60 608 (336) 59 1115 (1106) 0.8 % -507.00 [ -801.74, -212.26 ]
Kuitunen 2005 20 540 (259.4) 20 995 (281.7) 1.3 % -455.00 [ -622.83, -287.17 ]
Kunt 2005 40 188 (51.5) 46 818 (243.8) 1.6 % -630.00 [ -702.24, -557.76 ]
Laub 1994 16 722 (304) 16 1540 (800) 0.5 % -818.00 [ -1237.34, -398.66 ]
Lavee 1993 15 487 (121) 15 752 (404) 1.1 % -265.00 [ -478.42, -51.58 ]
Lemmer 1996 487 831.52 (650.03) 157 1286 (651.56) 1.5 % -454.48 [ -571.61, -337.35 ]
Lemmer˙1 1994 74 855 (671) 67 1503 (671.2) 1.1 % -648.00 [ -869.82, -426.18 ]
Lemmer˙2 1994 23 1225 (1563.44) 32 1979 (1600.88) 0.2 % -754.00 [ -1600.11, 92.11 ]
Levy 1995 188 1132.02 (1083.18) 65 1700 (1128.72) 0.8 % -567.98 [ -883.05, -252.91 ]
Li 2005 40 304.3 (105.64) 30 610.67 (193.37) 1.6 % -306.37 [ -382.92, -229.82 ]
Locatelli 1990 25 323.55 (136.42) 13 524.6 (147.47) 1.5 % -201.05 [ -297.41, -104.69 ]
Maccario 1994 61 387.21 (169.4) 32 621 (255.87) 1.5 % -233.79 [ -332.11, -135.47 ]
Menichetti 1996 24 298 (140) 24 811 (600) 1.0 % -513.00 [ -759.49, -266.51 ]
Misfeld 1998 14 290 (110) 14 760 (320) 1.2 % -470.00 [ -647.25, -292.75 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mohr 1992 34 442 (129.14) 16 780 (408) 1.1 % -338.00 [ -542.57, -133.43 ]
Moran 2000 24 162 (123.17) 14 450 (224) 1.4 % -288.00 [ -415.26, -160.74 ]
Murkin 1994 29 1409.7 (1251.51) 25 2765.8 (1240) 0.3 % -1356.10 [ -2022.24, -689.96 ]
Nuro¨zler 2008 25 423 (178) 26 748 (212) 1.5 % -325.00 [ -432.28, -217.72 ]
Parvizi 2007 81 555 (56) 81 805 (76) 1.7 % -250.00 [ -270.56, -229.44 ]
Penta de Peppo 1995 15 344 (106) 15 724 (280) 1.3 % -380.00 [ -531.51, -228.49 ]
Prendergast˙1 1996 18 510 (105) 20 550 (124) 1.6 % -40.00 [ -112.84, 32.84 ]
Prendergast˙2 1996 16 526 (95) 16 894 (120) 1.6 % -368.00 [ -442.99, -293.01 ]
Rodrigus 1996 45 1051 (944) 46 1933 (1189) 0.5 % -882.00 [ -1322.60, -441.40 ]
Rossi 1997 21 446 (155) 22 573 (304) 1.4 % -127.00 [ -270.29, 16.29 ]
Royston 1987 11 286 (159.2) 11 1509 (1286.85) 0.2 % -1223.00 [ -1989.26, -456.74 ]
Santamaria 2000 56 558 (301.64) 28 772 (336.1) 1.3 % -214.00 [ -361.44, -66.56 ]
Schweizer 2000 26 775 (314) 28 1185 (403) 1.2 % -410.00 [ -601.96, -218.04 ]
Speekenbrink 1995 15 270 (174) 15 674 (411) 1.1 % -404.00 [ -629.86, -178.14 ]
Speekenbrink 1996 75 581.95 (381.94) 37 1068 (1047) 0.7 % -486.05 [ -834.31, -137.79 ]
Stammers 1997 8 435.1 (169.6) 12 944 (585.1) 0.7 % -508.90 [ -860.19, -157.61 ]
Tabuchi 1994 19 416 (67) 17 841 (156) 1.6 % -425.00 [ -505.04, -344.96 ]
Tassani 2000 10 648 (202.4) 10 1284 (578.7) 0.6 % -636.00 [ -1015.98, -256.02 ]
Turkoz 2001 10 510 (139.14) 10 680 (183.41) 1.4 % -170.00 [ -312.69, -27.31 ]
Vedrinne 1992 30 328 (153.36) 30 834 (372.45) 1.4 % -506.00 [ -650.13, -361.87 ]
Wendel 1995 20 878.9 (438) 18 1353.6 (746.5) 0.6 % -474.70 [ -869.38, -80.02 ]
Subtotal (95% CI) 4132 3239 85.5 % -369.62 [ -408.95, -330.29 ]
Heterogeneity: Tau2 = 19799.20; Chi2 = 513.91, df = 74 (P<0.00001); I2 =86%
Test for overall effect: Z = 18.42 (P < 0.00001)
2 Orthopaedic surgery
Cvachovec 2001 20 379 (162) 22 505 (251) 1.4 % -126.00 [ -252.65, 0.65 ]
Hayes 1996 20 432 (270) 20 432 (162) 1.4 % 0.0 [ -138.00, 138.00 ]
Janssens 1994 20 653 (306) 20 830 (334) 1.2 % -177.00 [ -375.52, 21.52 ]
Lentschener 1999 35 812 (411) 37 1295 (719) 0.9 % -483.00 [ -751.72, -214.28 ]
Murkin 1995 29 502 (333.88) 24 778 (578.08) 0.9 % -276.00 [ -537.26, -14.74 ]
Petsatodis 2006 25 451.2 (161.9) 25 434 (169.7) 1.5 % 17.20 [ -74.74, 109.14 ]
Utada 1997 11 412 (243) 10 387 (242) 1.1 % 25.00 [ -182.65, 232.65 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 160 158 8.5 % -113.58 [ -223.69, -3.46 ]
Heterogeneity: Tau2 = 13702.50; Chi2 = 18.56, df = 6 (P = 0.005); I2 =68%
Test for overall effect: Z = 2.02 (P = 0.043)
3 Thoracic surgery
Apostolakis 2008 29 412.6 (199.2) 30 764.3 (213.9) 1.5 % -351.70 [ -457.13, -246.27 ]
Katzel 1998 12 402 (236) 12 843 (563) 0.7 % -441.00 [ -786.40, -95.60 ]
Subtotal (95% CI) 41 42 2.2 % -359.31 [ -460.15, -258.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 6.98 (P < 0.00001)
4 Orthognathic surgery
Stewart 2001 15 473 (190) 15 986 (356) 1.1 % -513.00 [ -717.21, -308.79 ]
Subtotal (95% CI) 15 15 1.1 % -513.00 [ -717.21, -308.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.92 (P < 0.00001)
5 Liver surgery
Marcel 1996 21 748 (120) 23 853 (179) 1.6 % -105.00 [ -194.36, -15.64 ]
Subtotal (95% CI) 21 23 1.6 % -105.00 [ -194.36, -15.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
6 Vascular surgery
Ehrlich 1998 25 717 (340) 25 920 (387) 1.1 % -203.00 [ -404.93, -1.07 ]
Subtotal (95% CI) 25 25 1.1 % -203.00 [ -404.93, -1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.97 (P = 0.049)
Total (95% CI) 4394 3502 100.0 % -345.88 [ -383.47, -308.29 ]
Heterogeneity: Tau2 = 21627.05; Chi2 = 620.49, df = 86 (P<0.00001); I2 =86%
Test for overall effect: Z = 18.03 (P < 0.00001)
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Analysis 1.11. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 11
Blood loss - Post-operative - Dose (Cardiac Surgery).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 11 Blood loss - Post-operative - Dose (Cardiac Surgery)
Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Prime Dose
Englberger 2002b 15 850 (231) 14 1227 (582) 0.7 % -377.00 [ -703.51, -50.49 ]
Fauli 2005 20 703 (894) 20 1157 (783) 0.4 % -454.00 [ -974.84, 66.84 ]
Hayashida 1997 55 415 (200.2) 57 535 (294.44) 1.5 % -120.00 [ -212.96, -27.04 ]
Kalangos 1994 55 784 (166) 55 1378 (375) 1.5 % -594.00 [ -702.38, -485.62 ]
Kipfer 2003 15 964 (355) 15 1193 (526) 0.7 % -229.00 [ -550.14, 92.14 ]
Kunt 2005 40 188 (51.5) 46 818 (243.8) 1.6 % -630.00 [ -702.24, -557.76 ]
Lavee 1993 15 487 (121) 15 752 (404) 1.1 % -265.00 [ -478.42, -51.58 ]
Lemmer 1996 159 899 (655.7) 157 1286 (651.56) 1.3 % -387.00 [ -531.13, -242.87 ]
Levy 1995 68 1420 (1088.5) 65 1700 (1128.72) 0.6 % -280.00 [ -657.13, 97.13 ]
Mohr 1992 17 487 (135) 16 780 (408) 1.1 % -293.00 [ -502.96, -83.04 ]
Rossi 1997 21 446 (155) 22 573 (304) 1.3 % -127.00 [ -270.29, 16.29 ]
Santamaria 2000 28 629 (338.8) 28 772 (336.1) 1.2 % -143.00 [ -319.77, 33.77 ]
Speekenbrink 1995 15 270 (174) 15 674 (411) 1.0 % -404.00 [ -629.86, -178.14 ]
Speekenbrink 1996 37 662 (467) 37 1068 (1047) 0.6 % -406.00 [ -775.40, -36.60 ]
Tabuchi 1994 19 416 (67) 17 841 (156) 1.6 % -425.00 [ -505.04, -344.96 ]
Subtotal (95% CI) 579 579 16.1 % -343.08 [ -458.13, -228.04 ]
Heterogeneity: Tau2 = 38644.59; Chi2 = 112.62, df = 14 (P<0.00001); I2 =88%
Test for overall effect: Z = 5.84 (P < 0.00001)
2 Low Dose
Alajmo 1989 22 486 (220) 11 830 (405) 0.9 % -344.00 [ -600.38, -87.62 ]
Alvarez 2001 26 890 (430) 29 1340 (560) 0.9 % -450.00 [ -712.41, -187.59 ]
Basora 1999 36 498.15 (372.58) 21 863.1 (755.5) 0.7 % -364.95 [ -710.24, -19.66 ]
Blauhut 1994 14 269 (142.18) 14 453 (192.56) 1.4 % -184.00 [ -309.38, -58.62 ]
Cicek 1996a 25 325 (237) 25 502 (178) 1.4 % -177.00 [ -293.19, -60.81 ]
Cicek 1996b 29 410.5 (174.8) 28 696.2 (247.7) 1.4 % -285.70 [ -397.35, -174.05 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cicekcioglu 2006 24 547.8 (170.6) 20 660.6 (213.4) 1.4 % -112.80 [ -228.58, 2.98 ]
Cosgrove 1992 56 866 (1636) 56 1121 (683) 0.4 % -255.00 [ -719.33, 209.33 ]
Dignan 2001 99 455 (298.5) 99 689 (298.5) 1.5 % -234.00 [ -317.16, -150.84 ]
Gherli 1992 9 270 (150) 13 660 (185) 1.3 % -390.00 [ -530.42, -249.58 ]
Golanski 2000 29 660 (221) 24 1215 (587) 0.9 % -555.00 [ -803.24, -306.76 ]
Hardy 1993 22 565 (589) 19 631 (423) 0.7 % -66.00 [ -377.05, 245.05 ]
Hayashida 1997 55 368 (126.1) 57 535 (294.44) 1.5 % -167.00 [ -250.39, -83.61 ]
Koster 2004 100 564 (425) 100 744 (497) 1.4 % -180.00 [ -308.17, -51.83 ]
Kuepper 2003 60 608 (336) 59 1115 (1106) 0.8 % -507.00 [ -801.74, -212.26 ]
Lemmer 1996 168 811 (661.04) 157 1286 (651.56) 1.3 % -475.00 [ -617.76, -332.24 ]
Levy 1995 59 1040 (1098.4) 65 1700 (1128.72) 0.6 % -660.00 [ -1052.23, -267.77 ]
Locatelli 1990 13 399.2 (170.2) 13 524.6 (147.47) 1.4 % -125.40 [ -247.82, -2.98 ]
Maccario 1994 29 372 (159) 32 621 (255.87) 1.5 % -249.00 [ -354.87, -143.13 ]
Misfeld 1998 14 290 (110) 14 760 (320) 1.2 % -470.00 [ -647.25, -292.75 ]
Moran 2000 12 182 (144) 14 450 (224) 1.3 % -268.00 [ -410.85, -125.15 ]
Nuro¨zler 2008 25 423 (178) 26 748 (212) 1.5 % -325.00 [ -432.28, -217.72 ]
Parvizi 2007 81 555 (56) 81 805 (76) 1.7 % -250.00 [ -270.56, -229.44 ]
Schweizer 2000 26 775 (314) 28 1185 (403) 1.1 % -410.00 [ -601.96, -218.04 ]
Subtotal (95% CI) 1033 1005 28.4 % -274.58 [ -316.48, -232.67 ]
Heterogeneity: Tau2 = 4792.81; Chi2 = 58.71, df = 23 (P = 0.00006); I2 =61%
Test for overall effect: Z = 12.84 (P < 0.00001)
3 High Dose
Asimakopoulos 2000 8 371 (62) 10 848 (126) 1.5 % -477.00 [ -566.13, -387.87 ]
Baele 1992 58 699 (429) 57 1198 (1124) 0.7 % -499.00 [ -810.98, -187.02 ]
Bidstrup 1989 40 309 (133) 37 573 (166) 1.6 % -264.00 [ -331.53, -196.47 ]
Bidstrup 1990 26 352 (138) 18 1393 (979) 0.5 % -1041.00 [ -1496.37, -585.63 ]
Bidstrup 2000 30 368.7 (164.3) 30 837.3 (404.9) 1.3 % -468.60 [ -624.96, -312.24 ]
Boldt 1991 10 260 (160) 10 390 (230) 1.2 % -130.00 [ -303.65, 43.65 ]
Boldt 1994 20 465 (195) 20 515 (155) 1.5 % -50.00 [ -159.17, 59.17 ]
Carrera 1994 51 431.8 (343) 51 895.2 (568) 1.2 % -463.40 [ -645.51, -281.29 ]
Cicek 1996a 25 295 (161) 25 502 (178) 1.5 % -207.00 [ -301.08, -112.92 ]
Cohen 1998 56 780 (262) 59 1497 (360) 1.4 % -717.00 [ -831.66, -602.34 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Corbeau 1995 43 834 (448) 20 1416 (559) 0.8 % -582.00 [ -861.19, -302.81 ]
Cosgrove 1992 57 720 (753) 56 1121 (683) 0.9 % -401.00 [ -665.98, -136.02 ]
Defraigne 2000 100 587 (328.82) 100 1060.5 (503.84) 1.4 % -473.50 [ -591.42, -355.58 ]
Deleuze 1991 30 380 (125) 30 852 (522) 1.1 % -472.00 [ -664.07, -279.93 ]
Desai 2009 38 603 (330) 37 810 (415) 1.2 % -207.00 [ -376.97, -37.03 ]
Dietrich 1990 19 738 (411) 20 1431 (760) 0.6 % -693.00 [ -1073.91, -312.09 ]
Dietrich 1992 902 678 (419) 882 1037 (671) 1.6 % -359.00 [ -411.04, -306.96 ]
Dietrich 1995 15 597 (312.4) 15 1496 (785.51) 0.5 % -899.00 [ -1326.80, -471.20 ]
Fauli 2005 20 349 (338) 20 1157 (783) 0.6 % -808.00 [ -1181.77, -434.23 ]
Feindt 1994 10 279 (29) 10 664 (108) 1.6 % -385.00 [ -454.31, -315.69 ]
Fraedrich 1989 38 652 (382) 38 1204 (705) 0.9 % -552.00 [ -806.94, -297.06 ]
Gherli 1992 9 290 (140) 13 660 (185) 1.4 % -370.00 [ -505.94, -234.06 ]
Greilich 2009 26 685 (505) 27 1002 (627) 0.8 % -317.00 [ -622.96, -11.04 ]
Harmon 2004 17 520 (287) 18 769 (303) 1.1 % -249.00 [ -444.46, -53.54 ]
Hendrice 1995 12 328 (84) 14 699 (261) 1.3 % -371.00 [ -515.74, -226.26 ]
Kalangos 1994 55 720 (152) 55 1378 (375) 1.5 % -658.00 [ -764.94, -551.06 ]
Klein 1998 36 597 (266) 29 772 (299) 1.3 % -175.00 [ -314.26, -35.74 ]
Kuitunen 2005 20 540 (259.4) 20 995 (281.7) 1.2 % -455.00 [ -622.83, -287.17 ]
Laub 1994 16 722 (304) 16 1540 (800) 0.5 % -818.00 [ -1237.34, -398.66 ]
Lemmer 1996 160 786 (632.46) 157 1286 (651.56) 1.3 % -500.00 [ -641.39, -358.61 ]
Lemmer˙1 1994 74 855 (671) 67 1503 (671.2) 1.0 % -648.00 [ -869.82, -426.18 ]
Lemmer˙2 1994 23 1225 (1563.44) 32 1979 (1600.88) 0.2 % -754.00 [ -1600.11, 92.11 ]
Levy 1995 61 900 (1062.19) 65 1700 (1128.72) 0.6 % -800.00 [ -1182.55, -417.45 ]
Li 2005 40 304.3 (105.64) 30 610.67 (193.37) 1.6 % -306.37 [ -382.92, -229.82 ]
Locatelli 1990 12 241.6 (98.7) 13 524.6 (147.47) 1.5 % -283.00 [ -380.70, -185.30 ]
Maccario 1994 32 401 (178.27) 32 621 (255.87) 1.5 % -220.00 [ -328.05, -111.95 ]
Menichetti 1996 24 298 (140) 24 811 (600) 0.9 % -513.00 [ -759.49, -266.51 ]
Mohr 1992 17 397 (123) 16 780 (408) 1.1 % -383.00 [ -591.29, -174.71 ]
Moran 2000 12 142 (98) 14 450 (224) 1.4 % -308.00 [ -437.78, -178.22 ]
Murkin 1994 29 1409.7 (1251.51) 25 2765.8 (1240) 0.2 % -1356.10 [ -2022.24, -689.96 ]
Penta de Peppo 1995 15 344 (106) 15 724 (280) 1.3 % -380.00 [ -531.51, -228.49 ]
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Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Prendergast˙1 1996 18 510 (105) 20 550 (124) 1.6 % -40.00 [ -112.84, 32.84 ]
Prendergast˙2 1996 16 526 (95) 16 894 (120) 1.6 % -368.00 [ -442.99, -293.01 ]
Rodrigus 1996 45 1051 (944) 46 1933 (1189) 0.5 % -882.00 [ -1322.60, -441.40 ]
Royston 1987 11 286 (159.2) 11 1509 (1286.85) 0.2 % -1223.00 [ -1989.26, -456.74 ]
Santamaria 2000 28 487 (259.2) 28 772 (336.1) 1.3 % -285.00 [ -442.21, -127.79 ]
Speekenbrink 1996 38 504 (275) 37 1068 (1047) 0.6 % -564.00 [ -912.51, -215.49 ]
Stammers 1997 8 435.1 (169.6) 12 944 (585.1) 0.6 % -508.90 [ -860.19, -157.61 ]
Tassani 2000 10 648 (202.4) 10 1284 (578.7) 0.6 % -636.00 [ -1015.98, -256.02 ]
Turkoz 2001 10 510 (139.14) 10 680 (183.41) 1.3 % -170.00 [ -312.69, -27.31 ]
Vedrinne 1992 30 328 (153.36) 30 834 (372.45) 1.3 % -506.00 [ -650.13, -361.87 ]
Wendel 1995 20 878.9 (438) 18 1353.6 (746.5) 0.6 % -474.70 [ -869.38, -80.02 ]
Subtotal (95% CI) 2520 2465 55.5 % -418.59 [ -470.96, -366.22 ]
Heterogeneity: Tau2 = 24914.32; Chi2 = 319.84, df = 51 (P<0.00001); I2 =84%
Test for overall effect: Z = 15.67 (P < 0.00001)
Total (95% CI) 4132 4049 100.0 % -367.69 [ -403.50, -331.87 ]
Heterogeneity: Tau2 = 19798.87; Chi2 = 578.67, df = 90 (P<0.00001); I2 =84%
Test for overall effect: Z = 20.12 (P < 0.00001)
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Analysis 1.12. Comparison 1 Aprotinin versus Control (Blood Transfusion & Blood Loss), Outcome 12
Blood loss - Total.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 1 Aprotinin versus Control (Blood Transfusion % Blood Loss)
Outcome: 12 Blood loss - Total
Study or subgroup Aprotinin Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Alderman 1998 401 664 (1009) 395 1168 (1022) 9.5 % -504.00 [ -645.11, -362.89 ]
Bert 2008 25 901.3 (514.6) 25 2132.2 (1487.5) 2.3 % -1230.90 [ -1847.90, -613.90 ]
Harder 1991 40 559 (689.38) 40 911 (1075.17) 4.3 % -352.00 [ -747.80, 43.80 ]
Harmon 2004 17 1158 (385) 18 1520 (614) 5.2 % -362.00 [ -699.57, -24.43 ]
Hendrice 1995 12 553 (168) 14 1100 (168) 9.8 % -547.00 [ -676.54, -417.46 ]
Isetta 1993 140 608 (717.62) 70 1000 (736) 7.9 % -392.00 [ -601.42, -182.58 ]
Parvizi 2007 81 555 (56) 81 805 (76) 11.5 % -250.00 [ -270.56, -229.44 ]
Subtotal (95% CI) 716 643 50.5 % -448.86 [ -612.82, -284.91 ]
Heterogeneity: Tau2 = 32951.29; Chi2 = 42.60, df = 6 (P<0.00001); I2 =86%
Test for overall effect: Z = 5.37 (P < 0.00001)
2 Orthopaedic surgery
Amar 2003 23 1700 (1000) 24 1600 (1400) 1.9 % 100.00 [ -593.35, 793.35 ]
D’Ambrosio 1999 30 715.6 (243.48) 30 965.35 (271.15) 9.8 % -249.75 [ -380.16, -119.34 ]
Garcia-Enguita 1998 15 1576 (452) 15 2021 (723) 3.9 % -445.00 [ -876.50, -13.50 ]
Hayes 1996 20 1186 (414) 20 1274 (347) 7.2 % -88.00 [ -324.74, 148.74 ]
Janssens 1994 20 1446 (514) 20 1943 (700) 4.6 % -497.00 [ -877.61, -116.39 ]
Jeserschek 2003 9 1771.3 (1153.2) 9 3604.4 (1393.4) 0.7 % -1833.10 [ -3014.77, -651.43 ]
Lentschener 1999 35 1935 (873) 37 2839 (993) 3.9 % -904.00 [ -1335.30, -472.70 ]
Llau 1998 10 817 (147) 10 1177 (325) 7.6 % -360.00 [ -581.08, -138.92 ]
Murkin 1995 29 1498 (592.37) 24 2096 (1092.47) 3.3 % -598.00 [ -1085.35, -110.65 ]
Petsatodis 2006 25 1073.2 (388.6) 25 1496.2 (545.1) 6.7 % -423.00 [ -685.41, -160.59 ]
Subtotal (95% CI) 216 214 49.5 % -399.09 [ -562.81, -235.37 ]
Heterogeneity: Tau2 = 34542.41; Chi2 = 22.67, df = 9 (P = 0.01); I2 =60%
Test for overall effect: Z = 4.78 (P < 0.00001)
Total (95% CI) 932 857 100.0 % -415.95 [ -520.38, -311.51 ]
Heterogeneity: Tau2 = 24649.74; Chi2 = 66.96, df = 16 (P<0.00001); I2 =76%
Test for overall effect: Z = 7.81 (P < 0.00001)
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Analysis 2.1. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 1
No. Exposed to Allogeneic Blood.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Tanaka 2001 47/73 26/26 0.65 [ 0.55, 0.78 ]
Karski 2005 24/147 41/165 0.66 [ 0.42, 1.03 ]
MacGillivray 2010 13/40 10/20 0.65 [ 0.35, 1.22 ]
Pleym 2003 7/40 8/39 0.85 [ 0.34, 2.13 ]
Mehr-Aein 2007 5/33 8/33 0.63 [ 0.23, 1.71 ]
Casati 2002 11/30 19/29 0.56 [ 0.33, 0.96 ]
Johansson 2005 8/47 23/53 0.39 [ 0.19, 0.79 ]
Benoni 2001 4/18 8/20 0.56 [ 0.20, 1.54 ]
Vanek 2005 3/32 6/30 0.47 [ 0.13, 1.71 ]
Casati 2004 9/52 13/50 0.67 [ 0.31, 1.42 ]
Jimenez 2007 9/24 19/26 0.51 [ 0.29, 0.90 ]
Casati 2001 2/20 4/20 0.50 [ 0.10, 2.43 ]
Wong 2008 23/73 30/74 0.78 [ 0.50, 1.20 ]
Shore-Lesserson 1996 10/17 12/13 0.64 [ 0.42, 0.98 ]
Katsaros 1996 11/104 27/106 0.42 [ 0.22, 0.79 ]
Niskanen 2005 5/19 8/20 0.66 [ 0.26, 1.66 ]
Husted 2003 2/20 7/20 0.29 [ 0.07, 1.21 ]
Benoni 2000 9/20 15/19 0.57 [ 0.33, 0.98 ]
Sadeghi 2007 12/32 20/35 0.66 [ 0.39, 1.12 ]
Benoni 1996 8/43 24/43 0.33 [ 0.17, 0.66 ]
Gill 2009 1/5 4/5 0.25 [ 0.04, 1.52 ]
0.002 0.1 1 10 500
Favours TXA Favours Control
(Continued . . . )
292Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lemay 2004 0/20 8/19 0.06 [ 0.00, 0.91 ]
Hardy 1998 28/42 27/44 1.09 [ 0.79, 1.49 ]
Orpen 2006 1/15 3/14 0.31 [ 0.04, 2.65 ]
Coffey 1995 9/16 8/14 0.98 [ 0.53, 1.84 ]
Mansour 2004 7/20 12/20 0.58 [ 0.29, 1.17 ]
Taghaddomi 2009 8/50 27/50 0.30 [ 0.15, 0.59 ]
Good 2003 3/27 14/24 0.19 [ 0.06, 0.58 ]
Penta de Peppo 1995 1/15 3/15 0.33 [ 0.04, 2.85 ]
Ellis 2001 1/10 7/10 0.14 [ 0.02, 0.96 ]
Claeys 2007 1/20 6/20 0.17 [ 0.02, 1.26 ]
Blauhut 1994 7/15 9/14 0.73 [ 0.37, 1.41 ]
Pinosky 1997 11/20 9/19 1.16 [ 0.63, 2.15 ]
Jares 2003 2/22 7/25 0.32 [ 0.08, 1.40 ]
Engel 2001 0/12 3/12 0.14 [ 0.01, 2.50 ]
Katoh 1997 7/62 10/31 0.35 [ 0.15, 0.83 ]
Armellin 2001 35/143 63/140 0.54 [ 0.39, 0.77 ]
Wei 2006 3/36 8/40 0.42 [ 0.12, 1.45 ]
Menichetti 1996 12/24 18/24 0.67 [ 0.42, 1.06 ]
Ekback 2000 1/20 1/20 1.00 [ 0.07, 14.90 ]
Garneti 2004 16/25 14/25 1.14 [ 0.72, 1.80 ]
Zohar 2004 3/20 12/20 0.25 [ 0.08, 0.75 ]
Corbeau 1995 15/41 12/20 0.61 [ 0.36, 1.05 ]
Jansen 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Isetta 1993 24/70 46/70 0.52 [ 0.36, 0.75 ]
Caglar 2008 15/50 10/50 1.50 [ 0.75, 3.01 ]
Speekenbrink 1995 13/15 11/15 1.18 [ 0.82, 1.70 ]
Veien 2002 0/15 2/15 0.20 [ 0.01, 3.85 ]
Kazemi 2010 4/32 11/32 0.36 [ 0.13, 1.02 ]
Sorin 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Brown 1997 18/60 20/30 0.45 [ 0.28, 0.71 ]
Pugh 1995 22/22 23/23 1.00 [ 0.92, 1.09 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kuitunen 2005 5/20 12/20 0.42 [ 0.18, 0.96 ]
Horrow 1995 37/121 7/27 1.18 [ 0.59, 2.36 ]
Dalmau 2000 29/42 37/40 0.75 [ 0.60, 0.93 ]
Hiipala 1995 10/15 12/13 0.72 [ 0.49, 1.07 ]
Murphy 2006 13/50 14/50 0.93 [ 0.49, 1.77 ]
Hiipala 1997 17/39 34/38 0.49 [ 0.34, 0.71 ]
Later 2009 57/99 73/103 0.81 [ 0.66, 1.00 ]
Horrow 1991 12/37 16/44 0.89 [ 0.49, 1.64 ]
Diprose 2005 20/60 27/60 0.74 [ 0.47, 1.17 ]
Santos 2006 7/29 12/31 0.62 [ 0.29, 1.36 ]
Andreasen 2004 6/20 5/17 1.02 [ 0.38, 2.76 ]
Wu 2006 0/106 17/108 0.03 [ 0.00, 0.48 ]
Yamasaki 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Total (95% CI) 2528 2314 0.61 [ 0.53, 0.70 ]
Total events: 707 (TXA), 1028 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 249.33, df = 63 (P<0.00001); I2 =75%
Test for overall effect: Z = 7.08 (P < 0.00001)
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Analysis 2.2. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 2
No. Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Andreasen 2004 6/20 5/17 1.02 [ 0.38, 2.76 ]
Armellin 2001 35/143 63/140 0.54 [ 0.39, 0.77 ]
Blauhut 1994 7/15 9/14 0.73 [ 0.37, 1.41 ]
Brown 1997 18/60 20/30 0.45 [ 0.28, 0.71 ]
Casati 2001 2/20 4/20 0.50 [ 0.10, 2.43 ]
Casati 2004 9/52 13/50 0.67 [ 0.31, 1.42 ]
Coffey 1995 9/16 8/14 0.98 [ 0.53, 1.84 ]
Corbeau 1995 15/41 12/20 0.61 [ 0.36, 1.05 ]
Diprose 2005 20/60 27/60 0.74 [ 0.47, 1.17 ]
Hardy 1998 28/42 27/44 1.09 [ 0.79, 1.49 ]
Horrow 1991 12/37 16/44 0.89 [ 0.49, 1.64 ]
Horrow 1995 37/121 7/27 1.18 [ 0.59, 2.36 ]
Isetta 1993 24/70 46/70 0.52 [ 0.36, 0.75 ]
Jares 2003 2/22 7/25 0.32 [ 0.08, 1.40 ]
Jimenez 2007 9/24 19/26 0.51 [ 0.29, 0.90 ]
Karski 2005 24/147 41/165 0.66 [ 0.42, 1.03 ]
Katoh 1997 7/62 10/31 0.35 [ 0.15, 0.83 ]
Katsaros 1996 11/104 27/106 0.42 [ 0.22, 0.79 ]
Kuitunen 2005 5/20 12/20 0.42 [ 0.18, 0.96 ]
Later 2009 57/99 73/103 0.81 [ 0.66, 1.00 ]
Mansour 2004 7/20 12/20 0.58 [ 0.29, 1.17 ]
Mehr-Aein 2007 5/33 8/33 0.63 [ 0.23, 1.71 ]
Menichetti 1996 12/24 18/24 0.67 [ 0.42, 1.06 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Murphy 2006 13/50 14/50 0.93 [ 0.49, 1.77 ]
Penta de Peppo 1995 1/15 3/15 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 9/19 1.16 [ 0.63, 2.15 ]
Pleym 2003 7/40 8/39 0.85 [ 0.34, 2.13 ]
Pugh 1995 22/22 23/23 1.00 [ 0.92, 1.09 ]
Santos 2006 7/29 12/31 0.62 [ 0.29, 1.36 ]
Shore-Lesserson 1996 10/17 12/13 0.64 [ 0.42, 0.98 ]
Speekenbrink 1995 13/15 11/15 1.18 [ 0.82, 1.70 ]
Taghaddomi 2009 8/50 27/50 0.30 [ 0.15, 0.59 ]
Vanek 2005 3/32 6/30 0.47 [ 0.13, 1.71 ]
Wei 2006 3/36 8/40 0.42 [ 0.12, 1.45 ]
Subtotal (95% CI) 1578 1428 0.68 [ 0.57, 0.81 ]
Total events: 459 (TXA), 617 (Control)
Heterogeneity: Tau2 = 0.15; Chi2 = 137.35, df = 33 (P<0.00001); I2 =76%
Test for overall effect: Z = 4.43 (P < 0.00001)
2 Orthopaedic surgery
Benoni 1996 8/43 24/43 0.33 [ 0.17, 0.66 ]
Benoni 2000 9/20 15/19 0.57 [ 0.33, 0.98 ]
Benoni 2001 4/18 8/20 0.56 [ 0.20, 1.54 ]
Claeys 2007 1/20 6/20 0.17 [ 0.02, 1.26 ]
Ekback 2000 1/20 1/20 1.00 [ 0.07, 14.90 ]
Ellis 2001 1/10 7/10 0.14 [ 0.02, 0.96 ]
Engel 2001 0/12 3/12 0.14 [ 0.01, 2.50 ]
Garneti 2004 16/25 14/25 1.14 [ 0.72, 1.80 ]
Gill 2009 1/5 4/5 0.25 [ 0.04, 1.52 ]
Good 2003 3/27 14/24 0.19 [ 0.06, 0.58 ]
Hiipala 1995 10/15 12/13 0.72 [ 0.49, 1.07 ]
Hiipala 1997 17/39 34/38 0.49 [ 0.34, 0.71 ]
Husted 2003 2/20 7/20 0.29 [ 0.07, 1.21 ]
Jansen 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Johansson 2005 8/47 23/53 0.39 [ 0.19, 0.79 ]
Kazemi 2010 4/32 11/32 0.36 [ 0.13, 1.02 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Lemay 2004 0/20 8/19 0.06 [ 0.00, 0.91 ]
MacGillivray 2010 13/40 10/20 0.65 [ 0.35, 1.22 ]
Niskanen 2005 5/19 8/20 0.66 [ 0.26, 1.66 ]
Orpen 2006 1/15 3/14 0.31 [ 0.04, 2.65 ]
Sadeghi 2007 12/32 20/35 0.66 [ 0.39, 1.12 ]
Sorin 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Tanaka 2001 47/73 26/26 0.65 [ 0.55, 0.78 ]
Veien 2002 0/15 2/15 0.20 [ 0.01, 3.85 ]
Wong 2008 23/73 30/74 0.78 [ 0.50, 1.20 ]
Yamasaki 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Zohar 2004 3/20 12/20 0.25 [ 0.08, 0.75 ]
Subtotal (95% CI) 722 659 0.49 [ 0.39, 0.62 ]
Total events: 193 (TXA), 328 (Control)
Heterogeneity: Tau2 = 0.12; Chi2 = 53.86, df = 25 (P = 0.00069); I2 =54%
Test for overall effect: Z = 6.20 (P < 0.00001)
3 Liver surgery
Dalmau 2000 29/42 37/40 0.75 [ 0.60, 0.93 ]
Wu 2006 0/106 17/108 0.03 [ 0.00, 0.48 ]
Subtotal (95% CI) 148 148 0.16 [ 0.00, 32.47 ]
Total events: 29 (TXA), 54 (Control)
Heterogeneity: Tau2 = 13.57; Chi2 = 14.23, df = 1 (P = 0.00016); I2 =93%
Test for overall effect: Z = 0.67 (P = 0.50)
4 Vascular surgery
Casati 2002 11/30 19/29 0.56 [ 0.33, 0.96 ]
Subtotal (95% CI) 30 29 0.56 [ 0.33, 0.96 ]
Total events: 11 (TXA), 19 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
5 Gynaecological surgery
Caglar 2008 15/50 10/50 1.50 [ 0.75, 3.01 ]
Subtotal (95% CI) 50 50 1.50 [ 0.75, 3.01 ]
Total events: 15 (TXA), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
Total (95% CI) 2528 2314 0.61 [ 0.53, 0.70 ]
Total events: 707 (TXA), 1028 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 249.33, df = 63 (P<0.00001); I2 =75%
Test for overall effect: Z = 7.08 (P < 0.00001)
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Analysis 2.3. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 3
No. Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Andreasen 2004 6/20 5/17 1.02 [ 0.38, 2.76 ]
Armellin 2001 35/143 63/140 0.54 [ 0.39, 0.77 ]
Benoni 1996 8/43 24/43 0.33 [ 0.17, 0.66 ]
Benoni 2001 4/18 8/20 0.56 [ 0.20, 1.54 ]
Blauhut 1994 7/15 9/14 0.73 [ 0.37, 1.41 ]
Brown 1997 18/60 20/30 0.45 [ 0.28, 0.71 ]
Caglar 2008 15/50 10/50 1.50 [ 0.75, 3.01 ]
Casati 2001 2/20 4/20 0.50 [ 0.10, 2.43 ]
Casati 2002 11/30 19/29 0.56 [ 0.33, 0.96 ]
Casati 2004 9/52 13/50 0.67 [ 0.31, 1.42 ]
Claeys 2007 1/20 6/20 0.17 [ 0.02, 1.26 ]
Corbeau 1995 15/41 12/20 0.61 [ 0.36, 1.05 ]
Dalmau 2000 29/42 37/40 0.75 [ 0.60, 0.93 ]
Diprose 2005 20/60 27/60 0.74 [ 0.47, 1.17 ]
Ekback 2000 1/20 1/20 1.00 [ 0.07, 14.90 ]
Ellis 2001 1/10 7/10 0.14 [ 0.02, 0.96 ]
Engel 2001 0/12 3/12 0.14 [ 0.01, 2.50 ]
Gill 2009 1/5 4/5 0.25 [ 0.04, 1.52 ]
Good 2003 3/27 14/24 0.19 [ 0.06, 0.58 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hardy 1998 28/42 27/44 1.09 [ 0.79, 1.49 ]
Hiipala 1995 10/15 12/13 0.72 [ 0.49, 1.07 ]
Hiipala 1997 17/39 34/38 0.49 [ 0.34, 0.71 ]
Horrow 1991 12/37 16/44 0.89 [ 0.49, 1.64 ]
Horrow 1995 37/121 7/27 1.18 [ 0.59, 2.36 ]
Husted 2003 2/20 7/20 0.29 [ 0.07, 1.21 ]
Isetta 1993 24/70 46/70 0.52 [ 0.36, 0.75 ]
Jansen 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Jares 2003 2/22 7/25 0.32 [ 0.08, 1.40 ]
Johansson 2005 8/47 23/53 0.39 [ 0.19, 0.79 ]
Katoh 1997 7/62 10/31 0.35 [ 0.15, 0.83 ]
Katsaros 1996 11/104 27/106 0.42 [ 0.22, 0.79 ]
Kazemi 2010 4/32 11/32 0.36 [ 0.13, 1.02 ]
Kuitunen 2005 5/20 12/20 0.42 [ 0.18, 0.96 ]
Later 2009 57/99 73/103 0.81 [ 0.66, 1.00 ]
Lemay 2004 0/20 8/19 0.06 [ 0.00, 0.91 ]
MacGillivray 2010 13/40 10/20 0.65 [ 0.35, 1.22 ]
Mansour 2004 7/20 12/20 0.58 [ 0.29, 1.17 ]
Mehr-Aein 2007 5/33 8/33 0.63 [ 0.23, 1.71 ]
Menichetti 1996 12/24 18/24 0.67 [ 0.42, 1.06 ]
Murphy 2006 13/50 14/50 0.93 [ 0.49, 1.77 ]
Niskanen 2005 5/19 8/20 0.66 [ 0.26, 1.66 ]
Orpen 2006 1/15 3/14 0.31 [ 0.04, 2.65 ]
Penta de Peppo 1995 1/15 3/15 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 9/19 1.16 [ 0.63, 2.15 ]
Pleym 2003 7/40 8/39 0.85 [ 0.34, 2.13 ]
Pugh 1995 22/22 23/23 1.00 [ 0.92, 1.09 ]
Santos 2006 7/29 12/31 0.62 [ 0.29, 1.36 ]
Shore-Lesserson 1996 10/17 12/13 0.64 [ 0.42, 0.98 ]
Sorin 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Taghaddomi 2009 8/50 27/50 0.30 [ 0.15, 0.59 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Vanek 2005 3/32 6/30 0.47 [ 0.13, 1.71 ]
Veien 2002 0/15 2/15 0.20 [ 0.01, 3.85 ]
Wei 2006 3/36 8/40 0.42 [ 0.12, 1.45 ]
Wong 2008 23/73 30/74 0.78 [ 0.50, 1.20 ]
Wu 2006 0/106 17/108 0.03 [ 0.00, 0.48 ]
Zohar 2004 3/20 12/20 0.25 [ 0.08, 0.75 ]
Subtotal (95% CI) 2156 1969 0.57 [ 0.48, 0.67 ]
Total events: 568 (TXA), 874 (Control)
Heterogeneity: Tau2 = 0.22; Chi2 = 248.97, df = 55 (P<0.00001); I2 =78%
Test for overall effect: Z = 6.63 (P < 0.00001)
2 No Transfusion Protocol
Benoni 2000 9/20 15/19 0.57 [ 0.33, 0.98 ]
Coffey 1995 9/16 8/14 0.98 [ 0.53, 1.84 ]
Garneti 2004 16/25 14/25 1.14 [ 0.72, 1.80 ]
Jimenez 2007 9/24 19/26 0.51 [ 0.29, 0.90 ]
Karski 2005 24/147 41/165 0.66 [ 0.42, 1.03 ]
Sadeghi 2007 12/32 20/35 0.66 [ 0.39, 1.12 ]
Speekenbrink 1995 13/15 11/15 1.18 [ 0.82, 1.70 ]
Tanaka 2001 47/73 26/26 0.65 [ 0.55, 0.78 ]
Yamasaki 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 372 345 0.76 [ 0.61, 0.96 ]
Total events: 139 (TXA), 154 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 15.48, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 2.36 (P = 0.018)
Total (95% CI) 2528 2314 0.61 [ 0.53, 0.70 ]
Total events: 707 (TXA), 1028 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 249.33, df = 63 (P<0.00001); I2 =75%
Test for overall effect: Z = 7.08 (P < 0.00001)
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Analysis 2.4. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 4
No. Exposed to Allogeneic Blood - Dose (Cardiac Surgery).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 4 No. Exposed to Allogeneic Blood - Dose (Cardiac Surgery)
Study or subgroup TXA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total dose < 2.0 grams
Blauhut 1994 7/15 9/14 2.7 % 0.73 [ 0.37, 1.41 ]
Brown 1997 18/60 20/30 3.5 % 0.45 [ 0.28, 0.71 ]
Coffey 1995 9/16 8/14 2.8 % 0.98 [ 0.53, 1.84 ]
Horrow 1991 12/37 16/44 2.9 % 0.89 [ 0.49, 1.64 ]
Horrow 1995 23/67 7/27 2.5 % 1.32 [ 0.65, 2.72 ]
Isetta 1993 24/70 46/70 3.9 % 0.52 [ 0.36, 0.75 ]
Jares 2003 2/22 7/25 1.0 % 0.32 [ 0.08, 1.40 ]
Kazemi 2010 4/32 11/32 1.6 % 0.36 [ 0.13, 1.02 ]
Mansour 2004 7/20 12/20 2.6 % 0.58 [ 0.29, 1.17 ]
Mehr-Aein 2007 5/33 8/33 1.7 % 0.63 [ 0.23, 1.71 ]
Menichetti 1996 12/24 18/24 3.5 % 0.67 [ 0.42, 1.06 ]
Penta de Peppo 1995 1/15 3/15 0.5 % 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 9/19 2.9 % 1.16 [ 0.63, 2.15 ]
Sadeghi 2007 12/32 20/35 3.2 % 0.66 [ 0.39, 1.12 ]
Santos 2006 7/29 12/31 2.3 % 0.62 [ 0.29, 1.36 ]
Shore-Lesserson 1996 10/17 12/13 3.6 % 0.64 [ 0.42, 0.98 ]
Speekenbrink 1995 13/15 11/15 3.9 % 1.18 [ 0.82, 1.70 ]
Vanek 2005 3/32 6/30 1.2 % 0.47 [ 0.13, 1.71 ]
Wei 2006 3/36 8/40 1.3 % 0.42 [ 0.12, 1.45 ]
Subtotal (95% CI) 592 531 47.4 % 0.70 [ 0.58, 0.84 ]
Total events: 183 (TXA), 243 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 26.93, df = 18 (P = 0.08); I2 =33%
Test for overall effect: Z = 3.89 (P = 0.00010)
2 Total dose 2.0 - 10.0 grams
Andreasen 2004 6/20 5/17 1.7 % 1.02 [ 0.38, 2.76 ]
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(. . . Continued)
Study or subgroup TXA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Armellin 2001 35/143 63/140 4.0 % 0.54 [ 0.39, 0.77 ]
Casati 2001 2/20 4/20 0.9 % 0.50 [ 0.10, 2.43 ]
Casati 2004 9/52 13/50 2.4 % 0.67 [ 0.31, 1.42 ]
Corbeau 1995 15/41 12/20 3.2 % 0.61 [ 0.36, 1.05 ]
Diprose 2005 20/60 27/60 3.5 % 0.74 [ 0.47, 1.17 ]
Hardy 1998 28/42 27/44 4.1 % 1.09 [ 0.79, 1.49 ]
Horrow 1995 14/54 14/54 2.8 % 1.00 [ 0.53, 1.89 ]
Jimenez 2007 9/24 19/26 3.1 % 0.51 [ 0.29, 0.90 ]
Karski 2005 24/147 41/165 3.5 % 0.66 [ 0.42, 1.03 ]
Katoh 1997 7/62 10/31 2.0 % 0.35 [ 0.15, 0.83 ]
Katsaros 1996 11/104 27/106 2.7 % 0.42 [ 0.22, 0.79 ]
Kuitunen 2005 5/20 12/20 2.1 % 0.42 [ 0.18, 0.96 ]
Later 2009 57/99 73/103 4.5 % 0.81 [ 0.66, 1.00 ]
Murphy 2006 13/50 14/50 2.8 % 0.93 [ 0.49, 1.77 ]
Pleym 2003 7/40 8/39 1.9 % 0.85 [ 0.34, 2.13 ]
Pugh 1995 22/22 23/23 4.8 % 1.00 [ 0.92, 1.09 ]
Taghaddomi 2009 8/50 27/50 2.6 % 0.30 [ 0.15, 0.59 ]
Subtotal (95% CI) 1050 1018 52.6 % 0.67 [ 0.52, 0.86 ]
Total events: 292 (TXA), 419 (Control)
Heterogeneity: Tau2 = 0.20; Chi2 = 107.97, df = 17 (P<0.00001); I2 =84%
Test for overall effect: Z = 3.15 (P = 0.0016)
Total (95% CI) 1642 1549 100.0 % 0.68 [ 0.58, 0.80 ]
Total events: 475 (TXA), 662 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 139.40, df = 36 (P<0.00001); I2 =74%
Test for overall effect: Z = 4.65 (P < 0.00001)
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Analysis 2.5. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 5
Trial Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 5 Trial Methodological Quality - Allocation Concealment
Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Benoni 1996 8/43 24/43 0.33 [ 0.17, 0.66 ]
Benoni 2000 9/20 15/19 0.57 [ 0.33, 0.98 ]
Benoni 2001 4/18 8/20 0.56 [ 0.20, 1.54 ]
Casati 2001 2/20 4/20 0.50 [ 0.10, 2.43 ]
Casati 2002 11/30 19/29 0.56 [ 0.33, 0.96 ]
Casati 2004 9/52 13/50 0.67 [ 0.31, 1.42 ]
Coffey 1995 9/16 8/14 0.98 [ 0.53, 1.84 ]
Gill 2009 1/5 4/5 0.25 [ 0.04, 1.52 ]
Good 2003 3/27 14/24 0.19 [ 0.06, 0.58 ]
Hardy 1998 28/42 27/44 1.09 [ 0.79, 1.49 ]
Husted 2003 2/20 7/20 0.29 [ 0.07, 1.21 ]
Jimenez 2007 9/24 19/26 0.51 [ 0.29, 0.90 ]
Johansson 2005 8/47 23/53 0.39 [ 0.19, 0.79 ]
Karski 2005 24/147 41/165 0.66 [ 0.42, 1.03 ]
Katsaros 1996 11/104 27/106 0.42 [ 0.22, 0.79 ]
Lemay 2004 0/20 8/19 0.06 [ 0.00, 0.91 ]
MacGillivray 2010 13/40 10/20 0.65 [ 0.35, 1.22 ]
Mansour 2004 7/20 12/20 0.58 [ 0.29, 1.17 ]
Mehr-Aein 2007 5/33 8/33 0.63 [ 0.23, 1.71 ]
Niskanen 2005 5/19 8/20 0.66 [ 0.26, 1.66 ]
Orpen 2006 1/15 3/14 0.31 [ 0.04, 2.65 ]
Pleym 2003 7/40 8/39 0.85 [ 0.34, 2.13 ]
Sadeghi 2007 12/32 20/35 0.66 [ 0.39, 1.12 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Shore-Lesserson 1996 10/17 12/13 0.64 [ 0.42, 0.98 ]
Taghaddomi 2009 8/50 27/50 0.30 [ 0.15, 0.59 ]
Tanaka 2001 47/73 26/26 0.65 [ 0.55, 0.78 ]
Vanek 2005 3/32 6/30 0.47 [ 0.13, 1.71 ]
Wong 2008 23/73 30/74 0.78 [ 0.50, 1.20 ]
Subtotal (95% CI) 1079 1031 0.59 [ 0.51, 0.69 ]
Total events: 279 (TXA), 431 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 41.35, df = 27 (P = 0.04); I2 =35%
Test for overall effect: Z = 6.80 (P < 0.00001)
2 Allocation concealment - Unclear
Armellin 2001 35/143 63/140 0.54 [ 0.39, 0.77 ]
Blauhut 1994 7/15 9/14 0.73 [ 0.37, 1.41 ]
Brown 1997 18/60 20/30 0.45 [ 0.28, 0.71 ]
Caglar 2008 15/50 10/50 1.50 [ 0.75, 3.01 ]
Claeys 2007 1/20 6/20 0.17 [ 0.02, 1.26 ]
Corbeau 1995 15/41 12/20 0.61 [ 0.36, 1.05 ]
Ekback 2000 1/20 1/20 1.00 [ 0.07, 14.90 ]
Ellis 2001 1/10 7/10 0.14 [ 0.02, 0.96 ]
Engel 2001 0/12 3/12 0.14 [ 0.01, 2.50 ]
Garneti 2004 16/25 14/25 1.14 [ 0.72, 1.80 ]
Isetta 1993 24/70 46/70 0.52 [ 0.36, 0.75 ]
Jansen 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Jares 2003 2/22 7/25 0.32 [ 0.08, 1.40 ]
Katoh 1997 7/62 10/31 0.35 [ 0.15, 0.83 ]
Kazemi 2010 4/32 11/32 0.36 [ 0.13, 1.02 ]
Menichetti 1996 12/24 18/24 0.67 [ 0.42, 1.06 ]
Penta de Peppo 1995 1/15 3/15 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 9/19 1.16 [ 0.63, 2.15 ]
Pugh 1995 22/22 23/23 1.00 [ 0.92, 1.09 ]
Sorin 1999 2/21 13/21 0.15 [ 0.04, 0.60 ]
Speekenbrink 1995 13/15 11/15 1.18 [ 0.82, 1.70 ]
Veien 2002 0/15 2/15 0.20 [ 0.01, 3.85 ]
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Study or subgroup TXA Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wei 2006 3/36 8/40 0.42 [ 0.12, 1.45 ]
Zohar 2004 3/20 12/20 0.25 [ 0.08, 0.75 ]
Subtotal (95% CI) 791 712 0.53 [ 0.37, 0.76 ]
Total events: 215 (TXA), 331 (Control)
Heterogeneity: Tau2 = 0.53; Chi2 = 209.62, df = 23 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.44 (P = 0.00059)
3 Allocation concealment - No
Andreasen 2004 6/20 5/17 1.02 [ 0.38, 2.76 ]
Dalmau 2000 29/42 37/40 0.75 [ 0.60, 0.93 ]
Diprose 2005 20/60 27/60 0.74 [ 0.47, 1.17 ]
Hiipala 1995 10/15 12/13 0.72 [ 0.49, 1.07 ]
Hiipala 1997 17/39 34/38 0.49 [ 0.34, 0.71 ]
Horrow 1991 12/37 16/44 0.89 [ 0.49, 1.64 ]
Horrow 1995 37/121 7/27 1.18 [ 0.59, 2.36 ]
Kuitunen 2005 5/20 12/20 0.42 [ 0.18, 0.96 ]
Later 2009 57/99 73/103 0.81 [ 0.66, 1.00 ]
Murphy 2006 13/50 14/50 0.93 [ 0.49, 1.77 ]
Santos 2006 7/29 12/31 0.62 [ 0.29, 1.36 ]
Wu 2006 0/106 17/108 0.03 [ 0.00, 0.48 ]
Yamasaki 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 658 571 0.73 [ 0.62, 0.86 ]
Total events: 213 (TXA), 266 (Control)
Heterogeneity: Tau2 = 0.02; Chi2 = 16.38, df = 11 (P = 0.13); I2 =33%
Test for overall effect: Z = 3.72 (P = 0.00020)
Total (95% CI) 2528 2314 0.61 [ 0.53, 0.70 ]
Total events: 707 (TXA), 1028 (Control)
Heterogeneity: Tau2 = 0.16; Chi2 = 249.33, df = 63 (P<0.00001); I2 =75%
Test for overall effect: Z = 7.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 2.6. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 6
Units Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 6 Units Allogeneic Blood Transfused - Transfused Patients
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armellin 2001 35 1.68 (1.2) 63 1.93 (1.3) 10.8 % -0.25 [ -0.76, 0.26 ]
Blauhut 1994 7 1.71 (0.95) 9 2.44 (1.13) 7.7 % -0.73 [ -1.75, 0.29 ]
Caglar 2008 15 1.8 (0.54) 10 1.6 (0.66) 10.9 % 0.20 [ -0.29, 0.69 ]
Corbeau 1995 15 2.19 (0.46) 12 2.83 (1.45) 8.7 % -0.64 [ -1.49, 0.21 ]
Dalmau 2000 29 7.72 (5.44) 37 8.38 (6.13) 2.2 % -0.66 [ -3.46, 2.14 ]
Diprose 2005 20 2.61 (1.55) 27 3.73 (4.47) 4.2 % -1.12 [ -2.94, 0.70 ]
Garneti 2004 16 2.31 (0.87) 14 1.29 (0.73) 10.4 % 1.02 [ 0.45, 1.59 ]
Good 2003 3 2.33 (1.53) 14 2.5 (1.02) 4.2 % -0.17 [ -1.98, 1.64 ]
Hiipala 1995 10 2.25 (0.87) 12 3.58 (1.57) 7.6 % -1.33 [ -2.37, -0.29 ]
Hiipala 1997 17 2.29 (0.52) 34 3.46 (1.25) 10.9 % -1.17 [ -1.66, -0.68 ]
Johansson 2005 8 2.13 (0.99) 23 2.48 (1.31) 8.6 % -0.35 [ -1.22, 0.52 ]
Murphy 2006 13 1.46 (0.97) 14 1.21 (0.43) 10.4 % 0.25 [ -0.32, 0.82 ]
Speekenbrink 1995 13 3.31 (1.62) 11 4.27 (3.15) 3.5 % -0.96 [ -3.02, 1.10 ]
Total (95% CI) 201 280 100.0 % -0.34 [ -0.80, 0.11 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 45.89, df = 12 (P<0.00001); I2 =74%
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 2.7. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 7
Units of Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 7 Units of Allogeneic Blood Transfused - All Patients
Study or subgroup TXA Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Armellin 2001 143 0.41 (0.93) 140 0.87 (1.3) -0.46 [ -0.72, -0.20 ]
Blauhut 1994 15 0.8 (1.08) 14 1.57 (1.5) -0.77 [ -1.73, 0.19 ]
Caglar 2008 50 0.3 (0.8) 50 0.3 (0.7) 0.0 [ -0.29, 0.29 ]
Corbeau 1995 41 0.8 (1.1) 20 1.7 (1.8) -0.90 [ -1.76, -0.04 ]
Dalmau 2000 42 5.33 (5.77) 40 7.75 (6.3) -2.42 [ -5.04, 0.20 ]
Diprose 2005 60 0.87 (1.52) 60 1.68 (3.51) -0.81 [ -1.78, 0.16 ]
Hiipala 1995 15 1.5 (1.3) 13 3.3 (1.8) -1.80 [ -2.98, -0.62 ]
Hiipala 1997 39 1 (1.2) 38 3.1 (1.6) -2.10 [ -2.73, -1.47 ]
Horrow 1990 18 0.92 (0.8) 20 0.76 (1.08) 0.16 [ -0.44, 0.76 ]
Jansen 1999 21 0.46 (1.45) 21 2.5 (2.47) -2.04 [ -3.26, -0.82 ]
Jimenez 2007 24 1.58 (0.49) 26 3.21 (0.55) -1.63 [ -1.92, -1.34 ]
Katoh 1997 62 1.42 (2.74) 31 3.03 (4.57) -1.61 [ -3.36, 0.14 ]
Kazemi 2010 32 0.31 (0.64) 32 0.84 (0.9) -0.53 [ -0.91, -0.15 ]
MacGillivray 2010 40 0.76 (0.75) 20 1.11 (0.97) -0.35 [ -0.83, 0.13 ]
Maddali 2007 111 2.03 (0.78) 111 3.17 (0.97) -1.14 [ -1.37, -0.91 ]
Murphy 2006 50 0.38 (0.81) 50 0.34 (0.59) 0.04 [ -0.24, 0.32 ]
Speekenbrink 1995 15 2.87 (1.9) 15 3.13 (3.3) -0.26 [ -2.19, 1.67 ]
Uozaki 2001 6 4.1 (2.23) 6 9.16 (6.6) -5.06 [ -10.63, 0.51 ]
Veien 2002 15 0 (0) 15 0.27 (0.7) 0.0 [ 0.0, 0.0 ]
Wei 2006 36 1.27 (0.07) 40 1.33 (0) 0.0 [ 0.0, 0.0 ]
Wong 2008 73 0.89 (1.8) 74 1.35 (2.16) -0.46 [ -1.10, 0.18 ]
Yassen 1993 10 7.9 (3.3) 10 12.4 (8) -4.50 [ -9.86, 0.86 ]
Zabeeda 2002 25 0.52 (0.9) 25 1.68 (1) -1.16 [ -1.69, -0.63 ]
Total (95% CI) 943 871 -0.87 [ -1.20, -0.53 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 154.24, df = 20 (P<0.00001); I2 =87%
Test for overall effect: Z = 5.04 (P < 0.00001)
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Analysis 2.8. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 8
Blood loss - Intra-operative.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 8 Blood loss - Intra-operative
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Katoh 1997 62 197 (117.8) 31 561 (746.1) 3.5 % -364.00 [ -628.27, -99.73 ]
Pinosky 1997 20 1318 (545.6) 19 1471 (675.6) 1.9 % -153.00 [ -539.60, 233.60 ]
Taghaddomi 2009 50 467 (170) 50 531 (164) 10.0 % -64.00 [ -129.47, 1.47 ]
Uozaki 2001 6 273 (290) 6 523 (450) 1.6 % -250.00 [ -678.36, 178.36 ]
Subtotal (95% CI) 138 106 17.0 % -166.76 [ -331.24, -2.27 ]
Heterogeneity: Tau2 = 12513.66; Chi2 = 5.36, df = 3 (P = 0.15); I2 =44%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Orthopaedic surgery
Benoni 1996 43 210 (140) 43 210 (130) 10.3 % 0.0 [ -57.10, 57.10 ]
Claeys 2007 20 423 (174) 20 516 (167) 8.4 % -93.00 [ -198.70, 12.70 ]
Hiipala 1995 15 428 (254) 13 415 (244) 5.4 % 13.00 [ -171.70, 197.70 ]
Hiipala 1997 39 283 (178) 38 318 (208) 9.2 % -35.00 [ -121.57, 51.57 ]
Johansson 2005 47 534 (316) 53 612 (304) 7.7 % -78.00 [ -199.90, 43.90 ]
Kazemi 2010 32 1024 (544) 32 1399 (587) 3.2 % -375.00 [ -652.29, -97.71 ]
Lemay 2004 20 820.5 (447.1) 19 911 (363) 3.6 % -90.50 [ -345.52, 164.52 ]
Niskanen 2005 19 626 (279.05) 20 790 (408.11) 4.4 % -164.00 [ -382.48, 54.48 ]
Sadeghi 2007 32 652 (228) 35 1108 (372) 6.7 % -456.00 [ -602.39, -309.61 ]
Wong 2008 73 1203 (1060) 74 1600 (1301) 1.9 % -397.00 [ -780.40, -13.60 ]
Yamasaki 2004 20 570 (191) 20 640 (215) 7.5 % -70.00 [ -196.04, 56.04 ]
Zhang 2007 51 256 (149) 51 306 (214) 9.8 % -50.00 [ -121.57, 21.57 ]
Subtotal (95% CI) 411 418 78.1 % -115.52 [ -187.88, -43.16 ]
Heterogeneity: Tau2 = 10071.83; Chi2 = 42.52, df = 11 (P = 0.00001); I2 =74%
Test for overall effect: Z = 3.13 (P = 0.0018)
3 Gynaecological surgery
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(. . . Continued)
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Caglar 2008 50 654 (460) 50 820 (558) 4.9 % -166.00 [ -366.45, 34.45 ]
Subtotal (95% CI) 50 50 4.9 % -166.00 [ -366.45, 34.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
4 Head % neck surgery
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 599 574 100.0 % -121.41 [ -180.19, -62.63 ]
Heterogeneity: Tau2 = 7861.99; Chi2 = 49.05, df = 16 (P = 0.00003); I2 =67%
Test for overall effect: Z = 4.05 (P = 0.000052)
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Analysis 2.9. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome 9
Blood loss - Post-operative.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 9 Blood loss - Post-operative
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Armellin 2001 143 447 (262) 140 720 (357) 3.9 % -273.00 [ -346.08, -199.92 ]
Blauhut 1994 15 403 (201.39) 14 453 (192.56) 3.1 % -50.00 [ -193.39, 93.39 ]
Coffey 1995 16 711 (384) 14 1160 (628.6) 1.2 % -449.00 [ -828.24, -69.76 ]
Corbeau 1995 41 1015 (409) 20 1416 (559) 1.8 % -401.00 [ -676.12, -125.88 ]
Horrow 1990 18 496 (228) 20 750 (314) 2.8 % -254.00 [ -427.30, -80.70 ]
Jimenez 2007 24 464 (369.2) 26 1037 (658) 1.6 % -573.00 [ -865.89, -280.11 ]
Katoh 1997 62 241 (79.27) 31 392 (305.67) 3.5 % -151.00 [ -260.40, -41.60 ]
Katsaros 1996 104 474 (244.75) 106 906 (525.1) 3.5 % -432.00 [ -542.48, -321.52 ]
Kuitunen 2005 20 802 (214.7) 20 995 (281.7) 3.0 % -193.00 [ -348.23, -37.77 ]
Kuitunen 2006 14 1008 (251) 15 1081 (654) 1.3 % -73.00 [ -429.12, 283.12 ]
Maddali 2007 111 633 (183.2) 111 980.9 (267.2) 4.1 % -347.90 [ -408.17, -287.63 ]
Mehr-Aein 2007 33 320 (38) 33 480 (75) 4.3 % -160.00 [ -188.69, -131.31 ]
Menichetti 1996 24 737 (400) 24 811 (600) 1.7 % -74.00 [ -362.50, 214.50 ]
Misfeld 1998 14 390 (120) 14 760 (320) 2.7 % -370.00 [ -549.02, -190.98 ]
Penta de Peppo 1995 15 534 (288) 15 724 (280) 2.4 % -190.00 [ -393.27, 13.27 ]
Pinosky 1997 20 600 (219.1) 19 1060 (553.5) 1.8 % -460.00 [ -726.76, -193.24 ]
Pleym 2003 40 475 (269) 39 713 (243) 3.5 % -238.00 [ -350.98, -125.02 ]
Shore-Lesserson 1996 17 649 (391) 13 923 (496) 1.4 % -274.00 [ -601.48, 53.48 ]
Speekenbrink 1995 15 352 (150) 15 674 (411) 2.2 % -322.00 [ -543.41, -100.59 ]
Taghaddomi 2009 50 471 (182) 50 844 (363) 3.5 % -373.00 [ -485.55, -260.45 ]
Uozaki 2001 6 646 (380) 6 846 (510) 0.7 % -200.00 [ -708.90, 308.90 ]
Zabeeda 2002 25 194 (135) 25 488 (238) 3.6 % -294.00 [ -401.26, -186.74 ]
Subtotal (95% CI) 827 770 57.5 % -272.87 [ -328.85, -216.89 ]
Heterogeneity: Tau2 = 9687.61; Chi2 = 83.41, df = 21 (P<0.00001); I2 =75%
-1000 -500 0 500 1000
Favours TXA Favours Control
(Continued . . . )
310Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 9.55 (P < 0.00001)
2 Orthopaedic surgery
Alvarez 2008 46 170 (109) 49 551 (352) 3.6 % -381.00 [ -484.47, -277.53 ]
Benoni 1996 43 520 (230) 43 1210 (480) 2.9 % -690.00 [ -849.09, -530.91 ]
Benoni 2001 18 199 (114.62) 20 388 (228.63) 3.5 % -189.00 [ -302.33, -75.67 ]
Claeys 2007 20 352 (152) 20 524 (244) 3.3 % -172.00 [ -297.99, -46.01 ]
Garneti 2004 25 411 (220) 25 353 (311) 3.0 % 58.00 [ -91.33, 207.33 ]
Lemay 2004 20 487 (234) 19 580 (290) 2.8 % -93.00 [ -258.89, 72.89 ]
MacGillivray 2010 40 569 (294) 20 918 (549) 1.9 % -349.00 [ -606.28, -91.72 ]
Sadeghi 2007 32 300 (54) 35 390 (65) 4.3 % -90.00 [ -118.53, -61.47 ]
Wong 2008 73 536 (471) 74 737 (524) 2.9 % -201.00 [ -362.02, -39.98 ]
Yamasaki 2004 20 655 (418) 20 890 (353) 2.1 % -235.00 [ -474.78, 4.78 ]
Zhang 2007 51 478 (172) 51 814 (156) 4.0 % -336.00 [ -399.73, -272.27 ]
Zohar 2004 20 121 (81) 20 249 (130) 4.0 % -128.00 [ -195.13, -60.87 ]
Subtotal (95% CI) 408 396 38.4 % -228.52 [ -321.76, -135.27 ]
Heterogeneity: Tau2 = 22019.78; Chi2 = 125.01, df = 11 (P<0.00001); I2 =91%
Test for overall effect: Z = 4.80 (P < 0.00001)
3 Gynaecological surgery
Caglar 2008 50 150 (167) 50 213 (113) 4.1 % -63.00 [ -118.89, -7.11 ]
Subtotal (95% CI) 50 50 4.1 % -63.00 [ -118.89, -7.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.21 (P = 0.027)
4 Head % neck surgery
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 1285 1216 100.0 % -247.17 [ -294.76, -199.58 ]
Heterogeneity: Tau2 = 13588.50; Chi2 = 248.36, df = 34 (P<0.00001); I2 =86%
Test for overall effect: Z = 10.18 (P < 0.00001)
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Analysis 2.10. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome
10 Blood loss - Post-operative - Dose (Cardiac Surgery).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 10 Blood loss - Post-operative - Dose (Cardiac Surgery)
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Total dose < 2.0 grams
Blauhut 1994 15 403 (201.39) 14 453 (192.56) 5.4 % -50.00 [ -193.39, 93.39 ]
Coffey 1995 16 711 (384) 14 1160 (628.6) 1.7 % -449.00 [ -828.24, -69.76 ]
Horrow 1990 18 496 (228) 20 750 (314) 4.7 % -254.00 [ -427.30, -80.70 ]
Kuitunen 2006 14 1008 (251) 15 1081 (654) 1.9 % -73.00 [ -429.12, 283.12 ]
Maddali 2007 111 633 (183.2) 111 980.9 (267.2) 7.7 % -347.90 [ -408.17, -287.63 ]
Mehr-Aein 2007 33 320 (38) 33 480 (75) 8.2 % -160.00 [ -188.69, -131.31 ]
Menichetti 1996 24 737 (400) 24 811 (600) 2.6 % -74.00 [ -362.50, 214.50 ]
Misfeld 1998 14 390 (120) 14 760 (320) 4.5 % -370.00 [ -549.02, -190.98 ]
Penta de Peppo 1995 15 534 (288) 15 724 (280) 4.0 % -190.00 [ -393.27, 13.27 ]
Pinosky 1997 20 600 (219.1) 19 1060 (553.5) 2.9 % -460.00 [ -726.76, -193.24 ]
Shore-Lesserson 1996 17 649 (391) 13 923 (496) 2.2 % -274.00 [ -601.48, 53.48 ]
Speekenbrink 1995 15 352 (150) 15 674 (411) 3.6 % -322.00 [ -543.41, -100.59 ]
Subtotal (95% CI) 312 307 49.4 % -245.03 [ -329.76, -160.29 ]
Heterogeneity: Tau2 = 11844.38; Chi2 = 46.53, df = 11 (P<0.00001); I2 =76%
Test for overall effect: Z = 5.67 (P < 0.00001)
2 Total dose 2.0 - 10.0 grams
Armellin 2001 143 447 (262) 140 720 (357) 7.4 % -273.00 [ -346.08, -199.92 ]
Corbeau 1995 41 1015 (409) 20 1416 (559) 2.8 % -401.00 [ -676.12, -125.88 ]
Jimenez 2007 24 464 (369.2) 26 1037 (658) 2.5 % -573.00 [ -865.89, -280.11 ]
Katoh 1997 62 241 (79.27) 31 392 (305.67) 6.4 % -151.00 [ -260.40, -41.60 ]
Katsaros 1996 104 474 (244.75) 106 906 (525.1) 6.3 % -432.00 [ -542.48, -321.52 ]
Kuitunen 2005 20 802 (214.7) 20 995 (281.7) 5.1 % -193.00 [ -348.23, -37.77 ]
Pleym 2003 40 475 (269) 39 713 (243) 6.3 % -238.00 [ -350.98, -125.02 ]
Taghaddomi 2009 50 471 (182) 50 844 (363) 6.3 % -373.00 [ -485.55, -260.45 ]
Uozaki 2001 6 646 (380) 6 846 (510) 1.1 % -200.00 [ -708.90, 308.90 ]
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(. . . Continued)
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Zabeeda 2002 25 194 (135) 25 488 (238) 6.4 % -294.00 [ -401.26, -186.74 ]
Subtotal (95% CI) 515 463 50.6 % -297.94 [ -364.49, -231.39 ]
Heterogeneity: Tau2 = 5796.93; Chi2 = 21.50, df = 9 (P = 0.01); I2 =58%
Test for overall effect: Z = 8.77 (P < 0.00001)
Total (95% CI) 827 770 100.0 % -272.87 [ -328.85, -216.89 ]
Heterogeneity: Tau2 = 9687.61; Chi2 = 83.41, df = 21 (P<0.00001); I2 =75%
Test for overall effect: Z = 9.55 (P < 0.00001)
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Analysis 2.11. Comparison 2 Tranexamic Acid versus Control (Blood Transfusion & Blood Loss), Outcome
11 Blood loss - Total.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 2 Tranexamic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 11 Blood loss - Total
Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Isetta 1993 70 602 (562) 70 1000 (736) 4.2 % -398.00 [ -614.93, -181.07 ]
Jimenez 2007 24 835 (1013.57) 26 1466 (2106.95) 1.2 % -631.00 [ -1536.72, 274.72 ]
Katoh 1997 62 437.5 (143.76) 31 954 (846.3) 3.7 % -516.50 [ -816.56, -216.44 ]
Kuitunen 2006 15 1008 (251) 15 1081 (654) 3.3 % -73.00 [ -427.50, 281.50 ]
Mehr-Aein 2007 33 320 (38) 33 480 (75) 5.0 % -160.00 [ -188.69, -131.31 ]
Uozaki 2001 6 919 (365) 6 1369 (544) 2.4 % -450.00 [ -974.18, 74.18 ]
Subtotal (95% CI) 210 181 19.8 % -300.47 [ -470.74, -130.21 ]
Heterogeneity: Tau2 = 21220.40; Chi2 = 12.19, df = 5 (P = 0.03); I2 =59%
Test for overall effect: Z = 3.46 (P = 0.00054)
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Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Orthopaedic surgery
Alvarez 2008 46 1301 (621) 49 1744 (804) 3.8 % -443.00 [ -730.89, -155.11 ]
Benoni 1996 43 730 (280) 43 1410 (480) 4.5 % -680.00 [ -846.09, -513.91 ]
Benoni 2001 18 759 (260.41) 20 996 (380.33) 4.3 % -237.00 [ -442.56, -31.44 ]
Claeys 2007 20 801 (244) 20 1038 (289) 4.5 % -237.00 [ -402.76, -71.24 ]
Ekback 2000 20 1130 (400) 20 1770 (523) 3.8 % -640.00 [ -928.56, -351.44 ]
Garneti 2004 25 1443 (809) 25 1340 (665) 3.0 % 103.00 [ -307.51, 513.51 ]
Hiipala 1995 15 847 (356) 13 1549 (574) 3.3 % -702.00 [ -1062.30, -341.70 ]
Hiipala 1997 39 689 (289) 38 1509 (643) 4.2 % -820.00 [ -1043.66, -596.34 ]
Husted 2003 20 814 (1264.92) 20 1231 (1617.47) 1.2 % -417.00 [ -1316.90, 482.90 ]
Jansen 1999 21 678 (352) 21 1419 (607) 3.7 % -741.00 [ -1041.11, -440.89 ]
Johansson 2005 47 969 (434) 53 1324 (577) 4.3 % -355.00 [ -553.81, -156.19 ]
Lemay 2004 20 1308 (462) 19 1469 (405) 3.9 % -161.00 [ -433.32, 111.32 ]
MacGillivray 2010 40 569 (294) 20 918 (549) 4.0 % -349.00 [ -606.28, -91.72 ]
Niskanen 2005 19 792 (360) 20 1102 (463.7) 3.9 % -310.00 [ -569.81, -50.19 ]
Orpen 2006 15 660 (296.15) 14 726 (308.29) 4.2 % -66.00 [ -286.32, 154.32 ]
Sadeghi 2007 32 960 (284) 35 1484 (374) 4.6 % -524.00 [ -682.22, -365.78 ]
Sorin 1999 21 678 (352) 21 1422 (637) 3.6 % -744.00 [ -1055.27, -432.73 ]
Wong 2008 73 1592 (1315) 74 2138 (1607) 2.6 % -546.00 [ -1020.40, -71.60 ]
Yamasaki 2004 20 1350 (477) 20 1667 (401) 3.9 % -317.00 [ -590.11, -43.89 ]
Zhang 2007 51 559 (159) 51 1208 (243) 4.9 % -649.00 [ -728.70, -569.30 ]
Subtotal (95% CI) 605 596 76.0 % -446.19 [ -554.61, -337.78 ]
Heterogeneity: Tau2 = 41720.91; Chi2 = 85.30, df = 19 (P<0.00001); I2 =78%
Test for overall effect: Z = 8.07 (P < 0.00001)
3 Liver surgery
Yassen 1993 10 6042 (3949) 10 12594 (11911) 0.0 % -6552.00 [ -14329.54, 1225.54 ]
Subtotal (95% CI) 10 10 0.0 % -6552.00 [ -14329.54, 1225.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
4 Gynaecological surgery
Caglar 2008 50 804 (482) 50 1047 (617) 4.2 % -243.00 [ -460.02, -25.98 ]
Subtotal (95% CI) 50 50 4.2 % -243.00 [ -460.02, -25.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.19 (P = 0.028)
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Study or subgroup TXA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
5 Head % neck surgery
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 875 837 100.0 % -414.06 [ -525.19, -302.92 ]
Heterogeneity: Tau2 = 63946.73; Chi2 = 249.58, df = 27 (P<0.00001); I2 =89%
Test for overall effect: Z = 7.30 (P < 0.00001)
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Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berenholtz 2009 85/91 85/91 17.1 % 1.00 [ 0.93, 1.08 ]
Kluger 2003 16/58 14/30 7.3 % 0.59 [ 0.34, 1.04 ]
Greilich 2009 15/25 17/27 9.6 % 0.95 [ 0.62, 1.47 ]
Hardy 1998 23/46 27/44 10.9 % 0.81 [ 0.56, 1.18 ]
Daily 1994 1/21 5/19 0.9 % 0.18 [ 0.02, 1.41 ]
Ray 2005 4/15 3/15 2.0 % 1.33 [ 0.36, 4.97 ]
Penta de Peppo 1995 3/15 3/15 1.7 % 1.00 [ 0.24, 4.18 ]
Menichetti 1996 4/24 18/24 3.7 % 0.22 [ 0.09, 0.56 ]
Pinosky 1997 7/20 9/19 4.9 % 0.74 [ 0.34, 1.58 ]
Harley 2002 4/22 7/24 2.8 % 0.62 [ 0.21, 1.84 ]
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(. . . Continued)
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Greilich 2001 5/23 13/25 4.1 % 0.42 [ 0.18, 0.99 ]
Troianos 1999 7/34 6/33 3.3 % 1.13 [ 0.43, 3.02 ]
Kreisler 2005 4/22 9/25 3.1 % 0.51 [ 0.18, 1.41 ]
Kikura 2006 12/50 9/50 4.8 % 1.33 [ 0.62, 2.88 ]
Dalmau 2000 36/42 37/40 15.9 % 0.93 [ 0.80, 1.08 ]
Amar 2003 12/22 13/24 7.8 % 1.01 [ 0.59, 1.71 ]
Total (95% CI) 530 505 100.0 % 0.81 [ 0.67, 0.99 ]
Total events: 238 (EACA), 275 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 41.12, df = 15 (P = 0.00031); I2 =64%
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 3.2. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 2 No. Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac Surgery
Daily 1994 1/21 5/19 0.9 % 0.18 [ 0.02, 1.41 ]
Greilich 2001 5/23 13/25 4.1 % 0.42 [ 0.18, 0.99 ]
Greilich 2009 15/25 17/27 9.6 % 0.95 [ 0.62, 1.47 ]
Hardy 1998 23/46 27/44 10.9 % 0.81 [ 0.56, 1.18 ]
Kikura 2006 12/50 9/50 4.8 % 1.33 [ 0.62, 2.88 ]
Kluger 2003 16/58 14/30 7.3 % 0.59 [ 0.34, 1.04 ]
Kreisler 2005 4/22 9/25 3.1 % 0.51 [ 0.18, 1.41 ]
Menichetti 1996 4/24 18/24 3.7 % 0.22 [ 0.09, 0.56 ]
Penta de Peppo 1995 3/15 3/15 1.7 % 1.00 [ 0.24, 4.18 ]
Pinosky 1997 7/20 9/19 4.9 % 0.74 [ 0.34, 1.58 ]
Troianos 1999 7/34 6/33 3.3 % 1.13 [ 0.43, 3.02 ]
Subtotal (95% CI) 338 311 54.4 % 0.70 [ 0.52, 0.93 ]
Total events: 97 (EACA), 130 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 16.38, df = 10 (P = 0.09); I2 =39%
Test for overall effect: Z = 2.43 (P = 0.015)
2 Orthopaedic Surgery
Amar 2003 12/22 13/24 7.8 % 1.01 [ 0.59, 1.71 ]
Berenholtz 2009 85/91 85/91 17.1 % 1.00 [ 0.93, 1.08 ]
Harley 2002 4/22 7/24 2.8 % 0.62 [ 0.21, 1.84 ]
Ray 2005 4/15 3/15 2.0 % 1.33 [ 0.36, 4.97 ]
Subtotal (95% CI) 150 154 29.8 % 1.00 [ 0.93, 1.08 ]
Total events: 105 (EACA), 108 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
3 Liver Surgery
Dalmau 2000 36/42 37/40 15.9 % 0.93 [ 0.80, 1.08 ]
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(. . . Continued)
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 42 40 15.9 % 0.93 [ 0.80, 1.08 ]
Total events: 36 (EACA), 37 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI) 530 505 100.0 % 0.81 [ 0.67, 0.99 ]
Total events: 238 (EACA), 275 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 41.12, df = 15 (P = 0.00031); I2 =64%
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 3.3. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 3 No. Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Amar 2003 12/22 13/24 7.8 % 1.01 [ 0.59, 1.71 ]
Berenholtz 2009 85/91 85/91 17.1 % 1.00 [ 0.93, 1.08 ]
Daily 1994 1/21 5/19 0.9 % 0.18 [ 0.02, 1.41 ]
Dalmau 2000 36/42 37/40 15.9 % 0.93 [ 0.80, 1.08 ]
Greilich 2001 5/23 13/25 4.1 % 0.42 [ 0.18, 0.99 ]
Greilich 2009 15/25 17/27 9.6 % 0.95 [ 0.62, 1.47 ]
Hardy 1998 23/46 27/44 10.9 % 0.81 [ 0.56, 1.18 ]
Harley 2002 4/22 7/24 2.8 % 0.62 [ 0.21, 1.84 ]
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(. . . Continued)
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kikura 2006 12/50 9/50 4.8 % 1.33 [ 0.62, 2.88 ]
Kluger 2003 16/58 14/30 7.3 % 0.59 [ 0.34, 1.04 ]
Kreisler 2005 4/22 9/25 3.1 % 0.51 [ 0.18, 1.41 ]
Menichetti 1996 4/24 18/24 3.7 % 0.22 [ 0.09, 0.56 ]
Penta de Peppo 1995 3/15 3/15 1.7 % 1.00 [ 0.24, 4.18 ]
Pinosky 1997 7/20 9/19 4.9 % 0.74 [ 0.34, 1.58 ]
Troianos 1999 7/34 6/33 3.3 % 1.13 [ 0.43, 3.02 ]
Subtotal (95% CI) 515 490 98.0 % 0.80 [ 0.65, 0.98 ]
Total events: 234 (EACA), 272 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 42.29, df = 14 (P = 0.00011); I2 =67%
Test for overall effect: Z = 2.12 (P = 0.034)
2 No Transfusion Protocol
Ray 2005 4/15 3/15 2.0 % 1.33 [ 0.36, 4.97 ]
Subtotal (95% CI) 15 15 2.0 % 1.33 [ 0.36, 4.97 ]
Total events: 4 (EACA), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
Total (95% CI) 530 505 100.0 % 0.81 [ 0.67, 0.99 ]
Total events: 238 (EACA), 275 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 41.12, df = 15 (P = 0.00031); I2 =64%
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 3.4. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 4 Trial Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 4 Trial Methodological Quality - Allocation Concealment
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Berenholtz 2009 85/91 85/91 17.1 % 1.00 [ 0.93, 1.08 ]
Daily 1994 1/21 5/19 0.9 % 0.18 [ 0.02, 1.41 ]
Greilich 2009 15/25 17/27 9.6 % 0.95 [ 0.62, 1.47 ]
Hardy 1998 23/46 27/44 10.9 % 0.81 [ 0.56, 1.18 ]
Kluger 2003 16/58 14/30 7.3 % 0.59 [ 0.34, 1.04 ]
Subtotal (95% CI) 241 211 45.7 % 0.82 [ 0.58, 1.16 ]
Total events: 140 (EACA), 148 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 14.35, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Allocation concealment - Unclear
Greilich 2001 5/23 13/25 4.1 % 0.42 [ 0.18, 0.99 ]
Harley 2002 4/22 7/24 2.8 % 0.62 [ 0.21, 1.84 ]
Kikura 2006 12/50 9/50 4.8 % 1.33 [ 0.62, 2.88 ]
Kreisler 2005 4/22 9/25 3.1 % 0.51 [ 0.18, 1.41 ]
Menichetti 1996 4/24 18/24 3.7 % 0.22 [ 0.09, 0.56 ]
Penta de Peppo 1995 3/15 3/15 1.7 % 1.00 [ 0.24, 4.18 ]
Pinosky 1997 7/20 9/19 4.9 % 0.74 [ 0.34, 1.58 ]
Ray 2005 4/15 3/15 2.0 % 1.33 [ 0.36, 4.97 ]
Troianos 1999 7/34 6/33 3.3 % 1.13 [ 0.43, 3.02 ]
Subtotal (95% CI) 225 230 30.6 % 0.68 [ 0.46, 1.03 ]
Total events: 50 (EACA), 77 (Control)
Heterogeneity: Tau2 = 0.14; Chi2 = 12.54, df = 8 (P = 0.13); I2 =36%
Test for overall effect: Z = 1.83 (P = 0.068)
3 Allocation concealment - No
Amar 2003 12/22 13/24 7.8 % 1.01 [ 0.59, 1.71 ]
Dalmau 2000 36/42 37/40 15.9 % 0.93 [ 0.80, 1.08 ]
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(. . . Continued)
Study or subgroup EACA Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 64 64 23.7 % 0.93 [ 0.81, 1.08 ]
Total events: 48 (EACA), 50 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Total (95% CI) 530 505 100.0 % 0.81 [ 0.67, 0.99 ]
Total events: 238 (EACA), 275 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 41.12, df = 15 (P = 0.00031); I2 =64%
Test for overall effect: Z = 2.05 (P = 0.040)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 3.5. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 5 Units of Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 5 Units of Allogeneic Blood Transfused - Transfused Patients
Study or subgroup EACA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amar 2003 12 3.12 (2.67) 13 3.32 (2.55) 7.7 % -0.20 [ -2.25, 1.85 ]
Dalmau 2000 36 7.81 (5.67) 37 8.38 (6.13) 4.4 % -0.57 [ -3.28, 2.14 ]
Kikura 2006 12 2.2 (0.7) 9 1.9 (0.7) 88.0 % 0.30 [ -0.30, 0.90 ]
Total (95% CI) 60 59 100.0 % 0.22 [ -0.34, 0.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 3.6. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 6 Units of Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 6 Units of Allogeneic Blood Transfused - All Patients
Study or subgroup EACA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amar 2003 22 1.7 (2.5) 24 1.8 (2.5) 14.5 % -0.10 [ -1.55, 1.35 ]
Berenholtz 2009 91 5.9 (4.7) 91 6.9 (5.4) 14.3 % -1.00 [ -2.47, 0.47 ]
Dalmau 2000 42 6.69 (5.92) 40 7.75 (6.3) 7.2 % -1.06 [ -3.71, 1.59 ]
Greilich 2009 25 1.7 (1.8) 27 1.8 (2) 18.3 % -0.10 [ -1.13, 0.93 ]
Liu 1998 20 6.8 (1.2) 20 9.4 (1.1) 21.4 % -2.60 [ -3.31, -1.89 ]
Rao 1999 15 1.2 (0.4) 15 3.2 (0.45) 24.4 % -2.00 [ -2.30, -1.70 ]
Total (95% CI) 215 217 100.0 % -1.30 [ -2.14, -0.45 ]
Heterogeneity: Tau2 = 0.73; Chi2 = 23.45, df = 5 (P = 0.00028); I2 =79%
Test for overall effect: Z = 3.01 (P = 0.0026)
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Analysis 3.7. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 7 Blood loss - Intra-operative.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 7 Blood loss - Intra-operative
Study or subgroup EACA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Liu 1998 20 1235 (207.6) 20 1443.9 (95) 55.5 % -208.90 [ -308.96, -108.84 ]
Pinosky 1997 20 1196 (451.7) 19 1471 (675.6) 9.8 % -275.00 [ -637.59, 87.59 ]
Subtotal (95% CI) 40 39 65.3 % -213.58 [ -310.03, -117.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
2 Orthopaedic surgery
Amar 2003 22 1300 (1100) 24 1000 (900) 4.1 % 300.00 [ -283.89, 883.89 ]
Berenholtz 2009 91 2938 (2315) 91 3273 (2195) 3.2 % -335.00 [ -990.45, 320.45 ]
Harley 2002 22 552 (331) 24 607 (331) 27.4 % -55.00 [ -246.49, 136.49 ]
Subtotal (95% CI) 135 139 34.7 % -40.66 [ -236.71, 155.38 ]
Heterogeneity: Tau2 = 2904.60; Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 175 178 100.0 % -156.63 [ -276.92, -36.33 ]
Heterogeneity: Tau2 = 4186.53; Chi2 = 5.01, df = 4 (P = 0.29); I2 =20%
Test for overall effect: Z = 2.55 (P = 0.011)
-1000 -500 0 500 1000
Favours EACA Favours Control
323Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.8. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 8 Blood loss - Post-operative.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 8 Blood loss - Post-operative
Study or subgroup EACA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery
Daily 1994 21 623 (380) 19 845 (339) 5.5 % -222.00 [ -444.82, 0.82 ]
Del Rossi 1989 170 617.2 (43.9) 180 883.2 (29.3) 12.7 % -266.00 [ -273.87, -258.13 ]
Greilich 2009 25 715 (394) 27 1002 (627) 4.1 % -287.00 [ -569.46, -4.54 ]
Kikura 2006 50 650 (261) 50 940 (627) 6.5 % -290.00 [ -478.25, -101.75 ]
Kreisler 2005 22 269 (113) 25 284 (128) 11.2 % -15.00 [ -83.90, 53.90 ]
Liu 1998 20 987.2 (103.7) 20 1298.3 (143.2) 10.9 % -311.10 [ -388.59, -233.61 ]
Menichetti 1996 24 512 (250) 24 811 (600) 4.5 % -299.00 [ -559.05, -38.95 ]
Penta de Peppo 1995 15 509 (148) 15 724 (280) 7.5 % -215.00 [ -375.27, -54.73 ]
Pinosky 1997 20 961 (661.9) 19 1060 (553.5) 2.6 % -99.00 [ -481.22, 283.22 ]
Rao 1999 15 372 (55.5) 15 494 (62.4) 12.1 % -122.00 [ -164.26, -79.74 ]
Troianos 1999 34 529 (241) 33 691 (286) 8.9 % -162.00 [ -288.82, -35.18 ]
Vander-Salm 1996 51 647 (488) 52 839 (634) 5.6 % -192.00 [ -410.25, 26.25 ]
Subtotal (95% CI) 467 479 92.0 % -200.27 [ -273.44, -127.09 ]
Heterogeneity: Tau2 = 10265.78; Chi2 = 97.18, df = 11 (P<0.00001); I2 =89%
Test for overall effect: Z = 5.36 (P < 0.00001)
2 Orthopaedic surgery
Berenholtz 2009 91 3265 (2416) 91 3695 (2341) 0.9 % -430.00 [ -1121.19, 261.19 ]
Harley 2002 22 315 (207) 24 591 (374) 7.1 % -276.00 [ -448.83, -103.17 ]
Subtotal (95% CI) 113 115 8.0 % -285.06 [ -452.73, -117.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 3.33 (P = 0.00086)
Total (95% CI) 580 594 100.0 % -207.49 [ -276.43, -138.54 ]
Heterogeneity: Tau2 = 9763.54; Chi2 = 97.46, df = 13 (P<0.00001); I2 =87%
Test for overall effect: Z = 5.90 (P < 0.00001)
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Analysis 3.9. Comparison 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion & Blood Loss),
Outcome 9 Blood loss - Total.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 3 Epsilon Aminocaproic Acid versus Control (Blood Transfusion % Blood Loss)
Outcome: 9 Blood loss - Total
Study or subgroup EACA Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Orthopaedic surgery
Amar 2003 22 1600 (1100) 24 1600 (1400) 9.5 % 0.0 [ -724.57, 724.57 ]
Harley 2002 22 867 (207) 24 1198 (544) 90.5 % -331.00 [ -565.20, -96.80 ]
Total (95% CI) 44 48 100.0 % -299.69 [ -522.54, -76.84 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 2.64 (P = 0.0084)
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Analysis 4.1. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
1 No. Exposed to Allogeneic Blood.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Mansour 2004 1/20 7/20 0.3 % 0.14 [ 0.02, 1.06 ]
Dietrich 2008 52/110 67/110 8.0 % 0.78 [ 0.61, 0.99 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Fergusson 2008 419/780 506/770 12.4 % 0.82 [ 0.75, 0.89 ]
Mengistu 2008 10/25 17/25 3.1 % 0.59 [ 0.34, 1.02 ]
Blauhut 1994 3/14 7/15 0.9 % 0.46 [ 0.15, 1.44 ]
Bernet 1999 11/28 17/28 3.1 % 0.65 [ 0.37, 1.12 ]
Menichetti 1996 2/24 12/24 0.6 % 0.17 [ 0.04, 0.67 ]
Engel 2001 5/12 0/12 0.2 % 11.00 [ 0.67, 179.29 ]
Isetta 1993 55/140 24/70 5.1 % 1.15 [ 0.78, 1.68 ]
Ickx 2006 24/24 27/27 12.6 % 1.00 [ 0.93, 1.08 ]
Corbeau 1995 15/43 15/41 2.9 % 0.95 [ 0.54, 1.69 ]
Casati 1999 19/67 17/70 3.0 % 1.17 [ 0.67, 2.05 ]
Casati 2000 185/518 178/522 10.3 % 1.05 [ 0.89, 1.24 ]
Speekenbrink 1995 12/15 13/15 6.3 % 0.92 [ 0.67, 1.27 ]
Penta de Peppo 1995 0/15 1/15 0.1 % 0.33 [ 0.01, 7.58 ]
Pugh 1995 21/21 22/22 12.3 % 1.00 [ 0.92, 1.09 ]
Later 2009 48/96 57/99 7.7 % 0.87 [ 0.67, 1.13 ]
Dalmau 2004 40/63 38/64 7.3 % 1.07 [ 0.81, 1.41 ]
Kuitunen 2005 11/20 5/20 1.5 % 2.20 [ 0.93, 5.18 ]
Diprose 2005 8/60 20/60 1.9 % 0.40 [ 0.19, 0.84 ]
Total (95% CI) 2124 2061 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 942 (Aprotinin), 1053 (TXA)
Heterogeneity: Tau2 = 0.02; Chi2 = 60.78, df = 20 (P<0.00001); I2 =67%
Test for overall effect: Z = 1.79 (P = 0.074)
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Analysis 4.2. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
2 No. Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Bernet 1999 11/28 17/28 3.1 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.9 % 0.46 [ 0.15, 1.44 ]
Casati 1999 19/67 17/70 3.0 % 1.17 [ 0.67, 2.05 ]
Casati 2000 185/518 178/522 10.3 % 1.05 [ 0.89, 1.24 ]
Corbeau 1995 15/43 15/41 2.9 % 0.95 [ 0.54, 1.69 ]
Dietrich 2008 52/110 67/110 8.0 % 0.78 [ 0.61, 0.99 ]
Diprose 2005 8/60 20/60 1.9 % 0.40 [ 0.19, 0.84 ]
Fergusson 2008 419/780 506/770 12.4 % 0.82 [ 0.75, 0.89 ]
Isetta 1993 55/140 24/70 5.1 % 1.15 [ 0.78, 1.68 ]
Kuitunen 2005 11/20 5/20 1.5 % 2.20 [ 0.93, 5.18 ]
Later 2009 48/96 57/99 7.7 % 0.87 [ 0.67, 1.13 ]
Mansour 2004 1/20 7/20 0.3 % 0.14 [ 0.02, 1.06 ]
Mengistu 2008 10/25 17/25 3.1 % 0.59 [ 0.34, 1.02 ]
Menichetti 1996 2/24 12/24 0.6 % 0.17 [ 0.04, 0.67 ]
Penta de Peppo 1995 0/15 1/15 0.1 % 0.33 [ 0.01, 7.58 ]
Pugh 1995 21/21 22/22 12.3 % 1.00 [ 0.92, 1.09 ]
Speekenbrink 1995 12/15 13/15 6.3 % 0.92 [ 0.67, 1.27 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Subtotal (95% CI) 2025 1958 79.9 % 0.87 [ 0.76, 0.99 ]
Total events: 873 (Aprotinin), 988 (TXA)
Heterogeneity: Tau2 = 0.03; Chi2 = 45.01, df = 17 (P = 0.00024); I2 =62%
Test for overall effect: Z = 2.14 (P = 0.032)
2 Liver surgery
Dalmau 2004 40/63 38/64 7.3 % 1.07 [ 0.81, 1.41 ]
Ickx 2006 24/24 27/27 12.6 % 1.00 [ 0.93, 1.08 ]
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(. . . Continued)
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 87 91 19.9 % 1.01 [ 0.91, 1.11 ]
Total events: 64 (Aprotinin), 65 (TXA)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.16 (P = 0.87)
3 Orthopaedic surgery
Engel 2001 5/12 0/12 0.2 % 11.00 [ 0.67, 179.29 ]
Subtotal (95% CI) 12 12 0.2 % 11.00 [ 0.67, 179.29 ]
Total events: 5 (Aprotinin), 0 (TXA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
Total (95% CI) 2124 2061 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 942 (Aprotinin), 1053 (TXA)
Heterogeneity: Tau2 = 0.02; Chi2 = 60.78, df = 20 (P<0.00001); I2 =67%
Test for overall effect: Z = 1.79 (P = 0.074)
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Analysis 4.3. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
3 No. Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Bernet 1999 11/28 17/28 3.1 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.9 % 0.46 [ 0.15, 1.44 ]
Casati 1999 19/67 17/70 3.0 % 1.17 [ 0.67, 2.05 ]
Casati 2000 185/518 178/522 10.3 % 1.05 [ 0.89, 1.24 ]
Corbeau 1995 15/43 15/41 2.9 % 0.95 [ 0.54, 1.69 ]
Dalmau 2004 40/63 38/64 7.3 % 1.07 [ 0.81, 1.41 ]
Dietrich 2008 52/110 67/110 8.0 % 0.78 [ 0.61, 0.99 ]
Diprose 2005 8/60 20/60 1.9 % 0.40 [ 0.19, 0.84 ]
Engel 2001 5/12 0/12 0.2 % 11.00 [ 0.67, 179.29 ]
Fergusson 2008 419/780 506/770 12.4 % 0.82 [ 0.75, 0.89 ]
Ickx 2006 24/24 27/27 12.6 % 1.00 [ 0.93, 1.08 ]
Isetta 1993 55/140 24/70 5.1 % 1.15 [ 0.78, 1.68 ]
Kuitunen 2005 11/20 5/20 1.5 % 2.20 [ 0.93, 5.18 ]
Later 2009 48/96 57/99 7.7 % 0.87 [ 0.67, 1.13 ]
Mansour 2004 1/20 7/20 0.3 % 0.14 [ 0.02, 1.06 ]
Mengistu 2008 10/25 17/25 3.1 % 0.59 [ 0.34, 1.02 ]
Menichetti 1996 2/24 12/24 0.6 % 0.17 [ 0.04, 0.67 ]
Penta de Peppo 1995 0/15 1/15 0.1 % 0.33 [ 0.01, 7.58 ]
Pugh 1995 21/21 22/22 12.3 % 1.00 [ 0.92, 1.09 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Subtotal (95% CI) 2109 2046 93.7 % 0.90 [ 0.80, 1.01 ]
Total events: 930 (Aprotinin), 1040 (TXA)
Heterogeneity: Tau2 = 0.03; Chi2 = 60.87, df = 19 (P<0.00001); I2 =69%
Test for overall effect: Z = 1.75 (P = 0.081)
2 No Transfusion Protocol
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(. . . Continued)
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Speekenbrink 1995 12/15 13/15 6.3 % 0.92 [ 0.67, 1.27 ]
Subtotal (95% CI) 15 15 6.3 % 0.92 [ 0.67, 1.27 ]
Total events: 12 (Aprotinin), 13 (TXA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
Total (95% CI) 2124 2061 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 942 (Aprotinin), 1053 (TXA)
Heterogeneity: Tau2 = 0.02; Chi2 = 60.78, df = 20 (P<0.00001); I2 =67%
Test for overall effect: Z = 1.79 (P = 0.074)
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Analysis 4.4. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
4 Trial Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 4 Trial Methodological Quality - Allocation Concealment
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Dietrich 2008 52/110 67/110 8.0 % 0.78 [ 0.61, 0.99 ]
Fergusson 2008 419/780 506/770 12.4 % 0.82 [ 0.75, 0.89 ]
Mansour 2004 1/20 7/20 0.3 % 0.14 [ 0.02, 1.06 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Subtotal (95% CI) 939 932 21.0 % 0.80 [ 0.69, 0.92 ]
Total events: 473 (Aprotinin), 583 (TXA)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.60, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 3.14 (P = 0.0017)
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(. . . Continued)
Study or subgroup Aprotinin TXA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 Allocation concealment - Unclear
Bernet 1999 11/28 17/28 3.1 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.9 % 0.46 [ 0.15, 1.44 ]
Casati 1999 19/67 17/70 3.0 % 1.17 [ 0.67, 2.05 ]
Casati 2000 185/518 178/522 10.3 % 1.05 [ 0.89, 1.24 ]
Corbeau 1995 15/43 15/41 2.9 % 0.95 [ 0.54, 1.69 ]
Engel 2001 5/12 0/12 0.2 % 11.00 [ 0.67, 179.29 ]
Ickx 2006 24/24 27/27 12.6 % 1.00 [ 0.93, 1.08 ]
Isetta 1993 55/140 24/70 5.1 % 1.15 [ 0.78, 1.68 ]
Mengistu 2008 10/25 17/25 3.1 % 0.59 [ 0.34, 1.02 ]
Menichetti 1996 2/24 12/24 0.6 % 0.17 [ 0.04, 0.67 ]
Penta de Peppo 1995 0/15 1/15 0.1 % 0.33 [ 0.01, 7.58 ]
Pugh 1995 21/21 22/22 12.3 % 1.00 [ 0.92, 1.09 ]
Speekenbrink 1995 12/15 13/15 6.3 % 0.92 [ 0.67, 1.27 ]
Subtotal (95% CI) 946 886 60.6 % 0.97 [ 0.88, 1.07 ]
Total events: 362 (Aprotinin), 350 (TXA)
Heterogeneity: Tau2 = 0.01; Chi2 = 19.25, df = 12 (P = 0.08); I2 =38%
Test for overall effect: Z = 0.58 (P = 0.56)
3 Allocation concealment - No
Dalmau 2004 40/63 38/64 7.3 % 1.07 [ 0.81, 1.41 ]
Diprose 2005 8/60 20/60 1.9 % 0.40 [ 0.19, 0.84 ]
Kuitunen 2005 11/20 5/20 1.5 % 2.20 [ 0.93, 5.18 ]
Later 2009 48/96 57/99 7.7 % 0.87 [ 0.67, 1.13 ]
Subtotal (95% CI) 239 243 18.4 % 0.93 [ 0.62, 1.39 ]
Total events: 107 (Aprotinin), 120 (TXA)
Heterogeneity: Tau2 = 0.10; Chi2 = 10.29, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 0.34 (P = 0.73)
Total (95% CI) 2124 2061 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 942 (Aprotinin), 1053 (TXA)
Heterogeneity: Tau2 = 0.02; Chi2 = 60.78, df = 20 (P<0.00001); I2 =67%
Test for overall effect: Z = 1.79 (P = 0.074)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 4.5. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
5 Units Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 5 Units Allogeneic Blood Transfused - Transfused Patients
Study or subgroup Aprotinin TXA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Blauhut 1994 3 1.68 (0.48) 7 1.71 (0.95) 16.9 % -0.03 [ -0.92, 0.86 ]
Casati 1999 19 1.9 (1.04) 17 1.94 (0.69) 41.0 % -0.04 [ -0.61, 0.53 ]
Corbeau 1995 15 2.29 (1.49) 15 2.19 (0.46) 21.5 % 0.10 [ -0.69, 0.89 ]
Dalmau 2004 40 5.2 (4.17) 38 5.09 (3.7) 4.4 % 0.11 [ -1.64, 1.86 ]
Diprose 2005 8 2.1 (1.42) 20 2.61 (1.55) 9.4 % -0.51 [ -1.71, 0.69 ]
Speekenbrink 1995 12 2.91 (1.94) 13 3.31 (1.62) 6.8 % -0.40 [ -1.81, 1.01 ]
Total (95% CI) 97 110 100.0 % -0.07 [ -0.44, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.97, df = 5 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 4.6. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
6 Units Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 6 Units Allogeneic Blood Transfused - All Patients
Study or subgroup Aprotinin TXA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Blauhut 1994 14 0.36 (0.47) 15 0.8 (1.08) 9.5 % -0.44 [ -1.04, 0.16 ]
Casati 1999 67 0.54 (1.02) 70 0.47 (0.9) 23.6 % 0.07 [ -0.25, 0.39 ]
Corbeau 1995 43 0.8 (1.4) 41 0.8 (1.1) 11.4 % 0.0 [ -0.54, 0.54 ]
Dalmau 2004 63 3.3 (4.16) 64 3.02 (3.79) 2.0 % 0.28 [ -1.10, 1.66 ]
Dietrich 2008 110 1.3 (1.8) 110 1.7 (1.8) 13.8 % -0.40 [ -0.88, 0.08 ]
Diprose 2005 60 0.28 (0.87) 60 0.87 (1.52) 15.4 % -0.59 [ -1.03, -0.15 ]
Hekmat 2004 60 0.7 (1.2) 58 0.8 (1.3) 14.9 % -0.10 [ -0.55, 0.35 ]
Mengistu 2008 25 0.8 (1.1) 25 1.8 (2.4) 3.6 % -1.00 [ -2.03, 0.03 ]
Speekenbrink 1995 15 2.33 (2.1) 15 2.87 (1.9) 1.9 % -0.54 [ -1.97, 0.89 ]
Wong 2000 39 2.03 (2.12) 38 2.49 (2.25) 4.0 % -0.46 [ -1.44, 0.52 ]
Total (95% CI) 496 496 100.0 % -0.24 [ -0.45, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 10.87, df = 9 (P = 0.28); I2 =17%
Test for overall effect: Z = 2.38 (P = 0.017)
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Analysis 4.7. Comparison 4 Aprotinin versus Tranexamic Acid (Blood Transfusion & Blood Loss), Outcome
7 Blood loss.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 4 Aprotinin versus Tranexamic Acid (Blood Transfusion % Blood Loss)
Outcome: 7 Blood loss
Study or subgroup Aprotinin TXA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery - Post-operative
Bernet 1999 28 844 (437) 28 879 (375) 5.0 % -35.00 [ -248.29, 178.29 ]
Blauhut 1994 14 269 (142.18) 15 403 (201.39) 8.1 % -134.00 [ -260.23, -7.77 ]
Casati 1999 67 283.4 (232.7) 70 310.9 (231.1) 10.3 % -27.50 [ -105.19, 50.19 ]
Corbeau 1995 43 834 (448) 41 1015 (409) 5.9 % -181.00 [ -364.31, 2.31 ]
Hekmat 2004 60 756 (347) 58 896 (354) 8.1 % -140.00 [ -266.53, -13.47 ]
Kuitunen 2005 20 540 (259.4) 20 802 (214.7) 7.2 % -262.00 [ -409.57, -114.43 ]
Landymore 1997 48 515 (339.48) 56 535 (336.75) 7.9 % -20.00 [ -150.39, 110.39 ]
Mengistu 2008 25 575 (228) 25 1033 (647) 3.7 % -458.00 [ -726.91, -189.09 ]
Menichetti 1996 24 298 (140) 24 737 (400) 6.4 % -439.00 [ -608.55, -269.45 ]
Misfeld 1998 14 290 (110) 14 390 (120) 9.9 % -100.00 [ -185.27, -14.73 ]
Penta de Peppo 1995 15 344 (106) 15 534 (288) 6.9 % -190.00 [ -345.30, -34.70 ]
Speekenbrink 1995 15 270 (174) 15 352 (150) 8.5 % -82.00 [ -198.26, 34.26 ]
Wong 2000 39 682 (382.8) 38 746 (436.7) 5.9 % -64.00 [ -247.61, 119.61 ]
Subtotal (95% CI) 412 419 93.9 % -145.81 [ -209.99, -81.62 ]
Heterogeneity: Tau2 = 8272.19; Chi2 = 33.86, df = 12 (P = 0.00071); I2 =65%
Test for overall effect: Z = 4.45 (P < 0.00001)
2 Cardiac surgery - Total
Isetta 1993 140 608 (717.62) 70 602 (562) 6.1 % 6.00 [ -171.38, 183.38 ]
Subtotal (95% CI) 140 70 6.1 % 6.00 [ -171.38, 183.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Total (95% CI) 552 489 100.0 % -136.44 [ -198.40, -74.47 ]
Heterogeneity: Tau2 = 8176.67; Chi2 = 35.68, df = 13 (P = 0.00067); I2 =64%
Test for overall effect: Z = 4.32 (P = 0.000016)
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Analysis 5.1. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 1 No. Exposed to Allogeneic Blood.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup Aprotinin EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Greilich 2009 18/26 15/25 3.4 % 1.15 [ 0.77, 1.74 ]
Fergusson 2008 419/780 514/780 84.9 % 0.82 [ 0.75, 0.89 ]
Eberle 1998 9/20 12/20 1.6 % 0.75 [ 0.41, 1.37 ]
Ray 2001 14/49 12/51 1.3 % 1.21 [ 0.63, 2.36 ]
Trinh-Duc 1992 12/29 18/27 2.2 % 0.62 [ 0.37, 1.03 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Dorman 2008 9/30 15/30 1.4 % 0.60 [ 0.31, 1.15 ]
Greilich 2001 7/24 5/23 0.6 % 1.34 [ 0.50, 3.63 ]
Menichetti 1996 2/24 4/24 0.2 % 0.50 [ 0.10, 2.48 ]
Casati 1999 19/67 23/66 2.3 % 0.81 [ 0.49, 1.35 ]
Ray 2005 2/15 4/15 0.2 % 0.50 [ 0.11, 2.33 ]
Amar 2003 11/23 12/22 1.8 % 0.88 [ 0.49, 1.55 ]
Total (95% CI) 1102 1098 100.0 % 0.82 [ 0.76, 0.89 ]
Total events: 522 (Aprotinin), 637 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.33, df = 11 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
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Analysis 5.2. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 2 No. Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup Aprotinin EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Casati 1999 19/67 23/66 2.3 % 0.81 [ 0.49, 1.35 ]
Dorman 2008 9/30 15/30 1.4 % 0.60 [ 0.31, 1.15 ]
Eberle 1998 9/20 12/20 1.6 % 0.75 [ 0.41, 1.37 ]
Fergusson 2008 419/780 514/780 84.9 % 0.82 [ 0.75, 0.89 ]
Greilich 2001 7/24 5/23 0.6 % 1.34 [ 0.50, 3.63 ]
Greilich 2009 18/26 15/25 3.4 % 1.15 [ 0.77, 1.74 ]
Menichetti 1996 2/24 4/24 0.2 % 0.50 [ 0.10, 2.48 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Ray 2001 14/49 12/51 1.3 % 1.21 [ 0.63, 2.36 ]
Trinh-Duc 1992 12/29 18/27 2.2 % 0.62 [ 0.37, 1.03 ]
Subtotal (95% CI) 1064 1061 98.0 % 0.82 [ 0.76, 0.89 ]
Total events: 509 (Aprotinin), 621 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.87, df = 9 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.06 (P < 0.00001)
2 Orthopaedic surgery
Amar 2003 11/23 12/22 1.8 % 0.88 [ 0.49, 1.55 ]
Ray 2005 2/15 4/15 0.2 % 0.50 [ 0.11, 2.33 ]
Subtotal (95% CI) 38 37 2.0 % 0.82 [ 0.48, 1.40 ]
Total events: 13 (Aprotinin), 16 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 1102 1098 100.0 % 0.82 [ 0.76, 0.89 ]
Total events: 522 (Aprotinin), 637 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.33, df = 11 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
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Analysis 5.3. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 3 No. Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup Aprotinin EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Amar 2003 11/23 12/22 1.8 % 0.88 [ 0.49, 1.55 ]
Casati 1999 19/67 23/66 2.3 % 0.81 [ 0.49, 1.35 ]
Dorman 2008 9/30 15/30 1.4 % 0.60 [ 0.31, 1.15 ]
Eberle 1998 9/20 12/20 1.6 % 0.75 [ 0.41, 1.37 ]
Fergusson 2008 419/780 514/780 84.9 % 0.82 [ 0.75, 0.89 ]
Greilich 2001 7/24 5/23 0.6 % 1.34 [ 0.50, 3.63 ]
Greilich 2009 18/26 15/25 3.4 % 1.15 [ 0.77, 1.74 ]
Menichetti 1996 2/24 4/24 0.2 % 0.50 [ 0.10, 2.48 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Subtotal (95% CI) 1009 1005 96.2 % 0.82 [ 0.76, 0.89 ]
Total events: 494 (Aprotinin), 603 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.45, df = 8 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 4.95 (P < 0.00001)
2 No Transfusion Protocol
Ray 2001 14/49 12/51 1.3 % 1.21 [ 0.63, 2.36 ]
Ray 2005 2/15 4/15 0.2 % 0.50 [ 0.11, 2.33 ]
Trinh-Duc 1992 12/29 18/27 2.2 % 0.62 [ 0.37, 1.03 ]
Subtotal (95% CI) 93 93 3.8 % 0.78 [ 0.47, 1.31 ]
Total events: 28 (Aprotinin), 34 (EACA)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.86, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.93 (P = 0.35)
Total (95% CI) 1102 1098 100.0 % 0.82 [ 0.76, 0.89 ]
Total events: 522 (Aprotinin), 637 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.33, df = 11 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
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Analysis 5.4. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 4 Trial Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 4 Trial Methodological Quality - Allocation Concealment
Study or subgroup Aprotinin EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Eberle 1998 9/20 12/20 1.6 % 0.75 [ 0.41, 1.37 ]
Fergusson 2008 419/780 514/780 84.9 % 0.82 [ 0.75, 0.89 ]
Greilich 2009 18/26 15/25 3.4 % 1.15 [ 0.77, 1.74 ]
Subtotal (95% CI) 826 825 90.0 % 0.86 [ 0.71, 1.05 ]
Total events: 446 (Aprotinin), 541 (EACA)
Heterogeneity: Tau2 = 0.01; Chi2 = 2.75, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Allocation concealment - Unclear
Casati 1999 19/67 23/66 2.3 % 0.81 [ 0.49, 1.35 ]
Dorman 2008 9/30 15/30 1.4 % 0.60 [ 0.31, 1.15 ]
Greilich 2001 7/24 5/23 0.6 % 1.34 [ 0.50, 3.63 ]
Menichetti 1996 2/24 4/24 0.2 % 0.50 [ 0.10, 2.48 ]
Penta de Peppo 1995 0/15 3/15 0.1 % 0.14 [ 0.01, 2.55 ]
Ray 2001 14/49 12/51 1.3 % 1.21 [ 0.63, 2.36 ]
Ray 2005 2/15 4/15 0.2 % 0.50 [ 0.11, 2.33 ]
Trinh-Duc 1992 12/29 18/27 2.2 % 0.62 [ 0.37, 1.03 ]
Subtotal (95% CI) 253 251 8.3 % 0.76 [ 0.58, 0.99 ]
Total events: 65 (Aprotinin), 84 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.19, df = 7 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
3 Allocation concealment - No
Amar 2003 11/23 12/22 1.8 % 0.88 [ 0.49, 1.55 ]
Subtotal (95% CI) 23 22 1.8 % 0.88 [ 0.49, 1.55 ]
Total events: 11 (Aprotinin), 12 (EACA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 1102 1098 100.0 % 0.82 [ 0.76, 0.89 ]
Total events: 522 (Aprotinin), 637 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 9.33, df = 11 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.11 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
0.01 0.1 1 10 100
Favours experimental Favours control
338Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 5 Units of Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 5 Units of Allogeneic Blood Transfused - Transfused Patients
Study or subgroup Aprotinin EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Casati 1999 19 1.9 (1.04) 23 2.24 (0.92) 56.8 % -0.34 [ -0.94, 0.26 ]
Eberle 1998 9 1.29 (0.88) 12 1.25 (0.67) 43.2 % 0.04 [ -0.65, 0.73 ]
Total (95% CI) 28 35 100.0 % -0.18 [ -0.63, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
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Analysis 5.6. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 6 Units of Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 6 Units of Allogeneic Blood Transfused - All Patients
Study or subgroup Aprotinin EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amar 2003 23 1.8 (1.5) 22 1.7 (2.5) 7.5 % 0.10 [ -1.11, 1.31 ]
Casati 1999 67 0.54 (1.02) 66 0.78 (1.2) 42.9 % -0.24 [ -0.62, 0.14 ]
Dorman 2008 30 0.56 (1.1) 30 1.46 (2.2) 13.2 % -0.90 [ -1.78, -0.02 ]
Eberle 1998 20 0.58 (0.87) 20 0.75 (0.81) 29.4 % -0.17 [ -0.69, 0.35 ]
Greilich 2009 26 2.5 (2.7) 25 1.7 (1.8) 7.0 % 0.80 [ -0.45, 2.05 ]
Total (95% CI) 166 163 100.0 % -0.21 [ -0.55, 0.14 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 5.14, df = 4 (P = 0.27); I2 =22%
Test for overall effect: Z = 1.18 (P = 0.24)
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Analysis 5.7. Comparison 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood Loss),
Outcome 7 Blood loss.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 5 Aprotinin versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 7 Blood loss
Study or subgroup Aprotinin EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery - Post-operative
Casati 1999 67 283.4 (232.7) 66 466.9 (234.2) 19.2 % -183.50 [ -262.85, -104.15 ]
Dorman 2008 30 423 (1363.83) 30 596 (2026.57) 1.4 % -173.00 [ -1047.11, 701.11 ]
Eberle 1998 20 391 (220) 20 582 (274) 14.8 % -191.00 [ -345.00, -37.00 ]
Greilich 2009 26 685 (505) 25 715 (394) 9.9 % -30.00 [ -278.06, 218.06 ]
Landymore 1997 48 515 (339.48) 44 343 (305.13) 16.2 % 172.00 [ 40.27, 303.73 ]
Menichetti 1996 24 298 (140) 24 512 (250) 17.2 % -214.00 [ -328.63, -99.37 ]
Penta de Peppo 1995 15 344 (106) 15 509 (148) 18.5 % -165.00 [ -257.13, -72.87 ]
Subtotal (95% CI) 230 224 97.4 % -111.43 [ -220.64, -2.21 ]
Heterogeneity: Tau2 = 14145.97; Chi2 = 25.74, df = 6 (P = 0.00025); I2 =77%
Test for overall effect: Z = 2.00 (P = 0.046)
2 Orthopaedic surgery - Total
Amar 2003 23 1700 (1000) 22 1600 (1100) 2.6 % 100.00 [ -515.06, 715.06 ]
Subtotal (95% CI) 23 22 2.6 % 100.00 [ -515.06, 715.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 253 246 100.0 % -106.01 [ -212.50, 0.47 ]
Heterogeneity: Tau2 = 13708.99; Chi2 = 26.30, df = 7 (P = 0.00045); I2 =73%
Test for overall effect: Z = 1.95 (P = 0.051)
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Analysis 6.1. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 1 No. Exposed to Allogeneic Blood.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup TXA EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fergusson 2008 506/770 514/780 35.8 % 1.00 [ 0.93, 1.07 ]
Pinosky 1997 11/20 7/20 7.9 % 1.57 [ 0.77, 3.22 ]
Casati 1999 17/70 23/66 12.3 % 0.70 [ 0.41, 1.18 ]
Menichetti 1996 12/24 4/24 4.7 % 3.00 [ 1.13, 7.99 ]
Maineri 2000 12/24 11/24 10.6 % 1.09 [ 0.60, 1.97 ]
Penta de Peppo 1995 1/15 3/15 1.1 % 0.33 [ 0.04, 2.85 ]
Dalmau 2000 29/42 36/42 26.5 % 0.81 [ 0.64, 1.02 ]
Camarasa 2006 1/35 4/32 1.1 % 0.23 [ 0.03, 1.94 ]
Total (95% CI) 1000 1003 100.0 % 0.97 [ 0.77, 1.21 ]
Total events: 589 (TXA), 602 (EACA)
Heterogeneity: Tau2 = 0.04; Chi2 = 14.01, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 0.29 (P = 0.77)
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Analysis 6.2. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 2 No. Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup TXA EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Casati 1999 17/70 23/66 12.3 % 0.70 [ 0.41, 1.18 ]
Fergusson 2008 506/770 514/780 35.8 % 1.00 [ 0.93, 1.07 ]
Maineri 2000 12/24 11/24 10.6 % 1.09 [ 0.60, 1.97 ]
Menichetti 1996 12/24 4/24 4.7 % 3.00 [ 1.13, 7.99 ]
Penta de Peppo 1995 1/15 3/15 1.1 % 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 7/20 7.9 % 1.57 [ 0.77, 3.22 ]
Subtotal (95% CI) 923 929 72.5 % 1.07 [ 0.79, 1.46 ]
Total events: 559 (TXA), 562 (EACA)
Heterogeneity: Tau2 = 0.06; Chi2 = 9.25, df = 5 (P = 0.10); I2 =46%
Test for overall effect: Z = 0.45 (P = 0.66)
2 Orthopaedic surgery
Camarasa 2006 1/35 4/32 1.1 % 0.23 [ 0.03, 1.94 ]
Subtotal (95% CI) 35 32 1.1 % 0.23 [ 0.03, 1.94 ]
Total events: 1 (TXA), 4 (EACA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
3 Liver surgery
Dalmau 2000 29/42 36/42 26.5 % 0.81 [ 0.64, 1.02 ]
Subtotal (95% CI) 42 42 26.5 % 0.81 [ 0.64, 1.02 ]
Total events: 29 (TXA), 36 (EACA)
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
Total (95% CI) 1000 1003 100.0 % 0.97 [ 0.77, 1.21 ]
Total events: 589 (TXA), 602 (EACA)
Heterogeneity: Tau2 = 0.04; Chi2 = 14.01, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 0.29 (P = 0.77)
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Analysis 6.3. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 3 No. Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup TXA EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Camarasa 2006 1/35 4/32 1.1 % 0.23 [ 0.03, 1.94 ]
Casati 1999 17/70 23/66 12.3 % 0.70 [ 0.41, 1.18 ]
Dalmau 2000 29/42 36/42 26.5 % 0.81 [ 0.64, 1.02 ]
Fergusson 2008 506/770 514/780 35.8 % 1.00 [ 0.93, 1.07 ]
Maineri 2000 12/24 11/24 10.6 % 1.09 [ 0.60, 1.97 ]
Menichetti 1996 12/24 4/24 4.7 % 3.00 [ 1.13, 7.99 ]
Penta de Peppo 1995 1/15 3/15 1.1 % 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 7/20 7.9 % 1.57 [ 0.77, 3.22 ]
Total (95% CI) 1000 1003 100.0 % 0.97 [ 0.77, 1.21 ]
Total events: 589 (TXA), 602 (EACA)
Heterogeneity: Tau2 = 0.04; Chi2 = 14.01, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 0.29 (P = 0.77)
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Analysis 6.4. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 4 Trial Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 4 Trial Methodological Quality - Allocation Concealment
Study or subgroup TXA EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Fergusson 2008 506/770 514/780 35.8 % 1.00 [ 0.93, 1.07 ]
Subtotal (95% CI) 770 780 35.8 % 1.00 [ 0.93, 1.07 ]
Total events: 506 (TXA), 514 (EACA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
2 Allocation concealment - Unclear
Casati 1999 17/70 23/66 12.3 % 0.70 [ 0.41, 1.18 ]
Maineri 2000 12/24 11/24 10.6 % 1.09 [ 0.60, 1.97 ]
Menichetti 1996 12/24 4/24 4.7 % 3.00 [ 1.13, 7.99 ]
Penta de Peppo 1995 1/15 3/15 1.1 % 0.33 [ 0.04, 2.85 ]
Pinosky 1997 11/20 7/20 7.9 % 1.57 [ 0.77, 3.22 ]
Subtotal (95% CI) 153 149 36.6 % 1.16 [ 0.68, 1.98 ]
Total events: 53 (TXA), 48 (EACA)
Heterogeneity: Tau2 = 0.19; Chi2 = 9.01, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 0.56 (P = 0.58)
3 Allocation concealment - No
Camarasa 2006 1/35 4/32 1.1 % 0.23 [ 0.03, 1.94 ]
Dalmau 2000 29/42 36/42 26.5 % 0.81 [ 0.64, 1.02 ]
Subtotal (95% CI) 77 74 27.5 % 0.63 [ 0.22, 1.84 ]
Total events: 30 (TXA), 40 (EACA)
Heterogeneity: Tau2 = 0.35; Chi2 = 1.58, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 1000 1003 100.0 % 0.97 [ 0.77, 1.21 ]
Total events: 589 (TXA), 602 (EACA)
Heterogeneity: Tau2 = 0.04; Chi2 = 14.01, df = 7 (P = 0.05); I2 =50%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 6.5. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 5 Units of Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 5 Units of Allogeneic Blood Transfused - Transfused Patients
Study or subgroup TXA EACA
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Camarasa 2006 1 1 (0) 4 1.5 (0.58) 0.0 [ 0.0, 0.0 ]
Casati 1999 17 1.94 (0.69) 23 2.24 (0.92) -0.30 [ -0.80, 0.20 ]
Dalmau 2000 29 7.72 (5.44) 36 7.81 (5.67) -0.09 [ -2.80, 2.62 ]
Maineri 2000 12 1.6 (1.19) 11 2.03 (0.36) -0.43 [ -1.14, 0.28 ]
Total (95% CI) 59 74 -0.34 [ -0.74, 0.07 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 2 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
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Analysis 6.6. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 6 Units of Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 6 Units of Allogeneic Blood Transfused - All Patients
Study or subgroup TXA EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Casati 1999 70 0.47 (0.9) 66 0.78 (1.2) 74.3 % -0.31 [ -0.67, 0.05 ]
Dalmau 2000 42 5.33 (5.77) 42 6.69 (5.92) 1.5 % -1.36 [ -3.86, 1.14 ]
Maineri 2000 24 0.8 (1.16) 24 0.93 (1.06) 24.1 % -0.13 [ -0.76, 0.50 ]
Total (95% CI) 136 132 100.0 % -0.28 [ -0.59, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
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Analysis 6.7. Comparison 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion & Blood
Loss), Outcome 7 Blood loss.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 6 Tranexamic Acid versus Epsilon Aminocaproic Acid (Blood Transfusion % Blood Loss)
Outcome: 7 Blood loss
Study or subgroup TXA EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Cardiac surgery - Post-operative
Casati 1999 70 310.9 (231.1) 66 466.9 (234.2) 17.8 % -156.00 [ -234.25, -77.75 ]
Landymore 1997 56 535 (336.75) 44 343 (305.13) 16.4 % 192.00 [ 65.87, 318.13 ]
Maineri 2000 24 750 (314) 24 790 (274) 15.0 % -40.00 [ -206.73, 126.73 ]
Menichetti 1996 24 737 (400) 24 512 (250) 14.2 % 225.00 [ 36.28, 413.72 ]
Penta de Peppo 1995 15 534 (288) 15 509 (148) 15.1 % 25.00 [ -138.86, 188.86 ]
Pinosky 1997 20 600 (219.1) 20 961 (661.9) 10.1 % -361.00 [ -666.56, -55.44 ]
Subtotal (95% CI) 209 193 88.4 % -4.36 [ -163.35, 154.63 ]
Heterogeneity: Tau2 = 31640.08; Chi2 = 33.81, df = 5 (P<0.00001); I2 =85%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Orthopaedic surgery - Total
Camarasa 2006 35 1095 (473) 32 1104 (603) 11.6 % -9.00 [ -270.16, 252.16 ]
Subtotal (95% CI) 35 32 11.6 % -9.00 [ -270.16, 252.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
3 Gynaecological surgery - Total
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 244 225 100.0 % -4.20 [ -147.29, 138.89 ]
Heterogeneity: Tau2 = 28391.91; Chi2 = 33.84, df = 6 (P<0.00001); I2 =82%
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 7.1. Comparison 7 Aprotinin versus Lysine Analogues (Blood Transfusion), Outcome 1 No.
Exposed to Allogeneic Blood.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome: 1 No. Exposed to Allogeneic Blood
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Eberle 1998 9/20 12/20 2.1 % 0.75 [ 0.41, 1.37 ]
Greilich 2009 18/26 15/25 3.7 % 1.15 [ 0.77, 1.74 ]
Fergusson 2008 419/780 1020/1550 10.6 % 0.82 [ 0.76, 0.88 ]
Dietrich 2008 52/110 67/110 6.5 % 0.78 [ 0.61, 0.99 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Mansour 2004 1/20 7/20 0.2 % 0.14 [ 0.02, 1.06 ]
Bernet 1999 11/28 17/28 2.4 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.7 % 0.46 [ 0.15, 1.44 ]
Dorman 2008 9/30 15/30 1.8 % 0.60 [ 0.31, 1.15 ]
Mengistu 2008 10/25 17/25 2.4 % 0.59 [ 0.34, 1.02 ]
Corbeau 1995 15/43 15/41 2.3 % 0.95 [ 0.54, 1.69 ]
Ray 2005 2/15 4/15 0.4 % 0.50 [ 0.11, 2.33 ]
Isetta 1993 55/140 24/70 4.1 % 1.15 [ 0.78, 1.68 ]
Menichetti 1996 2/24 16/48 0.5 % 0.25 [ 0.06, 1.00 ]
Ray 2001 14/49 12/51 1.8 % 1.21 [ 0.63, 2.36 ]
Greilich 2001 7/24 5/23 0.9 % 1.34 [ 0.50, 3.63 ]
Pugh 1995 21/21 22/22 10.3 % 1.00 [ 0.92, 1.09 ]
Casati 1999 19/67 23/66 2.8 % 0.81 [ 0.49, 1.35 ]
Casati 1999 19/67 17/70 2.3 % 1.17 [ 0.67, 2.05 ]
Casati 2000 185/518 178/522 8.5 % 1.05 [ 0.89, 1.24 ]
Ickx 2006 24/24 27/27 10.6 % 1.00 [ 0.93, 1.08 ]
Engel 2001 5/12 0/12 0.1 % 11.00 [ 0.67, 179.29 ]
Trinh-Duc 1992 12/29 18/27 2.7 % 0.62 [ 0.37, 1.03 ]
Penta de Peppo 1995 0/15 4/30 0.1 % 0.22 [ 0.01, 3.75 ]
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(. . . Continued)
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Speekenbrink 1995 12/15 13/15 5.0 % 0.92 [ 0.67, 1.27 ]
Later 2009 48/96 57/99 6.2 % 0.87 [ 0.67, 1.13 ]
Amar 2003 11/23 12/22 2.3 % 0.88 [ 0.49, 1.55 ]
Dalmau 2004 40/63 38/64 5.9 % 1.07 [ 0.81, 1.41 ]
Diprose 2005 8/60 20/60 1.5 % 0.40 [ 0.19, 0.84 ]
Kuitunen 2005 11/20 5/20 1.1 % 2.20 [ 0.93, 5.18 ]
Total (95% CI) 2407 3159 100.0 % 0.90 [ 0.81, 0.99 ]
Total events: 1043 (Aprotinin), 1690 (Lysine Analogues)
Heterogeneity: Tau2 = 0.02; Chi2 = 70.06, df = 29 (P = 0.00003); I2 =59%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Not applicable
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Analysis 7.2. Comparison 7 Aprotinin versus Lysine Analogues (Blood Transfusion), Outcome 2 No.
Exposed to Allogeneic Blood - Type of Surgery.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome: 2 No. Exposed to Allogeneic Blood - Type of Surgery
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Cardiac surgery
Bernet 1999 11/28 17/28 2.6 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.7 % 0.46 [ 0.15, 1.44 ]
Casati 1999 19/67 23/66 3.0 % 0.81 [ 0.49, 1.35 ]
Casati 2000 185/518 178/522 8.5 % 1.05 [ 0.89, 1.24 ]
Corbeau 1995 15/43 15/41 2.4 % 0.95 [ 0.54, 1.69 ]
Dietrich 2008 52/110 67/110 6.6 % 0.78 [ 0.61, 0.99 ]
Diprose 2005 8/60 20/60 1.6 % 0.40 [ 0.19, 0.84 ]
Dorman 2008 9/30 15/30 2.0 % 0.60 [ 0.31, 1.15 ]
Eberle 1998 9/20 12/20 2.2 % 0.75 [ 0.41, 1.37 ]
Fergusson 2008 419/780 1020/1550 10.3 % 0.82 [ 0.76, 0.88 ]
Greilich 2001 7/24 5/23 0.9 % 1.34 [ 0.50, 3.63 ]
Greilich 2009 18/26 15/25 3.9 % 1.15 [ 0.77, 1.74 ]
Isetta 1993 55/140 24/70 4.2 % 1.15 [ 0.78, 1.68 ]
Kuitunen 2005 11/20 5/20 1.2 % 2.20 [ 0.93, 5.18 ]
Later 2009 48/96 57/99 6.3 % 0.87 [ 0.67, 1.13 ]
Mansour 2004 1/20 7/20 0.2 % 0.14 [ 0.02, 1.06 ]
Mansour 2004 1/20 7/20 0.2 % 0.14 [ 0.02, 1.06 ]
Mengistu 2008 10/25 17/25 2.6 % 0.59 [ 0.34, 1.02 ]
Menichetti 1996 2/24 16/48 0.5 % 0.25 [ 0.06, 1.00 ]
Penta de Peppo 1995 0/15 4/30 0.1 % 0.22 [ 0.01, 3.75 ]
Pugh 1995 21/21 22/22 10.1 % 1.00 [ 0.92, 1.09 ]
Ray 2001 14/49 12/51 1.9 % 1.21 [ 0.63, 2.36 ]
Speekenbrink 1995 12/15 13/15 5.2 % 0.92 [ 0.67, 1.27 ]
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Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Trinh-Duc 1992 12/29 18/27 2.9 % 0.62 [ 0.37, 1.03 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Subtotal (95% CI) 2223 2969 80.7 % 0.86 [ 0.76, 0.96 ]
Total events: 943 (Aprotinin), 1599 (Lysine Analogues)
Heterogeneity: Tau2 = 0.03; Chi2 = 54.55, df = 24 (P = 0.00036); I2 =56%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 Orthopaedic surgery
Amar 2003 11/23 12/22 2.4 % 0.88 [ 0.49, 1.55 ]
Engel 2001 5/12 0/12 0.1 % 11.00 [ 0.67, 179.29 ]
Ray 2005 2/15 4/15 0.4 % 0.50 [ 0.11, 2.33 ]
Subtotal (95% CI) 50 49 3.0 % 1.06 [ 0.32, 3.48 ]
Total events: 18 (Aprotinin), 16 (Lysine Analogues)
Heterogeneity: Tau2 = 0.59; Chi2 = 4.17, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Liver surgery
Dalmau 2004 40/63 38/64 6.0 % 1.07 [ 0.81, 1.41 ]
Ickx 2006 24/24 27/27 10.3 % 1.00 [ 0.93, 1.08 ]
Subtotal (95% CI) 87 91 16.4 % 1.01 [ 0.91, 1.11 ]
Total events: 64 (Aprotinin), 65 (Lysine Analogues)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.14, df = 1 (P = 0.29); I2 =12%
Test for overall effect: Z = 0.16 (P = 0.87)
Total (95% CI) 2360 3109 100.0 % 0.89 [ 0.80, 0.98 ]
Total events: 1025 (Aprotinin), 1680 (Lysine Analogues)
Heterogeneity: Tau2 = 0.02; Chi2 = 75.01, df = 29 (P<0.00001); I2 =61%
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 7.3. Comparison 7 Aprotinin versus Lysine Analogues (Blood Transfusion), Outcome 3 No.
Exposed to Allogeneic Blood - Transfusion Protocol.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome: 3 No. Exposed to Allogeneic Blood - Transfusion Protocol
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Transfusion Protocol
Amar 2003 11/23 12/22 2.4 % 0.88 [ 0.49, 1.55 ]
Bernet 1999 11/28 17/28 2.5 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.7 % 0.46 [ 0.15, 1.44 ]
Casati 1999 19/67 23/66 2.9 % 0.81 [ 0.49, 1.35 ]
Casati 2000 185/518 178/522 8.6 % 1.05 [ 0.89, 1.24 ]
Corbeau 1995 15/43 15/41 2.4 % 0.95 [ 0.54, 1.69 ]
Dalmau 2004 40/63 38/64 6.0 % 1.07 [ 0.81, 1.41 ]
Dietrich 2008 52/110 67/110 6.6 % 0.78 [ 0.61, 0.99 ]
Diprose 2005 8/60 20/60 1.6 % 0.40 [ 0.19, 0.84 ]
Dorman 2008 9/30 15/30 1.9 % 0.60 [ 0.31, 1.15 ]
Eberle 1998 9/20 12/20 2.2 % 0.75 [ 0.41, 1.37 ]
Engel 2001 5/12 0/12 0.1 % 11.00 [ 0.67, 179.29 ]
Fergusson 2008 419/780 1020/1550 10.7 % 0.82 [ 0.76, 0.88 ]
Greilich 2001 7/24 5/23 0.9 % 1.34 [ 0.50, 3.63 ]
Greilich 2009 18/26 15/25 3.9 % 1.15 [ 0.77, 1.74 ]
Ickx 2006 24/24 27/27 10.7 % 1.00 [ 0.93, 1.08 ]
Isetta 1993 55/140 24/70 4.2 % 1.15 [ 0.78, 1.68 ]
Kuitunen 2005 11/20 5/20 1.2 % 2.20 [ 0.93, 5.18 ]
Later 2009 48/96 57/99 6.3 % 0.87 [ 0.67, 1.13 ]
Mansour 2004 1/20 7/20 0.2 % 0.14 [ 0.02, 1.06 ]
Mengistu 2008 10/25 17/25 2.5 % 0.59 [ 0.34, 1.02 ]
Menichetti 1996 2/24 16/48 0.5 % 0.25 [ 0.06, 1.00 ]
Penta de Peppo 1995 0/15 4/30 0.1 % 0.22 [ 0.01, 3.75 ]
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Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pugh 1995 21/21 22/22 10.4 % 1.00 [ 0.92, 1.09 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Subtotal (95% CI) 2232 2981 89.7 % 0.89 [ 0.80, 0.99 ]
Total events: 984 (Aprotinin), 1626 (Lysine Analogues)
Heterogeneity: Tau2 = 0.02; Chi2 = 66.84, df = 24 (P<0.00001); I2 =64%
Test for overall effect: Z = 2.05 (P = 0.040)
2 No Transfusion Protocol
Ray 2001 14/49 12/51 1.9 % 1.21 [ 0.63, 2.36 ]
Ray 2005 2/15 4/15 0.4 % 0.50 [ 0.11, 2.33 ]
Speekenbrink 1995 12/15 13/15 5.2 % 0.92 [ 0.67, 1.27 ]
Trinh-Duc 1992 12/29 18/27 2.8 % 0.62 [ 0.37, 1.03 ]
Subtotal (95% CI) 108 108 10.3 % 0.85 [ 0.65, 1.12 ]
Total events: 40 (Aprotinin), 47 (Lysine Analogues)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.31, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 2340 3089 100.0 % 0.89 [ 0.81, 0.98 ]
Total events: 1024 (Aprotinin), 1673 (Lysine Analogues)
Heterogeneity: Tau2 = 0.02; Chi2 = 70.40, df = 28 (P = 0.00002); I2 =60%
Test for overall effect: Z = 2.29 (P = 0.022)
Test for subgroup differences: Chi2 = 0.0, df = 1 (P = 0.0), I2 =0.0%
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Analysis 7.4. Comparison 7 Aprotinin versus Lysine Analogues (Blood Transfusion), Outcome 4 Units of
Allogeneic Blood Transfused - Transfused Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome: 4 Units of Allogeneic Blood Transfused - Transfused Patients
Study or subgroup Aprotinin Lysine Analogues
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Blauhut 1994 3 1.68 (0.48) 7 1.71 (0.95) 12.6 % -0.03 [ -0.92, 0.86 ]
Casati 1999 19 1.9 (1.04) 40 2.11 (0.83) 35.0 % -0.21 [ -0.74, 0.32 ]
Corbeau 1995 15 2.29 (1.49) 15 2.19 (0.46) 16.0 % 0.10 [ -0.69, 0.89 ]
Dalmau 2004 40 5.2 (4.17) 38 5.09 (3.7) 3.3 % 0.11 [ -1.64, 1.86 ]
Diprose 2005 8 2.1 (1.42) 20 2.61 (1.55) 7.0 % -0.51 [ -1.71, 0.69 ]
Eberle 1998 9 1.29 (0.88) 12 1.25 (0.67) 21.0 % 0.04 [ -0.65, 0.73 ]
Speekenbrink 1995 12 2.91 (1.94) 13 3.31 (1.62) 5.0 % -0.40 [ -1.81, 1.01 ]
Total (95% CI) 106 145 100.0 % -0.11 [ -0.42, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 6 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 7.5. Comparison 7 Aprotinin versus Lysine Analogues (Blood Transfusion), Outcome 5 Units of
Allogeneic Blood Transfused - All Patients.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome: 5 Units of Allogeneic Blood Transfused - All Patients
Study or subgroup Aprotinin Lysine Analogues
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amar 2003 23 1.8 (1.5) 22 1.7 (2.5) 1.8 % 0.10 [ -1.11, 1.31 ]
Blauhut 1994 14 0.36 (0.47) 15 0.8 (1.08) 7.1 % -0.44 [ -1.04, 0.16 ]
Casati 1999 67 0.54 (1.02) 136 0.62 (1.06) 24.6 % -0.08 [ -0.38, 0.22 ]
Corbeau 1995 43 0.8 (1.4) 41 0.8 (1.1) 8.7 % 0.0 [ -0.54, 0.54 ]
Dalmau 2004 63 3.3 (4.16) 64 3.02 (3.79) 1.4 % 0.28 [ -1.10, 1.66 ]
Dietrich 2008 110 1.3 (1.8) 110 1.7 (1.8) 11.0 % -0.40 [ -0.88, 0.08 ]
Diprose 2005 60 0.28 (0.87) 60 0.87 (1.52) 12.5 % -0.59 [ -1.03, -0.15 ]
Dorman 2008 30 0.56 (1.1) 30 1.46 (2.2) 3.4 % -0.90 [ -1.78, -0.02 ]
Eberle 1998 20 0.58 (0.87) 20 0.75 (0.81) 9.3 % -0.17 [ -0.69, 0.35 ]
Greilich 2009 26 2.5 (2.7) 25 1.7 (1.8) 1.7 % 0.80 [ -0.45, 2.05 ]
Hekmat 2004 60 0.7 (1.2) 58 0.8 (1.3) 12.1 % -0.10 [ -0.55, 0.35 ]
Mengistu 2008 25 0.8 (1.1) 25 1.8 (2.4) 2.5 % -1.00 [ -2.03, 0.03 ]
Speekenbrink 1995 15 2.33 (2.1) 15 2.87 (1.9) 1.3 % -0.54 [ -1.97, 0.89 ]
Wong 2000 39 2.03 (2.12) 38 2.49 (2.25) 2.8 % -0.46 [ -1.44, 0.52 ]
Total (95% CI) 595 659 100.0 % -0.25 [ -0.42, -0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 13.61, df = 13 (P = 0.40); I2 =4%
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
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Analysis 7.6. Comparison 7 Aprotinin versus Lysine Analogues (Blood Transfusion), Outcome 6 Trial
Methodological Quality - Allocation Concealment.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 7 Aprotinin versus Lysine Analogues (Blood Transfusion)
Outcome: 6 Trial Methodological Quality - Allocation Concealment
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Allocation concealment - Yes
Dietrich 2008 52/110 67/110 6.5 % 0.78 [ 0.61, 0.99 ]
Eberle 1998 9/20 12/20 2.1 % 0.75 [ 0.41, 1.37 ]
Fergusson 2008 419/780 1020/1550 10.6 % 0.82 [ 0.76, 0.88 ]
Greilich 2009 18/26 15/25 3.7 % 1.15 [ 0.77, 1.74 ]
Mansour 2004 1/20 7/20 0.2 % 0.14 [ 0.02, 1.06 ]
Vanek 2005 1/29 3/32 0.2 % 0.37 [ 0.04, 3.34 ]
Subtotal (95% CI) 985 1757 23.3 % 0.82 [ 0.71, 0.95 ]
Total events: 500 (Aprotinin), 1124 (Lysine Analogues)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.44, df = 5 (P = 0.27); I2 =22%
Test for overall effect: Z = 2.59 (P = 0.0096)
2 Allocation concealment - Unclear
Bernet 1999 11/28 17/28 2.4 % 0.65 [ 0.37, 1.12 ]
Blauhut 1994 3/14 7/15 0.7 % 0.46 [ 0.15, 1.44 ]
Casati 1999 19/67 23/66 2.8 % 0.81 [ 0.49, 1.35 ]
Casati 1999 19/67 17/70 2.3 % 1.17 [ 0.67, 2.05 ]
Casati 2000 185/518 178/522 8.5 % 1.05 [ 0.89, 1.24 ]
Corbeau 1995 15/43 15/41 2.3 % 0.95 [ 0.54, 1.69 ]
Dorman 2008 9/30 15/30 1.8 % 0.60 [ 0.31, 1.15 ]
Engel 2001 5/12 0/12 0.1 % 11.00 [ 0.67, 179.29 ]
Greilich 2001 7/24 5/23 0.9 % 1.34 [ 0.50, 3.63 ]
Ickx 2006 24/24 27/27 10.6 % 1.00 [ 0.93, 1.08 ]
Isetta 1993 55/140 24/70 4.1 % 1.15 [ 0.78, 1.68 ]
Mengistu 2008 10/25 17/25 2.4 % 0.59 [ 0.34, 1.02 ]
Menichetti 1996 2/24 16/48 0.5 % 0.25 [ 0.06, 1.00 ]
Penta de Peppo 1995 0/15 4/30 0.1 % 0.22 [ 0.01, 3.75 ]
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Study or subgroup Aprotinin Lysine Analogues Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Pugh 1995 21/21 22/22 10.3 % 1.00 [ 0.92, 1.09 ]
Ray 2001 14/49 12/51 1.8 % 1.21 [ 0.63, 2.36 ]
Ray 2005 2/15 4/15 0.4 % 0.50 [ 0.11, 2.33 ]
Speekenbrink 1995 12/15 13/15 5.0 % 0.92 [ 0.67, 1.27 ]
Trinh-Duc 1992 12/29 18/27 2.7 % 0.62 [ 0.37, 1.03 ]
Subtotal (95% CI) 1160 1137 59.7 % 0.95 [ 0.86, 1.04 ]
Total events: 425 (Aprotinin), 434 (Lysine Analogues)
Heterogeneity: Tau2 = 0.01; Chi2 = 26.77, df = 18 (P = 0.08); I2 =33%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Allocation concealment - No
Amar 2003 11/23 12/22 2.3 % 0.88 [ 0.49, 1.55 ]
Dalmau 2004 40/63 38/64 5.9 % 1.07 [ 0.81, 1.41 ]
Diprose 2005 8/60 20/60 1.5 % 0.40 [ 0.19, 0.84 ]
Kuitunen 2005 11/20 5/20 1.1 % 2.20 [ 0.93, 5.18 ]
Later 2009 48/96 57/99 6.2 % 0.87 [ 0.67, 1.13 ]
Subtotal (95% CI) 262 265 17.0 % 0.92 [ 0.67, 1.28 ]
Total events: 118 (Aprotinin), 132 (Lysine Analogues)
Heterogeneity: Tau2 = 0.07; Chi2 = 10.34, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 0.48 (P = 0.63)
Total (95% CI) 2407 3159 100.0 % 0.90 [ 0.81, 0.99 ]
Total events: 1043 (Aprotinin), 1690 (Lysine Analogues)
Heterogeneity: Tau2 = 0.02; Chi2 = 70.06, df = 29 (P = 0.00003); I2 =59%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Chi2 = 0.0, df = 2 (P = 0.0), I2 =0.0%
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Analysis 8.1. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 1 Re-
operation for bleeding.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 1 Re-operation for bleeding
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 11/436 19/434 0.58 [ 0.28, 1.20 ]
Alvarez 1995 6/49 2/51 3.12 [ 0.66, 14.73 ]
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Apostolakis 2008 0/29 0/30 0.0 [ 0.0, 0.0 ]
Ashraf 1997 0/19 0/19 0.0 [ 0.0, 0.0 ]
Asimakopoulos 2000 0/8 0/10 0.0 [ 0.0, 0.0 ]
Bert 2008 0/25 1/25 0.33 [ 0.01, 7.81 ]
Bidstrup 1989 0/40 2/40 0.20 [ 0.01, 4.04 ]
Bidstrup 1990 1/26 4/18 0.17 [ 0.02, 1.42 ]
Bidstrup 1993 0/43 3/47 0.16 [ 0.01, 2.93 ]
Bidstrup 2000 1/30 1/30 1.00 [ 0.07, 15.26 ]
Boldt 1994 0/20 0/20 0.0 [ 0.0, 0.0 ]
Casas 1995 1/47 0/51 3.25 [ 0.14, 77.88 ]
Cicekcioglu 2006 0/24 1/20 0.28 [ 0.01, 6.52 ]
Cosgrove 1992 4/113 0/56 4.50 [ 0.25, 82.14 ]
D’Ambra 1996 2/141 5/71 0.20 [ 0.04, 1.01 ]
Deleuze 1991 0/30 4/30 0.11 [ 0.01, 1.98 ]
Demeyere 2006 0/20 0/20 0.0 [ 0.0, 0.0 ]
Desai 2009 1/38 2/37 0.49 [ 0.05, 5.14 ]
Dietrich 1990 0/19 0/20 0.0 [ 0.0, 0.0 ]
Dietrich 1995 1/15 4/15 0.25 [ 0.03, 1.98 ]
Dignan 2001 2/101 2/99 0.98 [ 0.14, 6.82 ]
Diprose 2005 2/60 7/60 0.29 [ 0.06, 1.32 ]
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
(Continued . . . )
359Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ehrlich 1998 0/25 0/25 0.0 [ 0.0, 0.0 ]
Englberger 2002a 1/22 1/25 1.14 [ 0.08, 17.11 ]
Englberger 2002b 0/15 0/14 0.0 [ 0.0, 0.0 ]
Findlay 2001 1/33 4/30 0.23 [ 0.03, 1.92 ]
Garcia-Huete 1997 2/39 3/41 0.70 [ 0.12, 3.97 ]
Hardy 1993 1/22 0/19 2.61 [ 0.11, 60.51 ]
Hardy 1997 1/26 1/26 1.00 [ 0.07, 15.15 ]
Kipfer 2003 1/15 1/15 1.00 [ 0.07, 14.55 ]
Koster 2004 2/100 3/100 0.67 [ 0.11, 3.90 ]
Kuepper 2003 0/60 3/59 0.14 [ 0.01, 2.66 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Kunt 2005 0/40 0/46 0.0 [ 0.0, 0.0 ]
Kyriss 2001 0/18 2/20 0.22 [ 0.01, 4.32 ]
Lass 1995 0/51 2/47 0.18 [ 0.01, 3.75 ]
Later 2009 5/96 14/103 0.38 [ 0.14, 1.02 ]
Laub 1994 0/16 0/16 0.0 [ 0.0, 0.0 ]
Leijdekkers 2006 1/16 2/19 0.59 [ 0.06, 5.96 ]
Lemmer 1996 1/487 5/157 0.06 [ 0.01, 0.55 ]
Lemmer˙1 1994 1/108 2/108 0.50 [ 0.05, 5.43 ]
Levy 1995 6/215 5/72 0.40 [ 0.13, 1.28 ]
Liu 1993 0/20 1/20 0.33 [ 0.01, 7.72 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Mohr 1992 0/34 0/16 0.0 [ 0.0, 0.0 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Nuro¨zler 2008 0/25 2/26 0.21 [ 0.01, 4.12 ]
Nuttall 2000 6/45 1/45 6.00 [ 0.75, 47.85 ]
Parvizi 2007 1/81 5/81 0.20 [ 0.02, 1.67 ]
Penta de Peppo 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Pugh 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Ray 1997 1/21 2/23 0.55 [ 0.05, 5.61 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ray 1999 0/100 5/50 0.05 [ 0.00, 0.81 ]
Rodrigus 1996 1/46 7/47 0.15 [ 0.02, 1.14 ]
Rossi 1997 0/21 3/22 0.15 [ 0.01, 2.73 ]
Schweizer 2000 1/28 1/29 1.04 [ 0.07, 15.77 ]
Tabuchi 1994 0/20 3/20 0.14 [ 0.01, 2.60 ]
Taggart 2003 1/36 1/34 0.94 [ 0.06, 14.51 ]
Vedrinne 1992 0/30 0/30 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 3392 2725 0.46 [ 0.34, 0.62 ]
Total events: 66 (Treatment), 137 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 35.44, df = 42 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 5.03 (P < 0.00001)
2 Tranexamic Acid versus Control
Andreasen 2004 1/21 6/23 0.18 [ 0.02, 1.39 ]
Armellin 2001 4/150 5/150 0.80 [ 0.22, 2.92 ]
Brown 1997 0/60 1/30 0.17 [ 0.01, 4.04 ]
Casati 2002 2/29 2/29 1.00 [ 0.15, 6.63 ]
Casati 2004 1/52 3/50 0.32 [ 0.03, 2.98 ]
Demeyere 2006 0/20 0/20 0.0 [ 0.0, 0.0 ]
Diprose 2005 5/60 7/60 0.71 [ 0.24, 2.13 ]
Hardy 1998 3/43 1/45 3.14 [ 0.34, 29.03 ]
Horrow 1991 1/38 1/45 1.18 [ 0.08, 18.30 ]
Jares 2003 0/22 1/25 0.38 [ 0.02, 8.80 ]
Jimenez 2007 0/24 1/26 0.36 [ 0.02, 8.43 ]
Karski 1995 1/100 2/50 0.25 [ 0.02, 2.69 ]
Katsaros 1996 1/104 5/106 0.20 [ 0.02, 1.72 ]
Kuitunen 2005 1/20 0/20 3.00 [ 0.13, 69.52 ]
Kuitunen 2006 1/15 0/15 3.00 [ 0.13, 68.26 ]
Later 2009 14/99 14/103 1.04 [ 0.52, 2.07 ]
Maddali 2007 3/111 3/111 1.00 [ 0.21, 4.85 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Mehr-Aein 2007 0/33 1/33 0.33 [ 0.01, 7.90 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Murphy 2006 1/50 0/50 3.00 [ 0.13, 71.92 ]
Penta de Peppo 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Pleym 2003 0/40 1/39 0.33 [ 0.01, 7.75 ]
Pugh 1995 2/22 2/23 1.05 [ 0.16, 6.79 ]
Santos 2006 1/29 1/31 1.07 [ 0.07, 16.31 ]
Shore-Lesserson 1996 0/17 0/13 0.0 [ 0.0, 0.0 ]
Uozaki 2001 1/6 1/6 1.00 [ 0.08, 12.56 ]
Subtotal (95% CI) 1224 1162 0.80 [ 0.55, 1.17 ]
Total events: 44 (Treatment), 59 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.66, df = 23 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
3 Epsilon Aminocaproic Acid versus Control
Berenholtz 2009 0/91 2/91 0.20 [ 0.01, 4.11 ]
Del Rossi 1989 0/170 6/180 0.08 [ 0.00, 1.43 ]
Hardy 1998 1/46 1/45 0.98 [ 0.06, 15.17 ]
Kluger 2003 1/58 1/30 0.52 [ 0.03, 7.98 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Penta de Peppo 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Rao 1999 0/15 1/15 0.33 [ 0.01, 7.58 ]
Vander-Salm 1996 1/51 3/52 0.34 [ 0.04, 3.16 ]
Subtotal (95% CI) 470 452 0.32 [ 0.11, 0.99 ]
Total events: 3 (Treatment), 14 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.048)
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Analysis 8.2. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 2
Mortality.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 2 Mortality
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 6/436 7/434 0.85 [ 0.29, 2.52 ]
Alvarez 1995 1/49 0/51 3.12 [ 0.13, 74.80 ]
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Apostolakis 2008 0/29 0/30 0.0 [ 0.0, 0.0 ]
Ashraf 1997 0/19 0/19 0.0 [ 0.0, 0.0 ]
Bidstrup 1989 0/40 1/40 0.33 [ 0.01, 7.95 ]
Bidstrup 1993 2/43 0/47 5.45 [ 0.27, 110.51 ]
Bidstrup 2000 1/30 0/30 3.00 [ 0.13, 70.83 ]
Blauhut 1994 1/14 0/14 3.00 [ 0.13, 67.91 ]
Casas 1995 2/47 1/51 2.17 [ 0.20, 23.16 ]
Cicekcioglu 2006 0/24 0/20 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 0/59 5.26 [ 0.26, 107.27 ]
Colwell 2007 0/175 1/178 0.34 [ 0.01, 8.27 ]
Cosgrove 1992 9/113 4/56 1.12 [ 0.36, 3.46 ]
D’Ambra 1996 5/141 0/71 5.58 [ 0.31, 99.47 ]
Desai 2009 1/38 1/37 0.97 [ 0.06, 15.00 ]
Dietrich 1992 24/902 31/882 0.76 [ 0.45, 1.28 ]
Dietrich 1995 0/15 2/15 0.20 [ 0.01, 3.85 ]
Dignan 2001 0/101 0/99 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Ehrlich 1998 3/25 4/25 0.75 [ 0.19, 3.01 ]
Englberger 2002a 0/22 0/25 0.0 [ 0.0, 0.0 ]
Englberger 2002b 0/15 0/14 0.0 [ 0.0, 0.0 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Feindt 1994 0/10 0/10 0.0 [ 0.0, 0.0 ]
Findlay 2001 0/33 1/30 0.30 [ 0.01, 7.19 ]
Garcia-Huete 1997 1/39 3/41 0.35 [ 0.04, 3.23 ]
Golanski 2000 1/30 0/24 2.42 [ 0.10, 56.85 ]
Gott 1998 2/109 4/112 0.51 [ 0.10, 2.75 ]
Green 1995 1/48 1/36 0.75 [ 0.05, 11.59 ]
Greilich 2009 1/26 0/27 3.11 [ 0.13, 73.09 ]
Hardy 1993 0/22 2/22 0.20 [ 0.01, 3.94 ]
Hayashida 1997 1/110 2/57 0.26 [ 0.02, 2.80 ]
Jamieson 1997 1/24 0/36 4.44 [ 0.19, 104.67 ]
Kipfer 2003 0/15 0/15 0.0 [ 0.0, 0.0 ]
Koster 2004 0/100 0/100 0.0 [ 0.0, 0.0 ]
Kuepper 2003 0/60 0/59 0.0 [ 0.0, 0.0 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Kunt 2005 0/40 0/46 0.0 [ 0.0, 0.0 ]
Kyriss 2001 1/18 0/20 3.32 [ 0.14, 76.60 ]
Lass 1995 0/51 2/47 0.18 [ 0.01, 3.75 ]
Later 2009 2/96 1/103 2.15 [ 0.20, 23.29 ]
Leijdekkers 2006 1/16 1/19 1.19 [ 0.08, 17.51 ]
Lemmer 1996 12/526 3/178 1.35 [ 0.39, 4.74 ]
Lemmer˙1 1994 6/108 4/108 1.50 [ 0.44, 5.17 ]
Levy 1995 15/215 5/72 1.00 [ 0.38, 2.67 ]
Liu 1993 0/20 1/20 0.33 [ 0.01, 7.72 ]
Maccario 1994 1/61 0/32 1.60 [ 0.07, 38.11 ]
Misfeld 1998 0/14 0/14 0.0 [ 0.0, 0.0 ]
Mohr 1992 0/34 0/16 0.0 [ 0.0, 0.0 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Murkin 2000 1/228 1/68 0.30 [ 0.02, 4.71 ]
Norman 2009 4/11 9/9 0.39 [ 0.19, 0.83 ]
Nuttall 2000 0/45 2/45 0.20 [ 0.01, 4.05 ]
Okita 1996 0/39 1/21 0.18 [ 0.01, 4.31 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Palmer 2003 0/30 0/26 0.0 [ 0.0, 0.0 ]
Rocha 1994 0/28 0/28 0.0 [ 0.0, 0.0 ]
Rodrigus 1996 1/46 2/47 0.51 [ 0.05, 5.44 ]
Royston 1987 0/11 1/11 0.33 [ 0.02, 7.39 ]
Schweizer 2000 1/28 0/29 3.10 [ 0.13, 73.12 ]
Stammers 1997 1/8 0/12 4.33 [ 0.20, 94.83 ]
Swart 1994 2/49 4/49 0.50 [ 0.10, 2.60 ]
Van der Linden 2005 3/37 1/38 3.08 [ 0.34, 28.30 ]
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 4889 3987 0.81 [ 0.63, 1.06 ]
Total events: 116 (Treatment), 104 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 29.54, df = 43 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Tranexamic Acid versus Control
Andreasen 2004 1/21 0/23 3.27 [ 0.14, 76.21 ]
Armellin 2001 1/150 3/150 0.33 [ 0.04, 3.17 ]
Blauhut 1994 0/15 0/14 0.0 [ 0.0, 0.0 ]
Boylan 1996 0/25 3/20 0.12 [ 0.01, 2.11 ]
Brown 1997 1/60 0/30 1.52 [ 0.06, 36.34 ]
Casati 2002 2/29 2/29 1.00 [ 0.15, 6.63 ]
Coffey 1995 0/16 1/14 0.29 [ 0.01, 6.69 ]
Dalmau 2000 3/42 4/40 0.71 [ 0.17, 2.99 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Dryden 1997 1/22 4/19 0.22 [ 0.03, 1.77 ]
Hardy 1998 0/43 0/45 0.0 [ 0.0, 0.0 ]
Hiipala 1997 0/39 1/38 0.33 [ 0.01, 7.74 ]
Jares 2003 0/22 0/25 0.0 [ 0.0, 0.0 ]
Jimenez 2007 0/24 0/26 0.0 [ 0.0, 0.0 ]
Karski 2005 3/147 1/165 3.37 [ 0.35, 32.02 ]
Kaspar 1997 1/16 0/16 3.00 [ 0.13, 68.57 ]
Katoh 1997 1/62 0/31 1.52 [ 0.06, 36.36 ]
Katsaros 1996 0/104 2/106 0.20 [ 0.01, 4.19 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Later 2009 1/99 1/103 1.04 [ 0.07, 16.41 ]
Maddali 2007 0/111 0/111 0.0 [ 0.0, 0.0 ]
Mehr-Aein 2007 0/33 0/33 0.0 [ 0.0, 0.0 ]
Misfeld 1998 0/14 0/14 0.0 [ 0.0, 0.0 ]
Murphy 2006 0/50 0/50 0.0 [ 0.0, 0.0 ]
Nuttall 2000 0/45 2/45 0.20 [ 0.01, 4.05 ]
Sadeghi 2007 0/32 1/35 0.36 [ 0.02, 8.62 ]
Santos 2006 0/29 2/31 0.21 [ 0.01, 4.26 ]
Shore-Lesserson 1996 0/17 0/13 0.0 [ 0.0, 0.0 ]
Wu 2006 0/106 0/108 0.0 [ 0.0, 0.0 ]
Zabeeda 2002 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1478 1439 0.60 [ 0.33, 1.10 ]
Total events: 15 (Treatment), 28 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.00, df = 17 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.64 (P = 0.10)
3 Epsilon Aminocaproic Acid versus Control
Berenholtz 2009 0/91 1/91 0.33 [ 0.01, 8.08 ]
Daily 1994 0/21 0/19 0.0 [ 0.0, 0.0 ]
Dalmau 2000 3/42 4/40 0.71 [ 0.17, 2.99 ]
Del Rossi 1989 3/170 3/180 1.06 [ 0.22, 5.17 ]
Greilich 2009 0/25 0/27 0.0 [ 0.0, 0.0 ]
Hardy 1998 2/46 0/45 4.89 [ 0.24, 99.18 ]
Kluger 2003 1/58 0/30 1.58 [ 0.07, 37.56 ]
Vander-Salm 1996 1/51 0/52 3.06 [ 0.13, 73.36 ]
Subtotal (95% CI) 504 484 1.07 [ 0.44, 2.57 ]
Total events: 10 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.30, df = 5 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 8.3. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 3
Myocardial Infarction (MI).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 3 Myocardial Infarction (MI)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 12/410 16/421 0.77 [ 0.37, 1.61 ]
Alvarez 1995 2/49 0/51 5.20 [ 0.26, 105.65 ]
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Asimakopoulos 2000 0/8 0/10 0.0 [ 0.0, 0.0 ]
Baele 1992 4/58 8/57 0.49 [ 0.16, 1.54 ]
Bidstrup 1993 12/410 16/421 0.77 [ 0.37, 1.61 ]
Bidstrup 2000 2/30 2/30 1.00 [ 0.15, 6.64 ]
Carrera 1994 3/51 2/51 1.50 [ 0.26, 8.60 ]
Cicek 1996a 0/50 0/25 0.0 [ 0.0, 0.0 ]
Cicek 1996b 0/29 0/28 0.0 [ 0.0, 0.0 ]
Cicekcioglu 2006 0/24 0/20 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 0/59 5.26 [ 0.26, 107.27 ]
Colwell 2007 1/175 1/177 1.01 [ 0.06, 16.04 ]
Cosgrove 1992 14/113 4/56 1.73 [ 0.60, 5.03 ]
D’Ambra 1996 5/141 3/71 0.84 [ 0.21, 3.41 ]
Desai 2009 1/38 4/37 0.24 [ 0.03, 2.08 ]
Dignan 2001 3/101 5/99 0.59 [ 0.14, 2.40 ]
Diprose 2005 3/60 4/60 0.75 [ 0.18, 3.21 ]
Ehrlich 1998 0/25 1/25 0.33 [ 0.01, 7.81 ]
Englberger 2002a 1/22 1/25 1.14 [ 0.08, 17.11 ]
Englberger 2002b 1/15 1/14 0.93 [ 0.06, 13.54 ]
Golanski 2000 6/30 2/24 2.40 [ 0.53, 10.84 ]
Greilich 2009 6/26 7/27 0.89 [ 0.34, 2.30 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Harder 1991 0/40 0/40 0.0 [ 0.0, 0.0 ]
Hayashida 1997 4/110 5/57 0.41 [ 0.12, 1.48 ]
Kalangos 1994 1/110 1/55 0.50 [ 0.03, 7.84 ]
Kipfer 2003 1/15 1/15 1.00 [ 0.07, 14.55 ]
Klein 1998 2/38 2/30 0.79 [ 0.12, 5.28 ]
Kuitunen 2005 5/20 1/20 5.00 [ 0.64, 39.06 ]
Lass 1995 0/51 4/47 0.10 [ 0.01, 1.86 ]
Later 2009 1/96 8/103 0.13 [ 0.02, 1.05 ]
Lemmer 1996 22/526 4/178 1.86 [ 0.65, 5.33 ]
Lemmer˙1 1994 10/108 7/108 1.43 [ 0.56, 3.61 ]
Levy 1995 24/206 8/67 0.98 [ 0.46, 2.07 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Murkin 1994 3/29 3/25 0.86 [ 0.19, 3.90 ]
Murkin 2000 0/228 1/73 0.11 [ 0.00, 2.62 ]
Nuro¨zler 2008 0/25 0/26 0.0 [ 0.0, 0.0 ]
Parvizi 2007 1/81 2/81 0.50 [ 0.05, 5.41 ]
Poston 2006 1/29 3/31 0.36 [ 0.04, 3.23 ]
Ranaboldo 1997 1/66 3/62 0.31 [ 0.03, 2.93 ]
Rodrigus 1996 3/46 3/47 1.02 [ 0.22, 4.80 ]
Santamaria 2000 2/56 2/28 0.50 [ 0.07, 3.37 ]
Schweizer 2000 2/28 2/29 1.04 [ 0.16, 6.86 ]
Taggart 2003 1/36 1/34 0.94 [ 0.06, 14.51 ]
Van der Linden 2005 1/37 0/38 3.08 [ 0.13, 73.25 ]
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Wendel 1995 0/20 2/20 0.20 [ 0.01, 3.92 ]
Subtotal (95% CI) 4032 3105 0.87 [ 0.69, 1.11 ]
Total events: 163 (Treatment), 140 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 27.71, df = 38 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 Tranexamic Acid versus Control
Andreasen 2004 0/21 0/23 0.0 [ 0.0, 0.0 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Armellin 2001 1/150 0/150 3.00 [ 0.12, 73.06 ]
Brown 1997 0/60 0/30 0.0 [ 0.0, 0.0 ]
Casati 2002 1/29 1/29 1.00 [ 0.07, 15.24 ]
Diprose 2005 5/60 4/60 1.25 [ 0.35, 4.43 ]
Hardy 1998 1/43 2/45 0.52 [ 0.05, 5.56 ]
Hiipala 1995 1/15 0/13 2.63 [ 0.12, 59.40 ]
Horrow 1991 1/37 0/44 3.55 [ 0.15, 84.69 ]
Jares 2003 1/22 1/25 1.14 [ 0.08, 17.11 ]
Karski 1995 0/100 0/50 0.0 [ 0.0, 0.0 ]
Karski 2005 2/147 3/165 0.75 [ 0.13, 4.42 ]
Katsaros 1996 0/104 0/106 0.0 [ 0.0, 0.0 ]
Kuitunen 2005 1/20 1/20 1.00 [ 0.07, 14.90 ]
Later 2009 0/99 8/103 0.06 [ 0.00, 1.05 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Mehr-Aein 2007 0/33 0/33 0.0 [ 0.0, 0.0 ]
Murphy 2006 0/50 1/50 0.33 [ 0.01, 7.99 ]
Shore-Lesserson 1996 1/17 2/13 0.38 [ 0.04, 3.77 ]
Speekenbrink 1995 0/15 2/15 0.20 [ 0.01, 3.85 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Zabeeda 2002 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1117 1069 0.79 [ 0.41, 1.52 ]
Total events: 15 (Treatment), 25 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.84, df = 12 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Epsilon aminocaproic Acid versus Control
Berenholtz 2009 0/91 0/91 0.0 [ 0.0, 0.0 ]
Del Rossi 1989 4/170 10/180 0.42 [ 0.14, 1.32 ]
Greilich 2009 6/25 7/27 0.93 [ 0.36, 2.38 ]
Hardy 1998 2/46 2/45 0.98 [ 0.14, 6.65 ]
Kluger 2003 1/58 0/30 1.58 [ 0.07, 37.56 ]
Rao 1999 0/15 0/15 0.0 [ 0.0, 0.0 ]
Vander-Salm 1996 5/51 2/52 2.55 [ 0.52, 12.55 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 456 440 0.88 [ 0.48, 1.63 ]
Total events: 18 (Treatment), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.44, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
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Analysis 8.4. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 4
Stroke (CVA).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 4 Stroke (CVA)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Asimakopoulos 2000 0/8 1/10 0.41 [ 0.02, 8.84 ]
Bidstrup 1993 0/43 1/47 0.36 [ 0.02, 8.70 ]
Casas 1995 0/47 0/51 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 1/59 2.11 [ 0.20, 22.60 ]
Colwell 2007 0/175 1/177 0.34 [ 0.01, 8.22 ]
D’Ambra 1996 2/141 1/71 1.01 [ 0.09, 10.92 ]
Desai 2009 0/38 1/37 0.32 [ 0.01, 7.73 ]
Dignan 2001 1/101 1/99 0.98 [ 0.06, 15.45 ]
Ehrlich 1998 0/25 1/25 0.33 [ 0.01, 7.81 ]
Greilich 2009 2/26 1/27 2.08 [ 0.20, 21.55 ]
Kuitunen 2005 1/20 0/20 3.00 [ 0.13, 69.52 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Later 2009 1/96 1/103 1.07 [ 0.07, 16.92 ]
Lemmer 1996 3/526 1/178 1.02 [ 0.11, 9.70 ]
Levy 1995 1/215 5/72 0.07 [ 0.01, 0.56 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Murkin 1995 0/29 1/24 0.28 [ 0.01, 6.52 ]
Nuro¨zler 2008 1/25 0/26 3.12 [ 0.13, 73.06 ]
Okita 1996 2/39 1/21 1.08 [ 0.10, 11.19 ]
Poston 2006 0/29 1/31 0.36 [ 0.02, 8.39 ]
Ranaboldo 1997 1/66 0/62 2.82 [ 0.12, 67.97 ]
Santamaria 2000 2/56 0/28 2.54 [ 0.13, 51.26 ]
Van der Linden 2005 1/37 0/38 3.08 [ 0.13, 73.25 ]
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1862 1260 0.82 [ 0.44, 1.52 ]
Total events: 20 (Treatment), 19 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.97, df = 19 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Tranexamic Acid versus Control
Andreasen 2004 0/21 0/23 0.0 [ 0.0, 0.0 ]
Brown 1997 0/60 0/30 0.0 [ 0.0, 0.0 ]
Casati 2002 1/29 2/29 0.50 [ 0.05, 5.21 ]
Casati 2004 0/52 0/50 0.0 [ 0.0, 0.0 ]
Hardy 1998 1/43 0/45 3.14 [ 0.13, 74.95 ]
Horrow 1990 0/18 2/20 0.22 [ 0.01, 4.32 ]
Horrow 1991 1/37 0/44 3.55 [ 0.15, 84.69 ]
Jares 2003 0/22 0/25 0.0 [ 0.0, 0.0 ]
Karski 1995 3/100 0/50 3.53 [ 0.19, 67.13 ]
Karski 2005 1/147 1/165 1.12 [ 0.07, 17.79 ]
Katoh 1997 0/62 0/31 0.0 [ 0.0, 0.0 ]
Katsaros 1996 3/104 2/106 1.53 [ 0.26, 8.96 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Later 2009 1/99 1/103 1.04 [ 0.07, 16.41 ]
Maddali 2007 0/111 0/111 0.0 [ 0.0, 0.0 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Murphy 2006 0/50 0/50 0.0 [ 0.0, 0.0 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Zabeeda 2002 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1050 977 1.23 [ 0.49, 3.07 ]
Total events: 11 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.18, df = 7 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
3 Epsilon Aminocaproic Acid versus Control
Berenholtz 2009 0/91 1/91 0.33 [ 0.01, 8.08 ]
Daily 1994 0/21 0/19 0.0 [ 0.0, 0.0 ]
Del Rossi 1989 0/170 1/180 0.35 [ 0.01, 8.60 ]
Greilich 2009 1/25 1/27 1.08 [ 0.07, 16.36 ]
Hardy 1998 0/46 0/45 0.0 [ 0.0, 0.0 ]
Kluger 2003 2/58 0/30 2.63 [ 0.13, 53.04 ]
Rao 1999 0/15 0/15 0.0 [ 0.0, 0.0 ]
Vander-Salm 1996 0/51 2/52 0.20 [ 0.01, 4.14 ]
Subtotal (95% CI) 477 459 0.62 [ 0.16, 2.36 ]
Total events: 3 (Treatment), 5 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
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Analysis 8.5. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 5
Deep Vein Thrombosis (DVT).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 5 Deep Vein Thrombosis (DVT)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Amar 2003 0/23 3/24 0.15 [ 0.01, 2.73 ]
Capdevila 1998 0/12 1/11 0.31 [ 0.01, 6.85 ]
Colwell 2007 2/175 3/177 0.67 [ 0.11, 3.99 ]
D’Ambra 1996 1/141 0/71 1.52 [ 0.06, 36.87 ]
Engel 2001 1/12 0/12 3.00 [ 0.13, 67.06 ]
Hayes 1996 0/20 1/20 0.33 [ 0.01, 7.72 ]
Janssens 1994 1/20 4/20 0.25 [ 0.03, 2.05 ]
Jeserschek 2003 0/9 0/9 0.0 [ 0.0, 0.0 ]
Llau 1998 0/10 0/10 0.0 [ 0.0, 0.0 ]
Murkin 1995 0/29 1/24 0.28 [ 0.01, 6.52 ]
Murkin 2000 26/228 10/73 0.83 [ 0.42, 1.64 ]
Petsatodis 2006 0/25 0/25 0.0 [ 0.0, 0.0 ]
Poston 2006 3/29 1/31 3.21 [ 0.35, 29.11 ]
Ranaboldo 1997 1/66 1/62 0.94 [ 0.06, 14.70 ]
Ray 2005 0/15 0/15 0.0 [ 0.0, 0.0 ]
Samama 2002 3/40 1/18 1.35 [ 0.15, 12.11 ]
Subtotal (95% CI) 854 602 0.78 [ 0.47, 1.29 ]
Total events: 38 (Treatment), 26 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.22, df = 11 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
2 Tranexamic Acid versus Control
Benoni 1996 4/43 3/43 1.33 [ 0.32, 5.61 ]
Claeys 2007 0/20 0/20 0.0 [ 0.0, 0.0 ]
Ekback 2000 1/20 1/20 1.00 [ 0.07, 14.90 ]
Engel 2001 2/12 0/12 5.00 [ 0.27, 94.34 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Garneti 2004 0/25 0/25 0.0 [ 0.0, 0.0 ]
Gill 2009 0/5 0/5 0.0 [ 0.0, 0.0 ]
Good 2003 2/27 2/24 0.89 [ 0.14, 5.83 ]
Hiipala 1995 0/15 2/13 0.18 [ 0.01, 3.34 ]
Hiipala 1997 2/39 2/38 0.97 [ 0.14, 6.57 ]
Horrow 1990 0/18 0/20 0.0 [ 0.0, 0.0 ]
Horrow 1991 0/37 1/44 0.39 [ 0.02, 9.41 ]
Husted 2003 0/20 0/20 0.0 [ 0.0, 0.0 ]
Jansen 1999 0/21 2/21 0.20 [ 0.01, 3.93 ]
Johansson 2005 0/47 0/53 0.0 [ 0.0, 0.0 ]
Katoh 1997 0/62 0/31 0.0 [ 0.0, 0.0 ]
Katsaros 1996 0/104 1/106 0.34 [ 0.01, 8.24 ]
Kazemi 2010 0/32 1/32 0.33 [ 0.01, 7.89 ]
Lemay 2004 0/20 0/19 0.0 [ 0.0, 0.0 ]
Niskanen 2005 0/19 0/20 0.0 [ 0.0, 0.0 ]
Orpen 2006 0/15 0/14 0.0 [ 0.0, 0.0 ]
Sorin 1999 0/21 2/21 0.20 [ 0.01, 3.93 ]
Wong 2008 0/73 1/74 0.34 [ 0.01, 8.16 ]
Zhang 2007 0/51 0/51 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 746 726 0.71 [ 0.35, 1.43 ]
Total events: 11 (Treatment), 18 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.71, df = 11 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
3 Epsilon Aminocaproic Acid versus Control
Amar 2003 3/22 3/24 1.09 [ 0.25, 4.85 ]
Berenholtz 2009 0/91 2/91 0.20 [ 0.01, 4.11 ]
Harley 2002 0/22 0/24 0.0 [ 0.0, 0.0 ]
Ray 2005 0/15 0/15 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 150 154 0.78 [ 0.20, 3.03 ]
Total events: 3 (Treatment), 5 (Control)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 8.6. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 6
Pulmonary Embolism (PE).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 6 Pulmonary Embolism (PE)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Amar 2003 2/23 1/24 2.09 [ 0.20, 21.48 ]
Colwell 2007 2/175 2/177 1.01 [ 0.14, 7.10 ]
Ranaboldo 1997 2/66 1/62 1.88 [ 0.17, 20.20 ]
Samama 2002 0/40 0/18 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 304 281 1.49 [ 0.42, 5.29 ]
Total events: 6 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
2 Tranexamic Acid versus Control
Benoni 1996 0/43 1/43 0.33 [ 0.01, 7.96 ]
Benoni 2001 1/18 1/20 1.11 [ 0.07, 16.49 ]
Casati 2002 0/29 0/29 0.0 [ 0.0, 0.0 ]
Casati 2004 0/52 0/50 0.0 [ 0.0, 0.0 ]
Garneti 2004 1/25 0/25 3.00 [ 0.13, 70.30 ]
Hiipala 1995 0/15 1/13 0.29 [ 0.01, 6.60 ]
Hiipala 1997 0/39 1/38 0.33 [ 0.01, 7.74 ]
Horrow 1990 0/18 0/20 0.0 [ 0.0, 0.0 ]
Husted 2003 0/20 0/20 0.0 [ 0.0, 0.0 ]
Jares 2003 0/22 0/25 0.0 [ 0.0, 0.0 ]
Katoh 1997 0/62 0/31 0.0 [ 0.0, 0.0 ]
Katsaros 1996 0/104 1/106 0.34 [ 0.01, 8.24 ]
MacGillivray 2010 2/40 0/20 2.56 [ 0.13, 50.95 ]
Pleym 2003 0/40 1/39 0.33 [ 0.01, 7.75 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 527 479 0.67 [ 0.23, 1.99 ]
Total events: 4 (Treatment), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.81, df = 7 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
3 Epsilon Aminocaproic Acid versus Control
Amar 2003 0/22 1/24 0.36 [ 0.02, 8.46 ]
Berenholtz 2009 1/91 3/91 0.33 [ 0.04, 3.15 ]
Harley 2002 0/22 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 135 139 0.34 [ 0.06, 2.13 ]
Total events: 1 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 8.7. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 7
Other Thrombosis.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 7 Other Thrombosis
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Casas 1995 1/47 1/51 1.09 [ 0.07, 16.86 ]
D’Ambra 1996 1/141 0/71 1.52 [ 0.06, 36.87 ]
Findlay 2001 1/33 2/30 0.45 [ 0.04, 4.76 ]
Garcia-Huete 1997 1/39 0/41 3.15 [ 0.13, 75.08 ]
Lentschener 1997 0/48 0/49 0.0 [ 0.0, 0.0 ]
Murkin 1995 0/29 2/24 0.17 [ 0.01, 3.31 ]
Poston 2006 0/29 3/31 0.15 [ 0.01, 2.83 ]
Rocha 1994 0/28 0/28 0.0 [ 0.0, 0.0 ]
Thorpe 1994 1/8 0/9 3.33 [ 0.15, 71.90 ]
Subtotal (95% CI) 402 334 0.73 [ 0.25, 2.15 ]
Total events: 5 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.27, df = 6 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.57)
2 Tranexamic Acid versus Control
Alvarez 2008 0/46 0/49 0.0 [ 0.0, 0.0 ]
Boylan 1996 0/25 0/20 0.0 [ 0.0, 0.0 ]
Dalmau 2000 4/42 2/40 1.90 [ 0.37, 9.83 ]
Kaspar 1997 1/16 0/16 3.00 [ 0.13, 68.57 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Veien 2002 0/15 0/15 0.0 [ 0.0, 0.0 ]
Yamasaki 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Yassen 1993 0/10 0/10 0.0 [ 0.0, 0.0 ]
Zohar 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 244 240 2.10 [ 0.49, 8.99 ]
Total events: 5 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 1.00 (P = 0.32)
3 Epsilon Aminocaproic Acid versus Control
Berenholtz 2009 2/91 6/91 0.33 [ 0.07, 1.61 ]
Dalmau 2000 2/42 2/40 0.95 [ 0.14, 6.44 ]
Subtotal (95% CI) 133 131 0.51 [ 0.15, 1.72 ]
Total events: 4 (Treatment), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 8.8. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 8
Coronary artery graft occlusion.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 8 Coronary artery graft occlusion
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 54/340 36/328 71.2 % 1.45 [ 0.98, 2.14 ]
Poston 2006 0/29 3/31 28.8 % 0.15 [ 0.01, 2.83 ]
Total (95% CI) 369 359 100.0 % 0.76 [ 0.10, 5.67 ]
Total events: 54 (Treatment), 39 (Control)
Heterogeneity: Tau2 = 1.45; Chi2 = 2.28, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.27 (P = 0.79)
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Analysis 8.9. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 9
Renal Failure / Dysfunction.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 9 Renal Failure / Dysfunction
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Asimakopoulos 2000 0/8 0/10 0.0 [ 0.0, 0.0 ]
Baele 1992 3/58 2/57 1.47 [ 0.26, 8.50 ]
Cicek 1996b 0/29 0/28 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 1/59 2.11 [ 0.20, 22.60 ]
Colwell 2007 2/175 2/177 1.01 [ 0.14, 7.10 ]
D’Ambra 1996 13/141 0/71 13.69 [ 0.83, 227.03 ]
Desai 2009 0/38 0/37 0.0 [ 0.0, 0.0 ]
Dietrich 1992 21/902 19/882 1.08 [ 0.59, 2.00 ]
Dignan 2001 0/101 0/99 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Ehrlich 1998 4/25 2/25 2.00 [ 0.40, 9.95 ]
Englberger 2002a 1/22 1/25 1.14 [ 0.08, 17.11 ]
Englberger 2002b 0/15 0/14 0.0 [ 0.0, 0.0 ]
Gherli 1992 0/18 0/13 0.0 [ 0.0, 0.0 ]
Greilich 2009 8/26 9/27 0.92 [ 0.42, 2.02 ]
Kipfer 2003 1/15 1/15 1.00 [ 0.07, 14.55 ]
Later 2009 3/96 3/103 1.07 [ 0.22, 5.19 ]
Lemmer 1996 1/526 1/178 0.34 [ 0.02, 5.38 ]
Lemmer˙1 1994 7/108 6/108 1.17 [ 0.41, 3.36 ]
Levy 1995 19/215 6/72 1.06 [ 0.44, 2.55 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Okita 1996 3/39 0/21 3.85 [ 0.21, 71.18 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ranaboldo 1997 0/66 1/62 0.31 [ 0.01, 7.55 ]
Speekenbrink 1996 0/75 0/37 0.0 [ 0.0, 0.0 ]
Stammers 1997 0/8 0/12 0.0 [ 0.0, 0.0 ]
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 2904 2281 1.10 [ 0.79, 1.54 ]
Total events: 88 (Treatment), 56 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.64, df = 16 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Tranexamic Acid versus Control
Andreasen 2004 0/21 0/23 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Katsaros 1996 1/104 0/106 3.06 [ 0.13, 74.20 ]
Later 2009 3/99 3/103 1.04 [ 0.22, 5.03 ]
Mansour 2004 1/20 1/20 1.00 [ 0.07, 14.90 ]
Mehr-Aein 2007 0/33 1/33 0.33 [ 0.01, 7.90 ]
Murphy 2006 1/50 0/50 3.00 [ 0.13, 71.92 ]
Shore-Lesserson 1996 0/17 1/13 0.26 [ 0.01, 5.89 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 454 458 0.89 [ 0.33, 2.37 ]
Total events: 6 (Treatment), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 6 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
3 Epsilon Aminocaproic Acid versus control
Berenholtz 2009 1/91 1/91 1.00 [ 0.06, 15.75 ]
Greilich 2009 3/26 9/27 0.35 [ 0.11, 1.14 ]
Subtotal (95% CI) 117 118 0.41 [ 0.14, 1.22 ]
Total events: 4 (Treatment), 10 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.60 (P = 0.11)
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Analysis 8.10. Comparison 8 Adverse Events and Other Outcomes (Active versus Control), Outcome 10
Hospital Length of Stay.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 8 Adverse Events and Other Outcomes (Active versus Control)
Outcome: 10 Hospital Length of Stay
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aprotinin versus Control
Alderman 1998 401 7.6 (8.5) 395 7.8 (8.6) 6.1 % -0.20 [ -1.39, 0.99 ]
Amar 2003 23 9.8 (5.3) 24 9 (5.9) 1.7 % 0.80 [ -2.40, 4.00 ]
Apostolakis 2008 29 5.83 (1.65) 30 7.2 (3.61) 5.1 % -1.37 [ -2.79, 0.05 ]
Asimakopoulos 2000 8 6.3 (0.2) 10 7.6 (0.9) 8.9 % -1.30 [ -1.87, -0.73 ]
Cicekcioglu 2006 24 6.2 (1.8) 20 6.9 (2.1) 6.2 % -0.70 [ -1.87, 0.47 ]
Cohen 1998 56 10.9 (7.2) 59 9.9 (4.8) 2.9 % 1.00 [ -1.25, 3.25 ]
Englberger 2002a 22 8 (2.2) 25 9.1 (8) 1.6 % -1.10 [ -4.37, 2.17 ]
Englberger 2002b 15 9.7 (2.4) 14 11.3 (3.6) 2.9 % -1.60 [ -3.84, 0.64 ]
Fauli 2005 40 6.65 (1.81) 20 6.8 (2.1) 6.6 % -0.15 [ -1.23, 0.93 ]
Harmon 2004 17 11.8 (3.1) 18 11.8 (4.3) 2.5 % 0.0 [ -2.47, 2.47 ]
Janssens 1994 20 13.9 (5) 20 13.2 (2.3) 2.6 % 0.70 [ -1.71, 3.11 ]
Jeserschek 2003 9 17.6 (7.73) 9 27.8 (20.74) 0.1 % -10.20 [ -24.66, 4.26 ]
Kipfer 2003 15 9.7 (2.4) 15 10.2 (2.7) 3.9 % -0.50 [ -2.33, 1.33 ]
Kunt 2005 40 8 (1) 46 7 (2) 8.6 % 1.00 [ 0.34, 1.66 ]
Later 2009 96 7.8 (6.7) 103 8.5 (7.4) 3.5 % -0.70 [ -2.66, 1.26 ]
Liu 1993 20 7.3 (2.68) 20 7.6 (1.34) 5.6 % -0.30 [ -1.61, 1.01 ]
Mansour 2004 20 5.8 (1.8) 20 6.4 (3) 4.7 % -0.60 [ -2.13, 0.93 ]
Murkin 1994 29 11.1 (4.85) 25 15.4 (16) 0.5 % -4.30 [ -10.82, 2.22 ]
Murkin 1995 29 13.1 (9.15) 24 11.4 (6.37) 1.0 % 1.70 [ -2.49, 5.89 ]
Nuro¨zler 2008 25 5.3 (1.6) 26 5.5 (1.4) 7.7 % -0.20 [ -1.03, 0.63 ]
Poston 2006 29 8 (4.1) 31 7 (3.8) 3.4 % 1.00 [ -1.00, 3.00 ]
Stammers 1997 8 6.1 (0.8) 12 7.3 (2.5) 4.8 % -1.20 [ -2.72, 0.32 ]
Wei 2006 36 7.9 (1.2) 40 7.3 (1.2) 9.1 % 0.60 [ 0.06, 1.14 ]
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Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 1011 1006 100.0 % -0.25 [ -0.71, 0.20 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 50.13, df = 22 (P = 0.00056); I2 =56%
Test for overall effect: Z = 1.10 (P = 0.27)
2 Tranexamic Acid versus Control
Ellis 2001 10 10 (3) 10 10 (2) 3.9 % 0.0 [ -2.23, 2.23 ]
Jimenez 2007 24 4.5 (3.55) 26 4 (3.71) 4.7 % 0.50 [ -1.51, 2.51 ]
Kazemi 2010 32 13 (12.4) 32 15.5 (7.44) 0.9 % -2.50 [ -7.51, 2.51 ]
Later 2009 99 9.4 (8.6) 103 8.5 (7.4) 4.0 % 0.90 [ -1.32, 3.12 ]
Mansour 2004 20 5.8 (2.2) 20 6.4 (3) 6.5 % -0.60 [ -2.23, 1.03 ]
Mehr-Aein 2007 33 4.8 (0.4) 33 4.8 (0.9) 24.6 % 0.0 [ -0.34, 0.34 ]
Sadeghi 2007 32 4.3 (1.6) 35 5.8 (1.5) 16.6 % -1.50 [ -2.24, -0.76 ]
Wei 2006 36 7.1 (0.8) 40 7.3 (1.2) 22.3 % -0.20 [ -0.65, 0.25 ]
Wong 2008 73 9.19 (5.48) 74 8.47 (4.12) 6.9 % 0.72 [ -0.85, 2.29 ]
Zohar 2004 20 8 (2) 20 9 (2) 9.7 % -1.00 [ -2.24, 0.24 ]
Subtotal (95% CI) 379 393 100.0 % -0.34 [ -0.82, 0.13 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 18.42, df = 9 (P = 0.03); I2 =51%
Test for overall effect: Z = 1.41 (P = 0.16)
3 Epsilon Aminocaproic Acid versus Control
Amar 2003 22 11.9 (7.3) 24 9 (5.9) 40.5 % 2.90 [ -0.96, 6.76 ]
Berenholtz 2009 91 8.5 (3.9) 91 9.5 (8.6) 59.5 % -1.00 [ -2.94, 0.94 ]
Subtotal (95% CI) 113 115 100.0 % 0.58 [ -3.17, 4.33 ]
Heterogeneity: Tau2 = 5.18; Chi2 = 3.13, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.30 (P = 0.76)
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Analysis 9.1. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 1 Re-
operation for bleeding - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 1 Re-operation for bleeding - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 2/28 2/28 1.00 [ 0.15, 6.61 ]
Casati 1999 2/67 2/70 1.04 [ 0.15, 7.21 ]
Casati 2000 8/518 10/522 0.81 [ 0.32, 2.03 ]
Dalmau 2004 2/63 2/64 1.02 [ 0.15, 6.99 ]
Demeyere 2006 0/20 0/20 0.0 [ 0.0, 0.0 ]
Dietrich 2008 2/110 3/110 0.67 [ 0.11, 3.91 ]
Diprose 2005 2/60 5/60 0.40 [ 0.08, 1.98 ]
Fergusson 2008 43/780 62/770 0.68 [ 0.47, 1.00 ]
Kuitunen 2005 0/20 1/20 0.33 [ 0.01, 7.72 ]
Later 2009 5/96 14/99 0.37 [ 0.14, 0.98 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Mongan 1998 1/75 0/75 3.00 [ 0.12, 72.49 ]
Nuttall 2000 6/45 0/45 13.00 [ 0.75, 224.13 ]
Penta de Peppo 1995 0/15 1/15 0.33 [ 0.01, 7.58 ]
Pugh 1995 1/25 2/25 0.50 [ 0.05, 5.17 ]
Wong 2000 1/39 0/38 2.93 [ 0.12, 69.64 ]
Total (95% CI) 2005 2005 0.69 [ 0.51, 0.93 ]
Total events: 75 (Aprotinin), 104 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 8.90, df = 13 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
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Analysis 9.2. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 2 Re-
operation for bleeding - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 2 Re-operation for bleeding - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bennett-Guerrero 1997 4/99 3/105 1.41 [ 0.32, 6.16 ]
Casati 1999 2/67 3/66 0.66 [ 0.11, 3.80 ]
Fergusson 2008 43/780 64/780 0.67 [ 0.46, 0.98 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Penta de Peppo 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Ray 2001 0/49 0/51 0.0 [ 0.0, 0.0 ]
Total (95% CI) 1034 1041 0.70 [ 0.49, 1.00 ]
Total events: 49 (Aprotinin), 70 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.93, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.049)
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Analysis 9.3. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 3 Re-
operation for bleeding - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 3 Re-operation for bleeding - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 2/70 3/66 0.63 [ 0.11, 3.64 ]
Fergusson 2008 62/770 64/780 0.98 [ 0.70, 1.37 ]
Hardy 1998 3/43 1/46 3.21 [ 0.35, 29.69 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Penta de Peppo 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Total (95% CI) 922 931 1.00 [ 0.73, 1.39 ]
Total events: 68 (Tranexamic Acid), 68 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.81, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
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Analysis 9.4. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 4
Mortality - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 4 Mortality - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 0/28 0/28 0.0 [ 0.0, 0.0 ]
Blauhut 1994 1/14 0/15 3.20 [ 0.14, 72.62 ]
Casati 1999 1/67 0/70 3.13 [ 0.13, 75.57 ]
Casati 2000 12/518 10/522 1.21 [ 0.53, 2.77 ]
Dalmau 2004 1/63 4/64 0.25 [ 0.03, 2.21 ]
Dietrich 2008 2/110 1/110 2.00 [ 0.18, 21.74 ]
Diprose 2005 0/60 0/60 0.0 [ 0.0, 0.0 ]
Fergusson 2008 47/779 30/769 1.55 [ 0.99, 2.42 ]
Hekmat 2004 0/60 2/58 0.19 [ 0.01, 3.94 ]
Ickx 2006 0/24 2/27 0.22 [ 0.01, 4.45 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Landymore 1997 0/48 0/56 0.0 [ 0.0, 0.0 ]
Later 2009 1/96 0/99 3.09 [ 0.13, 75.00 ]
Misfeld 1998 0/14 0/14 0.0 [ 0.0, 0.0 ]
Mongan 1998 0/75 0/75 0.0 [ 0.0, 0.0 ]
Nuttall 2000 0/45 0/45 0.0 [ 0.0, 0.0 ]
Wong 2000 2/39 2/38 0.97 [ 0.14, 6.57 ]
Total (95% CI) 2060 2070 1.35 [ 0.94, 1.93 ]
Total events: 67 (Aprotinin), 51 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.78, df = 9 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 9.5. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 5
Mortality - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 5 Mortality - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 1/67 1/66 0.99 [ 0.06, 15.42 ]
Fergusson 2008 47/779 31/780 1.52 [ 0.98, 2.36 ]
Greilich 2009 1/26 0/25 2.89 [ 0.12, 67.75 ]
Landymore 1997 0/48 0/44 0.0 [ 0.0, 0.0 ]
Trinh-Duc 1992 3/29 2/27 1.40 [ 0.25, 7.73 ]
Total (95% CI) 949 942 1.51 [ 0.99, 2.30 ]
Total events: 52 (Aprotinin), 34 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
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Analysis 9.6. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 6
Mortality - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 6 Mortality - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 0/70 1/66 0.31 [ 0.01, 7.59 ]
Dalmau 2000 3/42 3/42 1.00 [ 0.21, 4.67 ]
Fergusson 2008 30/769 31/780 0.98 [ 0.60, 1.61 ]
Hardy 1998 0/43 2/46 0.21 [ 0.01, 4.33 ]
Landymore 1997 0/56 0/44 0.0 [ 0.0, 0.0 ]
Total (95% CI) 980 978 0.93 [ 0.59, 1.47 ]
Total events: 33 (Tranexamic Acid), 37 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.43, df = 3 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
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Analysis 9.7. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 7
Mortality - Aprotinin versus Lysine Analogues.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 7 Mortality - Aprotinin versus Lysine Analogues
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 0/28 0/28 0.0 [ 0.0, 0.0 ]
Blauhut 1994 1/14 0/15 3.20 [ 0.14, 72.62 ]
Casati 1999 1/67 1/136 2.03 [ 0.13, 31.95 ]
Casati 2000 12/518 10/522 1.21 [ 0.53, 2.77 ]
Dalmau 2004 1/63 4/64 0.25 [ 0.03, 2.21 ]
Dietrich 2008 2/110 1/110 2.00 [ 0.18, 21.74 ]
Diprose 2005 0/60 0/60 0.0 [ 0.0, 0.0 ]
Fergusson 2008 47/779 61/1549 1.53 [ 1.06, 2.22 ]
Greilich 2009 1/26 0/25 2.89 [ 0.12, 67.75 ]
Hekmat 2004 0/60 2/58 0.19 [ 0.01, 3.94 ]
Ickx 2006 0/24 2/27 0.22 [ 0.01, 4.45 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Landymore 1997 0/48 0/100 0.0 [ 0.0, 0.0 ]
Later 2009 1/96 0/99 3.09 [ 0.13, 75.00 ]
Misfeld 1998 0/14 0/14 0.0 [ 0.0, 0.0 ]
Mongan 1998 0/75 0/75 0.0 [ 0.0, 0.0 ]
Nuttall 2000 0/45 0/45 0.0 [ 0.0, 0.0 ]
Trinh-Duc 1992 3/29 2/27 1.40 [ 0.25, 7.73 ]
Wong 2000 2/39 2/38 0.97 [ 0.14, 6.57 ]
Total (95% CI) 2115 3012 1.39 [ 1.02, 1.89 ]
Total events: 71 (Aprotinin), 85 (Lysine Analogues)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.89, df = 11 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.039)
Test for subgroup differences: Not applicable
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Analysis 9.8. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 8
Myocardial Infarction - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 8 Myocardial Infarction - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 0/28 0/28 0.0 [ 0.0, 0.0 ]
Casati 1999 3/67 4/70 0.78 [ 0.18, 3.37 ]
Casati 2000 9/518 11/522 0.82 [ 0.34, 1.97 ]
Dalmau 2004 0/63 1/64 0.34 [ 0.01, 8.16 ]
Diprose 2005 3/60 5/60 0.60 [ 0.15, 2.40 ]
Fergusson 2008 33/717 28/727 1.20 [ 0.73, 1.96 ]
Hekmat 2004 2/60 4/58 0.48 [ 0.09, 2.54 ]
Kuitunen 2005 5/20 1/20 5.00 [ 0.64, 39.06 ]
Later 2009 1/96 0/99 3.09 [ 0.13, 75.00 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Mongan 1998 2/75 3/75 0.67 [ 0.11, 3.88 ]
Speekenbrink 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wong 2000 4/39 5/38 0.78 [ 0.23, 2.68 ]
Total (95% CI) 1778 1796 1.00 [ 0.71, 1.42 ]
Total events: 63 (Aprotinin), 62 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.18, df = 10 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
0.001 0.01 0.1 1 10 100 1000
Favours Aprotinin Favours TXA
390Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.9. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 9
Myocardial Infarction - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 9 Myocardial Infarction - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 3/67 3/66 8.3 % 0.99 [ 0.21, 4.71 ]
Eberle 1998 1/20 1/20 2.8 % 1.00 [ 0.07, 14.90 ]
Fergusson 2008 33/717 20/735 68.2 % 1.69 [ 0.98, 2.92 ]
Greilich 2009 6/26 6/25 20.7 % 0.96 [ 0.36, 2.59 ]
Total (95% CI) 830 846 100.0 % 1.42 [ 0.90, 2.22 ]
Total events: 43 (Aprotinin), 30 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.27, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 9.10. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 10
Myocardial Infarction - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 10 Myocardial Infarction - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 4/70 3/66 12.4 % 1.26 [ 0.29, 5.41 ]
Fergusson 2008 28/727 20/735 82.9 % 1.42 [ 0.80, 2.49 ]
Hardy 1998 1/43 2/46 4.7 % 0.53 [ 0.05, 5.69 ]
Total (95% CI) 840 847 100.0 % 1.33 [ 0.80, 2.23 ]
Total events: 33 (Tranexamic Acid), 25 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
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Analysis 9.11. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 11
Myocardial infarction - Aprotinin versus Lysine Analogues.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 11 Myocardial infarction - Aprotinin versus Lysine Analogues
Study or subgroup Aprotinin Lysine Analogues Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 0/28 0/28 0.0 [ 0.0, 0.0 ]
Casati 1999 3/67 7/136 0.87 [ 0.23, 3.26 ]
Casati 2000 9/518 11/522 0.82 [ 0.34, 1.97 ]
Dalmau 2004 0/63 1/64 0.34 [ 0.01, 8.16 ]
Diprose 2005 3/60 5/60 0.60 [ 0.15, 2.40 ]
Eberle 1998 1/20 1/20 1.00 [ 0.07, 14.90 ]
Fergusson 2008 33/717 48/1462 1.40 [ 0.91, 2.16 ]
Greilich 2009 6/26 6/25 0.96 [ 0.36, 2.59 ]
Hekmat 2004 2/60 4/58 0.48 [ 0.09, 2.54 ]
Kuitunen 2005 5/20 1/20 5.00 [ 0.64, 39.06 ]
Later 2009 1/96 0/99 3.09 [ 0.13, 75.00 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Mongan 1998 2/75 3/75 0.67 [ 0.11, 3.88 ]
Speekenbrink 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Wong 2000 4/39 5/38 0.78 [ 0.23, 2.68 ]
Total (95% CI) 1824 2642 1.11 [ 0.82, 1.50 ]
Total events: 70 (Aprotinin), 92 (Lysine Analogues)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.52, df = 12 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 9.12. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 12
Stroke (CVA) - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 12 Stroke (CVA) - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 0/28 0/28 0.0 [ 0.0, 0.0 ]
Fergusson 2008 22/759 28/753 0.78 [ 0.45, 1.35 ]
Kuitunen 2005 1/20 0/20 3.00 [ 0.13, 69.52 ]
Later 2009 1/96 1/99 1.03 [ 0.07, 16.25 ]
Mongan 1998 1/75 0/75 3.00 [ 0.12, 72.49 ]
Wong 2000 1/39 0/38 2.93 [ 0.12, 69.64 ]
Total (95% CI) 1017 1013 0.88 [ 0.52, 1.47 ]
Total events: 26 (Aprotinin), 29 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.91, df = 4 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 9.13. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 13
Stroke (CVA) - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 13 Stroke (CVA) - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin
Epsilon
Aminocaproic
Acid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fergusson 2008 22/759 22/768 94.2 % 1.01 [ 0.57, 1.81 ]
Greilich 2009 2/26 1/25 5.8 % 1.92 [ 0.19, 19.90 ]
Total (95% CI) 785 793 100.0 % 1.05 [ 0.60, 1.85 ]
Total events: 24 (Aprotinin), 23 (Epsilon Aminocaproic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 9.14. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 14
Stroke (CVA) - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 14 Stroke (CVA) - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fergusson 2008 28/753 22/768 1.30 [ 0.75, 2.25 ]
Hardy 1998 1/43 0/46 3.20 [ 0.13, 76.60 ]
Maineri 2000 0/24 0/24 0.0 [ 0.0, 0.0 ]
Total (95% CI) 820 838 1.33 [ 0.78, 2.29 ]
Total events: 29 (Tranexamic Acid), 22 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
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Analysis 9.15. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 15
Deep Vein Thrombosis (DVT) - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 15 Deep Vein Thrombosis (DVT) - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 0/67 0/70 0.0 [ 0.0, 0.0 ]
Engel 2001 1/12 2/12 0.50 [ 0.05, 4.81 ]
Landymore 1997 0/48 0/56 0.0 [ 0.0, 0.0 ]
Total (95% CI) 127 138 0.50 [ 0.05, 4.81 ]
Total events: 1 (Aprotinin), 2 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 9.16. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 16
Deep Vein Thrombosis (DVT) - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 16 Deep Vein Thrombosis (DVT) - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Amar 2003 0/23 3/22 0.14 [ 0.01, 2.51 ]
Casati 1999 0/67 0/66 0.0 [ 0.0, 0.0 ]
Landymore 1997 0/48 0/44 0.0 [ 0.0, 0.0 ]
Ray 2005 0/15 0/15 0.0 [ 0.0, 0.0 ]
Total (95% CI) 153 147 0.14 [ 0.01, 2.51 ]
Total events: 0 (Aprotinin), 3 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 9.17. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 17
Deep Vein Thrombosis (DVT) - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 17 Deep Vein Thrombosis (DVT) - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Camarasa 2006 0/35 0/32 0.0 [ 0.0, 0.0 ]
Casati 1999 0/70 0/66 0.0 [ 0.0, 0.0 ]
Landymore 1997 0/56 0/44 0.0 [ 0.0, 0.0 ]
Total (95% CI) 161 142 0.0 [ 0.0, 0.0 ]
Total events: 0 (Tranexamic Acid), 0 (EACA)
Heterogeneity: Tau2 = ; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 9.18. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 18
Pulmonary Embolism (PE) - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 18 Pulmonary Embolism (PE) - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 0/67 0/70 0.0 [ 0.0, 0.0 ]
Landymore 1997 0/48 0/56 0.0 [ 0.0, 0.0 ]
Total (95% CI) 115 126 0.0 [ 0.0, 0.0 ]
Total events: 0 (Aprotinin), 0 (Tranexamic Acid)
Heterogeneity: Tau2 = ; Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 9.19. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 19
Pulmonary Embolism (PE) - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 19 Pulmonary Embolism (PE) - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Amar 2003 2/23 0/22 4.79 [ 0.24, 94.53 ]
Casati 1999 0/67 1/66 0.33 [ 0.01, 7.92 ]
Landymore 1997 0/48 0/44 0.0 [ 0.0, 0.0 ]
Total (95% CI) 138 132 1.33 [ 0.10, 18.42 ]
Total events: 2 (Aprotinin), 1 (EACA)
Heterogeneity: Tau2 = 1.12; Chi2 = 1.45, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.21 (P = 0.83)
0.001 0.01 0.1 1 10 100 1000
Favours Aprotinin Favours EACA
401Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.20. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 20
Pulmonary Embolism (PE) - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 20 Pulmonary Embolism (PE) - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Casati 1999 0/70 1/66 0.31 [ 0.01, 7.59 ]
Landymore 1997 0/56 0/44 0.0 [ 0.0, 0.0 ]
Maineri 2000 0/24 0/24 0.0 [ 0.0, 0.0 ]
Total (95% CI) 150 134 0.31 [ 0.01, 7.59 ]
Total events: 0 (Tranexamic Acid), 1 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
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Analysis 9.21. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 21
Other Thrombosis - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 21 Other Thrombosis - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bernet 1999 0/28 0/28 0.0 [ 0.0, 0.0 ]
Dalmau 2004 2/63 4/64 0.51 [ 0.10, 2.68 ]
Landymore 1997 0/48 0/56 0.0 [ 0.0, 0.0 ]
Total (95% CI) 139 148 0.51 [ 0.10, 2.68 ]
Total events: 2 (Aprotinin), 4 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
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Analysis 9.22. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 22
Other Thrombosis - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 22 Other Thrombosis - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aproinin EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Landymore 1997 0/48 0/44 0.0 [ 0.0, 0.0 ]
Total (95% CI) 48 44 0.0 [ 0.0, 0.0 ]
Total events: 0 (Aproinin), 0 (EACA)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 9.23. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 23
Other Thrombosis - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 23 Other Thrombosis - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid EACA Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dalmau 2000 4/42 2/42 2.00 [ 0.39, 10.34 ]
Landymore 1997 0/56 0/44 0.0 [ 0.0, 0.0 ]
Total (95% CI) 98 86 2.00 [ 0.39, 10.34 ]
Total events: 4 (Tranexamic Acid), 2 (EACA)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
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Analysis 9.24. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 24
Renal Failure / Dysfunction - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 24 Renal Failure / Dysfunction - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Dalmau 2004 2/63 4/64 0.51 [ 0.10, 2.68 ]
Dietrich 2008 0/110 0/110 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 0/60 0.0 [ 0.0, 0.0 ]
Fergusson 2008 102/770 97/766 1.05 [ 0.81, 1.36 ]
Later 2009 3/96 3/99 1.03 [ 0.21, 4.98 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Total (95% CI) 1119 1119 1.02 [ 0.79, 1.31 ]
Total events: 107 (Aprotinin), 105 (Tranexamic Acid)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.20, df = 3 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
0.001 0.01 0.1 1 10 100 1000
Favours Aprotinin Favours TXA
405Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.25. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 25
Renal Failure / Dysfunction - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 25 Renal Failure / Dysfunction - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin
Epsilon
Aminocaproic
Acid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fergusson 2008 102/770 100/774 71.6 % 1.03 [ 0.79, 1.33 ]
Greilich 2009 8/26 3/25 28.4 % 2.56 [ 0.77, 8.58 ]
Total (95% CI) 796 799 100.0 % 1.33 [ 0.59, 2.99 ]
Total events: 110 (Aprotinin), 103 (Epsilon Aminocaproic Acid)
Heterogeneity: Tau2 = 0.22; Chi2 = 2.12, df = 1 (P = 0.15); I2 =53%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 9.26. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 26
Renal Failure / Dysfunction - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 26 Renal Failure / Dysfunction - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup Tranexamic Acid
Epsilon
Aminocaproic
Acid Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Fergusson 2008 97/766 100/774 100.0 % 0.98 [ 0.76, 1.27 ]
Total (95% CI) 766 774 100.0 % 0.98 [ 0.76, 1.27 ]
Total events: 97 (Tranexamic Acid), 100 (Epsilon Aminocaproic Acid)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
Test for subgroup differences: Not applicable
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Analysis 9.27. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 27
Hospital Length of Stay - Aprotinin versus Tranexamic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 27 Hospital Length of Stay - Aprotinin versus Tranexamic Acid
Study or subgroup Aprotinin Tranexamic Acid
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dietrich 2008 110 10.4 (4.3) 110 11.1 (5.1) 22.0 % -0.70 [ -1.95, 0.55 ]
Fergusson 2008 780 11.92 (14.02) 770 11.56 (10.86) 21.9 % 0.36 [ -0.89, 1.61 ]
Hekmat 2004 60 10.3 (4) 58 9 (3.1) 21.3 % 1.30 [ 0.01, 2.59 ]
Ickx 2006 24 26 (7) 27 31 (19) 1.2 % -5.00 [ -12.69, 2.69 ]
Later 2009 96 7.8 (6.7) 99 9.4 (8.6) 11.6 % -1.60 [ -3.76, 0.56 ]
Mansour 2004 20 5.8 (1.8) 20 5.8 (2.2) 22.0 % 0.0 [ -1.25, 1.25 ]
Total (95% CI) 1090 1084 100.0 % -0.05 [ -0.92, 0.83 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 9.14, df = 5 (P = 0.10); I2 =45%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 9.28. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 28
Hospital Length of Stay - Aprotinin versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 28 Hospital Length of Stay - Aprotinin versus Epsilon Aminocaproic Acid
Study or subgroup Aprotinin EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Amar 2003 23 9.8 (5.3) 22 11.9 (7.3) 11.3 % -2.10 [ -5.84, 1.64 ]
Fergusson 2008 780 11.92 (14.02) 780 12.2 (12.86) 88.7 % -0.28 [ -1.62, 1.06 ]
Total (95% CI) 803 802 100.0 % -0.49 [ -1.74, 0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
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Analysis 9.29. Comparison 9 Adverse Events and Other Outcomes (Active versus Active), Outcome 29
Hospital Length of Stay - Tranexamic Acid versus Epsilon Aminocaproic Acid.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 9 Adverse Events and Other Outcomes (Active versus Active)
Outcome: 29 Hospital Length of Stay - Tranexamic Acid versus Epsilon Aminocaproic Acid
Study or subgroup TXA EACA
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Fergusson 2008 770 11.56 (10.86) 780 12.2 (12.86) 100.0 % -0.64 [ -1.82, 0.54 ]
Total (95% CI) 770 780 100.0 % -0.64 [ -1.82, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 10.1. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 1 Re-operation for bleeding.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 1 Re-operation for bleeding
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 11/436 19/434 0.58 [ 0.28, 1.20 ]
Alvarez 1995 6/49 2/51 3.12 [ 0.66, 14.73 ]
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Ashraf 1997 0/19 0/19 0.0 [ 0.0, 0.0 ]
Asimakopoulos 2000 0/8 0/10 0.0 [ 0.0, 0.0 ]
Bert 2008 0/25 1/25 0.33 [ 0.01, 7.81 ]
Bidstrup 1989 0/40 2/40 0.20 [ 0.01, 4.04 ]
Bidstrup 1990 1/26 4/18 0.17 [ 0.02, 1.42 ]
Bidstrup 1993 0/43 3/47 0.16 [ 0.01, 2.93 ]
Bidstrup 2000 1/30 1/30 1.00 [ 0.07, 15.26 ]
Boldt 1994 0/20 0/20 0.0 [ 0.0, 0.0 ]
Casas 1995 1/47 0/51 3.25 [ 0.14, 77.88 ]
Cicekcioglu 2006 0/24 1/20 0.28 [ 0.01, 6.52 ]
Cosgrove 1992 4/113 0/56 4.50 [ 0.25, 82.14 ]
D’Ambra 1996 2/141 5/71 0.20 [ 0.04, 1.01 ]
Deleuze 1991 0/30 4/30 0.11 [ 0.01, 1.98 ]
Demeyere 2006 0/20 0/20 0.0 [ 0.0, 0.0 ]
Desai 2009 1/38 2/37 0.49 [ 0.05, 5.14 ]
Dietrich 1990 0/19 0/20 0.0 [ 0.0, 0.0 ]
Dietrich 1995 1/15 4/15 0.25 [ 0.03, 1.98 ]
Dignan 2001 2/101 2/99 0.98 [ 0.14, 6.82 ]
Diprose 2005 2/60 7/60 0.29 [ 0.06, 1.32 ]
Englberger 2002a 1/22 1/25 1.14 [ 0.08, 17.11 ]
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Englberger 2002b 0/15 0/14 0.0 [ 0.0, 0.0 ]
Hardy 1993 1/22 0/19 2.61 [ 0.11, 60.51 ]
Hardy 1997 1/26 1/26 1.00 [ 0.07, 15.15 ]
Kipfer 2003 1/15 1/15 1.00 [ 0.07, 14.55 ]
Koster 2004 2/100 3/100 0.67 [ 0.11, 3.90 ]
Kuepper 2003 0/60 3/59 0.14 [ 0.01, 2.66 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Kunt 2005 0/40 0/46 0.0 [ 0.0, 0.0 ]
Lass 1995 0/51 2/47 0.18 [ 0.01, 3.75 ]
Later 2009 5/96 14/103 0.38 [ 0.14, 1.02 ]
Laub 1994 0/16 0/16 0.0 [ 0.0, 0.0 ]
Leijdekkers 2006 1/16 2/19 0.59 [ 0.06, 5.96 ]
Lemmer 1996 1/487 5/157 0.06 [ 0.01, 0.55 ]
Lemmer˙1 1994 1/108 2/108 0.50 [ 0.05, 5.43 ]
Levy 1995 6/215 5/72 0.40 [ 0.13, 1.28 ]
Liu 1993 0/20 1/20 0.33 [ 0.01, 7.72 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Mohr 1992 0/34 0/16 0.0 [ 0.0, 0.0 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Nuro¨zler 2008 0/25 2/26 0.21 [ 0.01, 4.12 ]
Nuttall 2000 6/45 1/45 6.00 [ 0.75, 47.85 ]
Parvizi 2007 1/81 5/81 0.20 [ 0.02, 1.67 ]
Penta de Peppo 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Pugh 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Ray 1997 1/21 2/23 0.55 [ 0.05, 5.61 ]
Ray 1999 0/100 5/50 0.05 [ 0.00, 0.81 ]
Rodrigus 1996 1/46 7/47 0.15 [ 0.02, 1.14 ]
Rossi 1997 0/21 3/22 0.15 [ 0.01, 2.73 ]
Schweizer 2000 1/28 1/29 1.04 [ 0.07, 15.77 ]
Tabuchi 1994 0/20 3/20 0.14 [ 0.01, 2.60 ]
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Taggart 2003 1/36 1/34 0.94 [ 0.06, 14.51 ]
Vedrinne 1992 0/30 0/30 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 3248 2579 0.46 [ 0.34, 0.63 ]
Total events: 63 (Treatment), 128 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 34.56, df = 39 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 4.82 (P < 0.00001)
2 Tranexamic Acid versus Control
Andreasen 2004 1/21 6/23 0.18 [ 0.02, 1.39 ]
Armellin 2001 4/150 5/150 0.80 [ 0.22, 2.92 ]
Brown 1997 0/60 1/30 0.17 [ 0.01, 4.04 ]
Casati 2004 1/52 3/50 0.32 [ 0.03, 2.98 ]
Demeyere 2006 0/20 0/20 0.0 [ 0.0, 0.0 ]
Diprose 2005 5/60 7/60 0.71 [ 0.24, 2.13 ]
Hardy 1998 3/43 1/45 3.14 [ 0.34, 29.03 ]
Horrow 1991 1/38 1/45 1.18 [ 0.08, 18.30 ]
Jares 2003 0/22 1/25 0.38 [ 0.02, 8.80 ]
Jimenez 2007 0/24 1/26 0.36 [ 0.02, 8.43 ]
Karski 1995 1/100 2/50 0.25 [ 0.02, 2.69 ]
Katsaros 1996 1/104 5/106 0.20 [ 0.02, 1.72 ]
Kuitunen 2005 1/20 0/20 3.00 [ 0.13, 69.52 ]
Kuitunen 2006 1/15 0/15 3.00 [ 0.13, 68.26 ]
Later 2009 14/99 14/103 1.04 [ 0.52, 2.07 ]
Maddali 2007 3/111 3/111 1.00 [ 0.21, 4.85 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Mehr-Aein 2007 0/33 1/33 0.33 [ 0.01, 7.90 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Murphy 2006 1/50 0/50 3.00 [ 0.13, 71.92 ]
Penta de Peppo 1995 1/15 0/15 3.00 [ 0.13, 68.26 ]
Pleym 2003 0/40 1/39 0.33 [ 0.01, 7.75 ]
Pugh 1995 2/22 2/23 1.05 [ 0.16, 6.79 ]
Santos 2006 1/29 1/31 1.07 [ 0.07, 16.31 ]
Shore-Lesserson 1996 0/17 0/13 0.0 [ 0.0, 0.0 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Uozaki 2001 1/6 1/6 1.00 [ 0.08, 12.56 ]
Subtotal (95% CI) 1195 1133 0.79 [ 0.54, 1.17 ]
Total events: 42 (Treatment), 57 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 12.60, df = 22 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
3 Epsilon Aminocaproic Acid versus Control
Del Rossi 1989 0/170 6/180 0.08 [ 0.00, 1.43 ]
Hardy 1998 1/46 1/45 0.98 [ 0.06, 15.17 ]
Kluger 2003 1/58 1/30 0.52 [ 0.03, 7.98 ]
Menichetti 1996 0/24 0/24 0.0 [ 0.0, 0.0 ]
Penta de Peppo 1995 0/15 0/15 0.0 [ 0.0, 0.0 ]
Rao 1999 0/15 1/15 0.33 [ 0.01, 7.58 ]
Vander-Salm 1996 1/51 3/52 0.34 [ 0.04, 3.16 ]
Subtotal (95% CI) 379 361 0.35 [ 0.11, 1.17 ]
Total events: 3 (Treatment), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
Total (95% CI) 4822 4073 0.56 [ 0.44, 0.71 ]
Total events: 108 (Treatment), 197 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 54.09, df = 67 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 4.73 (P < 0.00001)
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Analysis 10.2. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 2 Mortality.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 2 Mortality
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 6/436 7/434 0.85 [ 0.29, 2.52 ]
Alvarez 1995 1/49 0/51 3.12 [ 0.13, 74.80 ]
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Ashraf 1997 0/19 0/19 0.0 [ 0.0, 0.0 ]
Bidstrup 1989 0/40 1/40 0.33 [ 0.01, 7.95 ]
Bidstrup 1993 2/43 0/47 5.45 [ 0.27, 110.51 ]
Bidstrup 2000 1/30 0/30 3.00 [ 0.13, 70.83 ]
Blauhut 1994 1/14 0/14 3.00 [ 0.13, 67.91 ]
Casas 1995 2/47 1/51 2.17 [ 0.20, 23.16 ]
Cicekcioglu 2006 0/20 0/24 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 0/59 5.26 [ 0.26, 107.27 ]
Colwell 2007 0/175 1/178 0.34 [ 0.01, 8.27 ]
Cosgrove 1992 9/113 4/56 1.12 [ 0.36, 3.46 ]
D’Ambra 1996 5/141 0/71 5.58 [ 0.31, 99.47 ]
Desai 2009 1/38 1/37 0.97 [ 0.06, 15.00 ]
Dietrich 1992 24/902 31/882 0.76 [ 0.45, 1.28 ]
Dietrich 1995 0/15 2/15 0.20 [ 0.01, 3.85 ]
Dignan 2001 0/101 0/99 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Englberger 2002a 0/22 0/25 0.0 [ 0.0, 0.0 ]
Englberger 2002b 0/15 0/14 0.0 [ 0.0, 0.0 ]
Feindt 1994 0/10 0/10 0.0 [ 0.0, 0.0 ]
Golanski 2000 1/30 0/24 2.42 [ 0.10, 56.85 ]
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Gott 1998 2/109 4/112 0.51 [ 0.10, 2.75 ]
Green 1995 1/48 1/36 0.75 [ 0.05, 11.59 ]
Greilich 2009 1/26 0/27 3.11 [ 0.13, 73.09 ]
Hardy 1993 0/22 2/22 0.20 [ 0.01, 3.94 ]
Hayashida 1997 1/110 2/57 0.26 [ 0.02, 2.80 ]
Jamieson 1997 1/24 0/36 4.44 [ 0.19, 104.67 ]
Kipfer 2003 0/15 0/15 0.0 [ 0.0, 0.0 ]
Koster 2004 0/100 0/100 0.0 [ 0.0, 0.0 ]
Kuepper 2003 0/60 0/59 0.0 [ 0.0, 0.0 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Kunt 2005 0/40 0/46 0.0 [ 0.0, 0.0 ]
Lass 1995 0/51 2/47 0.18 [ 0.01, 3.75 ]
Later 2009 2/96 1/103 2.15 [ 0.20, 23.29 ]
Leijdekkers 2006 1/16 1/19 1.19 [ 0.08, 17.51 ]
Lemmer 1996 12/526 3/178 1.35 [ 0.39, 4.74 ]
Lemmer˙1 1994 6/108 4/108 1.50 [ 0.44, 5.17 ]
Levy 1995 15/215 5/72 1.00 [ 0.38, 2.67 ]
Liu 1993 0/20 1/20 0.33 [ 0.01, 7.72 ]
Maccario 1994 1/61 0/32 1.60 [ 0.07, 38.11 ]
Misfeld 1998 0/14 0/14 0.0 [ 0.0, 0.0 ]
Mohr 1992 0/34 0/16 0.0 [ 0.0, 0.0 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Norman 2009 4/11 9/9 0.39 [ 0.19, 0.83 ]
Nuttall 2000 0/45 2/45 0.20 [ 0.01, 4.05 ]
Rocha 1994 0/28 0/28 0.0 [ 0.0, 0.0 ]
Rodrigus 1996 1/46 2/47 0.51 [ 0.05, 5.44 ]
Royston 1987 0/11 1/11 0.33 [ 0.02, 7.39 ]
Schweizer 2000 1/28 0/29 3.10 [ 0.13, 73.12 ]
Stammers 1997 1/8 0/12 4.33 [ 0.20, 94.83 ]
Swart 1994 2/49 4/49 0.50 [ 0.10, 2.60 ]
Van der Linden 2005 3/37 1/38 3.08 [ 0.34, 28.30 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 4444 3730 0.84 [ 0.64, 1.10 ]
Total events: 110 (Treatment), 94 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 26.44, df = 37 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.21)
2 Tranexamic Acid versus Control
Andreasen 2004 1/21 0/23 3.27 [ 0.14, 76.21 ]
Armellin 2001 1/150 3/150 0.33 [ 0.04, 3.17 ]
Blauhut 1994 0/15 0/14 0.0 [ 0.0, 0.0 ]
Brown 1997 1/60 0/30 1.52 [ 0.06, 36.34 ]
Coffey 1995 0/16 1/14 0.29 [ 0.01, 6.69 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Dryden 1997 1/22 4/19 0.22 [ 0.03, 1.77 ]
Hardy 1998 0/43 0/45 0.0 [ 0.0, 0.0 ]
Jares 2003 0/22 0/25 0.0 [ 0.0, 0.0 ]
Jimenez 2007 0/24 0/26 0.0 [ 0.0, 0.0 ]
Karski 2005 3/147 1/165 3.37 [ 0.35, 32.02 ]
Katoh 1997 1/62 0/31 1.52 [ 0.06, 36.36 ]
Katsaros 1996 0/104 2/106 0.20 [ 0.01, 4.19 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Later 2009 1/99 1/103 1.04 [ 0.07, 16.41 ]
Maddali 2007 0/111 0/111 0.0 [ 0.0, 0.0 ]
Mehr-Aein 2007 0/33 0/33 0.0 [ 0.0, 0.0 ]
Misfeld 1998 0/14 0/14 0.0 [ 0.0, 0.0 ]
Murphy 2006 0/50 0/50 0.0 [ 0.0, 0.0 ]
Nuttall 2000 0/45 2/45 0.20 [ 0.01, 4.05 ]
Santos 2006 0/29 2/31 0.21 [ 0.01, 4.26 ]
Shore-Lesserson 1996 0/17 0/13 0.0 [ 0.0, 0.0 ]
Zabeeda 2002 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1189 1153 0.58 [ 0.26, 1.28 ]
Total events: 9 (Treatment), 17 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.14, df = 11 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
3 Epsilon Aminocaproic Acid versus Control
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Daily 1994 0/21 0/19 0.0 [ 0.0, 0.0 ]
Del Rossi 1989 3/170 3/180 1.06 [ 0.22, 5.17 ]
Greilich 2009 0/25 0/27 0.0 [ 0.0, 0.0 ]
Hardy 1998 2/46 0/45 4.89 [ 0.24, 99.18 ]
Kluger 2003 1/58 0/30 1.58 [ 0.07, 37.56 ]
Vander-Salm 1996 1/51 0/52 3.06 [ 0.13, 73.36 ]
Subtotal (95% CI) 371 353 1.65 [ 0.50, 5.43 ]
Total events: 7 (Treatment), 3 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
Total (95% CI) 6004 5236 0.84 [ 0.65, 1.07 ]
Total events: 126 (Treatment), 114 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 36.51, df = 53 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 10.3. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 3 Myocardial Infarction.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 3 Myocardial Infarction
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alderman 1998 12/410 16/421 0.77 [ 0.37, 1.61 ]
Alvarez 1995 2/49 0/51 5.20 [ 0.26, 105.65 ]
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Asimakopoulos 2000 0/8 0/10 0.0 [ 0.0, 0.0 ]
Baele 1992 4/58 8/57 0.49 [ 0.16, 1.54 ]
Bidstrup 1993 12/410 16/421 0.77 [ 0.37, 1.61 ]
Bidstrup 2000 2/30 2/30 1.00 [ 0.15, 6.64 ]
Carrera 1994 3/51 2/51 1.50 [ 0.26, 8.60 ]
Cicek 1996a 0/50 0/25 0.0 [ 0.0, 0.0 ]
Cicek 1996b 0/29 0/28 0.0 [ 0.0, 0.0 ]
Cicekcioglu 2006 0/24 0/20 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 0/59 5.26 [ 0.26, 107.27 ]
Colwell 2007 1/175 1/177 1.01 [ 0.06, 16.04 ]
Cosgrove 1992 14/113 4/56 1.73 [ 0.60, 5.03 ]
D’Ambra 1996 5/141 3/71 0.84 [ 0.21, 3.41 ]
Desai 2009 1/38 4/37 0.24 [ 0.03, 2.08 ]
Dignan 2001 3/101 5/99 0.59 [ 0.14, 2.40 ]
Diprose 2005 3/60 4/60 0.75 [ 0.18, 3.21 ]
Englberger 2002a 1/22 1/25 1.14 [ 0.08, 17.11 ]
Englberger 2002b 1/15 1/14 0.93 [ 0.06, 13.54 ]
Golanski 2000 6/30 2/24 2.40 [ 0.53, 10.84 ]
Greilich 2009 6/26 7/27 0.89 [ 0.34, 2.30 ]
Harder 1991 0/40 0/40 0.0 [ 0.0, 0.0 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hayashida 1997 4/110 5/57 0.41 [ 0.12, 1.48 ]
Kalangos 1994 1/110 1/55 0.50 [ 0.03, 7.84 ]
Kipfer 2003 1/15 1/15 1.00 [ 0.07, 14.55 ]
Klein 1998 2/38 2/30 0.79 [ 0.12, 5.28 ]
Kuitunen 2005 5/20 1/20 5.00 [ 0.64, 39.06 ]
Lass 1995 0/51 4/47 0.10 [ 0.01, 1.86 ]
Later 2009 1/96 8/103 0.13 [ 0.02, 1.05 ]
Lemmer 1996 22/526 4/178 1.86 [ 0.65, 5.33 ]
Lemmer˙1 1994 10/108 7/108 1.43 [ 0.56, 3.61 ]
Levy 1995 24/206 8/67 0.98 [ 0.46, 2.07 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Murkin 1994 3/29 3/25 0.86 [ 0.19, 3.90 ]
Nuro¨zler 2008 0/25 0/26 0.0 [ 0.0, 0.0 ]
Parvizi 2007 1/81 2/81 0.50 [ 0.05, 5.41 ]
Poston 2006 1/29 3/31 0.36 [ 0.04, 3.23 ]
Rodrigus 1996 3/46 3/47 1.02 [ 0.22, 4.80 ]
Santamaria 2000 2/56 2/28 0.50 [ 0.07, 3.37 ]
Schweizer 2000 2/28 2/29 1.04 [ 0.16, 6.86 ]
Taggart 2003 1/36 1/34 0.94 [ 0.06, 14.51 ]
Van der Linden 2005 1/37 0/38 3.08 [ 0.13, 73.25 ]
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Wendel 1995 0/20 2/20 0.20 [ 0.01, 3.92 ]
Subtotal (95% CI) 3713 2945 0.90 [ 0.71, 1.14 ]
Total events: 162 (Treatment), 135 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 24.82, df = 35 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Tranexamic Acid versus Control
Andreasen 2004 0/21 0/23 0.0 [ 0.0, 0.0 ]
Armellin 2001 1/150 0/150 3.00 [ 0.12, 73.06 ]
Brown 1997 0/60 0/30 0.0 [ 0.0, 0.0 ]
Diprose 2005 5/60 4/60 1.25 [ 0.35, 4.43 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Hardy 1998 1/43 2/45 0.52 [ 0.05, 5.56 ]
Horrow 1991 1/37 0/44 3.55 [ 0.15, 84.69 ]
Jares 2003 1/22 1/25 1.14 [ 0.08, 17.11 ]
Karski 1995 0/100 0/50 0.0 [ 0.0, 0.0 ]
Karski 2005 2/147 3/165 0.75 [ 0.13, 4.42 ]
Katsaros 1996 0/104 0/106 0.0 [ 0.0, 0.0 ]
Kuitunen 2005 1/20 1/20 1.00 [ 0.07, 14.90 ]
Later 2009 0/99 8/103 0.06 [ 0.00, 1.05 ]
Mansour 2004 0/20 0/20 0.0 [ 0.0, 0.0 ]
Mehr-Aein 2007 0/33 0/33 0.0 [ 0.0, 0.0 ]
Murphy 2006 0/50 1/50 0.33 [ 0.01, 7.99 ]
Shore-Lesserson 1996 1/17 2/13 0.38 [ 0.04, 3.77 ]
Speekenbrink 1995 0/15 2/15 0.20 [ 0.01, 3.85 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Zabeeda 2002 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1073 1027 0.74 [ 0.37, 1.47 ]
Total events: 13 (Treatment), 24 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 7.21, df = 10 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
3 Epsilon Aminocaproic Acid versus Control
Del Rossi 1989 4/170 10/180 0.42 [ 0.14, 1.32 ]
Greilich 2009 6/25 7/27 0.93 [ 0.36, 2.38 ]
Hardy 1998 2/46 2/45 0.98 [ 0.14, 6.65 ]
Kluger 2003 1/58 0/30 1.58 [ 0.07, 37.56 ]
Rao 1999 0/15 0/15 0.0 [ 0.0, 0.0 ]
Vander-Salm 1996 5/51 2/52 2.55 [ 0.52, 12.55 ]
Subtotal (95% CI) 365 349 0.88 [ 0.48, 1.63 ]
Total events: 18 (Treatment), 21 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.44, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Total (95% CI) 5151 4321 0.88 [ 0.71, 1.09 ]
Total events: 193 (Treatment), 180 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 35.49, df = 51 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 10.4. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 4 Stroke.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 4 Stroke
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Asimakopoulos 2000 0/8 1/10 0.41 [ 0.02, 8.84 ]
Bidstrup 1993 0/43 1/47 0.36 [ 0.02, 8.70 ]
Casas 1995 0/47 0/51 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 1/59 2.11 [ 0.20, 22.60 ]
Colwell 2007 0/175 1/177 0.34 [ 0.01, 8.22 ]
D’Ambra 1996 2/141 1/71 1.01 [ 0.09, 10.92 ]
Desai 2009 0/38 1/37 0.32 [ 0.01, 7.73 ]
Dignan 2001 1/101 1/99 0.98 [ 0.06, 15.45 ]
Greilich 2009 2/26 1/27 2.08 [ 0.20, 21.55 ]
Kuitunen 2005 1/20 0/20 3.00 [ 0.13, 69.52 ]
Later 2009 1/96 1/103 1.07 [ 0.07, 16.92 ]
Levy 1995 1/215 5/72 0.07 [ 0.01, 0.56 ]
Moran 2000 0/28 0/14 0.0 [ 0.0, 0.0 ]
Nuro¨zler 2008 1/25 0/26 3.12 [ 0.13, 73.06 ]
Poston 2006 0/29 1/31 0.36 [ 0.02, 8.39 ]
Santamaria 2000 2/56 0/28 2.54 [ 0.13, 51.26 ]
Van der Linden 2005 1/37 0/38 3.08 [ 0.13, 73.25 ]
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1177 950 0.81 [ 0.40, 1.67 ]
Total events: 14 (Treatment), 15 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 10.55, df = 14 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 Tranexamic Acid versus Control
Andreasen 2004 0/21 0/23 0.0 [ 0.0, 0.0 ]
Brown 1997 0/60 0/30 0.0 [ 0.0, 0.0 ]
Casati 2004 0/52 0/50 0.0 [ 0.0, 0.0 ]
Hardy 1998 1/43 0/45 3.14 [ 0.13, 74.95 ]
Horrow 1990 0/18 2/20 0.22 [ 0.01, 4.32 ]
Horrow 1991 1/37 0/44 3.55 [ 0.15, 84.69 ]
Jares 2003 0/22 0/25 0.0 [ 0.0, 0.0 ]
Karski 1995 3/100 0/50 3.53 [ 0.19, 67.13 ]
Karski 2005 1/147 1/165 1.12 [ 0.07, 17.79 ]
Katoh 1997 0/62 0/31 0.0 [ 0.0, 0.0 ]
Katsaros 1996 3/104 2/106 1.53 [ 0.26, 8.96 ]
Kuitunen 2005 0/20 0/20 0.0 [ 0.0, 0.0 ]
Later 2009 1/99 1/103 1.04 [ 0.07, 16.41 ]
Maddali 2007 0/111 0/111 0.0 [ 0.0, 0.0 ]
Murphy 2006 0/50 0/50 0.0 [ 0.0, 0.0 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Zabeeda 2002 0/25 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 1021 948 1.44 [ 0.53, 3.91 ]
Total events: 10 (Treatment), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 6 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
3 Epsilon Aminocaproic Acid versus Control
Daily 1994 0/21 0/19 0.0 [ 0.0, 0.0 ]
Del Rossi 1989 0/170 1/180 0.35 [ 0.01, 8.60 ]
Greilich 2009 1/25 1/27 1.08 [ 0.07, 16.36 ]
Hardy 1998 0/46 0/45 0.0 [ 0.0, 0.0 ]
Kluger 2003 2/58 0/30 2.63 [ 0.13, 53.04 ]
Rao 1999 0/15 0/15 0.0 [ 0.0, 0.0 ]
Vander-Salm 1996 0/51 2/52 0.20 [ 0.01, 4.14 ]
Subtotal (95% CI) 386 368 0.70 [ 0.16, 3.10 ]
Total events: 3 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 3 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 2584 2266 0.95 [ 0.55, 1.63 ]
Total events: 27 (Treatment), 25 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 15.75, df = 25 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
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Analysis 10.5. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 5 Deep Vein Thrombosis (DVT).
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 5 Deep Vein Thrombosis (DVT)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Colwell 2007 2/175 3/177 0.67 [ 0.11, 3.99 ]
D’Ambra 1996 1/141 0/71 1.52 [ 0.06, 36.87 ]
Poston 2006 3/29 1/31 3.21 [ 0.35, 29.11 ]
Subtotal (95% CI) 345 279 1.29 [ 0.36, 4.58 ]
Total events: 6 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.18, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Tranexamic Acid versus Control
Horrow 1990 0/18 0/20 0.0 [ 0.0, 0.0 ]
Horrow 1991 0/37 1/44 0.39 [ 0.02, 9.41 ]
Katoh 1997 0/62 0/31 0.0 [ 0.0, 0.0 ]
Katsaros 1996 0/104 1/106 0.34 [ 0.01, 8.24 ]
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 221 201 0.37 [ 0.04, 3.47 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
Total (95% CI) 566 480 0.95 [ 0.31, 2.87 ]
Total events: 6 (Treatment), 6 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.09, df = 4 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
Analysis 10.6. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 6 Pulmonary Embolism.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 6 Pulmonary Embolism
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Tranexamic Acid versus Control
Casati 2004 0/52 0/50 0.0 [ 0.0, 0.0 ]
Horrow 1990 0/18 0/20 0.0 [ 0.0, 0.0 ]
Jares 2003 0/22 0/25 0.0 [ 0.0, 0.0 ]
Katoh 1997 0/62 0/31 0.0 [ 0.0, 0.0 ]
Katsaros 1996 0/104 1/106 0.34 [ 0.01, 8.24 ]
Pleym 2003 0/40 1/39 0.33 [ 0.01, 7.75 ]
Subtotal (95% CI) 298 271 0.33 [ 0.04, 3.15 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
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Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.96 (P = 0.34)
2 Aprotinin versus Control
Colwell 2007 2/175 2/177 1.01 [ 0.14, 7.10 ]
Subtotal (95% CI) 175 177 1.01 [ 0.14, 7.10 ]
Total events: 2 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
Total (95% CI) 473 448 0.63 [ 0.14, 2.74 ]
Total events: 2 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
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Analysis 10.7. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 7 Other Thrombosis.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 7 Other Thrombosis
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Casas 1995 1/47 1/51 1.09 [ 0.07, 16.86 ]
D’Ambra 1996 1/141 0/71 1.52 [ 0.06, 36.87 ]
Poston 2006 0/29 3/31 0.15 [ 0.01, 2.83 ]
Rocha 1994 0/28 0/28 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 245 181 0.62 [ 0.11, 3.36 ]
Total events: 2 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.40, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
2 Tranexamic Acid versus Control
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 50 50 0.0 [ 0.0, 0.0 ]
Total events: 0 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
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Analysis 10.8. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 8 Renal Failure / Dysfunction.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 8 Renal Failure / Dysfunction
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Aprotinin versus Control
Alvarez 2001 0/26 0/29 0.0 [ 0.0, 0.0 ]
Asimakopoulos 2000 0/8 0/10 0.0 [ 0.0, 0.0 ]
Baele 1992 3/58 2/57 1.47 [ 0.26, 8.50 ]
Cicek 1996b 0/29 0/28 0.0 [ 0.0, 0.0 ]
Cohen 1998 2/56 1/59 2.11 [ 0.20, 22.60 ]
Colwell 2007 2/175 2/177 1.01 [ 0.14, 7.10 ]
D’Ambra 1996 13/141 0/71 13.69 [ 0.83, 227.03 ]
Desai 2009 0/38 0/37 0.0 [ 0.0, 0.0 ]
Dietrich 1992 21/902 19/882 1.08 [ 0.59, 2.00 ]
Dignan 2001 0/101 0/99 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Englberger 2002a 1/22 1/25 1.14 [ 0.08, 17.11 ]
Englberger 2002b 0/15 0/14 0.0 [ 0.0, 0.0 ]
Gherli 1992 0/18 0/13 0.0 [ 0.0, 0.0 ]
Greilich 2009 8/26 9/27 0.92 [ 0.42, 2.02 ]
Kipfer 2003 1/15 1/15 1.00 [ 0.07, 14.55 ]
Later 2009 3/96 3/103 1.07 [ 0.22, 5.19 ]
Lemmer 1996 1/526 1/178 0.34 [ 0.02, 5.38 ]
Lemmer˙1 1994 7/108 6/108 1.17 [ 0.41, 3.36 ]
Levy 1995 19/215 6/72 1.06 [ 0.44, 2.55 ]
Mansour 2004 0/20 1/20 0.33 [ 0.01, 7.72 ]
Speekenbrink 1996 0/75 0/37 0.0 [ 0.0, 0.0 ]
Stammers 1997 0/8 0/12 0.0 [ 0.0, 0.0 ]
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Wei 2006 0/36 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 2774 2173 1.07 [ 0.76, 1.51 ]
Total events: 81 (Treatment), 53 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.78, df = 13 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
2 Tranexamic Acid versus Control
Andreasen 2004 0/21 0/23 0.0 [ 0.0, 0.0 ]
Diprose 2005 0/60 1/60 0.33 [ 0.01, 8.02 ]
Katsaros 1996 1/104 0/106 3.06 [ 0.13, 74.20 ]
Later 2009 3/99 3/103 1.04 [ 0.22, 5.03 ]
Mansour 2004 1/20 1/20 1.00 [ 0.07, 14.90 ]
Mehr-Aein 2007 0/33 1/33 0.33 [ 0.01, 7.90 ]
Murphy 2006 1/50 0/50 3.00 [ 0.13, 71.92 ]
Shore-Lesserson 1996 0/17 1/13 0.26 [ 0.01, 5.89 ]
Taghaddomi 2009 0/50 0/50 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 454 458 0.89 [ 0.33, 2.37 ]
Total events: 6 (Treatment), 7 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.52, df = 6 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
3 Epsilon Aminocaproic Acid versus control
Greilich 2009 3/26 9/27 0.35 [ 0.11, 1.14 ]
Subtotal (95% CI) 26 27 0.35 [ 0.11, 1.14 ]
Total events: 3 (Treatment), 9 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.081)
Total (95% CI) 3254 2658 0.97 [ 0.71, 1.33 ]
Total events: 90 (Treatment), 69 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 11.43, df = 21 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.19 (P = 0.85)
0.001 0.01 0.1 1 10 100 1000
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Analysis 10.9. Comparison 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac
Surgery, Outcome 9 Hospital Length of Stay.
Review: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
Comparison: 10 Adverse Events and Other Outcomes (Active versus Control) - Cardiac Surgery
Outcome: 9 Hospital Length of Stay
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aprotinin versus Control
Alderman 1998 401 7.6 (8.5) 395 7.8 (8.6) 7.3 % -0.20 [ -1.39, 0.99 ]
Asimakopoulos 2000 8 6.3 (0.2) 10 7.6 (0.9) 10.5 % -1.30 [ -1.87, -0.73 ]
Cohen 1998 56 10.9 (7.2) 59 9.9 (4.8) 3.6 % 1.00 [ -1.25, 3.25 ]
Englberger 2002a 22 8 (2.2) 25 9.1 (8) 2.0 % -1.10 [ -4.37, 2.17 ]
Englberger 2002b 15 9.7 (2.4) 14 11.3 (3.6) 3.6 % -1.60 [ -3.84, 0.64 ]
Fauli 2005 40 6.65 (1.81) 20 6.8 (2.1) 7.8 % -0.15 [ -1.23, 0.93 ]
Harmon 2004 17 11.8 (3.1) 18 11.8 (4.3) 3.1 % 0.0 [ -2.47, 2.47 ]
Kipfer 2003 15 9.7 (2.4) 15 10.2 (2.7) 4.7 % -0.50 [ -2.33, 1.33 ]
Kunt 2005 40 8 (1) 46 7 (2) 10.1 % 1.00 [ 0.34, 1.66 ]
Later 2009 96 7.8 (6.7) 103 8.5 (7.4) 4.3 % -0.70 [ -2.66, 1.26 ]
Liu 1993 20 7.3 (2.68) 20 7.6 (1.34) 6.7 % -0.30 [ -1.61, 1.01 ]
Mansour 2004 20 5.8 (1.8) 20 6.4 (3) 5.8 % -0.60 [ -2.13, 0.93 ]
Murkin 1994 29 11.1 (4.85) 25 15.4 (16) 0.6 % -4.30 [ -10.82, 2.22 ]
Nuro¨zler 2008 25 5.3 (1.6) 26 5.5 (1.4) 9.2 % -0.20 [ -1.03, 0.63 ]
Poston 2006 29 8 (4.1) 31 7 (3.8) 4.2 % 1.00 [ -1.00, 3.00 ]
Stammers 1997 8 6.1 (0.8) 12 7.3 (2.5) 5.8 % -1.20 [ -2.72, 0.32 ]
Wei 2006 36 7.9 (1.2) 40 7.3 (1.2) 10.7 % 0.60 [ 0.06, 1.14 ]
Subtotal (95% CI) 877 879 100.0 % -0.22 [ -0.73, 0.29 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 42.90, df = 16 (P = 0.00029); I2 =63%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Tranexamic Acid versus Control
Jimenez 2007 24 4.5 (3.55) 26 5 (3.71) 1.7 % -0.50 [ -2.51, 1.51 ]
Later 2009 99 9.4 (8.9) 103 8.5 (7.4) 1.3 % 0.90 [ -1.36, 3.16 ]
Mansour 2004 20 5.8 (2.2) 20 6.4 (3) 2.6 % -0.60 [ -2.23, 1.03 ]
Mehr-Aein 2007 33 4.8 (0.4) 33 4.8 (0.9) 61.0 % 0.0 [ -0.34, 0.34 ]
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(. . . Continued)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Wei 2006 36 7.1 (0.8) 40 7.3 (1.2) 33.3 % -0.20 [ -0.65, 0.25 ]
Subtotal (95% CI) 212 222 100.0 % -0.08 [ -0.34, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 4 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
-4 -2 0 2 4
Favours Treatment Favours Control
A P P E N D I C E S
Appendix 1. Search strategy
The original search strategy at the outset of the review included the following terms;
Exploded MeSH terms: ’aprotinin’ ’tranexamic acid’ ’Aminocaproic acids’ ’Blood transfusion’ ’Hemorrhage’ ’Anesthesia’.
Text-word terms:aprotinin, antilysin, contrical, kallikrein-trypsin, bovine pancreatic trypsin, tranexamic, cyklokapron, pharmacia, t-
amcha, amcha, ugurol, transamin, kabi, epsilon-aminocaproic acid, aminocaproic, lederle, amicar, transfusion$, bleed$, blood loss$,
hemorrhag$.
Appendix 2. Search strategy: 2010 update
Cochrane Injuries Group Specialised Register (searched July 2010)
(Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor* or
basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal
or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?
128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal
type trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or
riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren) or (tranexamic or Cyclo-
hexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-amcha or amca or kabi
2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclohexane carboxy-
late or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin or amikapron
or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane carbonic acid
or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or
aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336 or cyclo-
capron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA) or (aminocaproic or
amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*) or epsikapron or cy-116
or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic or amino n hexanoic or
acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol or cl 10304 or EACA
or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or epsilon aminocaproate
or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?177or neocaprol or nsc?
26154 or tachostyptan)
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MEDLINE(Ovid) 1950 to July Week 2 2010
1. exp Antifibrinolytic Agents/
2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or
fibrinolysis) adj3 inhibitor*)).ab,ti.
3. exp Aprotinin/
4. (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor*
or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or
pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128
or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?
52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren).ab,ti.
5. exp Tranexamic Acid/
6. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.
7. exp Aminocaproic Acids/ or exp 6-Aminocaproic Acid/
8. (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*)
or epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic
or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol
or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or
epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?
177or neocaprol or nsc?26154 or tachostyptan).ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. randomi?ed.ab,ti.
11. randomized controlled trial.pt.
12. controlled clinical trial.pt.
13. placebo.ab.
14. clinical trials as topic.sh.
15. randomly.ab.
16. trial.ti.
17. 10 or 11 or 12 or 13 or 14 or 15 or 16
18. (animals not (humans and animals)).sh.
19.17 not 18
20. 9 and 19
EMBASE (Ovid) 1980 to 2010 Week 28
1. exp Antifibrinolytic Agent/
2. (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* or ((plasmin or
fibrinolysis) adj3 inhibitor*)).ab,ti.
3. exp Aprotinin/
4. (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor*
or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal or
pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?128
or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal type
trypsin inhibitor* or (Kunitz adj3 inhibitor*) or midran or (pancrea* adj2 antitrypsin) or (pancrea* adj2 trypsin inhibitor*) or riker?
52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren).ab,ti.
5. exp Tranexamic Acid/
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6. (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA).ab,ti.
7. exp Aminocaproic Acid/
8. (((aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic) adj2 acid*)
or epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic
or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol
or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or
epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?
177or neocaprol or nsc?26154 or tachostyptan).ab,ti.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp Randomized Controlled Trial/
11. exp controlled clinical trial/
12. randomi?ed.ab,ti.
13. placebo.ab.
14. *Clinical Trial/
15. randomly.ab.
16. trial.ti.
17. 10 or 11 or 12 or 13 or 14 or 15 or 16
18. exp animal/ not (exp human/ and exp animal/)
19. 17 not 18
20. 9 and 19
Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3)
#1 MeSH descriptor Antifibrinolytic Agents explode all trees
#2 (anti-fibrinolytic* or antifibrinolytic* or antifibrinolysin* or anti-fibrinolysin* or antiplasmin* or anti-plasmin* ):ab,ti or ((plasmin
or fibrinolysis) near3 inhibitor*):ab,ti
#3 MeSH descriptor Aprotinin explode all trees
#4 (Aprotinin* or kallikrein-trypsin inactivator* or bovine kunitz pancreatic trypsin inhibitor* or bovine pancreatic trypsin inhibitor*
or basic pancreatic trypsin inhibitor* or BPTI or contrykal or kontrykal or kontrikal or contrical or dilmintal or iniprol or zymofren
or traskolan or antilysin or pulmin or amicar or caprocid or epsamon or epsikapron or antilysin or iniprol or kontrikal or kontrykal
or pulmin* or Trasylol or Antilysin Spofa or rp?9921 or antagosan or antilysin or antilysine or apronitin* or apronitrine or bayer a?
128 or bovine pancreatic secretory trypsin inhibitor* or contrycal or frey inhibitor* or gordox or kallikrein trypsin inhibitor* or kazal
type trypsin inhibitor or riker?52g or rp?9921or tracylol or trascolan or trasilol or traskolan or trazylol or zymofren or zymophren or
midran):ab,ti or ((Kunitz near3 inhibitor*) or (pancrea* near3 antitrypsin) or (pancrea* near3 trypsin next inhibitor*)):ab,ti
#5 MeSH descriptor Tranexamic Acid explode all trees
#6 (tranexamic or Cyclohexanecarboxylic Acid* or Methylamine* or amcha or trans-4-aminomethyl-cyclohexanecarboxylic acid* or t-
amcha or amca or kabi 2161 or transamin* or exacyl or amchafibrin or anvitoff or spotof or cyklokapron or ugurol oramino methylcyclo-
hexane carboxylate or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecarboxylic acid or AMCHA or amchafibrin
or amikapron or aminomethyl cyclohexane carboxylic acid or aminomethyl cyclohexanecarboxylic acid or aminomethylcyclohexane
carbonic acid or aminomethylcyclohexane carboxylic acid or aminomethylcyclohexanecarbonic acid or aminomethylcyclohexanecar-
boxylic acid or aminomethylcyclohexanocarboxylic acid or aminomethylcyclohexanoic acid or amstat or anvitoff or cl?65336 or cl65336
or cyclocapron or cyclokapron or cyklocapron or exacyl or frenolyse or hexacapron or hexakapron or tranex or TXA):ab,ti
#7 MeSH descriptor Aminocaproic Acids explode all trees
#8 MeSH descriptor 6-Aminocaproic Acid explode all trees
#9 (epsikapron or cy-116 or cy116 or epsamon or amicar or caprocid or lederle or Aminocaproic or aminohexanoic or amino caproic
or amino n hexanoic or acikaprin or afibrin or capracid or capramol or caprogel or caprolest or caprolisine or caprolysin or capromol
or cl 10304 or EACA or eaca roche or ecapron or ekaprol or epsamon or epsicapron or epsilcapramin or epsilon amino caproate or
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epsilon aminocaproate or epsilonaminocaproic or etha?aminocaproic or ethaaminocaproich or emocaprol or hepin or ipsilon or jd?
177or neocaprol or nsc?26154 or tachostyptan):ab,ti
#10 (aminocaproic or amino?caproic or aminohexanoic or amino?hexanoic or epsilon-aminocaproic or E-aminocaproic):ab,ti
#11 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10)
WH A T ’ S N E W
Last assessed as up-to-date: 31 January 2010.
Date Event Description
10 February 2011 New citation required but conclusions have not
changed
The editorial group is aware that a clinical trial by Prof.
Joachim Boldt has been found to have been fabricated
(Boldt 2009). As the editors who revealed this fabrica-
tion point out (Reinhart 2011; Shafer 2011), this casts
some doubt on the veracity of other studies by the same
author. All Cochrane Injuries Group reviews which in-
clude studies by this author have therefore been edited
to show the results with this author’s trials included
and excluded. Readers can now judge the potential im-
pact of trials by this author (Boldt 1991, Boldt 1994,
Mengistu 2008) on the conclusions of the review.
H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 1, 1999
Date Event Description
31 May 2010 New citation required and conclusions have changed The searches were updated to February 2010. An addi-
tional 40 trials have been included. The updated data
show a lower rate of death with the lysine analogues
than aprotinin, which has been withdrawn fromworld
markets
10 September 2008 Amended The text of ’Type of surgery’ under ’Aprotinin’ in the
’Effects of interventions’ section was amended
8 September 2008 Amended Converted to new review format.
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C O N T R I B U T I O N S O F A U T H O R S
Contributors (names are listed alphabetically)
Paul Carless (University of Newcastle) obtained relevant papers, applied inclusion/ exclusion criteria to retrieved papers, quality assessed
trials, extracted data from the trials, entered data into RevMan Analyses, entered study details into ReviewManager 4.2.8, and co-wrote
review; Dean Fergusson (ISPOTCoordinator*) co-conceived the review, performed the original literature searches, data extraction, and
analyses; David Henry (University of Newcastle) obtained funding for the study, was involved in study design, screened abstracts and
titles for relevant articles, and co-wrote review; Katharine Ker (London School of Hygiene & Tropical Medicine) performed updated
literature searches extracted data and co-wrote the updated review; Annette Moxey (University of Newcastle) obtained relevant papers,
applied inclusion/ exclusion criteria to retrieved papers, quality assessed trials, extracted data from the trials and entered data into
MetaView 3.1; Dianne O’Connell (University of Newcastle) provided statistical consultancy for the review, checked data for consistency,
analysed and interpreted the results, provided methodological content, and co-wrote review, Barrie Stokes (University of Newcastle)
provided statistical consultancy for the review and performed Bayesian analyses.
* ISPOT - International Study of Peri-Operative Transfusion
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Special purpose grant, Hunter Area Pathology Service, Australia.
External sources
• Australian Health Ministers’ Advisory Committee. National Health and Medical Research Council of Australia, Australia.
N O T E S
The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (Boldt 2009). As the
editors who revealed this fabrication point out (Reinhart 2011; Shafer 2011), this casts some doubt on the veracity of other studies
by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the
results with this author’s trials included and excluded. Readers can now judge the potential impact of trials by this author (Boldt 1991,
Boldt 1994, Mengistu 2008) on the conclusions of the review.
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Medical Subject Headings (MeSH)
6-Aminocaproic Acid [∗therapeutic use]; Antifibrinolytic Agents [∗therapeutic use]; Aprotinin [∗therapeutic use]; Blood Loss, Surgical
[∗prevention& control]; Erythrocyte Transfusion [∗utilization]; Randomized Controlled Trials as Topic; Tranexamic Acid [∗therapeutic
use]; Transplantation, Homologous
MeSH check words
Adult; Humans
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